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ii	
Summary 
New approaches to improve current detection and treatment of ovarian cancer (OC), 
now the fifth leading cause of cancer death among women in the United Kingdom, 
are increasingly needed. Current cytotoxic chemotherapy and targeted therapies have 
failed to significantly impact overall patient survival and drugs targeting epigenetic 
readers, writers and erasers are receiving much attention as potential sources of 
novel OC therapies. The identification of target molecules and/or epigenetic 
regulators with key roles in the OC phenotype and progression could facilitate the 
development of new effective treatment strategies. 
The main purpose of this study was to assess the role of the ‘histone 
acetyltransferase binding to ORC-1’ (HBO1), an epigenetic regulator that plays 
important roles in diverse molecular processes including DNA replication and 
transcription. Previous studies found HBO1 overexpressed in OC tissues and, 
although the molecular basis of its role is still unclear, it may represent a novel target 
involved in the modulation of the OC phenotype. 
To better understand the roles of HBO1 in OC, we first profiled its expression in 
cellular models and found it to be overexpressed compared to a non-cancerous cell 
model. Further analysis of the HBO1 downstream regulatory pathways through the 
use of two different silencing methodologies confirmed that HBO1 is involved in the 
regulation of important cancer associated pathways and processes, as well as 
individual oncogenes and tumour suppressor genes. Analysis of the biomechanical 
properties of OC cells using Atomic Force Microscopy outlined a role for HBO1 in 
the establishment of an aggressive cancerous phenotype, as the membranes of 
HBO1-overexpressing cells were significantly more elastic than their HBO1-
depleted counterparts. Overall, the results of this study suggest dynamic roles for 
HBO1, which ought to be studied further to determine whether this molecule could 
be considered an attractive target for the future development of OC therapies. 
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1.1 Human Reproductive Function 
Normal reproductive function is essential for the production of healthy offspring and 
therefore, survival of the species (Johnson & Everitt 2000). Unlike asexual 
reproduction, where progeny arise from a single organism, sexual reproduction is 
based on the combination of two morphologically distinct reproductive cells 
denominated gametes (Crow 1994). The male gametes are the spermatozoa 
(spermatozoon in singular) and the female gametes are the ova (ovum), both haploid 
germ cells that fuse during fertilization to conceive a zygote containing genetic 
material from the two progenitors (Piñon Jr 2002). Sexual reproduction and the 
merging of parental chromosomes provide the necessary biological variation to adapt 
in a changing environment (Johnson & Everitt 2000). 
 
The biological process that leads to the generation and maturation of reproductive 
cells or haploid gametes is known as gametogenesis (Johnson & Everitt 2000) or 
oogenesis in females (Gilbert 2000) and spermatogenesis in males (Cheng & Mruk 
2010). These biological processes take place in the reproductive/sex glands or 
gonads: testes in males and ovaries in females (Piñon Jr 2002). Both sexes are able 
to synthesize and secrete steroid/sex hormones such as androgens, estrogens and 
progesterone, which play vital roles both in the development and function of the 
reproductive organs and in sexual behaviour (Finlayson 2007). 
Unlike the continuous sperm production of the male, the maturation of the female 
gamete followed by its release from the ovary (ovulation) is cyclical (Fathalla 2015). 
During each ovarian/menstrual cycle, one gamete becomes fully mature and is 
expelled from the ovary in order to encounter the male gamete and merge (Johnson 
& Everitt 2000). 
 
1.1.1 Female reproductive system 
The female reproductive system is comprised of external and internal sex organs, 
commonly termed female external or internal genitalia respectively (Impey & Child 
2012). Whereas the female external genitalia have protective and stimulatory 
functions, the internal counterparts are involved in producing, nourishing and 
transporting functional female gametes, amongst other functions (Martini et al. 
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2012). The female internal genitalia localize to the pelvis, the lower part of the 
abdomen, and is surrounded by pelvic bones and muscles (Marieb & Hoehn 2015). 
These organs are also enclosed within an extensive mesentery known as the broad 
ligament of the uterus (Oats & Abraham 2016). It includes two fallopian tubes, two 
female gonads, uterus, cervix and vagina (Impey & Child 2012) (Fig. 1.1). 
 
 
	
Figure 1. 1 Schematic representation of the human female internal genitalia 
The image illustrates the main structures of the human female internal genitalia. 
Source: Adapted from an online source (Kenhub.com 2017). 
 
 
The two fallopian tubes, also called uterine tubes, oviducts or salpinges, each 
measure about 10 cm and extend laterally from the uterus, lying between the folds of 
the broad ligament (Jenkins et al. 2008) (Fig. 1.1). They receive the female gamete 
when it leaves the ovary, provide a route for sperm to reach it and transport fertilized 
ova from the ovaries to the uterus (Marieb & Hoehn 2015). To achieve this goal, one 
end of each fallopian tube is attached to the uterus and the other is close but not 
directly attached to the ovary, and therefore empties into the pelvic cavity (Oats & 
Abraham 2016). On the latter, the uterine tubes end in a fringe of long, finger like 
projections lined with ciliated epithelium called fimbria (Jenkins et al. 2008). The 
mucosal lining of the salpinges consists of fallopian tube epithelium (FTE) cells and 
connective tissue (Martini et al. 2012). 
 
The paired ovaries are small, lumpy, almond-shaped organs/glands that flank the 
uterus and are confined in the upper pelvic cavity (Widmaier et al. 2015) (Fig. 1.1). 
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A typical ovary is about 5cm long, 2.5 cm wide and 8 cm thick, weighs 6-8 g, 
displays either pink or yellowish colouration and has a nodular consistency (Martini 
et al. 2012). One on each side of the uterus, ovaries are held into position in the 
peritoneal cavity by a series of ligaments (Jenkins et al. 2008). The ovarian ligament 
extends from the uterus, near the attachment of the fallopian tube, to the medial 
surface of the ovaries (Marieb & Hoehn 2015). The suspensory ligament anchors the 
ovaries laterally to the pelvic wall and contains the major blood vessels of the 
ovaries: the ovarian artery and the ovarian vein (Martini et al. 2012). Lastly, the 
mesovarium, a thickened double-layered fold of mesentery that forms part of the 
broad ligament of the uterus, supports and stabilizes the position of the ovaries 
(Jenkins et al. 2008) (Fig. 1.1). 
 
A simple layer of epithelial cells called ovarian surface epithelium (OSE) covers 
each ovary externally (Auersperg et al. 2001). Immediately below the OSE, a layer 
of dense, fibrous, irregular connective tissue called tunica albuginea surrounds the 
interior tissues (stroma) of the ovary, which are divided into a superficial cortex and 
a deeper medulla (Martini et al. 2012). The ovarian cortex contains dense irregular 
connective tissue surrounding sac-like structures called ovarian follicles, which 
harbour the future gametes (Cambridge University Press 1995). Conversely, the 
medulla comprises more loosely arranged connective tissue and contains the largest 
blood vessels, lymphatic vessels and nerves (Oats & Abraham 2016). 
 
1.1.2 Female hormonal system 
To ensure the optimal regulation of the menstrual cycle, the female reproductive 
system is under hormonal control, which involves interplay between different 
endocrine glands: hypothalamus, anterior pituitary and the ovaries (Finlayson 2007). 
Various hormones are secreted at drastically disparate rates during different parts of 
the female monthly sexual cycle or period (Hall 2016) (Fig. 1.2). 
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Figure 1. 2 Diagram of the female menstrual cycle 
Diagrammatic representation of the menstrual cycle phases (ovarian and uterine), 
alongside with changes that occur in the anterior pituitary and ovarian hormones. 
The duration of the menstrual cycle is represented at the bottom of the panel. Source: 
Adapted from an online source (SportsMD 2015). 
 
 
The gonadotropin-releasing hormone (GnRH) is secreted by the hypothalamus and 
stimulates the synthesis and secretion of follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) at the anterior pituitary gland (Piñon Jr 2002). Its secretion 
is very low during childhood due to the negative feedback exerted by circulating 
steroid hormones (Jones & Lopez 2013). However, beginning with puberty and 
during a woman’s reproductive years, pulses of gonadotropin-releasing hormone are 
critical for the successful maturation of ova and completion of menstrual cycles 
(Finlayson 2007). Finally, the anterior pituitary sex hormones, follicle-stimulating 
hormone and luteinizing hormone, target the ovaries and stimulate the secretion of 
estrogens and progesterone (Johnson & Everitt 2000). 
 
An extremely complex interplay between these hormones regulates the female 
period, inducing cyclical changes in the ovaries, the fallopian tubes and the uterus 
(Donnez et al. 1985; Hall 2016) (Fig. 1.2). When the menstrual cycle ceases (age 45-
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55), the concomitant hormonal production concludes too, resulting in important 
hormonal imbalances (Marieb & Hoehn 2015). In an effort to palliate physical 
discomfort and to prevent skeletal and cardiovascular complications associated with 
the fall in hormone levels, physicians often prescribe hormonal replacement 
therapies (Jane et al. 2012). 
 
1.1.3 Formation of female gametes: Oogenesis 
During early embryonic development, primordial diploid germ cells migrate to the 
outer surface of the ovary and become oogonia or primordial ova (Witschi 1948). 
These undifferentiated primordial germ cells proliferate rapidly via mitosis and 
collect around them layers of epithelial cells to form structures called primordial 
follicles (Cambridge University Press 1995). Nonetheless, most primordial follicles 
degenerate in a process known as follicular atresia and only a few develop into 
primary follicles, containing primary oocytes/germ cells (Johnson & Everitt 2000). 
 
Approximately 1-2 million primary follicles, each containing one primary oocyte (a 
female’s presumed lifetime supply) are distributed in the cortex of immature ovaries 
at birth (Zuckerman 1951). However, certain studies claim to have demonstrated the 
existence of proliferative ovarian germline stem cells in the ovaries of adult mice 
(Johnson et al. 2004; Zou et al. 2009), and  more recently, that ovarian germline stem 
cells were isolated and characterized in the ovaries of postnatal mice and 
reproductive-age women (White et al. 2012). Nowadays, the field of reproductive 
biology is still divided between the supporters of this new neo-oogenesis theory 
(Pacchiarotti et al. 2010) and its opponents (Zhang et al. 2012). 
 
Over time, beginning in late foetal development and until the supply of primordial 
follicles is depleted (menopause), quiescent primordial follicles are recruited into a 
growing pool of primary follicles (Cambridge University Press 1995). All recruited 
primordial follicles undergo follicular atresia until hormone activation, starting in 
puberty, rescues a small portion from that fate. By then, an endowment of perhaps 
200,000-400,000 primary oocytes remain in the ovaries (Hall 2016). From this 
moment on, primordial follicles are continuously activated and enter a growth 
pattern (folliculogenesis) that will finally lead to ovulation (Johnson & Everitt 2000). 
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Figure 1. 3 Schematic representation of follicle development in the ovary 
Throughout a women’s life until menopause, quiescent primordial follicles undergo 
folliculogenesis, whose aim is to develop the structure containing the female 
gametes until they are released from the ovary. Source: ‘Female and male 
gametogenesis’ (Desai et al. 2013). 
 
 
Throughout the process of folliculogenesis, illustrated in Figure 1.3, primordial 
follicles evolve progressively over different stages: primary/pre-antral, 
secondary/antral and mature/graafian follicles. Alongside follicle development, 
primary oocytes evolve into secondary oocytes (Hall 2016). 
 
Even though 10-25 pre-antral follicles are recruited at the beginning of each 
menstrual cycle, only one –the dominant follicle– fully matures (Armstrong & Webb 
1997). By the 14th day of the menstrual cycle, the dominant follicle creates a 
prominent bulge in the surface of the ovary and eventually releases the secondary 
oocyte into the pelvic cavity (Murdoch et al. 2010). After the mature follicle 
discharges the secondary oocyte, it collapses and transforms into the corpus luteum, 
an endocrine structure that manufactures different hormones (Marieb & Hoehn 
2015). Around the time of ovulation, the beating cilia on the fimbria create currents 
in the peritoneal fluid that sweep the ovum into the fallopian tube as it emerges onto 
the ovarian surface (Widmaier et al. 2015). 
 
If a spermatozoon fertilizes the secondary oocyte on its way to the uterus, a zygote is 
formed. Conversely, if there is no fertilization, both the secondary oocyte and the 
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corpus luteum degenerate leading to menstruation and the beginning of a new 
ovarian cycle (Hall 2016). Approximately 400-500 primordial follicles develop 
enough to expel their ova throughout the reproductive life of a healthy woman 
(Widmaier et al. 2015). This incessant rupture-repair leads to scarred and pitted 
ovarian surfaces, with irregular contours and invaginations (Auersperg et al. 2001; 
Martini et al. 2012). 
 
Even though usually only one ovum is expelled every menstrual cycle, there are 
always many follicles at different stages of growth in an adult’s female ovary 
(Marieb & Hoehn 2015) (Fig. 1.3). Continuous ovarian proliferative activity, 
together with constant rupture-repair associated with ovulation and the stringent 
hormone control pose a significant risk of malfunctioning. This will impact on a 
woman’s ability to reproduce successfully but can also increase the risk of other 
health problems such as polycystic ovary syndrome and ovarian cancer (OC) 
(Hennessy et al. 2009; Sirmans & Pate 2013). 
 
 
1.2. Onset of Cancer and Tumour Progression 
The cells that are part of the female reproductive system, as any other in the human 
body, might experience environmental or internal alterations that disturb cell 
homeostasis (e.g. genetic mutations), eliciting abnormal attributes such as sustained 
proliferation, which may alter adjacent tissue structures (Cooper 2000; Weiderpass 
& Labrèche 2012). For instance, ovarian surface cells, which are in constant hustle 
due to hormonal and/or cytokine cues and membrane remodelling have a high risk of 
suffering homeostatic disturbances (Mendelsohn et al. 2015). 
 
Between a fully normal, well-differentiated tissue and an abnormal un-differentiated 
tissue (lost all tissue-specific traits) lies a broad spectrum of intermediate appearance 
growths, which are collectively denominated neoplasms or tumours (Mendelsohn et 
al. 2015). Tumours that grow locally without invading adjacent tissues are classified 
as benign; they represent the great majority of primary tumours arising in humans 
and are generally harmless to their host (Knowles & Selby 2005). On the contrary, 
tumours that invade underlying tissue, spread throughout the body and establish new 
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colonies or metastasise, are classified as malignant (Weinberg 2014). Although 
clinical oncologists and surgeons often reserve the word ‘cancer’ for these metastatic 
tumours, in contemporary cancer research it is commonly used to include all types of 
abnormal growths. 
 
1.2.1 Carcinogenesis 
The risk of uncontrolled cell proliferation, and the formation of tumours as a 
consequence, is substantial throughout the lives of humans (Weinberg 2014). In 
addition to innate malfunctioning, ‘age’ is the biggest risk factor for developing 
cancer, external agents (carcinogens) can cause or contribute to carcinogenesis, the 
initiation of a tumour (Knowles & Selby 2005). Carcinogens act at the molecular 
level, damaging the structure of deoxyribonucleic acid (DNA) strands and generating 
errors that can lead to mutations during DNA synthesis (Weston & Harris 2003). 
Interestingly, a dividing cell is more susceptible to carcinogens and thus mutations 
are more frequent in tissues with increased cellular activity (Baba & Catoi 2007). 
Exposure to chemical carcinogens such as ultraviolet radiation (UV) or certain 
elements contained within tobacco, alcohol or food are the main recognised 
aetiology for cancer in the western world (Thun et al. 2002; Boffetta et al. 2006; 
Loeb & Harris 2008; Khandekar et al. 2011). 
 
Tumour viruses like the human papillomavirus also possess the ability to induce 
carcinogenesis, forcing infected cells to thrive and proliferate uncontrollably rather 
than kill them (Moore & Chang 2010). For instance, human papilloma virus 
infection is linked with several cancers affecting the female genitalia (e.g. vagina, 
cervix), as well as others like head and neck cancer (Bansal et al. 2016). Other 
factors that either contribute directly to or pose an important risk of carcinogenesis 
include hereditary syndromes, chronic inflammation and hormonal cues (Shacter & 
Weitzman 2002; Banerjee 2011; Kulkarni & Carley 2016). 
 
Hereditary cancer syndromes entail the inheritance of genetic mutations in one or 
more genes, determine the tendency of an individual to develop certain cancers and 
may also cause the early onset of these cancers. The most common hereditary cancer 
syndromes are the ‘hereditary breast and ovarian cancer syndrome’ (HBOC) and the 
Introduction	
	 10	
‘hereditary non-polyposis colorectal cancer’ (HNPCC, also known as ‘Lynch 
syndrome’) (Kulkarni & Carley 2016). A localized chronic inflammation involves 
the accumulation of large numbers of inflammatory mediators, which contribute to 
carcinogenesis by inducing pro-tumorigenic internal (DNA mutations) and 
environmental alterations in the surrounding cells (Shacter & Weitzman 2002). 
Similarly, carcinogenic events might be potentiated or promoted by unbalanced 
hormones (Banerjee 2011). 
 
1.2.2 Tumour progression  
The formation of a tumour is an intricate multi-step process that usually takes 
decades. Once the affected cell has acquired a functionally advantageous genetic or 
epigenetic modification, it will proliferate more effectively than its neighbours and 
generate large clonal populations (Nowell 1976; Baxter et al. 2014). As years go by, 
tumour cells acquire more advantageous alterations and evolve progressively into 
un-differentiated malignant states (Mendelsohn et al. 2015). By the time of 
detection, tumours are described and classified upon grade and stage, depending on 
how far they have progressed in the tumorigenesis process. Tumour grading (I-IV) 
describes the abnormality of tumour cells and tissues observed under a microscope, 
where the highest ‘abnormality’ or un-differentiated state (IV) represents the highest 
malignancy and aggressiveness (Weinberg 2014). On the other hand, tumour staging 
(I-IV) determines the extent to which a tumour has developed by local growth (I) or 
invasive spreading (IV) (Greene & Sobin 2008). 
 
During the course of tumour progression or tumorigenesis, key changes occur in 
cancer cells, granting them the ability to survive and proliferate uncontrollably 
(Clark 1991) (Fig. 1.4). There are two broad classes of genes that play a key role in 
carcinogenesis and tumour progression: proto-oncogenes and tumour suppressor 
genes (Weinberg 2014). 
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Figure 1. 4 Diagram summarizing cell carcinogenesis and tumour progression 
DNA repair mechanisms maintain the integrity of DNA, which may acquire 
mutations during normal replication or prompted by the action of carcinogens. If 
mutations are accurately repaired, the mutant cell develops into a normal cell once 
again, but if they are not repaired, the mutant cell survives. The apoptotic machinery 
is responsible for detecting un-repaired mutant cells and provoke cell death if the 
mutations are un-reparable. However, if the suicide programme fails or the mutant 
cells are protected against it, more mutations occur, which could lead to uncontrolled 
cell proliferation. Depending on the tendency of the mutant cells to spread, tumours 
are classified into benign or malignant. Source: Encyclopaedia Britannica, Inc 
(2014). 
 
 
Proto-oncogenes are critical growth-controlling cellular genes and, as such, are 
tightly regulated under normal physiological circumstances (Todd & Wong 1999). 
As a result of epigenetic disturbances and genetic alterations such as mutations, gene 
amplifications and chromosome rearrangements, proto-oncogenes no longer respond 
to restrictive cellular signals (e.g. apoptosis signals), becoming active oncogenes and 
contributing to cancer progression (Pierotti et al. 2003) (Fig. 1.5). Regardless of the 
activating mechanism, an oncogene always behaves as a dominant allele in its ability 
to confer malignant properties on cells (Vogelstein & Kinzler 2004). 
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Figure 1. 5 Genetic mechanisms leading to oncogene activation 
Increased expression of normal growth-stimulating proteins result from various 
genetic mechanisms including: (1) chromosomal translocations, that situate the 
target gene under the regulation of a different promoter, (2) gene amplification and 
point mutations (insertion, deletion) within (3) the promoter element or (4) the gene 
body of a target proto-oncogene. Source: ‘Biochemistry for Medics©’ (Chhabra 
2013). 
 
 
The most frequently mutated oncogenes detected in human cancer are members of 
the RAS signalling family (h-RAS, k-RAS and n-RAS), involved in proliferation, 
differentiation, survival and other essential cellular mechanisms (Karnoub & 
Weinberg 2008). These genes are commonly targeted by single nucleotide/point 
mutations at conserved sites, eliciting the constitutive activation of Ras proteins 
(Prior et al. 2012). 
 
Tumour suppressor genes (TSGs) encode proteins that are functionally integrated 
into pathways that prevent unscheduled cell proliferation, stimulate cell death or 
trigger the induction of cell cycle arrest (Sherr 2004). Accordingly, TSGs act as 
negative regulators of cancer progression and hence mutations in these genes lead to 
pro-oncogenic effects (Berger et al. 2011) (Fig. 1.6). Equivalent to proto-oncogenes, 
TSGs are commonly inactivated via genetic and epigenetic alterations (Vogelstein & 
Kinzler 2004). 
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Figure 1. 6 Effect of genetic modifications on tumour suppressor genes 
Tumour-suppressor genes are under strict control and code key regulatory proteins. 
The mutation of a tumour suppressor gene could lead to uncontrolled cell growth, 
contributing to cancer progression. Source: ‘Principles of Cancer Biology’ 
(Kleinsmith 2006). 
 
 
Cancer-preventive effects of most TSGs normally require the presence of a single 
functional allele, a genetic property denominated haplo-sufficiency, which means 
that in order to achieve a successful malignant transformation both gene alleles must 
be inactivated (Mendelsohn et al. 2015). Usually, the first allele is inactivated via 
genetic mutation and the second gene copy (and its chromosomal surroundings) is 
lost through mechanisms that depend on loss of heterozygosity, including mitotic 
recombination, inappropriate chromosomal segregation or gene conversion (Lodish 
et al. 2000). This process is commonly observed when genetic mutations affect 
TSGs in germline cells, which are therefore inherited and responsible for hereditary 
cancer syndromes (Kulkarni & Carley 2016). In these cases, the hereditary pattern is 
dominant, since the inactivation of the remaining allele via loss of heterozygosity 
suffices to promote tumorigenesis (Weinberg 2014). 
 
On the other hand, certain TSGs like the ‘tumour protein tp53’ (TP53) only need one 
inactivated allele to induce tumour progression, a genetic property denominated 
haplo-insufficiency (Goh et al. 2011). The TP53 TSG encodes a multifunctional 
transcription factor which can impose cell cycle arrest, cellular quiescence or induce 
apoptosis when is activated in response to a variety of conditions including DNA 
damage, oxidative stress, osmotic shock and others (Kastan et al. 1991; Lu & Lane 
1993; Graeber et al. 1994; Kishi et al. 2001; Vousden & Lu 2002). Accordingly, 
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TP53 haplo-insufficiency and the loss of activity that it entails confer a relative 
advantage to cells, since the complete loss of function would lead to apoptosis or 
senescence (Berger et al. 2011). For instance, while wild-type (wt) p53 proteins bind 
DNA as tetramers, mutant p53 cannot bind DNA but still forms hetero-oligomers 
with wt-p53. Consequently, these complexes show impaired DNA association and 
transcriptional activity, resulting in loss of p53 function (Goh et al. 2011). 
 
Some TSGs, often called stability genes, encode proteins that are involved in DNA 
damage response and repair mechanisms, whose function is to keep genetic 
alterations to a minimum (Friedberg 2003). Deficiencies in DNA repair through 
inactivation of stability genes lead to higher rates of mutations, genomic instability, 
altered karyotype and thus tumour progression. Accordingly, stability genes are 
commonly inactivated in cancers (Jeggo et al. 2015). Most are haplo-sufficient 
(Weinberg 2014) and some are responsible for hereditary cancer syndromes (e.g. 
‘mutS homolog 2’ or MSH2) (Müller & Fishel 2002). 
 
 
Table 1. 1 List of eukaryotic DNA damage repair pathways 
 
DNA damage DNA repair pathway 
Single strand damage 
Base-excision repair 
Nucleotide-excision repair 
Mismatch repair 
Double-strand break Homologous recombination repair Non-homologous end joining 
 
 
There are 450 known genes implicated in DNA damage response and repair (Pearl et 
al. 2015), divided into distinct pathways responsible for specific types of DNA 
damage (Ciccia & Elledge 2010) (Table 1.1). Double-strand breaks (DSBs), the 
most lethal of DNA insults, are repaired using either the error-proof homologous 
recombination repair (HRR) or the error-prone non-homologous end joining (NHEJ) 
(Lieber 2010; Jasin & Rothstein 2013). Even though it has some limitations, the 
preferred pathway to repair DSBs is HRR, which involves breast cancer 
susceptibility genes 1 and 2 (BRCA1/2) and other nuclear enzymes such as poly-
ADP ribose polymerases (PARP) (O’Driscoll & Jeggo 2006). 
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BRCA1/2 are the most extensively studied DNA repair genes and deficiencies within 
either of them result in defective HRR and subsequent loss of efficient and effective 
DNA DSB repair (Gudmundsdottir & Ashworth 2006). Specifically, BRCA1 
interacts with other protein complexes stimulating HRR and repressing NHEJ for the 
initial processing of DSB ends (Chapman et al. 2012). In turn, BRCA2 acts as a 
scaffold for additional DSB-related factors on single strand DNA (Fradet-Turcotte et 
al. 2016). 
 
1.2.3 Hallmarks of cancer 
Over time, the activation of oncogenes and silencing of TSG/stability genes give 
tumour cells the ability to acquire certain molecular characteristics, the ‘Hallmarks 
of Cancer’, which are probably all necessary to a greater or lesser extent for tumour 
progression (Hanahan & Weinberg 2000; Hanahan et al. 2011) (Fig. 1.7 & Table 
1.2). 
 
 
Figure 1. 7 ‘Hallmarks of cancer’ 
The illustration encompasses the six hallmark capabilities originally proposed in 
‘Hallmarks of cancer’ plus two emerging hallmarks related to the avoidance of the 
immune system and cancer energetics, as well as two enabling characteristics of 
cancer: genome instability and tumour-promoting inflammation. Source: ‘Hallmarks 
of Cancer: The Next Generation’ (Hanahan et al. 2011). 
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Table 1. 2 Summary table of the ‘Hallmarks of cancer’ 
 
Hallmarks of Cancer 
Sustained 
proliferative 
signalling 
• The interaction of a growth factor with its specific receptor 
activates cellular signalling transduction cascades, ultimately 
responsible for cell proliferation and survival. Oncogenic 
alterations grant conditions to achieve growth self-
sufficiency. (Bower & Waxman 2015). 
• Recurrent targets: components of cellular signalling cascades, 
e.g. tyrosine kinase receptors (Yarden & Pines 2012). 
Evading growth 
suppressors 
• The cell cycle is a precisely programmed series of events that 
enables a cell to duplicate its contents and divide. Oncogenic 
alterations grant independency from anti-proliferative signals 
and cell cycle checkpoints (Barbacid et al. 2005). 
• Recurrent targets: cell cycle regulators, e.g. cyclins or cyclin-
dependent kinases (CDK) (Inoue & Fry 2015). 
Resisting cell 
death 
• Apoptosis is a pre-programmed process of cell death, 
characterized by a cascade of events that trigger the action of 
caspase proteases. Oncogenic alterations inactivate the 
apoptotic machinery in order to survive and thrive, e.g. TP53 
mutations (Pop & Salvesen 2009). 
Enabling 
replicative 
immortality 
• Telomeres are chromatin structures located at the ends of 
chromosomes that are not copied completely in each cycle of 
DNA replication, shortening progressively, leading to 
genomic instability and natural cell death. Oncogenic 
alterations activate telomerase activity, thus enabling cell 
death evasion (Aubert & Lansdorp 2008). 
Angiogenesis 
• Tumour masses recruit new blood vessels to access blood 
circulation in order to grow and metastasize. Oncogenic 
alterations modify the balance between pro- and anti-
angiogenic molecules in the tumour microenvironment, e.g. 
increased presence of vascular endothelial growth factor A 
(VEGFA) (pro-angiogenic) (Baeriswyl & Christofori 2009). 
Invasion and 
metastasis 
• Epithelial cancer cells, precursors to over 90% of human 
cancers, undergo a drastic morphology conversion 
denominated epithelial-mesenchymal transition (EMT) and 
acquire invasive properties (Yeung & Yang 2017). 
• This process may be followed by dissemination, invasion and 
colonization of new organs or metastasis (Obenauf & 
Massagué 2015). 
Avoid destruction 
by the host 
immune system  
• Cancer cells try to avoid destruction by the immune system 
and promote the generation of an immunosuppressive tumour 
microenvironment (Mittal et al. 2014). 
Deregulate 
metabolism 
• Cancer cells need to acquire the means to support abnormal 
cancer growth by means of triggering severe metabolic re-
programming (Courtnay et al. 2015). 
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1.2.4 Tumour heterogeneity and microenvironment 
Human cancers display substantial intra-tumour heterogeneity in most phenotypic 
features, such as cellular morphology, gene expression, metabolism and also 
angiogenic, proliferative, immunogenic and metastatic potential (Fidler & Hart 1982; 
Nicolson 1984; Heppner 1984). This heterogeneity is often attributed to intra-tumour 
clonal diversity, the outcome of a succession of clonal expansions where the rate of 
genetic change is so extreme that, at some point, genetically divergent clones co-
exist within a mass (Maley et al. 2004; Merlo et al. 2006; Marusyk & Polyak 2010). 
The discovery of cancer stem cells with the ability to self-renew and differentiate 
into bulk tumour non-stem cells (Dick 2008; O’Brien et al. 2010) led to the 
assumption that, in cancers that follow a stem cell model, cancer stem cells are the 
target of mutations and clonal selection (Shackleton et al. 2009). 
 
The last but no less important contribution to tumour intra-heterogeneity comes from 
the influence of the tumour microenvironment, the cellular environment surrounding 
the tumour with which it shares a constant and close interaction (Park et al. 2000). 
The tumour microenvironment is formed by differing concentrations of cells of 
haematopoietic origin (e.g. macrophages), cells of mesenchymal origin (e.g. 
fibroblasts) and non-cellular components (extracellular matrix) (Pattabiraman & 
Weinberg 2014). As a consequence, cancerous cells within a tumour experience a 
range of different micro-environmental signals, which translate into a range of 
phenotypic manifestations (Polyak et al. 2009). 
 
 
1.3 Cancer in the Ovaries: Ovarian Cancer 
The five areas of the female reproductive system that harbour major gynaecological 
cancer malignancies are: uterine cervix, uterine corpus (endometrium), ovaries, 
vulva and vagina (Siegel et al. 2016). Malignant tumours located at the ovaries can 
arise from any cell type contained within this structure, including germ, stromal and 
epithelial cells (National Academy of Medicine 2016). As a consequence, OC is a 
highly heterogeneous malignancy that encloses a myriad of distinct diseases which 
happen to share an anatomical location (Karnezis et al. 2016). 
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Ovarian cancers are broadly divided into two major types: epithelial ovarian cancers 
(EOCs) and non-epithelial ovarian cancers (NEOCs), which account for 
approximately 90% and 10% of all malignant OCs respectively (Matulonis et al. 
2016). Whereas NEOCs originate from germ and stromal cells within the ovaries, 
EOCs or ovarian carcinomas were traditionally thought to develop from the single 
layer of epithelium that covers the ovaries (Bell 2005). However, recent studies 
suggest that these malignancies actually develop from multiple sites, mostly outside 
the ovaries (Kurman & Shih 2010; Nezhat et al. 2015; Temkin et al. 2016). 
 
1.3.1 Origins of ovarian carcinomas 
The initial lesion that gives rise to ovarian carcinomas has thus far not been 
identified, and several theories regarding its origin have been put under the spotlight 
over the years (Cardenas et al. 2016). There are two unique ovarian functional 
characteristics that undoubtedly partake and/or boost the establishment of 
carcinomas: the cyclical ovulation process and the ovarian microenvironment 
(Fathalla 1971; Karnezis et al. 2016). 
 
Every menstrual cycle one ovary releases a single ovum that breaks through the 
OSE, which consequently has to be fully restored (Murdoch et al. 2010). This 
rupture generates a local pro-inflammatory microenvironment that may lead to DNA 
damage, replication errors and eventually the malignant transformation of cells 
(Murdoch et al. 2001; Richards et al. 2002; Murdoch 2005). Cyclical reparations of 
OSE and the continuous pro-inflammatory setting also lead to invaginations and the 
formation of cortical inclusion cysts (CICs) (Auersperg et al. 2001; Mehra et al. 
2011) (Fig. 1.8). As a consequence, either via invagination of normal or early-
malignant OSE CICs, local factors (e.g. hormones) are thought to influence ectopic 
cells to undergo tumorigenesis (Risch 1998; Zheng et al. 2000; Hennessy & Mills 
2006). 
 
Apart from OSE, ectopic fallopian tubal epithelium (FTE) can implant on the site of 
rupture when ovulation occurs –endosalpingosis–, resulting in the formation of a 
tubal CIC that may undergo malignant transformation (Prentice et al. 2012) (Fig. 
1.8). Furthermore, the pro-inflammatory microenvironment that recruits FTEs is also 
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able to recruit serous tubal intra-epithelial carcinomas (STICs) from the distal 
fimbriated end of the fallopian tube (Lee et al. 2007; Kindelberger et al. 2007) (Fig. 
1.8). These STICs fulfil anatomical, phenotypic and biological criteria as precursors 
of the most common sub-type of EOC, termed high-grade serous carcinoma (Karst, 
Levanon & Drapkin 2011; Perets et al. 2013). 
 
 
Figure 1. 8 Diagram representing the alleged origins of OC 
Ovarian cancer allegedly originates in the three distinct types of cells that are part of 
the ovary: sex cord-stromal, germ and epithelial cells. Other possible sources of OC 
initiation include retrograde menstruation and endosalpingosis of fallopian tube 
epithelium or serous tubal intra-epithelial carcinomas (STICs). Source: Adapted 
from (Gershenson 2016). 
 
 
A wide variety of cancers (e.g. breast, lung, gastrointestinal tract) often present 
dominant ovarian masses, highlighting the idea that the ovary accommodates a 
favourable environment for ectopic cell growths (Yang-Hartwich et al. 2014). In line 
with this, the settlement of endometrial cells (endometriosis) via retrograde 
menstruation is linked with the establishment of other EOC sub-types, endometrioid 
carcinomas and clear-cell carcinomas (Prowse et al. 2006; Worley et al. 2013) (Fig. 
1.8). Additionally, several studies have suggested the involvement of OSE and 
fimbrial stem cells that normally participate in post-ovulatory wound closure in the 
transformations that lead to OC (Szotek et al. 2008; Bowen et al. 2009; Paik et al. 
2012; Ng & Barker 2015). 
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1.3.2 Disease progression 
Regardless of the origin of the first cell that gave rise to OC, a tumour mass is 
formed either inside or adnexal to the ovary (Bower & Waxman 2015). If the tumour 
is localized within the organ, the disease progression is slower, as it will need to 
grow extensively and achieve sufficient size to cause the rupture of the ovary in 
order to progress. Conversely, tumours that arise from the surface of the ovary can 
spread quickly before a palpable mass is formed (Mendelsohn et al. 2015). 
OC metastasises either by direct extension from the ovarian tumour to neighbouring 
organs (e.g. fallopian tube, intestine, bladder, colon) or more typically when cancer 
cells detach from the primary tumour (Lengyel 2010) (Fig. 1.9). Cell detachment and 
subsequent spread is thought to occur either via transcoelomic passive dissemination 
or haematogenous metastasis (Yeung et al. 2015). 
 
 
 
Figure 1. 9 Schematic depiction of the most 
frequent OC metastasis sites 
Illustrative representation of the female internal 
organs localized in the upper/lower abdomen, 
which constitute the most common sites of OC 
metastasis. In this case, the image represents a 
case of cancer originally located in the right ovary 
with metastases in the abdominal cavity (1), on 
the intestines (2), against the diaphragm (3) and 
on the omentum (4). Red dots represent metastatic 
tumour cell implantations, with the highest 
density located on the omentum. This image was 
obtained from Mulier (2009) (Mulier 2009). 
 
 
 
The transcoelomic passive dissemination mechanism is the most common route of 
OC metastasis and involves the circulation of excess peritoneal fluid (ascites fluid) 
through the body cavities (Tan et al. 2006). The aetiology of this excess fluid is not 
well understood, but preclinical and clinical observations have demonstrated that the 
vascular permeability-enhancing factor VEGF is responsible for ascites 
accumulation (Xu et al. 2000). Currents of ascites fluids are thought to detach OC 
cells, carry them in the form of multicellular spheroids, and spread them throughout 
the peritoneal cavity, resulting in tumour nodules in the diaphragm, bowel, 
Introduction	
	 21	
parenchyma of liver or lung and most notably the omentum, OC primary metastasis 
site (Fig. 1.9) (Sehouli et al. 2009; Herold & Cannistra 2013). 
 
Implantation in peritoneal organs involves interaction between the cancer cells and 
the mesothelium, which covers all organs within the peritoneal cavity (Kenny et al. 
2014; Davidowitz et al. 2014). After implantation, the resultant inflammation 
stimulate mesothelial cells and their associated immune and stromal cells to release 
cytokines such as interleukin (IL)-1, -6 and -8, which subsequently enhance tumour 
angiogenesis and further ascites formation via increased secretion of VEGF by 
cancer cells, creating a favourable OC microenvironment (Freedman et al. 2004; 
Stadlmann et al. 2005; Thibault et al. 2014). The predilection for the omentum, a fat 
pad primarily composed of adipocytes, both for primary and recurrent OC, might be 
explained by the alleged contribution of those cancer-associated adipocytes to cancer 
progression (Fig. 1.9) (Dirat et al. 2010). For instance, studies have demonstrated 
that cancer-associated adipocytes promote cancer cell growth and invasion via 
cytokine secretion (e.g. interleukins) as well as serving as an energy source (Nieman 
et al. 2011; Clark et al. 2013). 
 
Ovarian cancer cells can also follow a traditional pattern of haematogenous 
metastasis via cell epithelial-mesenchymal transition (EMT), the detachment from 
the ovarian mass and intravasation to the blood circulatory system. Nevertheless, 
ovarian circulating tumour cells preferentially implant in the omentum and 
subsequently spread to other peritoneal surfaces (Pradeep et al. 2014). 
 
1.3.3 Epidemiology and clinical presentation 
Ovarian cancer is relatively uncommon, accounting for only 2.6% of new women 
cancer cases in the United States of America (USA) (Siegel et al. 2016) and 2% in 
the United Kingdom (UK) (Cancer Statistics UK 2014). Nevertheless, it is the fifth 
leading cause of cancer death among American and British women, accounting for 
5% of all women cancer deaths in each country. Specifically, 14,240 and 4,128 
women died from OC in the USA and the UK respectively, according to the latest 
estimates made public (Siegel et al. 2016; Cancer Statistics UK 2014). Indeed, 
although the estimated number of new OC cases each year among British and 
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American women is only one-tenth the number of new cases of breast cancer, the 
death-incidence ratio for OC is more than three times higher than that for breast 
cancer (Fig. 1.10). 
 
 
Figure 1. 10 Comparison of 
death-to-incidence rates for 
common female cancers 
Ratio between the death and 
incidence rates for cancer of the 
ovary, breast, endometrium and 
cervix per 100,000 women in the 
United States, 2008-2012. Source: 
‘Evolving paradigms…’ (National 
Academy of Medicine 2016). 
 
 
 
Most women with OC are diagnosed in later life, with a median age of diagnosis of 
63 years in the UK (Cancer Statistics UK 2014) and the lifetime risk for a woman to 
develop ovarian cancer is approximately 1 in 70 (Mendelsohn et al. 2015). However, 
roughly two-thirds of women diagnosed with OC present with an aggressive, late-
stage metastatic disease state (Herold & Cannistra 2013), thus largely explaining the 
staggering digits of OC-related deaths (Fig. 1.10). This late diagnosis is mostly due 
to the neglecting of early symptoms, since studies have shown that 90% of women 
with early-stage disease and 100% of women with late-stage disease reported having 
at least one symptom (Goff et al. 2004; Lataifeh et al. 2005). Symptoms of OC at 
initial presentation include abdominal bloating, pelvic and/or abdominal pain, 
fatigue, difficulty eating and urinary-related symptoms; mostly caused by 
accumulated ascites fluid (Goff et al. 2000). Because they are general, vague and 
non-specific, both patients and physicians usually overlook these symptoms or 
attribute them to other diseases (Goff et al. 2004). Accordingly, diagnosis frequently 
occurs tardily, when symptoms become apparent and severe as a result of the cancer 
reaching a late, aggressive and metastatic stage (Goff et al. 2000). 
 
Overall survival rates of OC have increased little in the last 20 to 30 years (Vaughan 
et al. 2011) and this slight improvement is mostly related to better surgery and new 
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chemotherapy options (Bristow et al. 2002). The 5-year survival rate of OC is 
currently below 46% and as low as 35-40% when considering only high-grade 
serous carcinomas, the deadliest and most common sub-type of disease, accounting 
for the worst prognosis of all gynaecological cancers (Cancer Research UK 2010; 
Quaresma et al. 2015). In comparison, other malignancies like breast cancer (80-
90%), endometrial cancer (70-80%) or cervical cancer (60-70%) have much higher 
5-year survival rates (Siegel et al. 2016; Cancer Statistics UK 2014). 
 
1.3.4 Risk factors and preventive actions 
Several aspects can impact the risk of developing OC, including genetic factors, 
hormonal treatments and reproductive history. Nonetheless, age represents the key 
risk factor, since most women who develop OC are diagnosed after menopause, at 
age 55 or older (Purdie et al. 2003). 
 
• Genetic factors: Approximately 18% of all OC patients carry germline mutations 
in genes associated with increased OC risk (Norquist et al. 2016). The most 
significant risk factors are germline BRCA1/2 mutations, found in 10-15% of all 
OC patients (Alsop et al. 2012). Besides BRCA1/2, other germline mutations in 
genes involved in DNA repair such as the ‘MutL homolog 1’ (MLH1), MSH2 or 
the ‘PMS1 homolog 2’ (PMS2) can also increase the risk of developing OC 
(Walsh et al. 2011; Pennington & Swisher 2012).  
• Hormonal treatments: Hormone replacement therapy consists in the use of 
female hormones (estrogen, progesterone) to treat common symptoms of 
menopause and aging (Hildebrand et al. 2010). In recent years, it has been shown 
to slightly increase the risk of OC in post-menopausal women, presumably due to 
carcinogenic effects of excess hormones (Shi et al. 2015). In contrast, the early 
use of oral contraceptives (also containing estrogen and progesterone) is generally 
associated with reductions in the risk of developing OC (Havrilesky et al. 2013), 
probably due to the decline in lifetime ovulation events (Fathalla 2013). 
• Reproductive history: Parity (Tourgeman et al. 2002), tubal ligation, 
unilateral/bilateral salpingectomy (removal of the fallopian tube) and/or 
oophorectomy (removal of the ovary) reduce the risk of OC (Rice et al. 2014; 
Gaitskell et al. 2016). Risk-reducing salpingo-oophorectomy, complete removal 
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of the ovaries and the fallopian tubes, reduces the risk of malignancy by up to 
96% (Rebbeck et al. 2002; Olivier et al. 2004). Non-hormonal interruption of 
incessant ovulation could also be a potential approach to reduce the risk of OC 
(Tung et al. 2005; Fathalla 2016). 
 
1.3.5 Diagnostic evaluation and staging 
In patients with indicative symptoms, a diagnostic evaluation includes: 
 
• Study of the family history of breast and ovarian cancers. The risk of OC is 
greatly increased when a family history of breast or ovarian cancer is present due 
to the possibility of carrying an inherited germline mutation (e.g. BRCA1/2) 
(Bergfeldt et al. 2002; Edlich et al. 2005). 
• Physical examinations such as abdominal/pelvic and recto-vaginal explorations. 
For instance, a palpable ovary is not a normal finding and raises suspicion of 
malignancy (Herold & Cannistra 2013). 
• Imaging tests: trans-vaginal/abdominal ultrasonography (Varras 2004), Doppler 
ultrasound (Shah et al. 2013), computed tomography (Santoso et al. 2014), 
positron emission tomography (Yoshida et al. 2009) and/or magnetic resonance 
imaging (Sohaib & Reznek 2007). 
• Blood tests: complete blood count, chemistry profiling and kidney/liver function 
tests are performed in order to determine a woman’s general health status. 
Specific tests for serum biomarkers such as inhibin A/B (Walentowicz et al. 
2014), beta-human chorionic gonadotropin (β-hCG) (Lenhard et al. 2012), and 
mostly cancer antigen 125/mucin 16 (CA-125/MUC16) can indicate the presence 
or absence of OC (Rustin et al. 2001), since they are commonly overrepresented, 
to a greater or lesser extent, in the bloodstream of OC patients (Sölétormos et al. 
2016). CA-125 is the most important biomarker for OC, and it is useful to assess 
the response of OC patients to chemotherapy as well as the detection of relapse 
(Bast 2010). Nevertheless, CA-125 levels are elevated in only 50% early-stage 
patients and can also be high in other tumours and normal tissues (Jacobs et al. 
1999; Kobayashi et al. 2008). The lack of specificity and sensitivity of current 
early detection biomarkers makes a screening test for general population 
impossible, although it should be common practice amongst female at increased 
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genetic risk (e.g. carriers of BRCA1/2 germline mutations) (Yurkovetsky et al. 
2010; Vaughan et al. 2011). 
• Paracentesis: In patients with ascites fluid (fluid build-up inside the abdomen), 
samples of this fluid can be extracted to clarify its origin (Decruze et al. 2010). 
 
If the results from the diagnostic testing, specially trans-vaginal ultrasonography, 
suggest the presence of a complex tumorigenic mass, the next step is a laparotomy 
surgery (Sokalska et al. 2009). The surgical process allows to obtain biopsies from 
the tumour, pelvis and abdomen for histological examination by pathology (tissue 
grading/staging), as well as remove as much tumour mass as possible (Herold & 
Cannistra 2013). Surgical approaches vary if a woman is suspected to have benign, 
borderline or early-stage tumours (Weber et al. 2011; Falcetta et al. 2016). The 
staging system for OC is derived from the International Federation of Gynaecology 
and Obstetrics or FIGO classification (Table 1.3). 
 
 
Table 1. 3 Summary of the international staging system for ovarian carcinomas 
 
Stage I Limited to ovary or ovaries 
IA One ovary, surface involvement or rupture 
IB Both ovaries, surface involvement or rupture 
IC Malignant ascites 
Stage II Pelvic extension 
IIA Involvement of the uterus or the fallopian tubes 
IIB Involvement of the other pelvic organs (e.g. bladder, rectum) 
Stage III Involvement of the upper abdomen or lymph nodes 
IIIA Microscopic peritoneal disease outside pelvis 
IIIB Macroscopic peritoneal metastases ≤ 2 cm diameter 
IIIC Macroscopic peritoneal metastases > 2 cm diameter 
Stage IV Distant organ involvement 
IVA Pleural effusion with positive cytology 
IVB Metastases to extra-abdominal sites 
Herold & Cannistra (2013) 
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If the disease is localized to the ovaries (stage I), the prognosis of OC is excellent, 
with up to 90% 5-year survival rates using currently available surgery and 
chemotherapy. As the disease spreads to the pelvis (II), the peritoneal cavity (III), or 
outside the abdomen (IV), the prognosis becomes progressively worse, with a 5-year 
survival of less than 10% in the last group (Mendelsohn et al. 2015). 
 
1.3.6 Histological classification 
As well as staging, post-surgical histo-pathological analysis of the cancerous tissue 
allows tumour grading and the classification of OCs depending on histological 
differences (Rosen et al. 2009). EOCs or ovarian carcinomas, the most common type 
of diagnosed malignant OC (~90%), are responsible for most OC-related deaths 
(Seidman et al. 2004; Braicu et al. 2011) and, as OC in general, they are highly 
heterogeneous themselves (Meinhold-Heerlein & Hauptmann 2014). 
 
EOCs are usually classified into sub-types or histo-types according to how closely 
tumour cells resemble the epithelia lining different organs in the female 
genitourinary tract (Chen et al. 2003). Specifically mucinous, endometrioid/clear 
cell, transitional and serous carcinomas exhibit morphological features similar to 
epithelial cells in the endocervix/intestine, endometrium, urinary bladder and 
fallopian tube respectively. Each histo-type exhibits distinct expression profiles, 
molecular composition, clinical features, patterns of spread, response to 
chemotherapy and outcome (Marquez et al. 2005; Gilks & Prat 2009) (Table 1.4). 
Consequently, ovarian carcinoma histo-types are considered different diseases 
(Köbel et al. 2008; Vaughan et al. 2011; Prat 2012b). 
 
Primary mucinous carcinomas (MCs) account for ~3-4% of all ovarian carcinomas 
(Seidman et al. 2003). They are usually confined to the ovary, have low response 
rate to standard chemotherapy (detailed in the next section: 1.4 Ovarian Cancer 
Treatment), and a generally favourable prognosis (Seidman et al. 2003; Hess et al. 
2004) (Table 1.4). The response rate (RR) defines the percentage of patients whose 
cancer shrinks or disappears after treatment. 
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Table 1. 4 Clinical features of the five most common sub-types of EOC 
 
 Proportion (%) Localization1 Chemo-sensitivity2 Prognosis 
MC 3-4 Confined ovary Low Favourable 
EC 8-10 
Confined pelvis 
High Favourable 
CCC 8-10 Low Intermediate 
HGSC 70-78 Transcoelomic 
spread 
High Poor 
LGSC 3-5 Intermediate Intermediate 
1Usual localization or pattern of spread 
2Chemo-sensitivity: response rate to standard chemotherapy treatment 
MC: Primary mucinous carcinoma; EC: Endometrioid carcinoma; CCC: Clear-cell 
carcinoma; HGSC: High-grade serous carcinoma; LGSC: Low-grade serous 
carcinoma 
 
 
Endometrioid carcinomas (ECs) and clear-cell carcinomas (CCCs) represent 
approximately 10% of all ovarian carcinomas respectively (Gilks & Prat 2009). 
These two subtypes are characterized by a well-defined association with atypical 
endometriosis (Yoshikawa et al. 2000; Erzen et al. 2001) and pelvic localization 
without transcoelomic spread. However, while ECs have good RR to standard 
chemotherapy and a favourable prognosis (Gilks et al. 2008), CCCs do not respond 
well to chemotherapy and have poor survival rates (Sugiyama et al. 2000; Lee et al. 
2011) (Table 1.4). 
 
Serous carcinomas (SCs, also referred to as serous-papillary carcinomas) are divided 
into two distinct diseases: low-grade serous carcinomas (LGSCs) and high-grade 
serous carcinomas (HGSCs) (Malpica et al. 2004; Lengyel 2010) (Table 1.4). 
LGSCs account for 3-5% of all ovarian carcinomas (Bell 2014). They follow a 
pattern of transcoloemic spread, have bad RR to standard chemotherapy and 
intermediate to poor survival rates (Charlie Gourley et al. 2014; Gershenson et al. 
2015). HGSCs are the most common type of OC, representing approximately 70-
80% of all ovarian carcinomas (Seidman et al. 2004; Soslow 2008) (Table 1.4). 
HGSC patients typically present with advanced stage disease (~80%), and even 
though the majority show a great response to standard chemotherapy, almost every 
patient experience incurable recurrences (Baldwin et al. 2012; Bowtell et al. 2015; 
Dao et al. 2016). Due to the overwhelming prevalence of HGSCs, from now on 
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when referring to historical or large-scale epidemiologic studies of OC readers can 
reasonably assume that most of the tumours were HGSCs. 
 
Other infrequent carcinomas include transitional carcinomas (< 0.5%) (Cuatrecasas 
et al. 2009) and ovarian carcinosarcomas, often termed epithelial-stromal or mixed 
mesodermal tumours, which display mixed histology and thus can be grouped with 
either EOC or NEOC (Harris et al. 2003; Makris et al. 2015). 
 
NEOC are a group of uncommon, histologically and clinically distinct tumours, 
further subdivided into germ-cell tumours and sex cord-stromal cell tumours 
(Koulouris & Penson 2009; Boussios et al. 2016). Germ cell tumours originate from 
the embryonic germ cells (ova/oocytes) of the ovary, occur principally in children or 
young women aged 10-30 and represent approximately ~3% of all diagnosed 
malignant OC cases (Zalel et al. 1996; Tavassoli & Deville 2003). On the other 
hand, sex cord-stromal tumours arise from the maturing follicles and stroma of the 
ovaries, occur over a wide age range and represent approximately 7% of all 
malignant OC cases (Tavassoli & Deville 2003). This group also includes other rare 
ovarian malignancies such as small cell carcinoma of the ovary, whose histology do 
not resemble any structure in the human body (Callegaro-Filho et al. 2016). 
 
1.3.7 Pathways of tumorigenesis: predominance of HGSC 
As well as the origin, the earliest events of OC tumorigenesis and the developmental 
progression model that follows are still unclear (Bowtell 2010). Evidence suggests 
that OC can progress, at least, along two different pathways: type I and type II (Shih 
& Kurman 2004; Kurman & Shih 2010). 
 
The type I pathway group includes LGSCs, low-grade MCs, low-grade ECs, low-
grade CCCs and transitional carcinomas (Shih & Kurman 2004). Type I tumours are 
highly differentiated (low-grade) and often diagnosed in early stages (Kurman & 
Shih 2008). They grow slowly and develop stepwise from well-recognized precursor 
lesions such as benign neoplasms and borderline tumours (Shih & Kurman 2005; 
Patrono et al. 2013). Although every sub-type is defined by specific molecular 
patterns, the main feature that characterizes type I tumours is the genetic stability 
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(low frequency of mutations), typified in the lack of TP53 mutations (Hauptmann et 
al. 2002; Bauerschlag et al. 2010). 
 
The type II group includes HGSC, high-grade ECs, undifferentiated carcinomas and 
carcinosarcomas (Shih & Kurman 2004). Type II tumours are poorly differentiated 
(high-grade) and often diagnosed in late stages (Kurman & Shih 2008). They grow 
aggressively without known or morphologically visible precursor lesions –‘de novo 
development’–, metastasize quickly and thus are associated with high mortality 
resulting from OC (Kurman & Shih 2010). Unlike type I, high-grade tumours are 
usually genetically unstable and more than 80% carry TP53 mutations (Hauptmann 
et al. 2002; Bauerschlag et al. 2010). Type II tumours account for approximately 
75% of all EOC and, within this group, HGSC is the most prevalent (Soslow 2008). 
 
 
	
Figure 1. 11 Representative examples of HGSC histological examinations 
Histological images of: (A) High-grade serous carcinoma (HGSC) sample displaying 
nuclear atypia, atypical mitotic figures and high mitotic/apoptotic rates (60x). (B) 
Solid HGSC sample; tumour cells are arranged in solid sheets with no glandular or 
papillary formations (10x). (C) Papillary HGSC; papillae covered by stratified, 
highly atypical epithelium (40x). All images were stained using haematoxylin & 
eosin. Source: ‘High-grade serous carcinoma involving fallopian tube, ovary and 
peritoneum’ (Al-Agha & Blake Gilks 2011). 
 
 
HGSCs are characterized by cytological features of high-grade malignancy, 
including nuclear atypia (high nuclear-to-cytoplasmic ratio, prominent nucleoli, 
bizarre nuclei), atypical mitotic figures (Bavle 2014), high mitotic/apoptotic rates 
(Malpica et al. 2004; Elmore 2007) and high proliferative index measured via Ki-67 
protein immune-staining (Mahadevappa et al. 2017) (Fig. 1.11 A). Microscopically, 
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HGSCs usually show either solid or papillary growth patterns (Fig. 1.11 B, C) (Prat 
2012a). 
 
Although diagnosis of HGSC is primarily based on routine cell morphology, certain 
immune-markers stain positively in the majority of HGSC and allow differentiate it 
from the rest of sub-types (Köbel et al. 2009). For instance, Ki-67 moderate to high 
expression levels distinguish between LGSC and HGSC samples. Others include 
estrogen receptor alpha (ERA/α) (positive HGSC, negative CC), p53 (positive 
HGSC, negative LGSC and CC) and the ‘Wilms tumour protein 1’ (WT1) (positive 
HGSC, negative EC and CC) (Al-Agha & Blake Gilks 2011). 
 
The mutational spectrum of HGSC is surprisingly simple (Network 2011). Apart 
from TP53 and BRCA1/2, other significant mutations are infrequent (2-6%) 
reflecting the underlying complexity of this disease (Bashashati et al. 2013). TP53 
mutations occur in almost 100% of HGSCs causing the loss of wild-type p53 
functions due to either gain of abnormal function of mutant p53, or absent-low 
mutant p53 protein (Ahmed et al. 2010; Cole et al. 2016). Approximately 50% of 
HGSC exhibit BRCA and/or HRR-related defects, establishing a ‘BRCAness’ patient 
profile (Rigakos & Razis 2012; Lord & Ashworth 2016). These defects include: 
 
• Germline and somatic mutations of BRCA1/2 (~22%) (Foster et al. 1996; Hilton 
et al. 2002). 
• Epigenetic silencing of BRCA1 via promoter hyper-methylation (Rae Lynn 
Baldwin et al. 2000). 
• Genetic or epigenetic alterations in genes whose function either affect or are 
affected by normal BRCA gene function. For instance, amplification of the 
‘BRCA2-interacting transcriptional repressor’ (EMSY) (Brown et al. 2006) or 
promoter hyper-methylation of the ‘Falconi anemia group F protein’ or FANCF 
(Lim et al. 2008). 
• Defects in proteins involved in DNA repair besides BRCA. For instance, focal 
deletion/mutation of the ‘tumour suppressor phosphate and tensin homolog’ 
(PTEN) or hyper-methylation of the ‘RAD51 paralog C’ (RAD51C) (Network 
2011). 
Introduction	
	 31	
HGSCs are characterized by genomic structural variation, an important mechanism 
to inactivate TSGs (Martins et al. 2014; Patch et al. 2015). Recurrent molecular 
alterations include de-regulated retinoblastoma protein (RB), phosphatidylinositol 3-
kinase (PI3K)/RAS and NOTCH signalling pathways (Fig. 1.12 A-C), as well as 
high level of somatic DNA copy number alterations affecting genes like ‘cyclin E1’ 
(CCNE1), MYC and the ‘telomerase reverse transcriptase’ (TERT) (Gorringe et al. 
2007; Etemadmoghadam et al. 2010; Network 2011). 
 
Figure 1. 12 Schematic representation of altered signalling pathways in HGSC 
(A) Retinoblastoma protein (RB), (B) PI3K/RAS and (C) NOTCH signalling 
pathways are commonly altered in HGSC. These alterations were defined by somatic 
mutations, DNA copy number changes (e.g. amplification) or, in some cases, by 
significant up- or down-regulation relative to expression in diploid tumours. 
Alteration frequencies are expressed as the percentage of all considered cases in the 
particular study. Activated genes are represented in red colour whereas inactivated 
genes are represented in blue. Source: ‘Integrated genomic analyses of ovarian 
carcinoma’ (Network 2011). CDKN2A: cyclin dependent kinase inhibitor 2A; 
CCND1/2: cyclin D1/2; RB1: RB transcriptional corepressor 1; NF1: Neurofibromin 
1; PIK3CA: PI3K catalytic subunit alpha; AKT1/2: AKT serine/threonine kinase 1/2; 
BRAF: B-Raf proto-oncogene, serine/threonine kinase; JAG1/2: Jagged 1/2; 
MAML1/2/3: mastermind like transcriptional coactivator 1/2/3. 
 
 
An important number of HGSCs are thought to arise from STICs, found in the 
fallopian tubes of both germline BRCA mutation carriers and sporadic HGSCs 
(~60%) (Przybycin et al. 2010; Karst, Levanon & Drapkin 2011; Kuhn et al. 2012) 
(Fig. 1.8). These carcinomas are in turn thought to progress from normal FTE, 
characterized by low proliferation rates, normal cell polarity and overexpression of 
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p53 protein present in the tubes regardless of BRCA status (George & Shaw 2014) 
(Fig. 1.13 A). With time, FTEs carrying the so-called ‘p53 signature’ progress to 
STICs, developing genomic alterations common to those observed in HGSCs, 
including CCNE1 and TERT amplification and up-regulation of the PI3K pathway 
(Kuhn et al. 2010; Sehdev et al. 2010; Karst, Levanon, Duraisamy, et al. 2011) (Fig. 
1.13). However, and consistent with mouse models, some HGSCs do not show a 
direct evolution from precursors in the fallopian tube (J. Kim et al. 2015) and their 
origin is still unclear (Perets et al. 2013; Howitt et al. 2015). 
 
	
Figure 1. 13 Models of initiation and progression of HGSC 
(A) Serous-tubal intraepithelial carcinomas (bottom three panels) are thought to 
progress from normal fallopian tube epithelium (top three panels). The top panel of 
both FTE and STIC histology display haematoxylin & eosin stain. The middle and 
bottom panels show p53 and Ki67 staining respectively. Source: ‘BRCA and early 
events…’ (George & Shaw 2014). (B) Model outlining the stages of the initiation 
and progression of HGSC. Loss of TP53 and BRCA, leading to a deficiency in 
homologous recombination repair, initiate chromosomal instability and widespread 
copy number changes. These alterations are thought to drive molecular subtype 
specification (C1, C2, C4, C5) resulting in global changes in gene expression. 
Subsequent mutations provide further advantages for tumour growth but may not be 
molecular subtype specific. Source: ‘The genesis and evolution…’ (Bowtell 2010). 
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There is currently no accepted model for initiation and progression of HGSC 
(Bowtell et al. 2015). TP53 mutation and stabilization is an early and invariant event 
in HGSCs but other than that, little is known of the temporal sequence of other 
molecular changes or the dynamics of chromosomal instability that drive HGSC 
progression (Berns & Bowtell 2012). Bowtell et al (2010) proposed a model for 
initiation and progression of BRCAness-associated HGSC, where TP53 mutations 
and deficiencies in HRR pathway lead to chromosomal instability and widespread 
copy number changes (Bowtell 2010) (Fig. 1.13 B). 
 
Based on different gene expression profiles and distinct clinical outcomes, HGSC 
has been further categorized into four subtypes: differentiated, immunoreactive, 
mesenchymal and proliferative; which are thought to account for HGSC histological 
variations (e.g. solid and/or papillary histology) (Tothill et al. 2008; Helland et al. 
2011; Network 2011) (Fig. 1.13 B). However, these molecular subtypes have not yet 
been integrated into the clinical setting (Bowtell et al. 2015). 
 
 
1.4 Ovarian Cancer Treatment 
1.4.1 First line treatment for advanced ovarian cancer 
The first line standard treatment for advanced stage OC starts with optimal 
cytoreduction, often via a extensive laparotomy surgery (Herold & Cannistra 2013). 
This procedure permits efficient tumour grading and staging, thereby allowing the 
precise selection of subsequent treatments (Weinberg 2014). In any case, surgery is 
currently followed by adjuvant intravenous or intraperitoneal (less frequent) 
chemotherapy with a platinum-based agent combined with anti-microtubule drugs 
(Piccart et al. 2000; Elit et al. 2007). Specifically, the most widely practiced first-line 
treatment regimen is six cycles of intravenous platinum (preferably carboplatin) with 
paclitaxel infusion once every three weeks (Ye et al. 2014). However, based on 
patient-susceptibility to the side effects of chemotherapy, carboplatin/pegylated 
liposomal doxorubicin is often used as alternative to standard therapy (Pignata et al. 
2011). 
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Chemotherapy treatment consists of the use of a drug or, most commonly, a 
combination of drugs (also known as chemotherapeutic/cytotoxic agents) to stop or 
slow the growth of cancer cells (Weinberg 2014). Common cytotoxic agents 
previously or currently used for OC treatment are summarized in Table 1.5.  
 
 
Table 1. 5 Cytotoxic agents in ovarian cancer treatment 
 
Cytotoxic agent Mechanism of action Examples OC treatment 
Alkylating 
agents 
Generation of DNA crosslinks, 
leading to cell apoptosis 
Cyclophosphamide 
(McGuire et al. 2003) 
Antimetabolites Interference of DNA production Gemcitabine, decitabine (Parker 2009) 
Intercalating 
agents 
Inhibition of DNA replication 
via DNA strand intercalation 
Platinum derivatives such as 
carboplatin and cisplatin 
(Monneret 2011) 
Spindle poisons Disruption of microtubule function, inhibiting cell division 
Taxanes such as paclitaxel 
(Wani & Horwitz 2014) 
Topoisomerase 
inhibitors 
Blockage of topoisomerase 
DNA arrangements, leading to 
cell apoptosis 
Doxorubicin, tocotecan 
(Nitiss 2009) 
 
 
Most cytotoxic agents are thought to preferentially attack high-rate proliferating 
cancerous cells, although the actual selection mechanism is not quite well 
understood (Amadori et al. 1997; Weinberg 2014). In fact, proliferation rates are 
quite low in some chemo-sensitive human cancers and the mechanism of tumour 
regression is unknown (Mitchison 2012). Nonetheless, major obstacles to successful 
cures with chemotherapy are the development of intrinsic or acquired mechanisms of 
drug resistance and a narrow therapeutic index, customarily having little difference 
between toxic and therapeutic doses (Crawford 2013). In general, the concept of 
selection for resistance implies that mutations either may pre-exist as small 
subpopulations within the cancer (intrinsic resistance) or may arise during the course 
of therapy (acquired resistance) (Lee & Swanton 2012). The standard of care 
following completion of platinum-based chemotherapy include physical 
examination, monitoring CA-125 levels, and imaging follow-up (Salani et al. 2011). 
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1.4.2 Ovarian cancer recurrence 
Approximately 70-80% of women with advanced OC suffer recurrence of their 
primary cancer following first-line treatment (Cannistra 2004). In most cases, these 
tumours acquire resistance to chemotherapy via overexpression of drug transporters 
(Patch et al. 2015) or restoration of BRCA genes by means of secondary somatic 
mutations (Norquist et al. 2011), amongst other strategies. Following definitive 
diagnosis of recurrent OC, several factors determine subsequent treatment options 
including location of metastases, complications from previous therapies, degree of 
platinum sensitivity and other patient-related issues (Matulonis et al. 2016) (Fig. 
1.14). In general terms, the choice of treatment for recurrent OC is based on the 
interval between the completion of the last platinum-based treatment and the 
detection of the relapse –platinum-free interval (Luvero et al. 2014). 
 
	
Figure 1. 14 Sensitivity to platinum chemotherapy of HGSC 
High-grade serous carcinoma recurrent tumours are classified into platinum-sensitive 
(intermediately, highly, extremely highly) or platinum-resistant according to their 
sensitivity to platinum chemotherapy. The platinum-resistant group include tumours 
that relapse within 6 months after chemotherapy and also those who do not respond 
to platinum treatment, also called refractory tumours. Source: ‘Redistribution of 
resistance…’ (Yokoyama 2013). 
 
 
The standard of care for patients with platinum-sensitive recurrent OC is the 
reutilization of combinatory platinum-based therapies (Raja et al. 2013). Even 
though response rates are approximately 50% (Pfisterer et al. 2006; Pujade-Lauraine 
et al. 2010), these responses usually last a few months and their efficiency decrease 
with subsequent platinum use until the tumour is declared platinum resistant 
(Markman et al. 2004; Hanker et al. 2012). 
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Platinum-resistant recurrent OC includes patients who do not respond or relapse 
within 6 months after first-line treatment and patients who relapse within 6 months 
of several lines of treatment for recurrent OC (Mantia-Smaldone et al. 2011) (Fig. 
1.14). The standard of care for these patients includes non platinum-based therapies 
using combinations or single-agent treatments of pegylated liposomal doxorubicin 
(Monk et al. 2010), paclitaxel (Thigpen et al. 1994), topotecan (ten Bokkel Huinink 
et al. 1997) and gemcitabine (Mutch et al. 2007). New cytotoxic compounds under 
clinical trials include microtubule inhibitors epothilones (Rustin et al. 2011) and the 
thymidylate synthase inhibitor pemetrexed (Vergote et al. 2009). Paclitaxel is 
considered the standard regimen in platinum-resistant OC, used in combination with 
a variety of non-chemotherapeutic agents (Rosenberg et al. 2002). 
 
1.4.3 Targeting cancer angiogenesis 
Chemotherapy remains the backbone of OC treatment, however, novel therapies, 
both in combination with chemotherapy and alone, have demonstrated significant 
improvements (Grunewald & Ledermann 2016). Even though there are several drugs 
being tested in OC patients, at the moment only two agents are licensed for OC 
treatment: Bevacizumab and Olaparib®, which target tumorigenic angiogenesis and 
BRCAness respectively (Symeonides & Gourley 2015). 
 
High-grade serous ovarian carcinomas express moderate to high levels of pro-
angiogenic proteins, particularly VEGFA and VEGFB (Bowtell et al. 2015). 
Inhibition of VEGFs restores the balance between pro and anti angiogenic factors, 
negatively influencing tumour growth and decreasing its metastatic potential 
(Mendelsohn et al. 2015). Bevacizumab is a humanized monoclonal antibody 
directed against circulating VEGFA (Ribatti 2011). It has been explored as a first-
line single agent, in combination with chemotherapy and as maintenance treatment 
post chemotherapy (Perren et al. 2011; Burger et al. 2011). Furthermore, it has been 
studied in the setting of second-line treatment of platinum-sensitive (Aghajanian et 
al. 2015) and platinum-resistant recurrent OC (Pujade-Lauraine et al. 2014). All 
these studies demonstrated statistically significant increase in progression-free 
survival, the length of time during and after treatment that a patient lives with cancer 
without detection of new disease progression (Korn & Crowley 2013), compared to 
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chemotherapy alone. However, there is still no evidence of increase in overall 
survival, the length of time from the date of diagnosis/start of treatment that patients 
diagnosed with the disease are still alive (Oliver & McGuire 2014). 
 
Resistance to bevacizumab emerges in most patients with HGSC who initially 
responded to the treatment (Bottsford-Miller et al. 2012). Nevertheless, there is a 
subset of patients that is clearly benefiting from anti-angiogenic therapies, although 
that effect is being diluted by the lack of predictive biomarkers, which are only now 
starting to emerge (Lambrechts et al. 2013). In fact, a recently identified 
transcriptomic signature predicts distinct responses to bevacizumab treatment in the 
different subtypes of HGSC (C Gourley et al. 2014). 
 
New anti-angiogenic strategies that are currently being studied include: trebananib 
(inhibitor of angiopoietins 1 and 2) (Monk et al. 2014), aflibercept (inhibitor of 
VEGF receptors 1 and 2) (Tew et al. 2014) and other multi-target tyrosine kinase 
inhibitors such as cediranib (Ledermann et al. 2016). 
 
1.4.4 Targeting cancer ‘BRCAness’ 
There are 17 members of the PARP nuclear superfamily, of which PARP1 and 
PARP2 have key roles in DNA repair (Amé et al. 1999; Rouleau et al. 2010). 
PARP1/2, together with the HRR pathway (Table 1.1), are essential in the reparation 
of collapsed replication forks happening alongside DNA replication (Bryant et al. 
2009; Fradet-Turcotte et al. 2016). 
 
Initially, PARP inhibitors were investigated due to their chemo-sensitizing potential, 
enhancing the cytotoxic effects of chemotherapy (Purnell & Whish 1980; Ferraris 
2010). More recently, they are being studied as single agents due to their ability to 
selectively kill cells with defects in DNA repair pathways (Drew 2015). PARP 
inhibition leads to accumulation of single-strand breaks (SSBs), unrepaired 
replication forks and ultimately DSBs which a cell with functional HRR is able to 
accurately and efficiently repair (Hoeijmakers 2001). On the contrary, those cells 
with homologous BRCA1/2 mutations either resolve these DBS via the error-prone 
NHEJ pathway or not repair them at all, which leads to genomic instability and 
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ultimately cell death (Ashworth 2008) (Fig. 1.15). Given the fact that 50% of HGSC 
patients display a ‘BRCAness’ profile, the use of PARP inhibitors has been 
extendedly studied (Network 2011). 
 
	
Figure 1. 15 Synthetic lethality coupling BRCA deficiency and PARP inhibition 
Cellular DNA is frequently subject to damage, although single strand breaks (SSBs) 
are normally efficiently repaired by base-excision repair (BER). PARP1/2 are key 
components of BER mechanisms and PARP inhibition leads, therefore, to 
persistence of SSBs, which might be encountered by a replication fork, collapse, and 
form double-strand breaks (DSBs). In the absence of BRCA1/2, DSBs are repaired 
by alternative pathways like the error-prone non-homologous end joining (NHEJ), 
which result in gross genomic instability and cell death. Source: ‘Making the best of 
PARP inhibitors in ovarian cancer’ (Banerjee et al. 2010). 
 
 
Olaparib® is a small molecule with activity against PARP1 and 2 that has been 
explored as first-line treatment (Fong et al. 2009) and as maintenance therapy for 
mutated BRCA1/2 platinum-sensitive recurrent HGSC, rendering significant 
improvements in patients’ progression-free survival (Ledermann et al. 2014; 
Domchek et al. 2016). Importantly, secondary mutations restoring mutated BRCA1/2 
predict resistance to chemotherapy and PARP inhibitors (Edwards et al. 2008; Sakai 
et al. 2008; Norquist et al. 2011). The use of combination therapies, e.g. targeting at 
the same time ‘BRCAness’ deficiencies and OC angiogenic potential, in order to 
improve responses and overcome resistance has yielded significant increase in 
progression-free survival (Liu et al. 2014). 
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Other PARP inhibitors that are currently under investigation in phase III studies 
include niraparib® (Mirza et al. 2016) or veliparib® (Coleman et al. 2015). 
 
1.4.5 Alternative ovarian cancer treatment strategies 
Distinctive traits of the OC malignancy have prompted a variety of therapeutic 
approaches, aside from the inhibition of PARPs and angiogenesis. These procedures 
include endocrine therapy, immunotherapy, antibody targeted therapies and 
epigenetic therapies: 
 
• Endocrine therapy is involved in managing cancers whose growth is dependent 
on hormones, and its aim is to antagonize hormone actions (Abdulkareem & 
Zurmi 2012; Simpkins et al. 2013). The most common example of effective 
endocrine therapy is the treatment of ERα-positive breast cancer with tamoxifen, 
which binds to the receptor blocking the tumorigenic effects of estrogen (Singh & 
Kumar 2005). 
HGSCs usually express ERα (60-70%) and the aromatase enzyme, which is 
responsible for the biosynthesis of estrogen (Rao & Slotman 1996; Kitawaki et al. 
1996); both molecules previously linked to OC growth stimulation in several OC 
cell lines (Galtier-Dereure et al. 1992; Langdon et al. 1994). However, clinical 
trials with anti-estrogenic therapies including tamoxifen and aromatase inhibitors, 
both in primary and recurrent OC settings, have shown disappointing therapeutic 
efficacy when compared to ERα-positive breast cancer associated responses 
(Schwartz et al. 1989; Ramirez et al. 2008; Argenta et al. 2009; Simpkins et al. 
2013). 
 
• Immunotherapy is the treatment of a disease by supplementing or strengthening 
the patient’s immune response against a tumour (Baxevanis et al. 2009). 
Accumulated evidence indicates that OC has therapeutic potential for immune-
based therapies via activation of effector immune cells or blockade of immune-
inhibitory pathways (Adams & Benencia 2015; Coukos et al. 2016). Accordingly, 
several strategies are currently being tested in clinical trials, including cancer 
vaccines (Kandalaft et al. 2013), immune checkpoint inhibitors (Duraiswamy et 
al. 2013) and T-cell-activating interleukins (Vlad et al. 2010). 
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• Antibody targeted therapies: Similar to bevacizumab, other antibodies 
specifically designed to target molecules involved in a variety of OC-related 
processes have been tested, e.g. the folate receptor alpha and the epidermal 
growth factor receptor 2 (ERBB2, also known as HER2). 
 
The folate cycle has a crucial role in biosynthesis reactions, essential for rapid cell 
growth (Elnakat & Ratnam 2006), and the main cellular receptor of folate is 
commonly overexpressed in HGSC (Kalli et al. 2008). However, monoclonal 
antibody farletuzumab and folate-conjugated vintafolide targeting folate receptor 
alpha did not show any significant benefit in phase III trials (Oza et al. 2015; 
Vergote et al. 2016). 
 
Trans-membrane epidermal growth factor receptors have key roles in cancer and 
ERBB2 is commonly overexpressed in HGSC (Serrano-Olvera et al. 2006; 
Teplinsky & Muggia 2014). Accordingly, breast cancer-approved anti-ERBB2 
agents such as herceptin/trastuzumab have been investigated in OC, although 
none have showed significant improvements in progression-free or overall 
survival thus far (Bookman et al. 2003; Teplinsky & Muggia 2015). 
 
• Epigenetic therapies: One of the most exciting areas of biology over the past 
decade has been the expanding understanding of how epigenetic control 
influences the patterns of gene expression in cells, a knowledge that has 
immediate translational implications for targeting epigenetic abnormalities in 
cancer for therapeutic purposes (Jones & Baylin 2007). Epigenetic regulation and 
therapies aimed at OC are discussed in the next section. 
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1.5 Epigenetic Regulatory Mechanisms in OC Progression 
In principle, ‘epigenetics’ refers to the somatically heritable differences in gene 
expression not attributable to intrinsic alterations in the primary sequence of DNA 
(Kouzarides 2007). Individual cells of different types all have the same genome, but 
have multiple different ‘epigenomes’ that define their respective phenotypes (Jones 
& Baylin 2002). In the same way, cancers of all types, and even different cell 
populations within a single patient’s cancer, undergo extensive and biologically 
significant changes in their epigenomes, ending with aberrant activation of 
oncogenes and inactivation of tumour suppressor genes favouring cancer progression 
(Allis & Jenuwein 2016). Furthermore, virtually all tumours harbour mutations in 
genes that encode proteins that control the epigenome (Azad et al. 2013). 
 
1.5.1 Basics of epigenetics 
The genetic material of eukaryotic cells is packaged into the nucleus in the form of 
chromatin fibres, consisting of nucleosomes, RNA and a number of other associated 
proteins (Kornberg 1974). Each nucleosome is composed of a segment of 147 base 
pairs of DNA wrapped almost two times around a cylindrical protein core containing 
two copies of each histone protein: histone 2A (H2A), histone 2B (H2B), histone 3 
(H3) and histone 4 (H4) (Kornberg 1974; Richmond et al. 1997) (Fig. 1.16). 
Histones are small basic proteins of around 14 kDa that contain a high percentage of 
positively charged amino acids and are the most abundant proteins bound to DNA in 
eukaryotic cells (Richmond et al. 1997). 
 
DNA packaging organization in a chromatin fibre generates restrictions for all 
processes involving DNA such as replication, repair, recombination and transcription 
(Ehrenhofer-Murray 2004). Chromatin structural rearrangements, also known as 
epigenetic changes, which include DNA methylation, covalent modification of 
histones, the incorporation of histone variants (Henikoff & Smith 2015) and non-
covalent remodelling by adenosine triphosphate (ATP)-dependent remodelling 
enzymes (Vignali et al. 2000), allow these constraints to be overcome (Ehrenhofer-
Murray 2004). Additionally, non-coding RNAs also play a role in epigenetic gene 
regulation (Peschansky & Wahlestedt 2014). Currently, the most studied and 
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recognized cancer-specific epigenetic changes are alterations in: DNA methylation 
and histone acetylation, a specific covalent post-translational modification of 
histones (Esteller 2008). 
 
 
Figure 1. 16 Chromatin structure 
This figure illustrates a representation of 
the structure of a chromatin fibre, whose 
basic units are the nucleosomes. Each 
nucleosome is composed of 
approximately 147 base pairs of DNA 
wrapped around an octamer of histones 
(two copies of H2A, H2B, H3 and H4). 
Histone H1 binds to the DNA that links 
two nucleosomes.  Source: ‘Epigenetic 
regulation in African trypanosomes…’ 
(Figueiredo et al. 2009). 
 
 
 
DNA methylation: DNA methylation occurs among cytosine residues in cytosine-
guanine (CpG) di-nucleotides, which are mostly distributed in CpG-rich regions or 
‘CpG islands’ (Holliday & Pugh 1975; Bird et al. 1985), and this reaction is 
catalysed by DNA methyl-transferase (DNMT) enzymes (Bestor & Ingram 1983). 
The addition of methyl groups to cytosine molecules alters the activity of DNA 
sequences; for instance, when located in a gene promoter, DNA methylation 
typically acts to repress gene transcription (Moore et al. 2013) (Fig. 1.17). Aberrant 
methylation of ‘CpG islands’ has been linked to tumour initiation and progression 
(Costello et al. 2000). While cancer-related DNA hyper-methylation is commonly 
associated with silencing of TSG (Feinberg & Tycko 2004), hypo-methylation is 
linked to transcriptional activation of oncogenes (Feinberg & Vogelstein 1983) (Fig. 
1.17). 
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Figure 1. 17 Epigenetic regulation of gene expression 
Broadly, gene expression is controlled at promoter regions by a combination of DNA 
methylation and chromatin configuration. In normal cells, gene expression is 
commonly silenced by the condensation of chromatin structures via DNA 
methylation and histone de-acetylation. By contrast, active genes are those 
characterized by open nucleosome spacing around the transcriptional start site, lack 
of DNA methylation and enhanced histone acetylation. Source: ‘The future of 
epigenetic therapy in solid tumours…’ (Azad et al. 2013). 
 
 
Covalent modification of histones: The N-terminal tail of histone proteins protrude 
from the nucleosome core and provide sites for reversible post-translational 
modifications (PTMs), including acetylation, ubiquitination, methylation, 
phosphorylation and sumoylation (Tessarz & Kouzarides 2014) (Fig. 1.18 A). PTMs 
can influence histone interactions or function as docking sites for other proteins that 
specifically recognize these modifications (Musselman et al. 2012). A new 
terminology describes molecules that lay down histone modifications as ‘writers’, 
those who remove them as ‘erasers’ and ‘readers’ as those who interpret the signals 
and influence subsequent changes (Dawson et al. 2012) (Fig. 1.18 B). By tightly 
condensing or loosening up the structure of chromatin, aberrant PTMs can de-
regulate DNA-accessibility and thus promote oncogene expression or silence 
TSG/stability genes (Seeber & van Diest 2012) (Fig. 1.17). 
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Figure 1. 18 Histone post-translational modifications 
(A) The majority of post-translational modifications (PTMs) occur in the N-terminus 
tail of histones protruded from nucleosome cores. These PTMs include the addition 
of phosphoryl, acetyl and methyl groups, amongst others. (B) Molecules 
denominated ‘writers’ introduce histone marks (e.g. methyltransferases), ‘erasers’ 
take them out (e.g. demethylases) and ‘readers’ can recognize particular forms of 
histone modification and influence subsequent changes. Source: ‘Chromatin proteins 
and modifications as drug targets’ (Helin & Dhanak 2013). 
 
 
Histone acetylation: The acetylation reaction is the process of substituting an active 
hydrogen atom of a protein for an acetyl group (C2H3O) (Phillips 1963). In cell 
biology, acetylation is a major regulatory mechanism, conferring reversible novel 
properties to altered proteins, including changes in enzymatic activity, localization, 
stability and interaction partners (Drazic et al. 2016). 
 
In the context of chromatin, the addition of an acetyl group to a protruding histone 
N-terminal tail disrupts the electrostatic interactions between the targeted histone 
and DNA by neutralizing positively charged lysine residues within histones 
(Carrozza et al. 2003). This action results in disruption of the nucleosomal structure 
and prompt unfolding of local DNA, making it more accessible by transcriptional 
machinery. As a consequence, the acetylation and de-acetylation of core histone 
proteins regulate gene transcription, replication and DNA repair processes, 
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influencing chromatin configuration and providing important platforms or docking 
sites for the recruitment of proteins and enzyme complexes required for further 
chromatin modelling (Shahbazian & Grunstein 2007) (Fig. 1.18 B). 
 
Histone N-terminal tails are acetylated in the ε-amino group of lysine residues, a 
reaction that relies on acetyl-coenzyme A (acetyl-CoA) and is carried out by lysine 
acetyltransferases (LATs or KATs) (Gershey et al. 1968; Yang 2004). Owing to the 
discovery of lysine acetylation as a PTM of histones (Phillips 1963), the enzymes 
that regulate global acetylation levels are termed histone acetyltransferases (HATs) 
and histone deacetylases (HDACs) (Kleff et al. 1995; Rundlett et al. 1996; Sadoul et 
al. 2008). HATs introduce acetyl groups into histones and are commonly associated 
with an open chromatin structure that facilitates transcription, whereas HDACs 
remove acetyl residues and consequently are associated with gene repression (Zhang 
& Dent 2005). 
 
1.5.2 Foundations of epigenetic therapies 
Mutations of genes involved in epigenetic mechanisms, such as DNMTs and 
HDACs, have been previously linked to cancer (Ley et al. 2010; Guglielmelli et al. 
2011). These mutations are thought to set up downstream abnormalities in the 
normal cell epigenome, remodelling it and establishing a completely different 
‘cancer epigenome’, prone to favour tumour progression (Berdasco & Esteller 2013). 
However, downstream genes affected by these epigenetic abnormalities are generally 
wild type for the underlying DNA sequence. Thus, normal function might be 
restored since, theoretically, reversing these epigenetic abnormalities should be 
easier than repairing the original upstream somatic mutations. Consequently, the aim 
of the so-called epigenetic therapies is to reverse key features of abnormal cancer 
epigenomes (Jones et al. 2016). 
 
Traditional therapies aimed at single gene abnormalities (e.g. OC targeted 
antibodies) commonly provide non-durable therapeutic responses, largely because 
the carcinogenic potential of most tumours relies on the existence of multiple 
signalling abnormalities, e.g. HGSCs (Mendelsohn et al. 2015; Matulonis et al. 
2016). Moreover, compensatory events can lead to resistance to the targeted 
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inhibition of any single gene-mediated event to which a cancer cell is addicted 
(Housman et al. 2014). Conversely, epigenetic therapies have the potential ability to 
simultaneously reverse tumorigenic abnormalities via multiple signalling pathways, 
mediating cell re-programming to inhibit cancer initiation and progression (Allis & 
Jenuwein 2016) (Fig. 1.19). 
 
 
Figure 1. 19 Potential targets of epigenetic therapy 
Targeting one signalling pathway or biological function can result in compensatory 
modulation of other, off-target drivers of tumorigenesis. The epigenetic control is 
involved in all the hallmarks of tumour initiation and progression (e.g. resistance to 
cell death, replicative immortality). Therefore, epigenetic therapy offers the ability to 
concurrently target, and reverse, multiple aberrant signalling pathways as well as the 
expected compensatory changes. Source: ‘The future of epigenetic therapy…’ (Azad 
et al. 2013). 
 
 
The hypothesis behind this assumption is based on the premises that for every 
genetic mutation in a given patient’s tumour, hundreds of genes have epigenetic 
abnormalities within the deviant cell signalling pathways that drive tumorigenesis 
(Herman & Baylin 2003; Ushijima & Asada 2010). Therefore, the loss of function or 
expression of many important candidate genes among the genes scattered throughout 
the pathways can be critical to the initiation and progression of tumours, as well as to 
their sensitivity and resistance to chemotherapy (Easwaran et al. 2012). 
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Figure 1. 20 Potential targets of epigenetic therapy in OC 
The progress of OC treatment, from diagnosis to recurrence, is depicted at the 
bottom panels, with the cell population thought to be present at each stage of this 
process shown within the shaded boxes. Potential opportunities for epigenetic 
therapies are depicted at the top panels, and include time points prior to treatment 
with chemotherapy, during remission and after recurrence. Source: ‘Targeting the 
epigenome in ovarian cancer’ (Murphy 2012). 
 
 
A shortcoming potentially applicable to most OC therapies is the inefficient targeting 
of cancer cells responsible for the disease itself or its recurrence, the ovarian cancer 
stem cells (Yinu Wang et al. 2014) (Fig. 1.20). Ovarian cancer stem cells have been 
isolated from established OC cell lines, ascites, primary and metastatic tumours and 
are hypothesized to be largely responsible for chemo-resistance (Bapat et al. 2005; S. 
Zhang et al. 2008; Curley et al. 2009). Similar to normal embryonic or tissue stem 
cells, ovarian cancer stem cells are believed to harbour a significantly altered 
epigenome, offering a useful arena for epigenetic therapies to develop strategies to 
target cancer stem-like cells (Balch et al. 2009; Y. Wang et al. 2014). 
 
1.5.3 Epigenetic therapies for the treatment of ovarian cancer 
Known aberrant epigenetic changes contribute to the inactivation of tumour 
suppressor genes and the activation of oncogenes in HGSC (Balch et al. 2009). Some 
altered epigenetic mechanisms include: 
 
• Epigenetic silencing via promoter hyper-methylation of TSGs such as BRCA1 (R 
L Baldwin et al. 2000), the ‘Ras association domain-containing protein 1’ 
Introduction	
	 48	
(RASSF1A) (BonDurant et al. 2011), the ‘opioid-binding protein/cell adhesion 
molecule’ (OPCML) (Sellar et al. 2003), MLH1, MSH2 (H. Zhang et al. 2008) or 
the ‘SPARC-like protein 1’ (SPARCL1) (Network 2011). 
• Epigenetic activation via promoter hypo-methylation of potential oncogenes, 
including the ‘preferentially expressed antigen in melanoma’ (PRAME) (Zhang et 
al. 2016), PARP1 (Bi et al. 2013), the ‘solute carrier family 6 member 8’ 
(SLC6A8) or nucleolin (NCL) (Shih et al. 2010). 
• Histone modifications, such as the promoter hypo-acetylation of the ‘deleted in 
lung and oesophageal cancer protein 1’ (DLEC1) TSG (Kwong et al. 2006) or the 
overexpression of sirtuin 1 (SIRT1) deacetylase (Shuang et al. 2015). 
• MicroRNAs: Epigenetic regulation via microRNA expression is significantly de-
regulated in HGSC (Vilming Elgaaen et al. 2014). Some microRNA act as TSGs 
and are down-regulated in HGSC (e.g. miR-152) (S. Zhang et al. 2015). Others, 
like the miR-200 family, are strongly up-regulated and promote tumorigenesis 
(Chen et al. 2013). 
 
Despite the relatively rudimentary understanding of the HGSC epigenome, these 
epigenetic aberrations underpin new therapeutic options (Nguyen et al. 2014). 
DNMT and HDAC inhibitors are the two major classes of epigenetic modulating 
agents that have been investigated for the treatment of OC, both as single agents and 
in combination with other therapies (Murphy 2012) (Table 1.6). Nonetheless, early 
clinical trials soon confirmed the lack of utility of these epigenetic drugs as single 
agents, similar to clinical findings observed in other diseases (Smith et al. 2017). 
 
Several DNMT inhibitors have been tested in clinical trials of patients with recurrent 
resistant OC (Fang et al. 2010; Falchook et al. 2013; Odunsi et al. 2014) (Table 1.6). 
Low doses of 5-aza-2'-deoxycytidine (decitabine) seemed to restore sensitivity to 
chemotherapy via de-methylation of individual TSGs (e.g. MLH1, RASSF1A) and 
multiple other important genes involved in key regulatory pathways. Specifically, 
pre-treatment with decitabine increased the objective response to re-treatment with 
platinum from <10% to 35% of patients (Matei et al. 2012). The objective response 
(rate) is defined as the proportion of patients with tumour size reduction of a 
predefined amount and for a minimum time period. A similar result was partially 
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achieved by 5-AzaC (azacitidine), which increased the objective response to a 22% 
of the patients (Fu et al. 2011) (Table 1.6). Larger trials testing de-methylating 
agents to overcome platinum resistance are currently on-going (Smith et al. 2017). 
However, while these studies indicate that DNMT inhibitors may improve response 
to platinum in patients with platinum-resistant OC, they failed to deliver any 
improvement in platinum-sensitive OC (Glasspool et al. 2014). 
 
 
Table 1. 6 Clinical experience with epigenetic therapies in OC 
	
Carbo = Carboplatin; 5AZA = 5-azacytidine; VPA = Valproic acid, PLD: Pegylated 
liposomal doxorubicin; LMP: Low malignant potential; CR = Complete response, 
absence of all detectable cancer; PR = Partial response, at least 50% reduction in 
measurable tumour; SD = Stable disease, cancer neither growing not shrinking not 
metastasizing further; ORR = Objective response rate, proportion of patients with 
tumour size reduction of a predefined amount and for a minimum time period; PFS = 
Progression-free survival, length of time during and after the treatment that a patients 
lives with the disease but it does not get worse; GI = Gastrointestinal. Source: 
‘Epigenetic therapy for the treatment of…’ (Smith et al. 2017). 
 
 
The experience with HDAC inhibitors has been less encouraging thus far. For 
instance, SAHA (Vorinostat) has shown recurrent toxicity issues and limited effects 
in platinum-resistant trial settings (Modesitt et al. 2008; Mendivil et al. 2013; 
Matulonis et al. 2015) (Table 1.6). Conversely, the effects of Belinostat range from 
absence of activity to discrete benefits when combined with paclitaxel/carboplatin 
chemotherapy (43% objective response rate) (Mackay et al. 2010; Dizon, Blessing, 
et al. 2012; Dizon, Damstrup, et al. 2012) (Table 1.6). 
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While response rates with single-agent epigenetic therapies have thus far been low, 
these agents have been able to at least mitigate platinum resistance and improve 
response to immunotherapy in pre-clinical studies and some early phase clinical 
trials, indicating that epigenetic agents may be best used in combination with other 
therapies (Paller et al. 2014; Smith et al. 2017). One study where low-dose 
decitabine was used in combination with dose-reduced paclitaxel and platinum 
chemotherapy in patients with platinum resistant/refractory OC produced a clinical 
benefit (either partial response or stable disease) in over 70% of the 17 patients 
included in the trial (Fu et al. 2011) (Table 1.6). In accordance, epigenetic agents 
such as DNMT and HDAC inhibitors are being extensively studied and represent an 
exciting and promising area of OC research. However, the development of new 
agents for targeting the OC cancer epigenome is also encouraged. 
 
As well as histone de-acetylation, other post-translational histone modifications that 
might offer new targets for OC treatment are currently being studied (Marsh et al. 
2014). Two of these new targets include histone H2B mono-ubiquitination and H3 
histone methylation, which are regulated by de-ubiquitinases (DUBs) and histone 
methyl-transferases (HMTs) respectively (Colland 2010). However, aberrantly 
expressed histone acetyltransferases, which have been previously linked to tumour 
growth and cancer progression, have not been investigated in OC settings (Wapenaar 
& Dekker 2016). 
 
1.5.3 Targeting histone acetyltransferases 
The human histone acetyltransferases are classified in two different groups: the type 
B HATs, which are cytoplasmic enzymes that modify free histones and other 
proteins in the cytoplasm, and type A HATs, which are (mainly) nuclear and 
responsible for the acetylation of histones and non-histone proteins in the nucleus 
(Parthun et al. 1996). Based on their sequence homology, most type A nuclear HATs 
are organized into three major groups or families: MYST (Utley & Côté 2003), 
Gcn5-related N-acetyltransferase (GNAT) family (Poux & Marmorstein 2003) and 
p300/CBP (Kalkhoven 2004). 
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HAT enzymes acetylate histone and non-histone proteins with various substrate 
specificities, which are modulated by the incorporation of HATs in large multi-
subunit complexes (Lee & Workman 2007). As well as HAT (‘writers’) and/or 
HDAC (‘erasers’) catalytic domains, complexes normally contain different histone 
‘readers’, as well as scaffolding domains that bridge the components of the complex 
together (Fig. 1.21). The function of the catalytic subunit (HAT or HDAC) in these 
multi-protein complexes depend largely on the context of the other subunits of the 
complex (Carrozza et al. 2003). 
 
 
Figure 1. 21 Structure of a canonical 
protein multi-subunit complex 
Multi-subunit protein complexes that exert 
epigenetic regulatory roles contain a wide 
variety of molecules, including epigenetic 
‘writers’, ‘readers’, and ‘erasers’ as well as 
scaffolding subunits. Source: ‘Perceiving the 
epigenetic landscape through histone 
readers’ (Musselman et al. 2012). 
 
 
 
Histone acetyltransferases have been shown to play a role in malignancies ranging 
from cancer and inflammatory diseases to neurological disorders (Yang 2004; 
Sheikh 2014). In cancer, HATs have been shown to suppress as well as to stimulate 
tumour growth and disease progression, even having opposite effects within the 
same type of cancer. For example, the ‘E1A binding protein p300’ gene (p300, also 
known as KAT3B) was suggested to function as a tumour suppressor gene in 
colorectal cancer (Gayther et al. 2000), but high levels of p300 transcripts were 
correlated with progression of the disease (Ishihama et al. 2007). Same counteracting 
effects are observed in the acetylation of non-histone targets. The ‘p300/CBP-
associated factor’ (PCAF, also known as KAT2B) is known to acetylate c-MYC 
oncogene increasing its stability, a process that may lead to cancer progression (Patel 
et al. 2004). At the same time, PCAF is known to acetylate tumour suppressor TP53 
protein activating its transcriptional activity, suggesting a protective function for 
PCAF (Liu et al. 1999). The exact role of HATs in cancer and the regulatory factors 
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influencing HAT activity are therefore still under investigation (Wapenaar & Dekker 
2016). 
 
In order to target functional disease-associated HAT activity, research has aimed at 
developing small molecule inhibitors as potential therapeutic agents (Legube & 
Trouche 2003; Yang & Seto 2007). Potential HAT inhibitors include molecules that 
interfere with acetyl-CoA and/or substrate binding, which would directly impair 
HAT activity. Such inhibition would affect the acetylation of histones and associated 
transcription of oncogenes or downstream oncogene targets, as well as the 
acetylation of non-histone substrates, such as p53, thereby affecting the stability of 
this transcription factor (Farria et al. 2015). Alternatively, small molecule inhibitors 
might be designed to either block interactions between HATs and other proteins, 
which would affect transcription of downstream targets, or the histone acetyl-lysine 
binding domain of HAT complexes, impairing the recognition of acetylated residues 
(Farria et al. 2015; Wapenaar & Dekker 2016). 
 
Almost all studies on HAT inhibitors are currently still in a pre-clinical phase and 
only curcumin has been moved forward into prostate cancer clinical trials as a 
potential anti-cancer therapy (Balasubramanyam et al. 2004). Curcumin is a natural 
HAT inhibitor that affects cell proliferation of prostate cancer cells through 
modulation of aberrantly activated Wnt signalling (Shah et al. 2012), suppresses 
p300 occupancy at androgen receptor (AR) target genes and inhibits xenograft 
tumour growth of androgen sensitive cells (Diederich et al. 2011). Even though 
curcumin is indeed a HAT inhibitor, its biological effect cannot be solely appointed 
to HAT inhibition. For instance, curcumin has been shown to induce apoptosis of 
OC cell lines in a concentration- and time-dependent manner, via inhibition of the 
sarco/endoplasmic reticulum calcium-ATPase, which leads to an aberrant influx of 
cytosolic calcium (Seo et al. 2015). The two major challenges in designing reliable 
HAT inhibitors with guaranteed physiological effects are the variety of cell 
substrates (histones, transcription factors, enzymes, nuclear receptors) and the multi-
protein complex structure, which determines HAT functions, enzymatic activity and 
substrate specificity (Wapenaar & Dekker 2016). 
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Surprisingly, most studies on HATs and cancer have been focused on the GNAT and 
p300/CBP families, leaving aside the highly conserved MYST family, whose 
members carry out a significant proportion of all nuclear acetylation and play central 
roles in fundamental cellular mechanisms including gene regulation (Thomas & 
Voss 2007). Originally named after its four founding members in yeast and 
mammals, the MYST family currently comprises five human HATs: ‘histone 
acetyltransferase binding to ORC-1’ (HBO1, also known as KAT7 and MYST2), ‘Tat 
interacting protein 60’ (Tip60, also known as KAT5), ‘lysine acetyltransferase 6B’ 
(KAT6B, also known as MORF), ‘lysine acetyltransferase 6A’ (KAT6A, also known 
as MOZ) and the ‘human males absent on the first’ (hMOF, also known as KAT8) (N 
Avvakumov & Côté 2007). MYST HATs are defined by a conserved MYST domain 
composed of an acetyl-CoA binding motif (LAT domain) and a canonical C2HC zinc 
finger (Cys-X2-Cys-X12-His-X3-Cys) (Utley & Côté 2003). Zinc fingers are small 
protein structural motifs, characterized by the coordination of one or more zinc ions 
that stabilize the fold, whose functions are extraordinarily diverse (Laity et al. 2001). 
This MYST domain possesses the ability to interact with DNA, RNA, proteins or 
other molecules through its zinc finger (Klug 2010) and introduce acetyl groups via 
the LAT motif (Yang 2004). Some family members also have additional chromatin 
recognition features such as extra plant homeodomain (PHD) zinc fingers and 
chromo-domains (Yang 2004). 
 
So far, only Tip60 among the MYST family members has been contemplated as a 
therapeutic target (Ghizzoni et al. 2012). Tip60 is crucial for DNA repair, and it has 
been shown to be down-regulated in primary melanoma cancer cells and up-
regulated in drug-resistant prostate cancer cells (Miyamoto et al. 2008; Chen et al. 
2012) respectively. Two newly identified Tip60 inhibitors are reported to inhibit cell 
proliferation and induce apoptosis in prostate cancer cells and breast cancer cells 
(Coffey et al. 2012; C. Gao et al. 2014). Interestingly, one of the least characterized 
members of the MYST family, HBO1, has been found overexpressed in OC tissues 
(Iizuka et al. 2009). 
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1.6 Histone Acetyltransferase Binding to ORC1 - HBO1 
The histone acetyltransferase binding to ORC-1 (HBO1) was originally identified 
interacting with the largest protein subunit of the human origin recognition complex 
(ORC) –ORC1 (Iizuka & Stillman 1999). ORC is a six-subunit protein complex that 
binds to replicator sequences to initiate DNA replication in eukaryotes (Bell & 
Stillman 1992; Dutta & Bell 1997; Masai et al. 2010). The interacting sequence was 
identified as a 611-amino acid protein (~80KDa) involved in multiple key cellular 
processes such as replication and transcription regulation. HBO1 is also known as 
‘lysine acetyltransferase 7’ (KAT7) (Allis et al. 2007) and ‘MYST histone 
acetyltransferase 2’ (MYST2). 
 
HBO1 has two noteworthy functional domains: a serine-rich region at the amino-
terminus domain (NTD) and a 270-amino acid MYST-type domain at the carboxyl-
terminus tail (Iizuka & Stillman 1999) (Fig. 1.22). 
 
	
Figure 1. 22 Schematic representation of the structure of human protein HBO1 
NTD: Amino-terminus domain; Ser-rich: Serine-rich domain; ZNF1, 2: Zinc finger 1 
and 2; NLS: Nuclear localization signal; LAT: Lysine acetyltransferase domain; 
CTD: Carboxyl-terminus domain; MYST: MYST domain. 
 
 
1.6.1 Structure and functions of the N-terminus domain 
The N-terminal domain encompasses a putative zinc finger structure (C2H2C, amino 
acids 189-211) (Georgiakaki et al. 2006) and a rather unique serine-rich domain 
(amino acids 1-169) that had not been reported in any other member of the MYST 
family (Sharma et al. 2000) (Fig. 1.22). The serine-rich domain is highly enriched 
with threonine (Thr), tyrosine (Tyr) and serine (Ser) residues and, as such, is prone 
to protein phosphorylation (Dephoure et al. 2008). In fact, HBO1’s Ser-rich domain 
is hyper-phosphorylated under normal conditions (Miotto & Struhl 2011) and some 
well documented phosphorylation sites include: Ser50, Ser53, Ser57, Thr85 and Thr88 
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(Wu & Liu 2008; Duong et al. 2013; Matsunuma et al. 2016). The phosphorylation 
of Thr85/Thr88 is carried out by the CDK1-Cyclin B protein complex, which creates a 
docking site for further phosphorylation by polo-kinase 1 (Plk1) at Ser57, activating 
HBO1’s enzymatic activity (Wu & Liu 2008). The residue Thr88 can also be 
phosphorylated by the CDK2-Cyclin E complex, a process that does not activate 
HBO1’s enzymatic activity (Duong et al. 2013). Ser50 and Ser53 are phosphorylated 
as a consequence of UV radiation (Matsunuma et al. 2016). The ‘mitogen-activated 
protein kinase kinase 1’ (Mek1) also phosphorylates HBO1 in vitro, marking HBO1 
for deleterious-ubiquitination, although the exact residue has not been specified (Zou 
et al. 2013). With regard to other PTMs such as ubiquitination (Iizuka et al. 2013; 
Zou et al. 2013; Matsunuma et al. 2016) and acetylation (Iizuka et al. 2006; Iizuka et 
al. 2013), which target protein residues alongside the entire HBO1 protein, it is 
interesting to highlight that many other acetyltransferases have ubiquitin-associated 
capabilities (Sadoul et al. 2008) and that HBO1 auto-acetylates itself in vitro (Iizuka 
et al. 2006; Iizuka et al. 2013). 
 
The NTD of HBO1 has been often conjectured as an intrinsic transcriptional 
repression domain (Sharma et al. 2000; Burke et al. 2001; Georgiakaki et al. 2006; 
Contzler et al. 2006). This theory is sustained by differing behaviours displayed by 
different HBO1 constructs in β-galactosidase assays (Smale 2010). Specifically, 
Sharma et al. (2000) conducted β-galactosidase experiments to compare the 
luciferase activity generated by full-length HBO1 protein, NTD-only or CTD 
(carboxyl-terminus domain)-only protein constructs. The highest levels of luciferase 
activity, and therefore the most transcriptionally active HBO1 structure, were 
detected with the CTD-only construct, followed by full-length HBO1 and finally 
NTD-only, suggesting the existence of a transcriptional repression function within 
the NTD domain of HBO1 (Sharma et al. 2000). Georgiakaki et al. (2006) obtained 
similar results when comparing full-length HBO1 and CTD-only constructs. 
Furthermore, when bound to AR, HBO1 represses transcription from AR element 
containing promoters, an effect totally abrogated by the deletion of the first 230 
amino acids of HBO1 (the NTD domain) (Sharma et al. 2000).  
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1.6.2 Structure and functions of the C-terminus domain 
The MYST-type region located at the C-terminus domain is highly conserved and 
has many structural similarities with several other MYST acetyltransferases (Utley 
& Côté 2003). It comprises a canonical zinc finger structure (C2HC, amino acids 
365-390), a LAT domain (Iizuka & Stillman 1999; Burke et al. 2001) and a bipartite 
nuclear localization signal (NLS, amino acids 400-417) (Georgiakaki et al. 2006). 
 
The MYST-domain, through the action of the LAT motif, acetylates histone H3 (at 
lysine residue K14 and possibly K9) (Kueh et al. 2011; Mishima et al. 2011; M. S. 
Kim et al. 2015), histone H4 (at lysine residues K5, K8, K12, K16) (Doyon et al. 
2006; Iizuka et al. 2009; M. S. Kim et al. 2015) and other non-histone substrates 
(Choudhary et al. 2009). Among these, HBO1 acetylates ORC2, the 
‘minichromosome maintenance complex component 2’ (MCM2), ‘cell division 
control protein 6’ (Cdc6), geminin, ERα and HBO1 itself (auto-acetylation) (Iizuka 
et al. 2006; Iizuka et al. 2013). In addition, the MYST domain is involved in the 
interaction with a myriad of proteins including: 
 
• Nuclear receptors: AR (Sharma et al. 2000), ERα (Iizuka et al. 2013), 
progesterone receptor (PR) and the ‘steroid-receptor coactivator-1’ (SRC-1) 
(Georgiakaki et al. 2006). 
• DNA replication complex-related proteins: ORC1 (Iizuka & Stillman 1999), 
MCM2 (Burke et al. 2001), the ‘chromatin licensing and DNA replication factor 
1’ (Cdt1) (Miotto & Struhl 2008) and geminin (Miotto & Struhl 2010). 
• Transcription complex-related proteins: the ‘JADE family PHD finger 1-3’ 
(JADE1/2/3) (Avvakumov et al. 2012) and the ‘bromodomain and PHD finger 
containing protein 1-3’ (BRPF1/2/3) (Mishima et al. 2011; Lalonde et al. 2013; 
Feng et al. 2015). 
• Other proteins such as CDK11p58 (Zong et al. 2005), Plk1 (Wu & Liu 2008) and 
p53 (Iizuka et al. 2008). 
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Despite being able to perform all these interactions, the preponderant competence of 
the MYST domain is the acetylation of histones. Because of this and to facilitate 
further descriptions, the MYST domain will be named the HAT domain and the 
capacity of this HAT domain to acetylate, HAT activity. 
 
1.6.3 HBO1 cell localization 
Northern blots showed HBO1 mRNA expressed ubiquitously in all tested healthy 
human tissues, with the lowest expression in liver, kidney, spleen and lung (Iizuka & 
Stillman 1999; Sharma et al. 2000; Kueh et al. 2011); and the highest in ovaries 
(Iizuka & Stillman 1999) or testis (Sharma et al. 2000; Kueh et al. 2011). For the 
most part, HBO1 is located evenly throughout the nucleoplasm in the nucleus 
(Sharma et al. 2000; Burke et al. 2001; Zong et al. 2005; Havasi et al. 2013), with 
the exception of the nucleoli where it does not accumulate (Doyon et al. 2006; Yan 
et al. 2016), and almost entirely associated with the chromatin fraction (Burke et al. 
2001; Miotto & Struhl 2008). Nonetheless, its degradation by the proteasome 
happens in the cytoplasm, where the ‘Skp-Cullin 1-F box Fbxw15’ (SCFFbxw15) 
protein binds and marks HBO1 with poly-ubiquitin chains at the Lys338 residue, a 
process accelerated by HBO1’s phosphorylation by the ‘mitogen-activated protein 
kinase kinase 1’ Mek1 (Zou et al. 2013). HBO1 protein has a short life span –
predicted half-life of ~3h– (Zou et al. 2013), resembling other acetyltransferases 
(Jain et al. 2012). 
 
1.6.4 Roles of HBO1 in DNA replication 
Replication is the mechanism through which our cells duplicate the genome in S 
phase (synthesis phase) of the cell cycle, once before each cellular division (Cooper 
2000). An efficient replication requires a tight regulation of gene expression and 
chromatin structure, amongst other aspects, in order to co-ordinately initiate 
thousands of DNA replication origins (Méchali 2010; Parker et al. 2017). 
 
The initiation of DNA replication can be divided into three tightly regulated steps. 
First, ORC is recruited onto replication origins as cells exit mitosis (Bell & Dutta 
2002). Second, pre-replication complexes (pre-RC) are assembled via the sequential 
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loading of licensing factors Cdt1, Cdc6, and Mcm2-7 in a process termed licensing 
(Méchali 2010) (Fig. 1.23 A-C). The resulting pre-RC complex is licensed for 
activation that will occur in the subsequent S phase (Thömmes & Blow 1997; Bell & 
Dutta 2002). Finally, the activation/firing of the pre-RC results in bidirectional DNA 
replication from the origin, whereupon the pre-RC disassembles, restricting DNA 
synthesis to once per cycle (DePamphilis 2003; Remus & Diffley 2009). 
 
Regulation of Cdt1 is the key event in replication licensing that permits the ordered 
assembly and disassembly of the pre-RC (Arias & Walter 2006). The Cdt1 protein 
lacks enzymatic activity and shares little resemblance to any other protein of known 
molecular function, yet it is essential for origin licensing in eukaryotes. In 
mammalian cells, small changes in Cdt1 control can lead to catastrophic 
consequences for genome stability, underscoring the paramount importance of this 
protein (Pozo & Cook 2016). 
 
	
Figure 1. 23 Regulation of DNA replication licensing by HBO1 
(A) From late mitosis (M) to Gap1 (G1) phase, ORC, Cdc6 and Cdt1 sequentially 
load onto chromatin to mark origins of replication. (B) Cdt1-assisted binding of 
HBO1 to origins results in acetylation of histone H4 at origins. (C) The presence of 
ORC-Cdc6-Cdt1 and acetylated histones facilitates the loading of Mcm2-7 complex. 
(D) Geminin binds to Cdt1 during S and Gap2 (G2) phases and blocks its interaction 
with Mcm2-7 as well as inhibiting HBO1-mediated H4-acetylation, thus preventing 
reloading of Mcm2-7 once replication is initiated. Source: ‘Histone acetylation by 
HBO1 tightens replication licensing’ (Chadha & Blow 2010). 
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Histone acetylation is linked to pre-RC assembly and licensing (J. Zhou et al. 2005; 
Kemp et al. 2005; Lucas et al. 2007; Goren et al. 2008). For instance, early-firing 
origins are typically localized in hyper-acetylated genomic regions, whereas late-
firing origins lie in silenced non-acetylated heterochromatic domains (Karnani et al. 
2007). 
 
HBO1 plays an active role in DNA replication and is thought to be required for 
normal cell cycle progression (Doyon et al. 2006). It is recruited to origins of 
replication in Gap1 (G1) phase via its interaction with Cdt1, where it acetylates H4 
K5/K12 inducing large-scale chromatin de-condensation that stimulates Mcm2-7 
complex recruitment thus enabling the pre-RC licensing (Iizuka et al. 2006; 
Johmura, Osada, et al. 2008; Miotto & Struhl 2008; Miotto & Struhl 2010) (Fig. 
1.23 B, C). Once in late S phase, geminin and the ‘histone deacetylase 11’ 
(HDAC11) associate with Cdt1-HBO1, inhibiting HBO1’s HAT activity, 
suppressing Mcm2-7 complex loading (likely by lose of H4 acetylation) and 
ultimately disassembling the pre-RC (Miotto & Struhl 2010; Wong et al. 2010). 
HBO1 may also be implicated in the acetylation of other targets apart from H4 in 
DNA replication. For instance, it is partly responsible for H3 hyper-acetylation at 
terminal repeat regions, latent replication origins of Kaposi’s sarcoma-associated 
herpesvirus (Stedman et al. 2004). The importance of HBO1 in replication licensing 
is highlighted by difficulties in progression through the replicative (S) phase, 
accumulation in the Gap2 (G2)/mitosis (M) DNA damage checkpoint and ultimately 
the reduced cell proliferation rates of HBO1 depleted cells (Doyon et al. 2006; Zou 
et al. 2013). 
 
Synchronous localization of HBO1 at origins and changes in HAT activity, most 
active during G1 phase (pre-RC assembly and licensing), are cell cycle regulated 
(Iizuka et al. 2006). Conversely, mRNA expression and protein level/stability remain 
fairly constant throughout the whole cell cycle (Zong et al. 2005; Iizuka et al. 2006; 
Miotto & Struhl 2008). Nonetheless, the association of HBO1 with non-origin target 
sites is not affected by cell cycle regulations, limiting these to origin-bound HBO1 
(Miotto & Struhl 2008). In line with this, HBO1 H4-dependent acetylation controls 
replication licensing independently of global effect at the transcriptional level 
(Miotto & Struhl 2010). 
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According to Iizuka et al. (2009), in an asynchronous population of normal human 
fibroblasts immortalized with telomerase there are 0.9 ~ 1.8 molecules of HBO1 per 
origin of replication. These results suggest that in normal cells HBO1 is in a critical 
concentration range and its activity must be tightly regulated to participate in both 
replication licensing and transcription regulation (Iizuka et al. 2009). 
 
1.6.5 Roles of HBO1 in transcription 
The first evidence of the role of HBO1 in transcription regulation was the 
identification of HBO1-AR mediated transcriptional repression, an attribute that has 
also been associated to other MYST HATs such as Tip60 (Sharma et al. 2000). In 
the same publication, Sharma et al. (2000) claimed that, unlike with AR, HBO1 had 
no inhibitory effect on either ERα or thyroid hormone receptor beta (TRβ) mediated 
transcription. Conversely, HBO1 enhances transcription mediated by PR, the 
mineralocorticoid receptor (MCR) or the glucocorticoid receptor (GCR) and strongly 
induces PR and ERα co-activation via interaction with the steroid-receptor 
coactivator-1 (SRC-1) (Georgiakaki et al. 2006). Furthermore, additional studies 
suggest that HBO1 enhances the activity of basic leucine zipper domain (bZIP) 
transcription factors (Miotto & Struhl 2006), JADE1 (Foy et al. 2008) and p53 
(Wright et al. 2016). This dichotomous behaviour of HBO1 displaying both 
activating and repressing properties was also observed with Chameau (Chm), the 
drosophila HBO1 homolog (Grienenberger et al. 2002; Miotto et al. 2006). HBO1 
expression in adult brain, a tissue consisting almost exclusively of post-mitotic cells, 
encouraged previous in vitro observations suggesting that HBO1 is likely to possess 
cellular functions aside from DNA replication in vivo (Kueh et al. 2011). 
 
Using chromatin immune-precipitation (ChIP) experiments, HBO1 was detected 
mainly near the transcription starting site (TSS) of genes, whose expression level 
was strongly correlated with HBO1 signal intensity, suggesting a role of HBO1 in 
transcription initiation (Mishima et al. 2011; Avvakumov et al. 2012; Feng et al. 
2015). Most importantly, HBO1 co-localizes with H3K4me3, a hallmark of actively 
transcribed protein-coding promoters in eukaryotes, permissive for acetylation and 
specifically connected to H3K9/14 acetylation (Wang et al. 2008; Hon et al. 2009). 
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Interestingly, a great proportion of replication origins also localize at TSSs (Picard et 
al. 2014), highlighting the importance of HBO1 in both cellular processes. 
 
 
 
Figure 1. 24 Model for HBO1 assembly 
in alternate multi-protein complexes 
The HBO1 catalytic subunit can be 
associated with different scaffolding 
proteins, leading to a switch in histone 
tail specificity for acetylation of 
chromatin substrates. Source: ‘Exchange 
of associated factors…’ (Lalonde et al. 
2013). 
 
 
 
Other HBO1 complex-interacting proteins that co-localize to either the surroundings 
of the TSS or the coding region of genes are the ‘inhibitor of growth family member 
4’ (ING4) (Hung et al. 2009), ING5 (Lalonde et al. 2013), JADE1 (Saksouk et al. 
2009) and BRPF1/2 (Lalonde et al. 2013). Combinations between these and other 
protein subunits (JADE2/3, BRPF3 and the ‘MYST/Esa1 associated factor 6’ or 
hEaf6) might form up to 12 distinct HBO1-transcription complexes (Yan et al. 2016) 
(Fig. 1.24). Despite the complications of having such variety of subunits, all 
complexes share certain characteristics: (1) JADE1/2/3 or BRPF1/2/3 form the 
scaffold subunit and determine acetylation specificity (Lalonde et al. 2013), (2) ING 
proteins direct complex binding towards target epigenetic marks (Hung et al. 2009; 
Saksouk et al. 2009), (3) HBO1 alone exerts the HAT activity (Iizuka et al. 2009) 
and (4) all complexes contain hEaf6, an uncharacterized protein also present in 
human Tip60 HAT complexes whose role is unknown (Avvakumov et al. 2012) 
(Fig. 1.24). 
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1.6.6 The HBO1 complex: JADE/BRPF families and ING4/5 
The ‘gene for apoptosis and differentiation in epithelia’ small family is comprised of 
three individual paralogs: JADE1 (PHF17), JADE2 (PHF15) and JADE3 (PHF16) 
(Ishikawa et al. 1998; Zhou et al. 2002). All three proteins contain two PHD fingers 
(Tzouanacou et al. 2003), well-characterized histone recognition motifs (Sanchez & 
Zhou 2011; Musselman et al. 2012) (Fig. 1.25). Furthermore, the three paralogs 
interact with HBO1, ING4/5 and hEaf6 subunits (Doyon et al. 2006). 
 
JADE1 is the most studied gene member of the JADE family (Panchenko 2016) and 
gives rise to two isoforms with different functions: JADE1L (long) and truncated 
JADE1S (short) (Tzouanacou et al. 2003) (Fig. 1.25). Apart from its part in histone 
acetylation (Panchenko et al. 2004), JADE1 is involved in cell cycle regulation 
(Siriwardana et al. 2015) and interacts with the ‘von Hippel-Lindau’ TSG (pVHL), 
suggesting a role in apoptosis and tumour suppression (Zhou et al. 2004; M. I. Zhou 
et al. 2005; Chitalia et al. 2008). Additionally, overexpression of JADE1L in Hela 
cells led to decreased colony formation in soft agar, a characteristic of TSGs 
(Avvakumov et al. 2012). 
 
	
Figure 1. 25 Schematic representation of the structure and interactions of 
human proteins JADE1L and JADE1S 
The picture depicts different models of interactions within JADE1L/S-HBO1 
complexes. I, II: JADE interacting domains; PHD-Zn-PHD: nucleosome binding 
domain. Source: ‘Conserved molecular interactions within the HBO1…’ 
(Avvakumov et al. 2012). 
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JADE1L functions as scaffold subunit of the HBO1 complex interacting directly and 
independently with hEaf6/ING4/5 and HBO1 (Avvakumov et al. 2012) (Fig. 1.25). 
When acting on chromatin, JADE1L’s PHD fingers recognize different states of 
H3K4 methylation and direct the HAT activity to histone 4 lysine residues (Saksouk 
et al. 2009; Avvakumov et al. 2012). On the contrary, the truncated version JADE1S 
is unable to interact with ING4/5 or hEaf6 (Saksouk et al. 2009) (Fig. 1.25). This 
change in subunit conformation promotes a shift on complex specificity toward 
methylated H3K36me3 (Saksouk et al. 2009), a mark found on coding regions of 
transcribed genes, just downstream of H3K4 methylation (Bannister et al. 2005). 
 
The ‘bromodomain and PHD finger containing protein’ family is comprised of three 
individual paralogs: BRPF1 (Thompson et al. 1994), BRPF2 (commonly known as 
BRD1) (McCullagh et al. 1999) and BRPF3 (Feng et al. 2015). All three proteins 
contain two PHD fingers, a bromo-domain and a chromo/Tudor-related Pro-Trp-Trp-
Pro (PWWP) domain (Ullah et al. 2008). BRPF proteins function as scaffolding 
subunits of HBO1 complexes interacting, equivalently to JADE1/2/3, with 
hEaf6/ING4/5 and HBO1 (Doyon et al. 2006; Mishima et al. 2011). When acting on 
chromatin, BRPF’s PHD fingers recognize different states of H3K4 methylation and 
direct the HAT activity to histone 3 lysine residues (Lalonde et al. 2013). The fact 
that BRPF proteins contain a PWWP domain that recognizes methylated H3K36 
(Vezzoli et al. 2010) agrees with HBO1 complexes located not only near the TSS but 
also across the coding region of genes (Saksouk et al. 2009). In this line, a role for 
HBO1 complexes in transcription elongation has been proposed in several 
publications (Saksouk et al. 2009; Kueh et al. 2011; Mishima et al. 2011). 
 
BPRF paralogs have separate functions despite their high similarity and large 
overlap in chromatin binding (Feng et al. 2015): 
• The BRPF1 gene is required for embryonic survival and development (You et al. 
2014; You et al. 2015), regulates growth and cell cycle progression (You et al. 
2015). BRPF1-HBO1 complexes preferentially target H3K9/14/23 acetylation 
(Lalonde et al. 2013; You et al. 2015; Feng et al. 2015). Besides HBO1, BRPF1 
interacts with MOZ/MORF acetyltransferases and enhances their HAT activity 
toward histone H3 (Ullah et al. 2008). 
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• The BRPF2 gene is required for embryonic survival and foetal liver 
erythropoiesis (Mishima et al. 2011). BRPF2-HBO1 complexes preferentially 
target H3K14 acetylation (Mishima et al. 2011; Mishima et al. 2014). 
• Unlike BRPF1 and BRPF2, the BRPF3 gene is non-essential for mouse 
development and survival (Yan et al. 2016). BRPF3-HBO1 complexes 
preferentially target H3K14 acetylation (Feng et al. 2015). Interestingly, BRPF3 
was identified as a candidate gene involved in DNA replication (Feng et al. 2015) 
and co-localizes with ORC1 (Dellino et al. 2013), HBO1 (Avvakumov et al. 
2012) and acetylated H3K14 (accession number: GSM521881). In line with this, 
Feng et al. (2015) proposed that BRPF3-HBO1 complexes promote H3K14 
acetylation near TSSs/origins thus regulating the ability of licensed origins to be 
activated in S phase. 
 
The ‘inhibitor of growth’ family has five members including ING4/5 which are 
involved in critical biological processes (He et al. 2005). ING4/5 proteins are part of 
HBO1 complexes and interact with the scaffolding subunits JADE1/2/3 (not 
JADE1S) and BRPF1/2/3 (Doyon et al. 2006; Mishima et al. 2011). Both ING4 and 
ING5 have a highly conserved PHD finger that interacts with H3K4me3 
(Champagne et al. 2008; Hung et al. 2009), promoting HBO1 HAT activity towards 
H3K4me3-containing TSSs of active genes (Avvakumov et al. 2012). 
 
ING4/5 are considered TSGs and display different activities (Piche & Li 2010): 
• ING4 harbours several anti-cancer activities such as inhibiting angiogenesis 
(Garkavtsev et al. 2004; Ozer & Bruick 2005) and cell migration (Shen et al. 
2007) or promoting cell death (Shiseki et al. 2003) and contact inhibition (Kim et 
al. 2004). Additionally, overexpression of ING4 in HeLa cells led to decreased 
colony formation in soft agar, a characteristic of TSGs (Avvakumov et al. 2012). 
ING4 expression is decreased in many cancer types (Liu et al. 2012), and this is 
often correlated with poor prognosis (Cui et al. 2015). 
• ING5 TSG properties include inhibition of cell growth (F. Zhang et al. 2011), 
abrogation of EMT (F. Zhang et al. 2015) and promotion of cell death (Shiseki et 
al. 2003). While low levels of ING5 expression correlate with advanced stages 
and metastases, high levels are associated with better prognoses (F. Zhang et al. 
Introduction	
	 65	
2015). Interestingly, ING5 depletion in 293T cells blocked cell cycle progression 
through S-phase while no effect was observed when depleting ING4 (Doyon et al. 
2006). 
 
1.6.7 HBO1 at the crossroads 
HBO1 gene knockout in mouse embryos led to loss of bulk H3K14 acetylation at 
gene coding regions and significant reduction in expression of key regulator genes 
involved in patterning the early embryo (e.g. MOZ, MORF, the ‘lysine 
acetyltransferase’ GCN5 and ‘sex determining region Y box 1/ 2’ or SOX1/2) (Kueh 
et al. 2011). This profile ultimately prompted embryonic lethality but, contrary to 
expectations, the embryo did not display any dysfunctionality in proliferation or 
DNA replication (Kueh et al. 2011). Surprisingly, Kueh et al. (2011) neither detected 
significant increases in expression of predicted HBO1-repressed genes or changes in 
H4 acetylation levels (Table 1.7). 
 
The preponderance of H3K14 as the main target of HBO1 acetylation was observed 
in other knockout and stable knockdown studies (Table 1.7). For instance, Mishima 
et al. (2011) detected a great descence in H3K14 acetylation when transfecting 
erythroblasts with short hairpin RNAs (shRNA) targeting HBO1. Kim et al. (2015) 
depleted HBO1 using shRNAs in murine embryonic stem cells, observing 
acetylation deffects in H3K14 and H4K12 and, in this case, HBO1 knockdown also 
led to significant up and down regulation of gene targets (M. S. Kim et al. 2015) 
(Table 1.7). As with the latter, a considerable group of studies have reported H4 
acetylation as the main target of HBO1 acetylation, highlighting its deeply 
specialised role in a tissue specific context (Sauer et al. 2015). Similarly, HBO1 is 
reported to have multiple and diverse roles, yet is non essential for cancer cell 
growth, as shown by the majority of knockdown experiments conducted thus far 
(Table 1.7). 
 
HBO1 complexes play important roles both in DNA replication and transcription. As 
a consequence, it is reasonable to speculate that defects in its function might induce 
critical consequences to the cell and can easily lead to carcinogenesis (Nikita 
Avvakumov & Côté 2007). For instance, origin hyper-activation in response to 
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oncogenic signalling can drive genome instability (Halazonetis et al. 2008; Alver et 
al. 2014). In line with this, Iizuka et al. (2009) confirmed that HBO1 shows 
overexpression in testicular germ cell tumours, breast adenocarcinomas and ovarian 
serous carcinomas. 
 
 
Table 1. 7 List of previous HBO1 knockdown experiments 
 
Experiment Altered Acetylation (ac) Related phenotype 
Small interfering RNA 
293T embryonic kidney cells 
(Doyon et al. 2006) 
H4ac  -Reduced proliferation -Affected DNA synthesis 
Small interfering RNA 
HeLa cervical cancer cells 
(Avvakumov et al. 2012) 
- -Down-regulation of p53-regulated genes 
Small interfering RNA 
MCF7 breast cancer cells 
(Iizuka et al. 2013) 
- -Enhanced anti-proliferative effects of tamoxifen 
Small interfering RNA 
MLE-12 murine lung cells 
(Zou et al. 2013) 
H3K14ac  -Reduced cell proliferation 
Short hairpin RNA 
K562 leukemic cells 
(Mishima et al. 2011) 
H3K14ac  - 
Short hairpin RNA 
76NE6-LMW-E cells1 
(Duong et al. 2013) 
- 
-Reduced mammosphere 
formation 
-Reduced expression EMT 
markers 
Short hairpin RNA 
THP-1 leukemic cells 
(Sauer et al. 2015) 
H4K5ac  -Increased colony formation 
Short hairpin RNA 
Murine embryonic stem cells 
(M. S. Kim et al. 2015) 
H3K14ac 
H4K12ac 
-Regulation of the Nanog 
homeobox (Nanog) expression 
KnockOUT 
-/- Mice 
(Kueh et al. 2011) 
H3K14ac  
-Embryonic lethal E10.5 
-Reduction of key gene 
regulators 
176NE6-LMW-E cells: human mammary epithelial cells derived from mammoplasty 
were transfected with vectors expressing low molecular weight cyclin E isoform, 
subjected to mice xenograft transplantation and in vivo passaging. Tumours were 
removed and injected back for 4 successive generations to generate the resultant cell 
line (Duong et al. 2013). 
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1.6.8 Pro-oncogenic features of HBO1 
Genome localization is amongst the reasons why HBO1 is often considered an 
oncogene (Hu et al. 2009), since HBO1 maps to 17q21.3, a region that shows 
frequent allelic gains in a variety of tumours, including breast cancer (Clark et al. 
2002), where this amplification is associated with poor prognosis (Hyman et al. 
2002; Pollack et al. 2002). Furthermore, the HBO1 locus site has been identified as a 
common retroviral integration site, leading to myeloid leukaemia and B/T-cell 
lymphoma in mice (Suzuki et al. 2002). Notably, different lines of study point to a 
prominent role of HBO1 in breast cancer tumour progression: 
 
• In line with amplification events happening at the 17q21.3 locus, HBO1 was 
found overexpressed in breast cancer tissues (Iizuka et al. 2009; Wang et al. 2010; 
Iizuka et al. 2013) and several breast cancer cell lines (Clark et al. 2002; Iizuka et 
al. 2009; Duong et al. 2013). 
• Overexpression of HBO1 dramatically enhances the ability of MCF-7 and 
SKBR3 breast cancer cells to grow without anchorage (anoikis), a crucial step in 
the acquisition of malignancy (Hu et al. 2009). 
• Depletion of HBO1 enhances the anti-proliferative effect of tamoxifen on MCF7 
cells (Iizuka et al. 2013) and decreases cancer stem cell-associated properties of 
several breast cancer cell lines (e.g. mammosphere formation) (Duong et al. 
2013). 
 
Approximately two thirds of human breast cancers are dependent on estrogen for 
proliferation and express ERα (Jordan 1997). As mentioned earlier, HBO1 interacts 
with ERα and enhances its transcriptional activity, suggesting a role of HBO1 in 
regulating ERα-positive breast cancer progression. In fact, HBO1 has been shown to 
modulate ERα stability in MCF7 cells (Iizuka et al. 2013), and its expression is 
regulated by estradiol (E2) (Wang et al. 2010). However, while Wang et al. (2010) 
found that HBO1 expression is significantly correlated with ERα expression in 
breast cancer tissues, Iizuka et al. (2013) did not. 
 
The tumour suppressor gene TP53 is often mutated in cancer and regulates multiple 
key cell cycle and apoptotic processes via transcription dependent and independent 
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mechanisms (Vogelstein et al. 2000; Harris & Levine 2005; Moll et al. 2005). In 
order to efficiently coordinate these actions, the stability and activity of p53 are in 
turn regulated by several HATs including p300, Tip60, PCAF and HBO1 (Barlev et 
al. 2001; Sykes et al. 2006; Tang et al. 2006; Sykes et al. 2009; Wright et al. 2016). 
HBO1 interacts with p53 (Iizuka et al. 2008) and participates of p53-mediated 
transcription via its HAT activity (Wright et al. 2016), regulating important genes 
such as the ‘cyclin dependent kinase inhibitor 1A’ (CDKN1A also known as p21) 
(Avvakumov et al. 2012; Wright et al. 2016). Interestingly, the interaction of p53 
protein with HBO1 has the ability to inhibit HBO1’s HAT activity (Iizuka et al. 
2008), linking stress with replication halt. 
 
HBO1 has also been associated with chemotherapy resistance, specifically with 
gemcitabine resistance in pancreatic cancer. In this setting, excess Plk1 
phosphorylates HBO1 promoting the overexpression of transcription factors like 
cFos, a feature that eventually contributes to gemcitabine resistance (Song et al. 
2013). 
 
1.6.9 Anti-oncogenic features of HBO1 
The presence of HBO1 in complexes with TSGs ING4/5 and JADE paralogs imply 
that, as the catalytic subunit of each respective complex, HBO1 itself may contribute 
to TSG activities and cancer protection (N Avvakumov & Côté 2007). Nonetheless, 
this is not the only setting where HBO1 seems to play a protective role in cancer. For 
instance, HBO1 expression is suppressed in patients with acute myeloid leukaemia 
(Sauer et al. 2015). Accordingly, the acetylation of HBO1’s main target in this cell 
background –H4K5– was also suppressed, a circumstance that is associated with 
poor prognosis (Sauer et al. 2015). Furthermore, depletion of HBO1 in THP-1 and 
SEM human hematopoietic cell lines enhanced anchorage-independent growth 
(Sauer et al. 2015), while overexpression of HBO1 in NIH-3T3 mouse cells inhibited 
the growth of independent colonies (Johmura et al. 2008). 
 
Other features of HBO1 that could indicate TSG behaviour are the cooperation with 
CDK11p58 and the ‘nuclear factor kappa B’ (NF-κβ). CDK11p58 is a protein kinase 
involved in the negative regulation of AR (Zong et al. 2007) whose expression is 
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abnormally low in prostate cancer (Chi et al. 2014). Interestingly, CDK11p58 
interacts with HBO1, another negative regulator of AR (Sharma et al. 2000), 
enhancing its HAT activity (Zong et al. 2005), which suggests a cooperative role in 
growth inhibition. 
 
On the other hand, the NF-κβ protein complex is a crucial player in tumorigenesis, 
immunity, inflammation, apoptosis and cell proliferation, and as such, it is 
constitutively active in many cancers (Hoesel & Schmid 2013). HBO1 was shown to 
inhibit NF-κβ activity, stimulated either by ‘tumour necrosis factor alpha’ (TNFα) or 
by the overexpression of other co-activators of NF-κβ signalling, in a dose-
dependent manner. However, HBO1 does not interact with NF-κβ neither reduces its 
DNA binding capabilities, and so it has been proposed that HBO1 inhibits NF-κβ 
activity by co-activator sequestration (Contzler et al. 2006). 
 
1.6.10 HBO1 and ovarian cancer 
As previously indicated, HBO1 was found overexpressed in a number of primary OC 
tissues (Iizuka et al. 2009). Specifically, Iizuka et al (2009) examined two 
independent panels of tumour samples containing 20 and 7 OC cases each. The first 
panel consisted of ovarian serous carcinomas (without any further histo-type 
differentiation), whereas no information about the histology of the second panel was 
provided. Five OC samples of the first panel (25%) revealed strong positive signal 
for HBO1 and 30% of cases in the second panel showed more than 50% positive 
stained cells (Iizuka et al. 2009). 
 
In accordance with HBO1 overexpression in OC tissues, MCM proteins are highly 
expressed in CICs (Freeman et al. 1999), possibly linking replication abnormalities 
with cancer progression. The role of HBO1 in replication is also linked with the 
promotion of adipogenesis (Johmura, Osada, et al. 2008), a critical phenomenon that 
boosts OC rapid metabolism, growth,  and metastasis (Nieman et al. 2011). 
Additionally, ING4, an important partner of HBO1 and candidate TSG, is frequently 
mutated in OC (Liu et al. 2012; Cui et al. 2015). 
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1.7 Research Aims 
The main goal of the work reported herein was to explore the impact of HBO1 in 
OC, looking at its regulatory role of the transcriptome and epigenome in advanced 
forms of disease. This information will help to determine whether HBO1 would be a 
suitable target to develop a future therapeutic strategy. 
 
In order to study the functions of HBO1 in OC, an important pre-requisite was the 
selection of a panel of OC cell lines representative of different disease sub-types, as 
well as a normal ovarian epithelial non-cancerous control. This panel enabled feature 
comparisons between cancerous and non-cancerous cells, and, depending on the 
selected cell lines, comparisons amongst different sub-types or cancer staging. Once 
the panel of cell lines was established, the first goal was to define the expression 
pattern of HBO1. Assuming that HBO1 regulates important OC tumorigenic 
pathways, and as previously observed in cancer cell lines and OC tissues, its 
expression was expected to be higher in OC cell lines compared to the control. 
 
Due to HBO1 known effects on steroid hormone-dependent transcription (e.g. via 
AR or ER nuclear receptors), its potential overexpression might functionally link 
DNA replication and transcription affecting growth and cell proliferation in OC. In 
order to find a possible correlation between the expression of nuclear receptors such 
as AR/ER and HBO1, their pattern of expression in the OC cell lines was assessed. 
Additionally, the existence of a potential causative relationship between hormones 
and HBO1 expression was studied. 
 
Due to its HAT activity, overexpressed HBO1 protein is expected to localize nearby 
promoters/enhancers of OC-related oncogenes. To test that hypothesis, a chromatin 
immune-precipitation combined with sequencing (ChIP-Seq) experiment was 
planned. Prior to ChIP-Seq, a step-wise procedure for the optimization of ChIP 
experiments following the ENCODE (encyclopaedia of DNA elements) guidelines 
was observed. The validation of HBO1 protein enrichment in known genome sites 
was the most crucial step amongst the different stages of optimization. In order to 
help with this procedure, publicly available databases were perused to generate a 
battery of candidate HBO1 targets, which are potentially regulated by HBO1 in an 
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OC setting. The downloaded material was handled using an SQL database system, 
which allowed for the reliable linkage and comparison of numerous datasets. 
 
One important aim of the work reported herein was to unravel the functions of 
HBO1 in OC. A number of strategies aimed at knocking down the expression of 
HBO1 in OC cell lines, either transiently or permanently, were assessed in order to 
examine the specific roles of HBO1. These strategies included the complete 
knockout (KO) of HBO1 gene expression, the stable lentiviral transduction of 
shRNAs and the transient transfection of small interfering RNAs (siRNAs). If the 
hypothesis is correct, and HBO1 is involved in OC-oncogene up-regulation, the 
decrease of HBO1 transcript and protein expression levels would lead to the 
subsequent down-regulation of these potential targets, and more importantly, to the 
inhibition of HBO1-related OC tumorigenic features. However, a role of HBO1 as a 
tumour suppressor gene cannot be discounted, as it has been previously observed in 
the literature. 
 
Successful modulation of HBO1 levels followed by gene profiling experiments, 
including RNA sequencing (RNA-Seq) and microarrays, was used to identify 
potential HBO1 targets. These gene transcripts were analysed using a set of 
bioinformatics tools to decipher signalling pathway involvement, as well as potential 
biological effects caused by the down-regulation of HBO1. The results obtained 
from the pathway analysis were used to select and design specific assays to confirm 
predicted phenotypical variations in vitro (e.g. proliferation assay). As well as the 
gene names and pathways involved in the OC HBO1 regulatory network, successful 
knockdown allowed the identification of histone acetylation targets within this 
setting. 
 
Altogether, the successful completion of these goals would provide significant 
insights into the roles of HBO1 in OC progression, determining its suitability as 
biomarker and/or therapeutic target. 
 
 
 
2. Materials and Methods 
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2.1 Cell Lines and Culturing 
All cell lines purchased and used for experimentation throughout this thesis 
dissertation are depicted in Table 2.1. As well as multiple OC and cervical cancer 
derived cell lines; the Human Ovarian Surface Epithelial Cells (HOSEpiC) were 
used as non-cancerous control. 
 
 
Table 2. 1 List of cell lines used as in vitro model 
 
Origin Cell line Product Provider 
Non-cancerous HOSEpiC (Murdoch 1995) #7310 ScienceCell™ 
Ovarian Cancer 
OVCAR-3 (Hamilton et al. 1983) HTB-161™ 
ATCC® 
SKOV-3 (Fogh et al. 1977) HTB-77™ 
UWB1.289 (DelloRusso et al. 2007) CRL-2945™ 
UACC-1598 (Heiskanen et al. 2000) CRL-3128™ 
TOV-112D (Provencher et al. 2000) CRL-11731™ 
TOV-21G (Provencher et al. 2000) CRL-11730™ 
COV644 (Berg-Bakker et al. 1993) 07071908 Sigma® 
Cervical Cancer HeLa (Scherer et al. 1953) CCL-2™ ATCC® 
 
 
The different cell lines were maintained in their particular culture media, depending 
on special nutrient requirements, detailed in Table 2.2. Each media type was 
supplemented with a variety of compounds including foetal calf/bovine serum (FBS) 
(SH30071, HyClone™) in different concentrations and 1% penicillin/streptomycin 
solution (30-002-CI, Corning), which includes 100 U/mL of penicillin and 100 
µg/mL of streptomycin (Table 2.2). HOSEpiC cells were grown in extracellular 
matrix coated-flasks (G299, abm®) and all cell lines were maintained at 37°C in a 
humidified 5% CO2 incubator. 
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Table 2. 2 List of cell lines culture media 
 
Cell line Culture media Provider Supplements 
HOSEpiC 
Prigrow I 
(TM001) 
abm® 
10% FBS + 0.01% 
Ovarian Epithelial Cell 
Growth Supplement 
(#7352, ScienceCell™) 
OVCAR-3 RPMI1-1640 
(30-2001) 
ATCC® 
20% FBS + 10 µg/mL 
insulin solution from 
bovine pancreas 
(I0516, Sigma®) SKOV-3 
UWB1.289 DMEM
2/F-12  
+ GlutaMAX™ 
(10565) 
Thermo 
Scientific™ 
10% FBS 
UACC-1598 
TOV-112D MCDB 105 (M6395) 
+ M199 (M4530) 
(1/2) 
Sigma® 
15% FBS + NaHCO3 
(3.7 gr/L) TOV-21G 
COV644 
DMEM  
+ GlutaMAX™ 
(10566) 
Thermo 
Scientific™ 
10% FBS 
HeLa EMEM3 (30-2003) ATCC® 10% FBS 
1RPMI: Roswell park memorial institute medium 
2DMEM: Dulbecco’s modified Eagle’s medium 
3EMEM: Eagle’s minimum essential medium 
 
 
Depending on doubling time and confluence, cells were ordinarily passaged every 2-
3 days using 0.25% trypsin (25-053-CI, Corning) for cell detachment. A Bright-Line 
and Hy-Lite counting chamber (267110, Thermo Scientific™), also called hema-
cytometer, and rectangular cover glasses (2026H001, Thermo Scientific™) were 
used for cell counting and seeding. In order to avoid extensive cell sub-culturing, cell 
pellets were frozen at low passages using 5% dimethyl-sulfoxide (DMSO) (C6295, 
Sigma®) diluted in growth medium (medium supplemented with pertinent amounts 
of FBS and antibiotics). The stock of frozen cell pellets was preserved either in -
80°C incubators (maximum 2-3 weeks) or Liquid Nitrogen Dewars (SPI supplies®). 
After being thawed, all cells were passaged at least twice prior to their use in 
experimentation, allowing them to properly recover from the freezing procedure. 
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2.2 Antibodies 
The commercial antibodies described in Table 2.3 were used throughout this thesis 
in experiments such as western blot (WB), immune-precipitation (IP), immune-
fluorescence (IF), dot-blot (DB), chromatin immune-precipitation (ChIP) and ChIP 
combined with sequencing (ChIP-Seq). 
 
Table 2. 3 List of commercial antibodies 
 
Primary antibodies Application Quantity Product Provider 
HBO1 (AB70) 
WB 1:1000 
ab70183 Abcam® 
IP 1µg 
ChIP 
ChIP-Seq 3-10 µg 
IF 1:100 
DB 1:1000 
HBO1 (G-2) 
WB 1:500 
sc-398346 Santa Cruz® IP 1µg 
ChIP 5µg 
H4ac (pan-acetyl) 
WB 
1:1000 39244 
Active motif® H3K14ac 1:1000 39599 
Histone H4 1:1000 39269 
GAPDH 1:1000 sc-25778 
Santa Cruz® 
CyPA/PPIA 1:250 sc-133494 
XRCC1 1:100 sc-56254 
EGFR 1:250 sc-03-G 
Ubiquitin (P4D1) 1:100 sc-8017 
ING4 1:500 ab108621 Abcam® 
Anti-V5 tag  DB 1:1000 ab27671 Abcam® β-Actin (AC-15) ab6276 
H3K4me3 
ChIP 
3µg 39159 Active motif® 
HBO1 (T-20) 5µg sc-13284 
Santa Cruz® 
HBO1 (N-18) 5µg sc-13283 
HBO1 (H-180) 5µg sc-25379 
Normal rabbit IgG 5µg sc-2027 
Normal mouse IgG 5µg sc-2025 
 
Secondary antibodies Application Quantity Product Provider 
Alexa Fluor® 488 
(anti-rabbit) IF 1/500 A-11034 Invitrogen™ 
IgG anti-rabbit WB  1:2000 sc-2004 Santa Cruz® IP 1µg 
IgG anti-mouse 
WB 1:2000 
sc-2005 Santa Cruz® IP 1µg 
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2.3 Two Step quantitative Real Time-Polymerase Chain Reaction 
2.3.1 Extraction of RNA and synthesis of complementary DNA 
First, confluent monolayers of cells were washed with phosphate buffered saline 
solution (PBS) (SH30256, HyClone™) pre-warmed at room temperature (RT) and 
then lysed using the RNA extraction RNeasy Kit (74104, Qiagen®) RLT buffer. 
Subsequently, total cell RNA was isolated following manufacturer’s instructions and 
quantified using a Nanodrop® Spectrophotometer ND-1000 (GE Healthcare, Version 
3.8.1). Two hundred nanograms of total RNA were reverse transcribed to 
complementary DNA (cDNA) using SuperScript® II reverse transcriptase, 
dithiothreitol (DTT, 0.1M) (18064-014, Invitrogen™), random primers (48190-011, 
Thermo Scientific™), RNAseOUT recombinant ribonuclease inhibitor (10777-019, 
Invitrogen™) and a mix of deoxy-nucleotide triphosphates (dNTPs, 10mM) (18427-
013, Thermo Scientific™) following the first-strand synthesis protocol 
(Invitrogen™). The cDNA synthesis was conducted in a MJ Mini™Personal 
Thermal Cycler (PTC1148EDU, Bio-rad). 
 
2.3.2 Design and characterization of primers 
At first, the messenger RNA (mRNA) sequence of the transcript of interest was 
extracted from the Reference Sequences Database (RefSeq) via the National Centre 
for Biotechnology Information (NCBI) website (O’Leary et al. 2016; NCBI 2017). 
The consensus coding DNA sequence or CCDS was uploaded into Primer3, a tool 
that generates batteries of candidate synthetic oligonucleotides, commonly named 
primers (Untergasser et al. 2012). The constitution and main characteristics of these 
primers was carefully analysed in order to select the most suitable choices. All 
quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) primers selected for 
and used in this thesis share common characteristics: 
 
• Product sizes range from 70 to 160 base pairs. 
• Melting temperature close to 60°C, unless specified otherwise. 
• Primer PCR suitability assessed using the online tool ‘PCR Primer Stats’ from 
the ‘Sequence Manipulation Suite’ site, which analyses individual primers and 
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returns a report describing their main structural and stability properties (Stothard 
2000). 
• Guanine-cytosine content lower than 60%. 
• When possible, primers span exon-exon boundaries to preclude amplification of 
genomic DNA (gDNA). The University of California Santa Cruz (UCSC) ‘In-
Silico PCR’ tool was used to verify mRNA product amplification (Kent et al. 
2002). 
• If possible and unless specifically stated, all primers amplify a region shared 
among all the isoforms of the pertinent gene target. NCBI’s ‘Primer-BLAST’ 
tool was used to confirm product amplification (Ye et al. 2012). 
 
All primers were purchased from Sigma® and received lyophilized. After a quick 
spin, each primer was reconstituted to a concentration of 100µM (e.g. 50nmol/500µl) 
in 1X TE buffer solution containing 1M Tris-HCl (15568-025, Thermo Scientific™) 
and 100mM ethylenediaminetetraacetic acid (EDTA) (AM9260G, Thermo 
Scientific™), diluted in 1µM stocks and stored at -20°C. 
 
Prior to their experimental use, primers were tested in order to confirm the 
generation of single melting curves. Two primer pairs were always designed and 
purchased for each target gene so that at least one would amplify an individual 
product. All validated primers used for qRT-PCR in this thesis are listed in Table 
2.4. 
 
 
Table 2. 4 List of qRT-PCR primers 
 
Primers used throughout the thesis 
Target / Primer Sequence Product size 
GAPDH 
(Reference gene) 
F:  5’-TCTTTTGCGTCGCCAGCCGA-3’ 
R:  3’-CCAGGCGCCCAATACGACCA-5’ 91 
RPL5 
(Reference gene) 
F:  5’-GCAGGATGGGGTTTGTTAAA-3’ 
R:  3’-CAAGCGTTTCCGAGCATAAT-5’ 113 
HBO1 
(All isoforms) 
F:  5’-CTATGGGAACACACGGGAAC-3’ 
R:  3’-TTGCTTCCCTCTGTGATTTG-5’ 138 
CDKN1A/p21 F:  5’-GCACTCAGAGGAGGCGCCATGT-3’ R: 3’-GCAGCCCGCCATTAGCGCAT -5’ 141 
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3. HBO1 Expression and Regulation in Ovarian Cancer 
Target / Primer Sequence Product size 
HBO1 
Isoform 1 
F:  5’-TGTCCTACACCAGGCTGTAACT-3’ 
R:  3’-TGTGCTCTCACCTTGCATTC-5’ 122 
HBO1 
Isoform 2 
F: 5’-GGCTGTAACTCTCTAGGACACC-3’ 
R: 3’-CGTTGGTGCCTTGCATT-5’ 108 
HBO1 
Isoform 3 
F:  5’-GCCAGAGTTCTCAAGGACACC-3’ 
R: 3’-TGTGCTCTCACCTTGCATTC-5’ 109 
HBO1 
Isoform 4 
F:  5’-GCAAGTGGTTGATTTTTCAG-3’ 
R:  3’-ATACAGTGGGCATCCTGAG-5’ 82 
HBO1 
Isoform 5 
F:  5’-GCCAGAGTTCTCAAGGACACC-3’ 
R:  3’-TTGGTGCCTTGCATTCGT-5’ 105 
AR F:  5’-CGCTGAAGGGAAACAGAAGT-3’ R:  3’-CGAAGACGACAAGATGGACA-5’ 93 
ER1/α F:  5’-TGCTGCTGGCTACATCATCT-3’ R:  3’-TCCAGAGACTTCAGGGTGCT-5’ 130 
ER2/β F:  5’-GTGGTCCATCGCCAGTTATC-3’ R:  3’-ACGGTTCCCACTAACCTTCC-5’ 129 
CASP4 F:  5’-TCTCCAGCATCCTTGGAAGT-3’ R:  3’-TCTCCAGGACACGTTGTGTG-5’ 132 
KRT7 F:  5’-CAGGATGTGGTGGAGGACTT-3’ R:  3’-TTGCTCATGTAGGCAGCATC-5’ 116 
LCN2 F:  5’-CTCTACGGGAGAACCAAGGA-3’ R:  3’-CAGGGAAGACGATGTGGTTT-5’ 100 
TRAP1 F:  5’-CTTGGAAAAACTGCGTCACA-3’ R:  3’-TCCTGTGTCATCCCGATACC-5’ 129 
JADE1L F:  5’-CTGTGTGCAAAGTCCAGGAA-3’ R:  3’-TTTTCCAGTGAGGAGGAGGA-5’ 106 
JADE1S F:  5’-GAAGAGGACAATCTAGCCAAGC-3’ R:  3’-TCAATCATTACCCTCTCCAGGT-5’ 98 
JADE2 F:  5’-TCGGAGCTTAAGGAGATGGA-3’ R: 3’-CAACATCCTCGTCGTACTCG-5’ 148 
JADE3 F:  5’-GGAGTTGGCAGCATCTGTTT-3’ R:  3’-TGGCGTTCCAGGACTTCTAC-5’ 147 
BRPF1 F:  5’-AAGATGCCCCGAGAAGGTAT-3’ R:  3’-CACTGCCAGGTTCGTTTGTT-5’ 149 
BRPF2 F:  5’-AGCGGAAGAAGCAGTTTGTG-3’ R:  3’-GCAGCCTTCATCTCCTCATC-5’ 154 
BRPF3 F:  5’-TCAAACGAGAGCAGGTCAAA-3’ R:  3’-TGACTGGTTCTGCGAAGATG-5’ 132 
ING4 F:  5’-GGAGAAGAAAGCTGCTCGTG-3’ R:  3’-CTTCTTCTGGGCAGTCTTGG-5’ 76 
ING5 F:  5’-CATCCTGGCTGCAGAGTACA-3’ R:  3’-CACTTGCTGTAGGCGTTCTG-5’ 120 
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5. Functional HBO1 Evaluation using a Stable RNAi-based Knockdown System 
Target / Primer Sequence Product size 
HDAC6 
F:  5’-CTCAACAGAAACACCGCATC-3’ 
R:  3’-GCGGTGGATGGAGAAATAGA-5’ 119 
SNAP47 
F:  5’-TCAGAAGCGCAAGAACCTCT-3’ 
R:  3’-GTTCCTGGGTATCTGCCTCA-5’ 174 
STAT6 
F:  5’-GGAAGGGCACTGAGTCTGTC-3’ 
R:  3’-GGCTTTGGCATTGTTGTCTT-5’ 155 
PCM1 
F:  5’-CCCAGAGCAGGCAGAATTAG-3’ 
R:  3’-AAGGGCTTTCGGTTTTCACT-5’ 141 
PSM2 
F:  5’-CACTACCTGTGCGCCATAAG-3’ 
R:  3’-CAGGCTGTCGTTTTCCTTGT-5’ 147 
TFRC 
F:  5’-TGGACAGCACAGACTTCACC-3’ 
R:  3’-ACGCCAGACTTTGCTGAGTT-5’ 146 
 
6. Functional HBO1 Evaluation using a Transient RNAi-based Knockdown 
System 
Target / Primer Sequence Product size 
BST2 F:  5’-TCTCCTGCAACAAGAGCTGA-3’ R:  3’-CCCTCAAGCTCCTCCACTTT-5’ 150 
ISG15 F:  5’-GACAAATGCGACGAACCTCT-3’ R:  3’-GCTCACTTGCTGCTTCAGG-5’ 111 
STAT1 F:  5’-TGGGCTCAGCTTTCAGAAGT-3’ R:  3’-CTGGCGTTAGGACCAAGAAG-5’ 113 
CD46 F:  5’-GTCCAGTGCCTCAGGTCCTA-3’ R:  3’-CACAGCAATGACCCAAACAT-5’ 115 
FGFR4 F:  5’-TGGAGTCCCGGAAGTGTATC-3’ R:  3’-GCCCAAAGTCAGCAATCTTC-5’ 90 
YAP1 F:  5’-CTCGAACCCCAGATGACTTC-3’ R:  3’-TCCAAGGTCCACATTTGTCC-5’ 140 
AAK1 F:  5’-GGCACAGGCGTATTCTCAGT-3’ R:  3’-GAGGAGAGCCTGATGGAGTG-5’ 147 
NUCKS1 F:  5’-CGGCCTGTCAGAAATAGGAA-3’ R:  3’-GCCCGAATCTCTTCCATAATC-5’ 87 
STK11IP F:  5’-GCTCTTCCTGGATGTTGAGG-3’ R:  3’-CGGTCAGACACAACCACAAG-5’ 123 
MIB1 F:  5’-TGCCAATGGAGATGTTGCTA-3’ R:  3’-GACATCCACGTTTTGCTTCA-5’ 154 
SPAST F:  5’-GGTCCTGCTCCTACCACTCA-3’ R:  3’-AAGGTTGCTGTCCACATTCC-5’ 126 
SUMO1 F:  5’-CAAAGACAGGGTGTTCCAATG-3’ R:  3’-TCCATTCCCAGTTCTTTTGG-5’ 103 
CCNG2 F:  5’-GCTACCCCGGAGAATGATAA-3’ R:  3’-AAGAGCCAAGAACCTGTCCA-5’ 144 
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DACT1 F:  5’-ACAGACAGTCGGCCTAGCTC-3’ R:  3’-GTGCTGGAATGACAACTGGA-5’ 116 
SLC2A12 F:  5’-AGGGATGCTCTTTGGAACAA-3’ R:  3’-TGAGGCTGTTTTGGCACTAA-5’ 112 
NIPAL1 F:  5’-CCTCTGGGTGCTTTGAGTGT-3’ R:  3’-CCATCACAGTTGACCCCAAT-5’ 121 
PLAGL2 F:  5’-GCAACCAGAGCAGAGACCAT-3’ R:  3’-GTCCTTGCGGTGAAACATCT-5’ 151 
SAR1A F:  5’-CAATATCCAATGTGCCAATCC-3’ R:  3’-ATTCCCCTTTCCTGTGGTCT-5’ 119 
H2AFY F:  5’-GCCCTGGCTGATGATAAGAA-3’ R:  3’-TGGAGATGGCCTTCAGAATC-5’ 112 
TSPAN2 F:  5’-TCCGAACAGGTCCAACCTAC-3’ R:  3’-CCAATACCGACAATTCCAATG-5’ 116 
KAT2B F:  5’-AGATCCTGATGTGGCTGGTT-3’ R:  3’-AGCAAGGGTTTTGTGTTTCG-5’ 113 
MYC F:  5’-CAGCGACTCTGAGGAGGAAC-3’ R:  3’-CTGTGAGGAGGTTTGCTGTG-5’ 132 
MUC16 F:  5’-CCCTACACCCTGGACAGAAA-3’ R:  3’-GAGAGGGCCAGCAGATGTAG-5’ 153 
DDX60 F:  5’-AGGGAGATGACCCAGAGGAT-3’ R:  3’-TAGCCCTCTTTCACCAGGAA-5’ 142 
IFI44 F:  5’-AGCCGTAGTGGGGTCTGATA-3’ R:  3’-TGTCATCCATGCACAGTCCT-5’ 152 
RSAD2 F:  5’-CTCGCCAGTGCAACTACAAA-3’ R:  3’-AGAAATGGCTCTCCACCTGA-5’ 148 
IFNA/α F:  5’-CTGAAACCATCCCTGTCCTC-3’ R:  3’-ATCACACAGGCTTCCAGGTC-5’ 151 
IFNB/β F:  5’-CAGCAGTTCCAGAAGGAGGA-3’ R:  3’-AGCCAGGAGGTTCTCAACAA-5’ 126 
IFNG/γ F:  5’-TGACCAGAGCATCCAAAAGA-3’ R:  3’-TGTATTGCTTTGCGTTGGAC-5’ 147 
 
 
2.3.3 qRT-PCR 
qRT-PCR experiments were conducted in a LightCycler®480 II instrument 
(05015243001, Roche) with the LightCycler®480 Software 1.5.0 SP3 (Version 
1.5.0.39), using 384-well LightCycler®480 Multi-well Plates (4729749001, Roche) 
and Thermal Seal RT™ sealing films (TS2-100, EXCEL Scientific, Inc.). Each qRT-
PCR reaction was used to detect the presence of a specific cDNA sequence in the 
target sample by means of primer pair amplification, allowing for the determination 
of gene transcript enrichment relative to a standard or reference gene (Bustin et al. 
2009). 
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The different components of each qRT-PCR reaction were assembled in a sample 
mixture that contained: 5µl of 2X Roche 480 SYBR Green I MasterMix 
(04707516001, Roche), 1µl of nuclease-free water (AM9937, Thermo Scientific™), 
2µl of diluted cDNA sample (1/10 dilution in nuclease-free water unless specified 
otherwise) and 2µl of primer mix (1µl of each forward and reverse primer stock 
[1µM]). An example of the process of preparation of qRT-PCR reaction mixtures is 
depicted in Table 2.5. 
 
 
Table 2. 5 Example of master mix sample preparation for qRT-PCR 
 
Master mix 
(MM) 
Composition Vol. 
MM 
Separation 
3 reactions 
Addition of 
Primer mix 
Total Vol. 
(Reaction) 
Treatment 
(3 reactions) 
15µl SYBR 
24µl 
8µl 2µl Reference 
10µl 
3µl water 8µl 2µl Query 1 
6µl cDNA  8µl 2µl Query 2 
Control 
(3 reactions) 
15µl SYBR 
24µl 
8µl 2µl Reference 
3µl water 8µl 2µl Query 1 
6µl cDNA  8µl 2µl Query 2 
 
 
In the first place and depending on the number of interrogated transcripts/qRT-PCR 
reactions, different quantities of SYBR Green, water and cDNA were pooled 
together in a master mix (Table 2.5). Next, each master mix was separated into a 
number of 8µl aliquots using 8-Strip Tubes (T-3218, BioExpress) and loaded into the 
384-well plate. After this, the correspondent primer mix (2µl) was added to the wells 
in order to achieve a final volume per reaction of 10µl (Table 2.5). This 
methodology ensured that every qRT-PCR reaction, both interrogating queried 
transcripts and reference genes, used the same cDNA. 
 
After the sample preparation, loaded 384-well plates were centrifuged for 3 min 
(4°C) to help mixing of the qRT-PCR reagents. Then, the 384-plate was loaded into 
the LightCycler®480 II instrument where it was subjected to 40 cycles of 
amplification. The specific conditions (e.g. temperature, length) of the amplification 
steps are described in Table 2.6. All samples and controls were assayed in 
duplicates. 
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Table 2. 6 Amplification steps used in qRT-PCR experiments 
 
Steps Temp (°C) Length Ramp (°C/s) Acquisition Cycles 
Pre-incubation 95 10:00 4.8 None 1 
Amplification 
95 00:10 4.8 None 
40 Variable1 00:20 2.5 None 
72 00:20 4.8 Single 
Melting curve 
95 00:05 4.8 None 
1 
65 01:00 2.5 None 
97 - 0.11 
Continuous 
(5 per °C) 
Hold 40 00:30 2.5 None 1 
1Variable: primer pair-dependent, typically 60°C. 
 
 
2.3.4 Analysis of qRT-PCR data 
Relative gene expression was determined following the comparative double delta 
cycle threshold method (ΔΔCT) (Yuan et al. 2006), using ‘glyceraldehyde-3-
phosphate dehydrogenase’ (GAPDH) or ‘ribosomal protein L5’ (RPL5) as 
housekeeping genes to calculate normalised gene expression. The outcome of this 
analysis is a fold-change value (FC), an estimation that measures changes in gene 
expression levels (increase or decrease). An example of the calculation process of 
fold-change values is depicted in Table 2.7. Fold-change values representing a 
decrease in gene expression levels (0 to 1) were converted using the formula [-
1/Fold-change] to facilitate comparisons (Table 2.7: Fold-change) (Schmittgen & 
Livak 2008). 
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Table 2. 7 Example of fold-change calculation following the ΔΔCT method 
 
 
 
The unpaired one-way analysis of variance (ANOVA) statistical analysis was 
performed on treatment and control ΔCT values using Graphpad Prism (Version 6). 
The Tukey’s Honest Significant Difference (HSD) test was used to correct for 
multiple comparisons testing and a confidence level of 95% was selected, defining 
the statistical significance in p-value < 0.05 (*) (Yuan et al. 2006; Rieu & Powers 
2009). Even though certain assumptions (Gaussian/normal distribution) required for 
the use of ANOVA are not fulfilled to perfection on small sample sizes such as those 
used for qRT-PCR, this analysis is commonly used in detriment of more stringent 
non-parametrical test. 
 
 
2.4 End-point Polymerase Chain Reaction 
The Phusion® High-Fidelity DNA Polymerase (M0530S, New England BioLabs®) 
was used to perform end-point polymerase-chain reaction (PCR) experiments using a 
MJ Mini™Personal Thermal Cycler (PTC1148EDU, Bio-Rad). Apart from the 
Phusion® proprietary polymerase and buffer, other components of end-point PCRs 
were dNTPs (10mM), specific primers (10µM) and target DNA or cDNA templates 
(~50ng). Negative controls consisting of regular PCR components without the target 
DNA were conducted alongside every PCR reaction. The concentration of reagents 
and steps conditions of PCR reactions used throughout this thesis are summarized in 
Table 2.8. 
 
Sample Target Average CT 
(𝑥 CT) ΔCT (CT Query – CT Reference) ΔΔCT (ΔCT Treatment – ΔCT Control) Fold-change  (2^(-ΔΔCT)) 
Treatment 
Reference 19.43 - 0 1 
Query 1 27.495 8.06 -1.3 2.46 
Query 2 33.78 14.35 1.61 0.32 (-3.05) 
Control 
Reference 19.75 -   
Query 1 29.11 9.36   
Query 2 32.49 12.74   
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Table 2. 8 Basic components and amplification steps used in end-point PCR 
 
Basic components  Amplification 
Components Quantity  Steps Temp (°C) Length 
Phusion® 
Polymerase 0.5µl  Pre-incubation 98 00:30 
5X Phusion® 
Buffer 4µl  
Amplification 
(25-35 cycles) 
98 00:10 
10mM dNTPs 0.4µl  Variable 00:20 
10µM Primers 1µl  72 Flexible1 
Template DNA 
(~50ng) Variable  Final extension 72 10:00 
Water Variable  Hold 10 ∞ 
1Flexible: Approximately 15-30 seconds per Kb. 
 
 
The size of PCR reaction products was corroborated running the end-samples in 1-
2% agarose gels (A2500, Apex™) using a 1X Tris-acetate-EDTA electrophoresis 
buffer (B49, Thermo scientific™). Ethidium bromide (15585011, Thermo 
scientific™) was used for DNA staining and the resulting fluorescence was observed 
using an Alpha Innotech Fluorchem® FC2 gel imager (10732, Cambridge Scientific). 
Unknown band sizes were determined by comparison with a GeneRuler 100bp DNA 
ladder (SM0241, Thermo scientific™). 
 
 
Table 2. 9 List of primers used for DNA sequencing 
 
Target Sequence Experiment 
HBO1-Tag2B 
(Fig. 2.10) 
F:  5’-CTATGGGAACACACGGGAAC-3’ 
R:  3’-TTGCTTCCCTCTGTGATTTG-5’ 
HBO1-expressing 
vector 
Genomic DNA 
 (Fig. 2.5) 
F:  5’-TTGAACTTGGGGTTTTCAGTG-3’ 
R:  3’-CAGTCAGCCAGATGTGAGGA-5’ 
Gene knock-out 
 
 
When necessary, PCR products were sent to ‘Lone Star Labs’ for DNA sequencing. 
Each PCR product (5 ng/µl) was sequenced twice using specific forward and reverse 
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primers [5µM], achieving a read definition of approximately 600-700 nucleotides per 
primer. The same procedure was applied when sequencing an expression vector; 
only in this case the required product quantity was higher (200 ng/µl) (Table 2.9). 
The 4Peaks (Version 1.7, Nucleobytes) software was used to visualize the resulting 
chromatograms and Clustal Omega was used to perform sequence multiple 
alignment (Sievers et al. 2011). 
 
 
2.5 Western immune-blotting 
2.5.1 Protein extraction and quantification 
Confluent monolayers of cells were washed with ice-cold PBS and then lysed with 
Radio-Immune-Precipitation Assay (RIPA) buffer. RIPA buffer contains 150mM 
NaCl (AM9760G, Thermo Scientific™), 50mM Tris-HCl pH = 7.5 (15567027, 
Thermo Scientific™), 0.5% sodium deoxycholate (D6750, Sigma®), 0.1% Sodium 
Dodecyl Sulfate (SDS) (28312, Thermo Scientific™) and 1% Triton X-100 (T8787, 
Sigma®). Protease inhibitor cocktail (PIC) cOmplete™ (50X) (11697498001, Roche) 
was added to the RIPA buffer (50:1) before each protein extraction. The PIC was 
originally received in individual tablets, which were diluted in 1mL of double-
distilled water, separated into aliquots and stored at -20°C as 50X PIC stock 
solution. Lysed cells were thoroughly agitated every five minutes for half an hour 
using a vortex to ensure cell lysis and release of the protein extract. After this, 
samples were centrifuged at 14,000 rpm (5415R, Eppendorf) (4°C) to isolate the 
protein-containing supernatants. 
 
The concentration of each sample was determined using a standardised bovine serum 
albumin (BSA) concentration curve (A3803, Sigma®) following the Bio-Rad DC™ 
protein assay method (500-0116, Bio-Rad). Both unknown samples and the standard 
curve were loaded into Corning™ Clear Polystyrene 96-well micro-plates 
(Corning™) and tested in triplicates. Finally, a Safire2 micro-plate reader (Tecan) 
and the XFluor4SafireII software (Version 4.62n) were used to calculate samples’ 
absorbance at 750nm. At this point, protein extracts were either used for western blot 
or stored at -80°C for future experimentation. 
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2.5.2 Gel electrophoresis 
All western blots were performed with 10µg of total protein and at RT conditions, 
unless otherwise specified. Protein extracts were mixed 1:1 with 2X Laemmli 
Sample Buffer (161-0737, Bio-Rad) containing 2-Mercaptoethanol (M6250, 
Sigma®), de-naturalised at 98°C for 10 min and then separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) using NuPAGE™ Bis-Tris gels 
(Invitrogen™) and MOPS SDS Running Buffer (NP0001, Thermo scientific™). 
Four-to-twelve per cent gels (NP0321, Thermo scientific™) were commonly used to 
detect medium to large sized proteins, while 10% gels (NP0301, Thermo 
scientific™) allowed for an improved separation of smaller peptides such as 
histones. Samples were then transferred to an Immune-blot® Polyvinylidene 
difluoride (PVDF) membrane (1620177, Bio-Rad), previously activated with High 
Performance Liquid Chromatography (HPLC)-grade methanol (A452, Fisher 
Scientific) for 5 minutes and washed with double-distilled water. 
 
After ninety minutes of transference in NuPAGE® Transfer Buffer (NP0006, Bio-
Rad) containing 20% HPLC-grade methanol, membranes were blocked for 2h with 
5% Non-Fat powdered milk (P-1400, Boston BioProducts) diluted in TBS-T, a Tris-
buffered saline solution (28358, Thermo scientific™) supplemented with 0.1% of 
Tween®20 detergent (10113103, Fisher BioReagents™). All membranes were 
incubated over-night (O/N) on a slow rocking platform at 4°C with the 
correspondent primary antibodies diluted in fresh blocking solution (5% milk in 
TBS-T). Prior to the incubation with the pertinent horseradish peroxidase (HRP)-
conjugated secondary antibody, membranes were heavily washed with TBS-T in a 
rocking platform for thirty minutes. Membranes were then incubated with the 
secondary antibody at RT for 2h in a slow rocking platform shaker (444-0143, 
VWR®) and thoroughly washed again before the band detection. 
 
2.5.3 Band detection and analysis 
Target membranes were treated with Luminata™ Classico (WBLUC0500, 
Millipore™) for 1 minute and then exposed to Blue basic autorad films (F-9023, 
Bioexpress) in the dark. The exposure was conducted using Monotec cassettes 
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(5706, Spectroline®) and the duration of the process varied depending on the 
abundance of the protein of interest and the concentration and specificity of the 
selected antibody. Exposed films were developed in an X-ray film processor (SRX-
101A, Konica Minolta) and digital images were captured and saved as Tag Image 
File Format files (TIFF) using an Alpha Innotech Fluorchem® FC2 gel imager. If 
needed, membranes were stripped for 10 minutes on a fast-paced rocking platform 
using PLUS Stripping Buffer (46430, Thermo scientific™) followed by another 10 
minutes of PBS wash and a new O/N primary antibody incubation. 
 
ImageJ, image processing and analysis in Java software, was used to compare the 
intensity of bands in WB experiments (Schneider et al. 2012). The files were loaded 
onto ImageJ and converted into simple 8-bit grey scale images, formed of shades of 
grey where each pixel carries only intensity information. An example of the process 
of calculation of relative density values and the ratio of intensity is depicted in Table 
2.10. 
 
 
Table 2. 10 Example of relative density calculations in WB analysis 
 
Antibody Peaks Area Per cent (P) 
Relative Density (RD) 
(P target / P standard) 
Ratio  
(R, %) 
Target 
Treatment 3,451 7.91 0.283 28.79 
Control 13,883 31.82 0.983 100 
Standard 
Treatment 12,184 27.92   
Control 14,111 32.34   
 
 
Following the Luke Miller’s outline analysis methodology (Miller 2010), each dark 
band detected on the film was recorded as a peak whose area depended on signal 
intensity. These areas were assigned a percentage value (P) that was subsequently 
used to calculate the relative density (RD) of target antibody samples, treatment and 
control, compared to the correspondent loading standard (Table 2.10). GAPDH 
protein expression was used as standard control throughout the thesis in all WB 
experiments. In cases where the RD of the control peak was very low and to avoid 
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extremely high ratio values of treatment samples, R was expressed in natural 
logarithms. 
 
Even though theoretical investigation points toward a log-normal distribution of WB 
data instead of a Gaussian type, its actual statistical distribution is unknown (Kreutz 
et al. 2007), however, it is quite common to assume that WB data falls within 
parameters close to normality allowing for the use of Student’s t-test and ANOVA 
(Fay & Gerow 2013). Except for those experiments aimed to optimize antibody 
conditions, all immune-blots were performed three times. Two-tailed unpaired 
Student’s t-tests and unpaired one-way ANOVA statistical analyses were performed 
on protein relative density values using Graphpad Prism (Table 2.10). The Tukey’s 
Honest Significant Difference test was used to correct for multiple comparisons 
testing and a confidence level of 95% was selected, defining the statistical 
significance in p-value < 0.05 (*). 
 
 
2.6 Protein Immune-Precipitation 
Every step of the protein immune-precipitation (IP) protocol was performed at 4°C 
unless specifically stated. Approximately 300,000-350,000 cells were cultured 
(37°C) in TC dishes (60x15mm, Falcon®) aiming for 80-90% confluence at the 
moment of extraction. After 24h, total protein was isolated as explained earlier in the 
western immune-blot section using IP-RIPA buffer (150mM NaCl, 50mM Tris pH 
7.5, 1% Triton X-100). In the meantime, Protein A/G beads (sc-2003, Santa Cruz®) 
were centrifuged at 14,000 rpm for one minute (RT), washed twice with PBS and 
one last time with IP-RIPA buffer before they were finally re-suspended in the 
aforementioned buffer (prepared beads). Apart from protein A/G, protein G beads 
(sc-2002, Santa Cruz®) were also tested for IP but rendered disappointing results. 
 
Next, the whole protein extract was pre-cleared by rotation with ‘prepared beads’ for 
1h to reduce non-specific background. Once the clearance step was finished, the 
sample was centrifuged at 14,000 rpm for one minute and the remaining protein 
present in the supernatant was quantified as explained in the western immune-blot 
section. 
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One hundred micrograms of whole protein extract were transferred to a new tube 
labelled ‘Input’ and kept at -20°C to use as antibody-specificity control. The rest of 
the sample was split in two halves (50-50) and subjected to O/N antibody immune-
precipitation on a rotation platform. The first half was incubated with an antibody 
that recognizes the target protein of interest, labelled ‘IP’. Instead, the second half or 
negative control was incubated with a non-specific immunoglobulin G (IgG) 
antibody, labelled ‘IgG’. If possible, both selected specific and non-specific 
antibodies were grown in the same host (e.g. rabbit). 
 
After the O/N IP step, samples were incubated for 2h with newly prepared beads on 
a rotation platform. Immune complexes (bead-antibody-protein) were then 
centrifuged at 14,000 rpm for one minute and washed three times with IP-RIPA 
buffer. At this point, the ‘Input’ was thawed and further processed alongside the ‘IP’ 
and ‘IgG’ samples. All samples were re-suspended in NuPAGE® LDS Sample 
Buffer (NP0007, Thermo Scientific™) and boiled at 98°C for ten minutes prior 
addition of NuPAGE® Sample Reducing agent (NP0004, Invitrogen™). After a 
quick spin to deposit the beads, isolated proteins in the supernatant were separated 
by SDS-PAGE, transferred to a PVDF membrane and incubated for antibody 
detection as indicated previously in the western immune-blot section. 
 
The Clean-Blot IP Detection Kit (21232, Thermo Scientific™) was employed for 
western immune-blots where the resolution of proteins of interest was interfered by 
fragments of de-natured IgG (e.g. ING4). This kit contains special blocking buffer, 
detection reagent and chemo-luminescent substrate, which substitute the western 
immune-blot materials used in the steps following the transference of proteins to a 
PVDF membrane. The protocol was performed according to manufacturer’s 
instructions.  
 
 
2.7 Hormonal Treatment 
Cells were cultured O/N (37°C) in Costar™ Corning™12-Well Clear TC-treated 
plates until they reached 70-80% confluence. Prior to the treatment, growth medium 
was replaced with DMEM/F-12 medium (without phenol red) (11039021, Thermo 
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Scientific™) supplemented with 10% of Charcoal Stripped FBS (12676029, Thermo 
Scientific™). After 24h, cells were treated with estradiol (1-10-100nM) (E2758, 
Sigma®) diluted in absolute ethanol (BP2818, Fisher Bioreagents™) for 4, 8, 24 and 
48h, whereupon RNA samples were collected. Cells treated with absolute ethanol 
alone (vehicle) were used as control. 
 
 
2.8 Immune-fluorescence Staining 
Cells were cultured O/N (37°C) in Nunc™ Lab-Tek™ II 4-Well Chamber Slides 
(154526, Thermo Scientific™) to achieve 50-60% confluence. After 24h, cells were 
washed with PBS twice and fixed with 3.7% Formaldehyde (F8775, Sigma®) diluted 
in PBS for 10 minutes (RT). Then, cells were washed three times for 10 minutes, 
permeabilized with 0.25% Triton X-100 and washed three times again. 
Subsequently, the slides were blocked for 1h with 3% BSA diluted in PBS. 
Following this step, fixed-cells were incubated with the selected primary antibody 
diluted in blocking solution for 4h in a dark humidified chamber (4°C). Samples 
were then washed three times, incubated with secondary antibody for 1h (same 
conditions as with the primary antibody) and washed three times again. One chamber 
was always incubated with secondary antibody alone as fluorescence control. 
 
Finally, the samples were mounted with Fisherbrand™ Rectangle Cover Glasses 
(12-545K, Fisher Scientific), prior addition of a drop of Vectashield® mounting 
solution containing 4’, 6-Diamidine-2’-phenylindole dihydrochloride (DAPI) (H-
1200, Vector Laboratories). To prevent any coverslip motion and for long-term 
storage, the edges of the cover glass were secured using Electron Microscopy 
Sciences nail polish (72180, Fisher Scientific). 
Bright-field cell images were taken with a Nikon Eclipse Ti (Nikon®) microscope 
supplied with a Photometrics® CoolSNAP HQ2 camera (Roper Scientific™) and the 
NIS-Elements Advanced Research imaging software (Version 4.00.07, Build 787). 
Additionally, DAPI and fluorescein signal were detected using this instrument. 
DAPI staining emits blue fluorescence upon binding to adenosine-thymidine regions 
of DNA, whereas the Alexa Fluor® 488 secondary antibody emits green 
fluorescence. 
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2.9 Subcellular Protein Fractionation 
The Subcellular Protein Fractionation Kit for Cultured Cells (78840, Thermo 
Scientific™) was used to separate cytoplasmic, membrane, nuclear soluble and 
chromatin-bound protein extracts in mammalian cells. The protocol was conducted 
following manufacturer’s instructions, using approximately 200,000 cells grown in a 
Corning® 100mm TC-treated Culture Dish (430167, Corning®) for 24h (37°C). After 
the extraction, protein extracts were quantified, run through SDS-PAGE 
electrophoresis and analysed following the protocol described previously in the 
western blot section. The subcellular protein fractionation was performed three times 
with three biological replicates of UWB1.289 cells. Percentages of localization were 
calculated following the indications illustrated in Table 2.11 below these lines. 
 
 
Table 2. 11 Example of ‘percentage of cell localization’ calculations 
 
Antibody Peaks Area 𝒙 Percentage 
Target 
Cytoplasmic fraction 6,053 14.76 ± SD 
Membrane fraction 956 2.33 ± SD 
Nuclear soluble fraction 16,262 39.66 ± SD 
Chromatin-bound fraction 17,730 43.24 ± SD 
 
 
 
2.10 Chromatin Immune-precipitation coupled to qRT-PCR 
Different ChIP procedures were used throughout the elaboration of this thesis: EZ-
Magna ChIP™ A/G (17-10086, Millipore™), Chromatrap® Pro-A ChIP Kit 
(500189, Chromatrap), Chromatrap® Native ChIP Kit (500237, Chromatrap) and a 
non-commercial ChIP protocol outlined in the laboratory of Paul Webb in the 
Houston Methodist Research Institute, Houston, United States. In addition, the Cell 
Fixation protocol of the Active Motif® Epigenetics Services was followed in order to 
fix and prepare UWB1.289 cells for shipment to the Active Motif® laboratories. The 
main protocol stages of the general ChIP procedure are depicted in Figure 2.1 A. 
 
Materials	and	Methods	
	 92	
	
Figure 2. 1 Main characteristics of ChIP and ChIP-qRT-PCR primer design 
(A) Main protocol stages of general ChIP procedures; image taken from ‘First 
Analysis of Tumor-Suppressor Interactions with Whole Genome…’ (McNulty & 
Gender 2011). (B) Illustrative depiction of antibody binding for anti-HBO1, anti-
H3K4me3, IgG and ‘Input’ ChIP samples on a putative HBO1-target gene. Images 
were obtained using the Integrative Genomics Viewer. (C) Generation of specific 
ChIP-qRT-PCR primers targeting both enriched and negative control regions. 
 
 
Common to all ChIP protocols, cells were cultured in 100x20mm TC-treated dishes 
(25-203, Genesee Scientific) (37°C) to reach 90-95% confluence (~10-12 million 
cells). Next, a 1% formaldehyde solution (F8775, Sigma®) was used to cross-link 
chromatin with adjacent interacting proteins and protein complexes, followed by a 
series of chromatin isolation steps that are detailed in the manual of instructions of 
each manufacturer. Cross-linked chromatin was then sheared using a Bioruptor™ 
(UCD-200, Diagenode) (4°C) under different sonication settings, which were 
optimized for each cell line and include varying number, length and power (low, 
medium or high) of sonication cycles. The sonication efficiency was validated 
resolving sheared-chromatin fragments by electrophoresis in 1-2% agarose gels. 
 
All ChIP protocols targeted cross-linked chromatin for immune-precipitation with at 
least 3 different antibodies: (1) the target antibody (e.g. anti-HBO1) (2) a positive 
control antibody (e.g. anti-H3K4me3) and (3) a negative control IgG antibody from 
the same species as the selected target antibody (e.g. rabbit) (Fig. 2.1 B). Likewise, 
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all ChIP protocols set aside a fraction of cross-linked sheared chromatin that is not 
selectively enriched with any antibody, the ‘Input’. This chromatin fraction is used 
as base-line control of antibody enrichment for ChIP-qRT-PCR and ChIP-Seq. 
 
2.10.1 Chromatrap® and EZ-Magna ChIP protocols 
Unlike the other ChIP protocols, the Chromatrap® Native ChIP protocol did not 
require chromatin cross-linking and sonication, using an enzymatic approach to 
segment chromatin naturally bound to protein complexes. The Native ChIP protocol 
was performed following manufacturer’s instructions, using 10K MWCO 3mL 
Slide-A-Lyzer® Dialysis Cassettes (66380, Thermo Scientific™), Slide-A-Lyzer® 
Cassette Syringes (66490, Thermo Scientific™) and Float Buoys (66430, Thermo 
Scientific™) for the O/N dialysis procedure. Additionally, the DNA purification step 
required the use of Sodium Acetate Solution (3M, pH = 5.2) (R1181, Thermo 
Scientific™). 
 
The Chromatrap® Pro-A ChIP Kit (Chromatrap) uses spin columns with an inert, 
porous polymer covalently bound to Protein A that captures the target 
chromatin/antibody complex. Protein A was selected in detriment of Protein G for 
anti-HBO1 antibody purification due to its higher affinity and specificity for the tail 
region (fragment crystallisable region, Fc) of rabbit (Table 2.3: AB70) and mouse 
IgG2b (Table 2.3: G-2) antibodies, according to New England BioLabs®. The 
protocol was conducted following manufacturer’s instructions. In addition to the 
components provided by Chromatrap®, a GeneJET PCR Purification Kit (K0701, 
Thermo Scientific™) was used for DNA purification. 
 
The EZ-Magna ChIP™ A/G Kit protocol was performed following manufacturer’s 
instructions. As the main feature, it uses a blend of protein A and protein G 
paramagnetic beads to isolate sheared cross-linked chromatin, which demanded the 
use of a magnetic article separator DynaMag™-2 (12321D, Invitrogen™). 
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2.10.2 Non-commercial ChIP protocol 
The buffers and solutions used in this protocol are detailed in Table 2.12. As 
opposed to the commercial ChIP protocols, this one is designed to immune-
precipitate DNA from 30M cells (~3x 100x20mm TC-treated dishes), and can be 
scaled to up to 100-200M. 
 
In day one of the protocol, 1mg of Dynabeads® Protein A magnetic beads (1001D, 
Thermo Scientific™) were washed with 1mL of blocking buffer (0.5% BSA diluted 
in PBS) three times for 5 minutes and incubated O/N on a rotation platform (4°C) 
with 0.5mL of blocking buffer and the appropriate volume of target antibody (10µg). 
Bead washes were conducted using the magnetic article separator DynaMag™-2. 
The day after, adherent cells were fixed with a 1% formaldehyde solution (1mL 11% 
formaldehyde solution + 10mL cold PBS) for 10 minutes in a slow rocking platform 
at RT (Table 2.12). Importantly, all buffers and solutions used during the fixation 
and sonication steps were supplemented with fresh 1X Halt™ PIC (78430, Thermo 
Scientific™). 
 
The cross-linking process was quenched by the addition of 2.5M Glycine (G7403, 
Sigma®) for three minutes whereupon cells were washed with cold PBS twice, 
scraped and transferred to a Nunc™ Conical Sterile tube 15mL (339651, Thermo 
Scientific™). Immediately after, cells were centrifuged at 1350G for 5 minutes 
(4°C), re-suspended in 5mL of lysis buffer 1 and incubated 10 minutes on a rotation 
platform (4°C). The same procedure was repeated with the lysis buffer 2 (Table 
2.12). 
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Table 2. 12 Recipes for the non-commercial ChIP protocol 
 
Solution Composition Target concentration 
11% Formaldehyde 
solution 
 
1M Hepes-KOH, pH = 7.51 50 mM 
5M NaCl 100 mM 
0.5M EDTA, pH = 8.0 1 mM 
0.5M EGTA, pH = 8.02 0.5 mM 
37% Formaldehyde 11% 
Lysis buffer 1 
1M Hepes-KOH, pH = 7.5 50 mM 
5M NaCl 140 mM 
0.5M EDTA, pH = 8.0 1 mM 
Glycerol 10% 
NP-40 / Igepal CA-6303 0.5 % 
Triton X-100 0.25 % 
Lysis buffer 2 
Tris-HCl, pH = 7.5 10 mM 
5M NaCl 200 mM 
0.5M EDTA, pH = 8.0 1 mM 
0.5M EGTA, pH = 8.0 0.5 mM 
Sonication buffer 
1M Hepes-KOH, pH = 7.5 50 mM 
5M NaCl 140 mM 
0.5M EDTA, pH = 8.0 1 mM 
0.5M EGTA, pH = 8.0 1 mM 
Triton X-100 1% 
Sodium deoxycholate 0.1 % 
Sonication buffer 
high salt 
1M Hepes-KOH, pH = 7.5 50 mM 
5M NaCl 500 mM 
0.5M EDTA, pH = 8.0 1 mM 
0.5M EGTA, pH = 8.0 1 mM 
Triton X-100 1% 
Sodium deoxycholate 0.1 % 
SDS 0.1 % 
Lithium chloride 
wash buffer 
Tris-HCl, pH = 7.5 20 mM 
0.5M EDTA, pH = 8.0 1 mM 
Lithium chloride4 250 mM 
NP-40 / Igepal CA-630 0.5 % 
Sodium deoxycholate 0.5 % 
Elution buffer 
Tris-HCl, pH = 7.5 50 mM 
0.5M EDTA, pH = 8.0 10 mM 
SDS 1 % 
1Hepes-KOH (1M) pH = 7.5 (EK-654013, E&K Scientific Inc.) 
2EGTA (0.5M) pH = 8.0 (50-255-956, Bioworld) 
3NP-40 / Igepal CA-630 (I8896, Sigma®) 
4Lithium chloride (L121, Fisher Bioreagents™) 
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Following the lysis step, cell pellets were re-suspended in sonication buffer 
containing SDS (~0.25mL/5M cells) and placed in Bioruptor® Plus TPX tubes 
(C30010010, Diagenode) for sonication. Subsequently, samples were centrifuged at 
top speed for 10 minutes, after which a small fraction of the supernatant was stored 
at -20°C as ‘Input’ and the rest diluted in sonication buffer without SDS (~1mL/5M 
cells). At this point, a fresh blocking solution was used to wash bead-antibody 
complexes (from day one) three times for 5 minutes on a rotation platform (4°C). 
Re-suspended bead-antibody complexes were added to the diluted chromatin and 
incubated on a rotation platform O/N (4°C). 
 
In order to test the sonication efficiency, 10µl of cross-linked chromatin were mixed 
with 90µl of nuclease-free water and 10µl of NaCl (5M), and then boiled for 15 
minutes (98°C). After this, the chromatin sample was incubated with 1µl of RNAse 
A (10 mg/mL) (EN0531, Thermo Scientific™) for 15 minutes (37°C) and 
immediately after with 1µl of Proteinase K solution (20 mg/mL) (AM2548, Thermo 
Scientific™) for another 15 minutes (67°C). The final chromatin sample was 
purified using the MinElute Reaction Cleanup Kit (28204, Qiagen®) and run through 
a 1-2% agarose gel. 
 
On day three of the protocol, the complexes (bead-antibody-protein-chromatin) were 
collected and washed on a rotation platform for 5 minutes (4°C) with different 
buffers in the following order: twice with sonication buffer, once with sonication 
buffer high salt, lithium chloride wash buffer and NaCl-TE Buffer (50µl 5M NaCl + 
5mL (1X) TE pH = 8.0) (Table 2.12). After a quick spin (960G for 3 minutes), bead 
complexes were re-suspended with 200µl of elution buffer and eluted on a heat block 
at 65°C for 15 minutes. After a new spin (20,000G for 30 seconds at RT), the 
supernatant, which contained eluted antibody-protein-chromatin complexes, was 
placed in a heat block at 65°C O/N with NaCl (5M) to reverse cross-linking. At this 
point, the ‘Input’ fraction was thawed, supplemented with 150µl of EB and placed 
together with the rest of the samples in the heat block O/N. 
 
On day four of the protocol, 8µl of RNase A (10 mg/mL) were added to each 
sample, which were then incubated at 37°C for 2h. Subsequently, 7µl of CaCl2 and 
4µl of Proteinase K (20 mg/mL) were added to the samples for a 30 minute 
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incubation at 55°C. Next, 400µl of Ultrapure™ Phenol:Chloroform:Isoamyl Alcohol 
(25:24:1) (15593031, Thermo Scientific™) were added to the mixture. Samples 
were then transferred to a MaXtract High Density tube (129046, Qiagen®) and 
centrifuged at 14,000G for 5 minutes (RT). The isolated DNA fraction was 
transferred to a new tube and mixed with 16µl of 5M NaCl, 1.5µl of Ultrapure™ 
Glycogen (20 µg/µL) (10814010, Thermo Scientific™) and 880µl of 100% Ethanol 
(BP2818, Fisher Bioreagents™). At this point, samples were cooled at -80°C for 1-
2h, centrifuged for 20 minutes at 20,000G (4°C), washed with 0.5mL of 70% ethanol 
and centrifuged again in the same conditions. Finally, DNA pellets were left to air 
dry for approximately 30 minutes and re-suspended in nuclease-free water. 
 
2.10.3 Design and characterization of ChIP-qRT-PCR primers 
First of all, the Integrative Genomics Viewer (IGV, Broad Institute, V 2.3.88) was 
used to localize the target chromosome region to interrogate by ChIP-qRT-PCR 
(Robinson et al. 2011; Thorvaldsdóttir et al. 2013) (Fig. 2.1 B). The selection of 
specific chromosome regions was based on preliminary ChIP-Seq data, including 
positive (expected antibody enrichment) and negative (no expected enrichment) 
regions (Fig. 2.1 B, C). Coordinates for this exact location in the genome were 
copied into the UCSC Genome Browser which enables, through the function ‘Get 
DNA’, the extraction of raw DNA sequences lying between those coordinates 
(human genome assembly GRCh37/hg19) (Kent et al. 2002). Once isolated the target 
DNA region, it was uploaded into Primer3 to, from then on, follow the rest of steps 
used in the design of qRT-PCR primers, except those applied exclusively to mRNA 
features. 
 
To test the efficacy of ChIP-qRT-PCR primers, gDNA was extracted from different 
cell lines using the GeneJET Genomic DNA Purification Kit and sonicated to 
accurately mimic the DNA status of a normal ChIP-qRT-PCR reaction. All validated 
primers used for ChIP-qRT-PCR in this thesis can be found in Table 2.13. 
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Table 2. 13 List of ChIP-qRT-PCR primers 
 
Target Sequence Coordinates GRCh37/hg19 
LMNB2 F: 5’-CTCCACCCCCAAGGAAAAAG-3’ R: 3’-GGCAGGGTCCCATGCA-5’ 
chr19: 2,428,005-
2,428,081 
MCM4 F: 5’-TCTGCACTCCGTTCAGCTCCTCTG-3’ R: 3’-GAGTGAGGATGCCAGGTCATCTCC-5’ 
chr8: 48,874,080-
48,874,400 
SNHG12 F: 5’-GCATAGCTGCTGTGGTCAAA-3’ R: 3’-CGTTCTGCTGTTCTGTGGAA-5’ 
chr1: 28,907,355-
28,907,535 
LUC7L F: 5’-CAGCGCTTGACAGTCGTTAG-3’ R: 3’-ATCTGCACAGCCCTGAGAAT-5’ 
chr16: 278,536-
278,719 
IGR 1 F: 5’-AAATCCGGTGCTGTATCCTG-3’ R: 3’-TTGATTGTGGGGAAGGTTGT-5’ 
chr7: 118,998,664-
118,998,812 
IGR 2 F: 5’-TTGGAGGCTTTGTTCATTCC-3’ R: 3’-TGAGGATTTCGTGACACCTG-5’ 
chr12: 63731970-
63732119 
IGR 3 F: 5’-GTGCATGCAAGCCAGAGTTA-3’ R: 3’-GGGCTAATCACCTGAAACCA-5’ 
chr1: 80,854,465-
80,854,562 
CYR61 F: 5’-CCGAGTCTCACGCGTATCTT-3’ R: 3’-AGTCCTCGTTGAGCTGCTTG-5’ 
chr1: 86,047,015-
86,047,174 
ERBB2 F: 5’-CTCCGGGAACTTGTCAAAGA-3’ R: 3’-GAGGCTGCCAACTGGAAAG-5’ 
chr17: 37856807-
37856949 
ABCC4 F: 5’-GGGGTGTCTCTCTGCTTCTG-3’ R: 3’-TGGGGAGACAATGAAAGTCC-5’ 
chr16: 16,044,012-
16,044,147 
ALCAM F: 5’-GAATTTCCAGGACCTGCTCA-3’ R: 3’-GAGGGTGTGGAAAGGGATTT-5’ 
chr3: 105,087,011-
105,087,165 
TLN1 F: 5’-CCCTGACTCTGCATTTCACA-3’ R: 3’-ATGTGCGGATTAAAGGTTGG-5’ 
chr9: 35,730,626-
35,730,762 
ANKRD1 F: 5’- TTTTGCATTGGAGGTTTTCC-3’ R: 3’- ATGCTTGGAAGGACATTTGG-5’ 
chr10: 92677412-
92677561 
CASP7 F: 5’-TGGTTGAGTGGGACTGAGTG-3’ R: 3’-ACGAGCCCTCCTCTCCTAAA-5’ 
chr10: 115,439,860-
115,440,027 
PKP4 F: 5’-CGGCTGTCTGTCCTTCTAGC-3’ R: 3’-AGTACAGGACTTCGGGGACA-5’ 
chr2: 159314186-
159314292 
MRS2 F: 5’-GTCCCACTCGCTCAGAATG-3’ R: 3’-GAGGAGAAGGCAGAGGGTTG-5’ 
chr6: 24,403,627-
24,403,708 
NR2F2 F: 5’-GTCGCCTTTATGGACCACAT-3’ R: 3’-CTCAGGTAGGAAGGAGCCCT-5’ 
chr15: 96,876,802-
96,877,994 
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2.10.4 Analysis of ChIP-qRT-PCR data 
ChIP-qRT-PCR experiments were conducted using the same machinery, reagents 
and protocols as in the qRT-PCR section. However, due to the low abundance of 
immune-precipitated DNA, samples were not diluted in nuclease-free water during 
the master mix preparation step (Table 2.5). Antibody enrichment was determined 
using the percentage of input calculation methodology (Nagaki et al. 2003; Cawley 
et al. 2004), illustrated below these lines in Table 2.14. Input CT values obtained 
with the EZ-Magna ChIP™ Kit protocol were adjusted from 1% to 100% before the 
analysis. All samples and controls were assayed in duplicates. 
 
 
Table 2. 14 Example of ‘percentage of input’ enrichment calculations 
 
Sample Antibody 
Average CT 
(𝒙 CT) Percentage of Input (%) (100*2^(Input CT - IP CT)) 
Target region 
(Table 2.13) 
IP 
Target protein 30.88 0.10 
Positive control 25.89 3.34 
Negative control 30.98 0.098 
No IP Input 20.00  
 
 
 
2.11 Structured Query Language Relational Database 
Structured query language (SQL) relational databases allow for the efficient and 
convenient storage of, and access to, massive amounts of information (Rice et al. 
2004). Its design is based on the relational model of data, which organizes data into 
tables of columns and rows with unique keys identifying each column (Codd & F. 
1970). Specifically, an SQL relational database containing information about OC 
and HBO1 was built, allowing the comparison and association of personal data (e.g. 
gene profiles) and accessible online material (NCBI databases). The SQL relational 
database was built using the SQLite library, accessible through the Mozilla Firefox® 
add-on SQLite Manager. An example of one of the common uses of this SQL 
database is depicted in Figure 2.2 below these lines. 
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Figure 2. 2 Example of SQL relational database correlations 
The ‘Tables’ or datasets of an SQL relational database store vast amounts of data, 
which can be interconnected through the use of SQL language, thus rendering 
meaningful combinatorial outcomes. In this instance, the database was used to 
correlate the results of an Illumina® microarray, which provides solely Illumina® 
probe identifiers for each target gene, with a dataset containing the official gene 
symbols associated to each Illumina® probe identifier. As a result of this comparison, 
microarray expression results could be directly associated with official gene 
symbols, facilitating to a large extent further analyses. 
 
 
 
2.12 ChIP combined with Sequencing 
2.12.1 Preparation of samples and acquisition of data 
During the development of this thesis, ChIP-Seq data was gathered from multiple 
sites including: (1) the Gene Expression Omnibus data repository of the NCBI (GEO 
Datasets), (2) the Epigenetics Services of Active Motif® (AM) and (3) the 
Epigenomics Core Facility of Weill Cornell Medical College. 
 
The Active Motif® Epigenetics Services ChIP-Seq raw data was obtained performing 
a ChIP Antibody Validation procedure on a fixed pellet of UWB1.289 cells. 
According to the AM results report, 30µg of UWB1.289 cell chromatin and 5µg of 
AB70 HBO1 antibody were used to conduct a ChIP-Seq. The process included the 
use of a True-Seq ChIP Library Preparation Kit (IP-202-1012, Illumina®) and a 
HiSeq 2500 System (Illumina®) that generated approximately 2M reads. ChIP-Seq 
raw data was then deposited to a downloadable File Transfer Protocol (FTP) site. 
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Six ChIP samples, two ‘Input’, two ‘HBO1’ and two ‘H3K4me3’ IPs obtained from 
UWB1.289 cells using the Chromatrap® Pro-A ChIP kit, were sent to the 
Epigenomics Core Facility at Weill Cornell Medical College to conduct ChIP-Seq. 
The Quant-iT™ dsDNA High-Sensitivity Assay Kit (Q-33120, Thermo Scientific™) 
was used to accurately quantify DNA concentrations. The DNA quantification was 
performed following manufacturer’s instructions, using a Corning™ Clear 
Polystyrene 96-well micro-plate (Corning™) to measure samples, blank and 
standards in triplicates. The standard curve was designed to cover a low DNA 
quantity range (0-20ng) due to the small amounts of immune-precipitated samples. 
Resulting fluorescence was measured with a Safire2 micro-plate reader and the 
XFluor4SafireII software at standard fluorescein wavelengths (480Ex/530Em nm). The 
final sample quantities sent to the Epigenomics Core Facility were 60ng of ‘Input’ (5 
ng/µl) and ~22-25ng of ‘H3K4me3’ and ‘HBO1’ (1 ng/µl). 
 
Again, the Epigenomics Core used the True-Seq ChIP Library Preparation Kit and a 
HiSeq 2500 System to conduct Single-Read Clustering DNA Sequencing (1x50 
sequencing cycles, maximum 50bps per DNA). All samples were multiplexed into 
one lane, allowing the sequencing of approximately 30M reads per sample and the 
ChIP-Seq raw data was finally deposited to PubShare for downloading. 
 
2.12.2 Analysis of ChIP-Seq raw data 
ChIP-Seq raw data, including at least a sample and the corresponding ‘Input’ in 
FASTQ format, were downloaded and deposited into a Linux high performance 
computer (HPC) cluster server. Alongside the ChIP-Seq data analysis, the terminal 
tool for Mac Os X provided a line interface to control the underpinnings of the Linux 
operating system, while FileZilla 2 was used to transfer HPC data results to a 
personal computer. 
 
Occasionally, ChIP-Seq GEO DataSets were compiled into Sequence Read Archives 
files or SRAs, in which case the SRA ToolKit was used to convert them into FASTQ 
files (Staff 2011). Prior to the ChIP-Seq analysis, the FastQC programme (Leggett et 
al. 2013) was used to assess the quality of next-generation sequencing data (Fig. 
2.3). 
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Figure 2. 3 Workflow diagram of the ChIP-Sequencing analysis pipeline 
 
 
ChIP-Seq reads were aligned to the GRCh37/hg19 genome alignment using Bowtie 
(Langmead et al. 2009), which generated SAM files that were subsequently 
converted into BAM format using SAMTools (Li et al. 2009) (Fig 2.3). At this point, 
the software for ChIP-Seq Analytics and Confidence Estimation (CHANCE) (Diaz 
et al. 2012) was used to derive genome-wide indications of ChIP enrichment 
(‘Sample’ versus ’Input’), estimating the strength and quality of immune-
precipitation to identify potentially failed experiments (Fig. 2.3 & Fig. 2.4). As well 
as with the FastQC programme, this report is merely an indication of ChIP-Seq 
quality, and its result does not preclude from pursuing the whole analysis. 
 
Next, BAM files were analysed using the Model-based Analysis for ChIP-Seq 2 
(MACS2) (Y. Zhang et al. 2008; Feng et al. 2012) in order to derive significantly 
enriched peaks in the pertinent sample compared to the ‘Input’. MACS2 package 
analysis generated Browser Extensible Data (BED) files, which included the 
genomic localization and intensity of each derived peak. Using a SQL relational 
database and a Python script (Bassi 2007), genomic peak localizations compiled into 
BED files were linked to potential gene regulatory mechanisms based on sequence 
proximity. 
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Additionally, BAM files were used to derive individual Trusted Data Format or TDF 
files, viewable in the IGV browser (Fig. 2.1 B). In doing so, BAM files were 
processed using BEDTools (Quinlan 2014) and IGVTools (Broad Institute). 
 
 
	
Figure 2. 4 Example of CHANCE analysis on ChIP-Sequencing data 
To estimate IP strength, CHANCE decomposes the population of IP reads into two 
distinct components: those pulled down by the antibody or signal reads, and 
background reads. The level of IP enrichment strength is used to classify whether an 
experiment was (A) successful or (B) failed. 
 
 
 
2.13 Plasmid DNA Transfections 
Several plasmid transfection methods were used throughout the elaboration of this 
thesis. In order to test the efficiency and toxicity of each reagent, a pmaxGFP™ 
Vector (Lonza) was transfected into target cells. Green fluorescent protein (GFP) 
signal was then visualized using the imaging equipment described in the immune-
fluorescence section. 
 
Generally, cells were cultured O/N (37°C) in Costar™ Corning™12-Well Clear TC-
treated plates to reach 60-80% confluence, depending on the cell line (e.g. 
UWB1.289 70,000 cells/well), and analysed 24h post-transfection. The amounts of 
pmaxGFP™ Vector and transfection reagent were selected following manufacturer’s 
indications. The different transfection reagents used in this thesis are listed below 
these lines (Table 2.15). 
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Table 2. 15 List of reagents used for plasmid DNA transfection 
 
Transfection Reagent Product Provider 
FuGENE® HD E2311 Promega® 
Lipofectamine® 3000 L3000 Invitrogen® 
Lipofectamine® LTX & PLUS™ 15338 Invitrogen® 
TransFectin™ Lipid 170335 Bio-rad 
TurboFect™ R0531 Thermo Scientific™ 
UltraCruz® 395739 Santa Cruz® 
X-tremeGENE™ 9 6365779 Roche 
X-tremeGENE™ HP 6366244 Roche 
 
 
Alternatively, certain DNA plasmids were transfected via electroporation using the 
Nucleofector™ 2b Device (AAB-1001, Lonza) following manufacturer’s 
instructions. The Amaxa® Cell Line Optimization Nucleofector® Kit (VCO-1001N, 
Lonza) and the pmaxGFP™ Vector were used to optimize the electroporation 
conditions of UWB1.289 cells. Efficient transfection of UWB1.289 cells was 
achieved with the Nucleofector™ Kit V (Programme A-020). 
 
 
2.14 Dot-blot 
The aim of the dot-blot (DB) experiments performed in this thesis was to simply 
detect either the presence or absence of a target protein in a cell protein lysate; hence 
there was no need to conduct protein quantification. Total protein extraction was 
conducted as described previously in the first part of the western immune-blot 
section and every step of the dot-blot, apart from the aforementioned protein 
extraction, was conducted at RT. 
 
Immediately after the protein extraction, a small fraction of each sample (usually 
2µl) was loaded onto two different Amersham™ Hybond™-ECL nitrocellulose 
membranes (RPN303D, GE Healthcare) and left to dry in order to fix the proteins for 
2h. During the fixation process, membranes were kept still and inside a container to 
avoid contamination. Next, non-specific sites were blocked using blocking solution 
(TBS-T with 2% milk) for 30 minutes in a slow rocking platform. At this point, 
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while one membrane was incubated with the target antibody, the other was incubated 
with a control antibody, both diluted in blocking solution. A β-Actin antibody was 
used as control in all DB experiments since the GAPDH antibody did not work very 
well in this particular setting. Membranes were incubated with primary antibodies 
for one hour in a slow rocking platform, followed by repeated washes with TBS-T 
and the incubation with the pertinent secondary antibody for another hour. After 
several final washes, the absence or presence of protein dots in the membranes was 
analysed as indicated in the band detection part of the western blot section. 
 
 
2.15 HBO1 Knock-OUT 
2.15.1 Knock-OUT preliminary steps 
The Alt-R™ CRISPR-Cas9 System (Clustered Regularly Interspaced Short 
Palindromic Repeats) from IDT® was selected to manipulate the genome of OC cells 
seeking to constitutively eradicate HBO1 expression (knock-out, KO). The specific 
aim of CRISPR-Cas9 was to disrupt the HBO1 locus genome sequence, altering the 
function of the resulting protein and/or completely abolishing its derivate expression. 
The principal constituents of the CRISPR/Cas-9 mediated gene disruption system 
were: a CRISPR RNA sequence guide (crRNA guide) specific to the target DNA 
(Fig. 2.5), a recombinant form of Cas9 protein with endonuclease activity and a 
trans-activating crRNA sequence (tracrRNA), which interacts with both the Cas9 
protein and the crRNA (Fig. 2.5 C). The resulting complex causes target-specific 
double-stranded DNA cleavage, which is commonly repaired by the NHEJ DNA 
repair pathway, an error-prone process that could result in insertions and/or deletions 
(INDELs) that disrupt gene function. 
 
Specific crRNA guides targeting the HBO1 locus were designed using the CRISPR 
Design tool following manufacturer’s recommendations (Haeussler et al. 2016), 
which pinpointed the importance of early INDEL target sites that could render more 
altered proteins in case of the introduction of frame-shift mutations. Accordingly, the 
selected target region for HBO1 KO was the exon 2, common to the five alternative 
splice variants of HBO1 and localised in chromosome 17 with coordinates 
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47,869,247-47,869,395  (GRCh37/hg19) (Fig. 2.5 A). As a result of the ‘CRISPR 
Design’ search, eight potential crRNA guides were found in this region, each one 
with a score depending on individual qualities (Fig. 2.5 A, B). A determining aspect 
for the selection of crRNA guides is the presence of a 5’-NGG-3’ (N: any nucleotide 
base) proto-spacer adjacent motif (PAM) immediately following the targeted DNA 
sequence (Fig. 2.5 B, C). This motif is recognized by the Cas9 protein and is 
indispensable for gene editing. 
 
	
Figure 2. 5 Selection of CRISPR RNAs targeting the HBO1 locus 
(A) Graphical depiction of the localization of target CRISPR RNA guides in regard 
to the HBO1 exon 2 locus, including (B) respective quality scores provided by the 
‘CRISPR Design’ tool and (C) the main structure of potential crRNA:tracrRNA 
complexes. 
 
 
CRISPR RNA guides 1 and 3 (2nmol) (Table 2.16), Alt-R™ S.p. Cas9 Expression 
Plasmid (1072566) (Fig. 2.6 A) and the CRISPR-Cas9 Control Kit (1072554) were 
purchased from IDT®. The latter included crRNA targeting positive control 
‘hypoxanthine phosphoribosyltransferase 1’ (HPRT) (2nmol), crRNA Negative 
Control (2nmol), tracrRNA (5nmol), HPRT PCR Primer Mix (2nmol each primer) 
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and Nuclease-Free Duplex Buffer. The Alt-R™ CRISPR Negative Control crRNA 
contains a nucleotide sequence that is computationally designed to be non-targeting 
in the human genome. 
 
 
Table 2. 16 List of CRISPR RNA sequences and HBO1-knockOUT primers 
 
Target Sequence Description 
HBO1 exon 2 
(Fig. 2.5 A) 
5’-GGUGACUCGAGCAGAUCGUC-3’ crRNA 1; KO 
5’-UGUAGAAAAAUCGGAAUCUU-3’ crRNA 3; KO 
F:  5’-GAGAGCGAATGAAACGGAAG-3’ 
R:  3’- TATCACTGGCCCAGGAAAAG-5’ Primers; T7EI test 
 
 
The Alt-R™ S.p. Cas9 expression plasmid was transformed into NEB® 5-alpha 
competent Escherichia coli (E. coli) cells following manufacturer’s instructions. 
Transformed E. coli cells were spread onto lysogeny broth agar selection plates 
(BP9724, Fisher BioReagents™) containing 50 µg/mL of ampicillin (A0166, 
Sigma®) and incubated O/N at 37°C. Next, positive colonies were grown in 5mL of 
steriliSed lysogeny broth (BP9723, Fisher BioReagents™) containing 50 µg/mL of 
ampicillin (O/N, 37°C). A considerable fraction of the broth containing O/N grown 
cells (4/5) was mixed 2:1 with 50% Glycerol (BP229, Fisher BioReagents™) and 
kept in -80°C as a stock. The remaining cells were subjected to plasmid extraction 
using a QIAprep Spin Miniprep Kit (27104, Qiagen®). 
 
Aside from the Streptococcus pyogenes (S.p.) Cas9 gene (Marraffini 2016), an 
ampicillin resistance cassette and a cytomegalovirus (CMV) promoter, the Alt-R™ 
S.p. Cas9 Expression Plasmid encompasses a V5 epitope tag (Southern et al. 1991), 
which facilitates the recognition of Cas9-expressing cells via dot-blot (Fig. 2.6 A). 
Prior to dot-blotting V5, the Anti-V5 Tag antibody was tested via western blot to 
ensure the recognition of a single band. 
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Figure 2. 6 Methodology to transiently express Cas9 in OC cells 
(A) Structure of the Alt-R™ S.p. Cas9 expression plasmid. (B) Table summarizing 
an exemplary calculation of the required volume of Ad-GFP-Cas9 adenoviruses to 
successfully infect mammalian cell lines. Poly A: Polyadenylation tail; AMP: 
Ampicillin resistance cassette; CMV: Cytomegalovirus promoter; V5: Epitope tag; 
MOI: Multiplicity of infection; PFU: plaque-forming units. 
 
 
Another approach that aimed to introduce transient Cas9 expression in UWB1.289 
was the use of Cas9-expressing adenoviruses (Ad-GFP-Cas9) (1901, Vector 
Biolabs) (Gong et al. 2017). To test the suitability of this approach, cells were 
cultured O/N (37°C) in Costar™ Corning™ 12-Well Clear TC-treated plates (70,000 
cells/mL), followed by adenovirus infection and ascertainment of GFP-expression 
and concomitant cell cytotoxicity (Nikon Eclipse Ti microscope). The initial titre of 
pre-packaged Ad-GFP-Cas9 adenoviruses was 1x1010 plaque-forming units per mL 
(PFU/mL), a typical measuring unit of the number of infectious virus particles within 
a sample stock. Different concentrations of polybrene (sc-134220, Santa Cruz®), a 
positively charged polycation commonly used to boost virus transduction events, 
were included in an effort to enhance adenoviral infection efficiency. 
 
In order to select the appropriate number of adenoviruses to successfully infect 
UWB1.289 cells (total plaque-forming units), different virus/cell ratio were tested 
(Fig. 2.6 B). The average number of virus particles infecting each cell is commonly 
known as multiplicity of infection (MOI) and ranges from 10 to 100 or more, 
depending on the type and number of cells (Gong et al. 2017). In this case and to 
calculate MOI, the number of cells was established on 140,000 after 24h O/N 
culturing, assuming an average of 1 cycle of doubling time (Fig. 2.6 B). 
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2.15.2 Knock-OUT and T7EI surveyor nuclease assay 
In an attempt to knock-OUT HBO1 using Ad-GFP-Cas9 adenoviruses, cells were 
cultured O/N (37°C) in Costar™ Corning™ 6-Well Clear TC-treated plates and 
infected with an appropriate MOI of Ad-GFP-Cas9 for 24h. After this, cells were 
transfected with pertinent crRNAs following manufacturer’s instructions. Otherwise, 
approximately 1-2M UWB1.289 cells grown in Corning® 100mm TC-treated 
Culture Dishes were electroporated with Alt-R™ S.p. Cas9 expression plasmid and 
subsequently split into Costar™ Corning™ 6-Well Clear TC-treated plates; each of 
which was transfected with different concentrations of target crRNAs and controls. 
 
Complexes of crRNA:tracrRNA [30-60nM] were transfected to UWB1.289 cells 
using 1µl of DharmaFECT Transfection Reagent 4 (T-2004, Dharmacon™) per mL 
of medium, following manufacturer’s instructions and recommendations. The culture 
medium was replenished in 24h, after which samples were grown for another 24-72h 
depending on cell viability and proliferative activity. Finally, gDNA samples were 
isolated in order to confirm possible mutation events. 
 
The detection of INDELs in CRISPR DNA target regions using the T7 Endonuclease 
I (T7EI) (M03025, New England BioLabs®) surveyor nuclease assay was performed 
following manufacturer’s instructions (Qiu et al. 2004). First, Phusion® High-
Fidelity DNA Polymerase, primers targeting the HBO1 exon 2 locus region and a MJ 
Mini™Personal Thermal Cycler were used to generate the PCR product 
encompassing the potential mutation site (Table 2.16 & Fig. 2.7 A). Next, the 
resulting material of the previous PCR reaction was subjected to a process 
denominated heteroduplex formation, using 384-well LightCycler®480 Multi-well 
Plates and a LightCycler®480 II machine (Fig. 2.7 B). Finally, half of the 
heteroduplex reaction volume was treated with T7EI enzyme (1 U/µl) and the other 
half was mixed with NEB Buffer 2 (B7002S, New England BioLabs®) alone as 
negative control, following manufacturer’s instructions. Agarose gels (1-2%) were 
used to visualize T7EI mismatch endonuclease results (Fig. 2.7 C, D) and ImageJ 
was used to measure the percentage of cleavage comparing the non-cleaved band 
with the cleaved bands (mutagenesis efficiency), assuming that an efficient digestion 
would generate the same number of band fractions (Fig. 2.7 C). 
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Figure 2. 7 Analysis of CRISPR mutagenesis efficiency using the T7EI assay 
(A) Specific PCR amplification generated one or more DNA products, depending on 
INDEL events. (B) These DNA products were separated into individual strands and 
pulled back together, giving rise to the formation of potential heteroduplexes, prone 
to T7EI cleavage. (C) The digestion of T7EI generated different sized DNA 
products; (D) which ran through electrophoresis gels allow for the observation of 
distinct bands and thus the calculation of mutagenesis efficiency. 
 
 
After the T7 Endonuclease testing confirmation, individual cells were cultured in 
Costar™ Corning™ 96-Well Clear TC-treated plates (37°C) until they reached 
enough confluence to allow protein/gDNA extractions alongside with further cell 
proliferation. In addition, and in order to improve the isolation of individual 
colonies, a single pipette device was used to separate potential UWB1.289 KO cells. 
In both cases, cells were grown for approximately 3-4 weeks, during which cell 
culture medium was replenished every 3-4 days. Finally, protein samples were 
interrogated using dot-blot and/or western blot, whereas gDNA samples were sent 
for DNA sequencing. These different assays confirmed or denied the presence of 
DNA mutations in the target HBO1 locus. 
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2.16 Small interfering RNA Knockdown 
The ON-TARGETplus Human KAT7 siRNA-SMARTpool (11143, Dharmacon™) 
was purchased to transiently knockdown HBO1 and the ON-TARGETplus non-
targeting pool (Dharmacon™) was used as negative control (Table 2.17 & Fig. 2.8). 
To confirm the specific effect of each one of the four small interfering RNAs 
(siRNAs) that are part of the pool, the corresponding set of four de-convoluted 
siRNAs was also acquired. Each non-overlapping siRNA is formed by two RNA 
strands forming a duplex of 19-25 base pairs where the antisense strand (guide) is a 
perfect reverse complement of the target HBO1 mRNA (Table 2.17 & Figure 2.8). 
 
 
Table 2. 17 List of small interfering RNAs 
 
Target Guide sequence Code Product 
HBO1 
5’-GAACCGAAGAUUCCGAUUU-3’ J-017668-05 
ON-TARGET 
SMARTpool 
5’-GAGGGAAGCAACAUGAUUA-3’ J-017668-06 
5’-UAGGACACCUUACAGGAAA-3’ J-017668-07 
5’-GGCAAGAUGCUUAUUGAUU-3’ J-017668-08 
Non-
specific 
5’-UGGUUUACAUGUCGACUAA-3’ 
5’-UGGUUUACAUGUUGUGUGA-3’ 
5’-UGGUUUACAUGUUUUCUGA-3’ 
5’-UGGUUUACAUGUUUUCCUA-3’ 
D-001810-
10-05 
ON-TARGET 
Non-targeting 
Pool 
 
	
Figure 2. 8 Targeting sites of small interfering RNAs 
Each horizontal row represents an HBO1 isoform (depicted as translated mRNA) 
and the numbered markers indicate sites of siRNA targeting. These isoforms are 
described in a more detailed manner in chapter 3: Expression and Regulation of 
HBO1 in Ovarian Cancer. 
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Small interfering RNAs delivered in dry state were re-suspended in 1X siRNA 
Buffer (B-002000-UB, Dharmacon™) following manufacturer’s instructions. The 
concentration of re-suspended siRNA molecules was confirmed using a Nanodrop® 
Spectrophotometer ND-1000; siRNA stocks were separated into small aliquots and 
stored at -20°C, up to four weeks, or -80°C for long-term storage. 
 
Cells were cultured O/N (37°C) in Costar™ Corning™ Clear TC-treated plates 
(Fisher Scientific) with pertinent medium without antibiotics and differing plating 
densities (Table 2.18). Costar® Clear TC-treated plates used in this thesis for siRNA 
include 12-well (3527, Corning™), 24-well (3526, Corning™), 48-well (3548, 
Corning™) and 96-well (3585, Corning™). 
 
 
Table 2. 18 List of siRNA transfection conditions for OC cell lines 
 
Cell line Plating density (cells/mL) 
Transfection 
Reagent (TR) 
TR 
Reference 
OVCAR-3 67,000 DharmaFECT 1 Dharmacon™ 
UWB1.289 50,000 DharmaFECT 4 Chang et al. 2014 
SKOV-3 50,000 DharmaFECT 1 Dharmacon™ 
TOV-112D 50,000 DharmaFECT 1 Test 1 and 4 
UACC-1598 150,000 DharmaFECT 1 Test 1 and 4 
 
 
After 24h, cells were transfected with the siRNA pool [25nM] or individual siRNAs 
[6.25nM] using the correspondent DharmaFECT Transfection Reagent following 
manufacturer’s instructions (Table 2.18). One microliter of DharmaFECT 4 or 
DharmaFECT 1 (T-2001, Dharmacon™) was included per millilitre of transfection 
medium. In addition to the transfection of siRNAs targeting HBO1, cells were also 
transfected with non-targeting siRNAs (‘siCtrl’) and transfection reagent alone 
(‘Control’) in order to minimize off-target effects (Jackson & Linsley 2010). Whole 
cell lysates were then harvested 24, 48 or 72h post- transfection. 
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2.17 Lentiviral transduction of short hairpin RNAs 
2.17.1 Characteristics and structure of selected molecules 
A set of three SMARTvector™ Lentiviral Human KAT7 hCMV-TurboGFP short 
hairpin RNA (shRNA) particles (V3SH7596-00EG11143, Dharmacon™) was 
purchased in order to constitutively knockdown HBO1 (Table 2.19 & Fig. 2.9). The 
SMARTvector Non-targeting hCMV-TurboGFP Control particles (Dharmacon™) 
were used as negative control (Table 2.19). All vials of lentiviral particles contained 
108 transducing units per millilitre (TU/mL), a tittering calculation based on the 
identification, through fluorescent-activated cell sorting, of functional particles that 
delivered the packaged RNA of interest in human embryonic kidney (HEK) 293T 
cells. 
 
The main structure of the SMARTvector™ lentiviral shRNA vector is illustrated in 
Figure 2.9 A, below these lines. Briefly, each vector contains the machinery for 
lentiviral integration in the host cell genome, a human CMV promoter, a green 
fluorescent protein reporter (TurboGFP) for visual tracking, a puromycin resistance 
(PuroR) element and a microRNA-adapted shRNA. The microRNA-adapted shRNA 
consists of an shRNA stem structure surrounded by a loop and flanking sequences of 
an endogenous microRNA (Fig. 2.9 A). The shRNA structure contains the guide 
sequence that is a perfect reverse complement of the target HBO1 mRNA and the 
endogenous microRNA scaffold enhances the efficiency and reduces the cytotoxicity 
of the process (Table 2.19 & Fig. 2.9). 
 
 
Table 2. 19 List of short hairpin RNAs 
 
Target Guide Sequence Code Product 
HBO1 
5’-UUCUAAAAGAGGUUCCCGU-3’ 227169180 SMARTvector 
Lentiviral Human 
V3SH7590 
5’-UUUGCGAUAUAUCUCAUCA-3’ 227619297 
5’-UACUGUACUUGCCAAUCAC-3’ 230346186 
Non-
specific 
5’-UGGUUUACAUGUUGUGUGA-3’ S-00500-01 
SMARTvector 
Non-targeting 
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Figure 2. 9 Short hairpin RNAs targeting HBO1 
(A) Schematic representation of the structure of a SMARTvector™ lentiviral shRNA 
vector. LTR: Long terminal repeat; Ψ: Psi packaging sequence; RRE: Rev response 
element; tGFP: TurboGFP; hCMV: human cytomegalovirus; IRES: Internal 
ribosomal entry site; PuroR: Puromycin resistance, WPRE: Woodchuck hepatitis 
post-transcriptional regulatory element; SIN LTR: self-inactivating LTR; (B) Each 
horizontal row represents an HBO1 isoform (depicted as translated mRNA plus the 
3’UTR region) and the numbered markers indicate sites of shRNA targeting. These 
isoforms are described in a more detailed manner in chapter 3: Expression and 
Regulation of HBO1 in Ovarian Cancer. UTR: Un-translated region. 
 
 
2.17.2 Optimization of the lentiviral transduction 
Prior to the utilization of lentiviral particles, target cells were tested for optimal 
transduction conditions and resistance to puromycin. First, non-infected cells were 
cultured O/N (37°C) in Costar™ Corning™ 96-Well Clear TC-treated plates at 
different platting densities (5,000–7,500–10,000 cells/well) with normal growth 
medium. After 24h, growth medium was replaced with FBS and FBS-free 
‘Transduction Medium’ containing different concentrations of polybrene (0-14 
µg/mL). Next, after 2-3 days of culture, cell confluence and morphologic/phenotypic 
alterations were assessed using a Nikon Eclipse Ti microscope. This test allowed for 
the selection of the optimal conditions for UWB1.289 transduction: 5,000 initial cell 
density and ‘Transduction Medium’ containing FBS and 10 µg/mL of polybrene.  
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Next, non-infected cells were cultured O/N (37°C) in Costar™ Corning™ 96-Well 
Clear TC-treated plates with normal growth medium containing different 
concentrations of puromycin (0.1-10 µg/µl) (sc-108071, Santa Cruz®). Each well 
was seeded with ~20,000 cells, assuming that a potential initial seeding of 5,000 
cells would achieve that number after 3-4 days of culture (~24h doubling time). 
Cells were grown for 48h and confluence was measured 6, 24 and 48h after the 
addition of puromycin. The UWB1.289 optimal puromycin concentration, 1 µg/µl, 
achieved a 95% cell death after 48h of antibiotic treatment. 
 
2.17.3 Transduction of shRNAs targeting HBO1 
Cells were cultured O/N (37°C) in Costar™ Corning™ 96-Well Clear TC-treated 
plates at the specific density (5,000 cells/well) determined on previous lentiviral 
transduction sections. The next day, non-targeting control particles were diluted in 
‘Transduction Medium’ (FBS + 10 µg/mL polybrene) and added to the cells, prior 
removal of normal growth medium, for 6-8h incubation. Decreasing quantities of 
lentiviral particles were added to different wells in order to find the optimal 
conditions for transduction, including lower cytotoxicity and higher transduction 
efficiency. After the 6-8h incubation, cells were supplemented with normal growth 
medium and cultured for another 48-72h. 
 
Finally, the efficacy of each lentiviral transduction was assessed via GFP 
observation in a Nikon Eclipse Ti microscope. Low quantities of lentiviral particles 
resulted in limited GFP expression, whereas high quantities displayed noticeable 
cytotoxic effects, leaving one remaining sample as the ideal condition for optimal 
transduction (~2.5x104 viral particles). In this particular case, and assuming a total 
number of ~1x104 cells per well at the time of adding the viruses, it could be 
considered that each cell was targeted by approximately 2-3 lentiviral particles, thus 
limiting the number of insertions per genome to minimise potential off-target gene 
disruptions. 
 
Once established the optimal conditions for lentiviral transduction, new cells were 
cultured and transduced with both HBO1 and non-targeting shRNA lentiviral vectors 
following the guidelines described earlier in this section. Forty-eight hours after the 
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addition of lentiviral particles, the culture medium was removed and substituted with 
selection medium containing puromycin (1 µg/µl). Infected cells were cultured in 
this medium for 72h, trypsinized and expanded into a larger culture vessel with new 
medium containing puromycin (0.5 µg/µl). After 48h, infected cells were tested for 
HBO1 knockdown, as well as GFP expression and expanded until an adequate cell 
number was achieved. At this point, cells were either used for further 
experimentation or frozen and stored as described in the cell culture section. 
 
 
2.18 Design and construction of an HBO1-expressing vector 
2.18.1 Plasmid design 
A pCMV-Tag2B epitope tagged mammalian expression vector (211172, Agilent 
Technologies) was selected for HBO1 sequence insertion (Fig 2.10). First of all, the 
pCMV-Tag2B multiple cloning site region was interrogated in search for restriction 
enzymes that could create sticky ends in the DNA backbone (Fig 2.10 B, C). 
 
	
Figure 2. 10 Design and construction of an HBO1-expressing plasmid 
(A) Structure of the pCMV-Tag2B vector. (B) Illustrative depiction of the pCMV-
Tag2B multiple cloning site region. (C, D) Selected restriction enzymes cleavage 
sites (C) and digestion conditions (D). 
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Laboratory stock availability and buffer activity complementation led to the election 
of HindIII (R0104, New England BioLabs®) and SalI-HF® (R3138, New England 
BioLabs®) restriction enzymes, as well as NEBuffer 2.1 (B7202S, New England 
BioLabs®), for plasmid digestion (Fig. 2.10 D). The HBO1 sequence was obtained 
from cDNA of HOSEpiC cells. 
 
2.18.2 Plasmid construction 
The production of an HBO1 insert from HOSEpiC cDNA was undertaken using a 
pair of primers designed to bind un-translated regions (UTR) of the HBO1 transcript 
to create a template for nested PCR (Table 2.20). This template was subjected to a 
new PCR using specific primers pre-designed to introduce target sites for the 
selected restriction enzymes (Table 2.20). Both the empty pCMV-Tag2B plasmid 
(1µg) and the HBO1 template (500ng) were digested at 37°C for 90 min following 
manufacturer’s recommendations. The resultant digested products were then purified 
using a GeneJET PCR Purification Kit (K0701, Thermo Scientific™). 
 
 
Table 2. 20 List of primers used to construct an HBO1-expression plasmid 
 
Name Sequence Step 
HBO1-
UTR 
F:  5’-GCAGGATTGGGACTGATACAG-3’ 
R:  3’-CTCACTGAGGCCGAAACAAC-5’ 
Nested 
PCR 1 
Tag2B-
HBO1 
F:  5’-GCAAAGCTTATGCCGCGAAGGAAG-3’ 
R:  3’-GGTTCCCGTGAATTCAGCTGTCA-5’ 
Nested 
PCR 2 
FLAG-
HBO1 
F:  5’-CACCATGGATTACAAGGATGAC 
GACGATAAG-3’ 
R:  3’-TTGCTTCCCTCTGTGATTTG-5’ 
Colony 
Check 
G485A-
HBO1 
F:  5’-CTCAGTACATGAGACAGGCCTATGGC 
AAGATGCTTATTG-3’ 
R:  3’-CAATAAGCATCTTGCCATAGGCCTGT 
CTCATGTACTGAG-5’ 
Mutagenesis 
wt: GGC (G) 
mut: GCC (A) 
 
 
Once digested, both products were ligated O/N (16°C) using T4 DNA Ligase 
(M0202, New England BioLabs®). The NEBioCalculator was used to determine the 
appropriate amounts of plasmid/DNA for the T4 DNA ligation (1:3, vector/insert). 
Empty pCMV-Tag2B plasmid was used as negative control (pCMV-Tag2B-Ø). 
Materials	and	Methods	
	 118	
After the O/N incubation, T4 ligase was inactivated for 10 min (65°C) and the 
mixture was cooled on ice. Finally, a fraction of the newly synthesized HBO1-
expressing plasmid (5µl) was transformed into NEB® 5-alpha competent E.coli cells 
following manufacturer’s instructions. 
 
2.18.3 Plasmid isolation 
Transformed E.coli cells were spread onto lysogeny broth agar selection plates 
containing 50 µg/mL of kanamycin (K0253, Sigma®) and incubated O/N at 37°C. 
Colonies derived from the O/N incubation were re-suspended with super optimal 
broth with catabolite repression medium or SOC (15544034, Invitrogen®) and a 
small fraction (1µl) was subjected to PCR in order to confirm presence or absence 
(Ø) of plasmid-template ligation (Table 2.20). Positive colonies were grown O/N 
(37°C) in 5mL of sterilized lysogeny broth containing 50 µg/mL of kanamycin. A 
considerable fraction of the broth containing O/N grown cells (4/5) was mixed 2:1 
with 50% Glycerol and kept in -80°C as a stock. The remaining cells (1/5) were 
subjected to plasmid extraction using a QIAprep Spin Miniprep Kit. Plasmid DNA 
sequencing and western experiments were conducted to re-assure the integrity of the 
HBO1-expression plasmid. 
 
2.18.4 Directed-site mutation of the HBO1-expression plasmid 
The QuickChange Primer Design software (Agilent Technologies) was used to 
generate a pair of primers that introduce a mutation in the HBO1 template inserted in 
the pCMV-Tag2B plasmid. The specific mutation, glycine to alanine (G485A) (Yan 
et al. 2000; Iizuka et al. 2009), was introduced using the QuickChange II Site-
Directed Mutagenesis Kit (200523, Agilent Technologies). The pCMV-Tag2B-
hHBO1 plasmid was subjected to end-point PCR (Table 2.20) followed by the 
incubation with DPN I enzyme (10 U/µl) for 1h (37°C). After this, 5µl of the DPN I 
reaction were transformed into new NEB® 5-alpha competent E.coli cells which 
were then incubated O/N (37°C) on lysogeny broth agar selection plates (50 µg/mL 
kanamycin). Finally, isolated plasmids were sequenced to confirm mutation events 
(Fig. 2.11). 
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Figure 2. 11 Generation of an HBO1-mutant via site-directed mutagenesis 
Wild type (wt) and three mutant (mut) colonies of E.coli expressing pCMV-Tag2B-
hHBO1 and potential pCMV-Tag2B-hHBO1 (G485A) plasmids respectively were 
sequenced to confirm the introduction of the selected mutation. 
 
 
 
2.19 Sequencing of messenger RNA 
2.19.1 Sample collection and sequencing 
Total RNA samples were obtained following the method described previously in the 
qRT-PCR section, quantified using a Nanodrop® Spectrophotometer ND-1000 and 
sent to the Epigenomics Core Facility at Weill Cornell Medical College to conduct 
RNA-seq. Specifically, total RNA samples were extracted from three biological 
replicates of UWB1.289 cells transduced with the shRNA vector numbered 
227169180 targeting HBO1 and the non-targeting vector (Table 2.19). The required 
sample concentration for each replicate was 50 ng/µl in a volume of 10µl. 
 
The Epigenomics Core performed ‘TruSeq Stranded RNA-seq (polyA) Library 
Preparation’ for each sample using the Illumina TruSeq Stranded mRNA Library 
Preparation kit (RS-122-21, Illumina®). This approach retains the strand orientation 
of the transcripts and captures both known and novel mRNA features. Samples were 
multiplexed into one sequencing lane, allowing for approximately 40-45 million 
reads per sample. The Epigenomics Core conducted Paired-End RNA Sequencing 
(2x50 sequencing cycles, maximum 100bps per RNA) on a HiSeq 2500 System 
(Illumina®). RNA-Seq raw data was finally deposited to PubShare for downloading. 
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2.19.2 Data analysis 
Resulting RNA-Seq raw data (FASTQ files) was downloaded and deposited into a 
Linux HPC cluster server. Prior to the RNA-Seq analysis, the UCSC goldenPath 
repository website was used to download the hg19 transcriptome (reference) to 
which the reads were aligned to. Also, next-generation sequencing data was run 
through the FastQC programme (Leggett et al. 2013) to pre-assess sequencing 
quality. 
 
	
Figure 2. 12 Workflow diagram of the RNAseq analysis pipeline 
 
 
RNA-seq reads were aligned onto the hg19 indexed reference transcriptome using 
Bowtie (Langmead et al. 2009), which generated ‘Sequence Alignment Map’ (SAM) 
files, a text-based format to store biological sequences aligned to a reference (Li et 
al. 2009) (Fig. 2.12). In order to continue the analysis, SAM files were converted 
into BAM files (binary SAM files) using SAMTools (Li et al. 2009) and 
subsequently filtered to exclude reads with unmapped mates (RNA samples only 
read in one direction) using BAMTools (Barnett et al. 2011). Next, eXpress (Roberts 
& Pachter 2013) was used to quantify the expression level, generating a single text 
file that contains the effective count of every single RNA transcript in each one of 
the 6 samples (Fig. 2.12). 
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Finally, the RNA-Seq differential expression tool package DESeq2 (Love et al. 
2014), implemented within R, was used to determine significantly modified 
transcripts comparing the eXpress results (Fig. 2.12). Specifically, DESeq2 
normalized the raw counts, applied a modified unpaired statistical Student’s t-test 
(Wald Test) and corrected for multiple hypothesis testing via false discovery rate 
(FDR) estimation. The outcome of the DESeq2 package analysis included FC values, 
p-values and q-values (FDR adjusted p-values). 
 
 
2.20 Gene Expression Profiling – Microarrays 
2.20.1 Synthesis of complementary RNA 
Selected total RNA samples (450µg) were used to generate biotinylated, amplified 
complementary RNA (cRNA) for hybridization with human whole genome 
expression Illumina® arrays (HumanHT-12 v4). The synthesis and labelling of 
cRNA were performed using Illumina® TotalPrep™-96 RNA Amplification Kit 
(4393543, Ambion®) following manufacturer’s instructions. 
 
All incubation steps were conducted in a MJ Mini™Personal Thermal Cycler (Bio-
rad). A 96-well Magnetic-Ring Stand (AM10050, Ambion®) and a Heidolph 
Titramax 101 shaker (544-11300-00, Heidolph) were used during the cDNA and 
cRNA purification steps. The labelling in vitro transcription reaction was performed 
at 37°C for 14h. Purified cRNA was quantified with a Quant-iT™ RNA Assay Kit 
(Q33140, Invitrogen™) using Corning™ Clear Polystyrene 96-well micro-plates 
(Corning™), a Safire2 micro-plate reader at 644Ex/673Em nm and the XFluor4SafireII 
software. After this, cRNA samples were either stored at -20°C O/N for next-day 
hybridization or at -80°C for long-term storage. The required cRNA quantity for a 
12-Sample BeadChip is 750ng and the total sample volume is 5µl. In order to 
concentrate the cRNA to meet this criteria, samples were occasionally vacuum 
centrifuged using a Vacufuge plus (022822993, Eppendorf). 
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2.20.2 BeadChip hybridization, scan and analysis 
Biotinylated cRNA samples were hybridized to arrays at 58°C for 18h in accordance 
with manufacturer’s instructions. The whole hybridization process was conducted 
using Illumina® equipment (Hyb Oven, Hyb Chamber, Hyb Chamber gasket/inserts, 
Hybex Waterbath, Hybex Heating Base, Transfer Wash Rack). The BeadArray 
Reader (iScan System, Illumina®) was used to scan the arrays and the GenomeStudio 
software converted the scanned data into meaningful results. The output consisted of 
text files containing approximately 47,000 rows; each one representing different 
probes (gene transcripts). For each probe, GenomeStudio provided a non-normalized 
expression level value (AVG_Signal), the standard error of the bead replicates 
(BEAD_STDERR), the number of beads (Avg_NBEADS) and a detection p-value 
(Detection_pval), which estimates the probability of a gene being detected above the 
background level. 
 
All microarrays were conducted on at least three biological replicates of treatment 
and control samples. Data obtained from GenomeStudio was background-subtracted 
and quantile-normalized using the lumi package (Du et al. 2008) within R. The lumi 
package is a tool for the analysis and comprehension of high-throughput genomic 
data and it was downloaded from an open-source software site named Bioconductor. 
The Multiple Experiment Viewer (MEV) (Chu et al. 2008) was utilized to perform 
statistical analyses and correct for multiple hypotheses testing via FDR estimation. 
MEV provides several statistical analysis methods for microarray data, being the 
Linear Models for Microarray Data or LIMMA the most frequently used (Smyth 
2004). Nonetheless, the two-class paired rank product method is less stringent and 
more appropriate for the elevated variability of the biological replicates in this study 
and hence it was applied to all analysis (Breitling et al. 2004; Koziol 2010). 
Consequently, MEV provided a list of differentially expressed genes together with 
their associated FC and q-values (FDR adjusted p-values) (Noble 2009). The SQL 
database was used to link Illumina® probe identifiers with standardised gene 
symbols. 
The lists of differentially expressed genes were compared graphically using Venny 
(Hulsen et al. 2008). 
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2.21 Pathway Analysis of Gene Expression Profiles 
2.21.2 Gene Set Enrichment Analysis 
The role of Gene Set Enrichment Analysis (GSEA, Broad Institute) is to interpret 
results obtained in gene expression profiling experiments comparing two sample 
classes (e.g. Treatment and Control), in order to gain insights into driver biological 
mechanisms (Subramanian et al. 2005). For this purpose, the GSEA algorithm is 
designed to determine whether members of a Gene-Set (GS) are randomly 
distributed or primarily found at the top (up-regulated) or bottom (down-regulated) 
of a ranked list of differentially expressed genes. Gene-Sets are groups of genes that 
share common characteristics (e.g. biological function, chromosomal location, 
pathway regulation) and are defined based on prior biological knowledge. They are 
grouped in collections, which can be downloaded from the Molecular Signatures 
Database or MSigDB. Specifically, the Hallmarks collection, which contains 50 GSs 
representing well-defined biological states, was intersected with expression profile 
data (microarrays) to anticipate alterations of main canonical pathways (e.g. Wnt/β-
catenin signalling) and processes (e.g. cell apoptosis) caused by gene expression 
changes. 
 
First, text files containing microarray quantile-normalized data were uploaded to the 
GSEA proprietary programme, which ranked the ~47,000 genes detected by the 
Illumina® HumanHT-12 v4 array based on differential expression levels between the 
classes (e.g. Treatment and Control) (Fig. 2.13 A). Next, the GSEA algorithm 
calculated an enrichment score (ES) reflecting the degree to which a defined GS is 
overrepresented at the top or bottom of the entire ranked gene list (Fig. 2.13 B). The 
ES was calculated by walking down the entire list of genes incrementing or 
decreasing the sum-value when confronting or not GS hits. The magnitude of the 
increment depended on the correlation of the gene with the phenotype (higher if the 
gene is found at the extremes of the ranked list) and the final ES was the maximum 
deviation from zero encountered in the walk. The leading-edge subset was 
interpreted as the core of a GS that accounted for the ES signal (Fig. 2.13 B) 
(Subramanian et al. 2005). 
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Figure 2. 13 Example of GSEA analysis comparing two samples 
(A) Approximately 47,000 genes analysed by the Illumina® arrays were ranked 
according to their differential expression between the samples ‘Treatment’ and 
‘Control’. The 200 genes that belong to the studied Gene-Set displayed a 
characteristic distribution along the target ranked gene list. (B) Out of the 200 genes 
of the studied Gene-Set, 50 were located at the top of the ranked gene list (leading-
edge subset). This tendency to be grouped at the top or the bottom of a given ranked 
gene list is converted into enrichment score values by GSEA. 
 
 
Finally, ES values were subjected to statistical analysis and adjusted for multiple 
hypothesis testing, which estimated the probability that a normalized Gene-Set ES 
(NES) represented a false positive finding (Subramanian et al. 2005). The outcome 
generated by GSEA included the GSs displaying higher NES, either at the top (gene 
up-regulation) or the bottom (down-regulation) of the ranked gene list, their 
associated q-value, an enrichment plot (Fig. 2.13 B) and the list of GS genes 
involved in such biological pathway or function. 
 
2.21.2 Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA, Ingenuity Systems®, Qiagen®) is a web-based 
software application that enables analysis, integration, and understanding of data 
from gene expression microarrays or RNA-seq. Using prior biological knowledge 
and a refined suite of algorithms and tools, IPA is able to predict alterations of main 
canonical pathways (e.g. Wnt/β-catenin signalling) and downstream effects on 
biological functions (e.g. cell proliferation) caused by the observed gene expression 
changes (Krämer et al. 2014). 
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Files containing differentially expressed genes and their associated FC values were 
uploaded into the IPA proprietary software. Unlike GSEA, where the input consisted 
of entire normalized gene microarrays (~47,000 genes), IPA generated significant 
predictions using selected cohorts of differentially expressed genes only. The 
outcome generated by the IPA ‘Canonical pathways’ feature included the most 
significant affected pathways, their associated p-value, z-score and a list of the 
modified genes involved in such pathway. Significance values (p-values) were 
calculated using a Fisher’s exact test right-tailed statistical analysis and z-scores 
predicted either an overall increase or decrease in the activity of the pathway. 
 
	
Figure 2. 14 Example of an IPA ‘Downstream effects’ outcome 
(A) Table summarizing an exemplary outcome of the IPA ‘Downstream effects’ 
analysis. (B) IPA illustrative depiction of the biological effects caused by observed 
gene expression changes. Specific biological functions are represented as coloured 
rectangles enclosed in ‘IPA categories’, whose size is proportional to the number of 
modified genes associated to that function. Scale is shown at the bottom. 
 
 
The IPA ‘Downstream effects’ feature anticipated the increase or decrease of certain 
biological functions, foretelling the development of biological processes and 
diseases. Similar to the results obtained with the ‘Canonical pathways’, the outcome 
of the IPA ‘Downstream effects’ feature included the affected biological function, a 
significance p-value, z-score, a prediction of the activation state (increased or 
decreased), and the list of genes involved in the biological process. A summarized 
exemplary outcome of the IPA ‘Downstream effects’ feature is depicted in Figure 
2.14 A above these lines. As well as the aforementioned report, IPA ‘Downstream 
effects’ analysis provided illustrative pictures showing the effect of gene expression 
changes on broad biological areas or ‘IPA categories’ (e.g. cell death) (Fig. 2.14 B). 
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2.22 Atomic Force Microscopy 
Atomic Force Microscopy (AFM) was selected to study cell mechanics, which affect 
important factors of cellular function, including shape, motility, differentiation, 
division or adhesion, and, most importantly, can act as a reliable indicator of the 
structure and function of the underlying cytoskeleton (Moeendarbary & Harris 
2014). The AFM technique is based on measuring the attractive and repulsive forces 
acting between the atoms of a tip and those of the sample’s surface. AFM 
instruments developed for cell biology research setups are known as bio-AFMs and 
are capable of combining live-cell fluorescence with force measurements at desired 
cellular locations (Gavara 2017). 
 
Cells were cultured O/N in 60x15mm TC dishes (Falcon®) (37°C) until they reached 
~70% confluence. After 24h, cells were analysed in growth medium at 37°C using a 
BioScope Catalyst™ BioAFM (Bruker Instruments). Borosilicate colloidal probes 
(Novascan) with a sphere radius of 2.5µm, a spring constant of 0.17 N/m and a 
deflection sensitivity of 20.11 nm/V were used to analyse a total of 40 cells per 
sample. Three force curves were acquired on the centre of each cell, using a ramp 
size of 3.5µm, a ramp speed of 1Hz and an applied force of 400pN. The region of 
contact in each approach curve was fitted with the Hertz model using the Nanoscope 
Analysis software (Version 1.5, Bruker Instruments). Each retraction curve was 
analysed for the presence of adhesion events and only data displaying a goodness-of-
fit higher than 0.9 was taken into consideration. Data distribution and statistical 
analysis were performed using Wolfram Mathematica 10 and Minitab (Version 17). 
 
All data was analysed for normality using the Kolmogorov-Smirnov test with 
datasets shown to be statistically different to normal distribution (p-value < 0.05) 
designated as non-parametric. Following the assumption of variance, pairwise data 
comparisons were undertaken using the Mann-Whitney U test, with statistical 
difference stated at 95% confidence intervals (p-value < 0.05). 
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2.23 Scratch/Wound-healing and Cell Invasion Assays 
The stages of the assay described by Straatman (Straatman 2008) were followed in 
order to perform a scratch/wound-healing assay. First, cells were cultured in 
Costar™ Corning™ 24-Well Clear TC-treated plates to reach 95-100% confluence 
after 24h (37°C). Then, two ‘scratches’ were made on the surface of the plate (one 
horizontal, one vertical) using a small pipette tip, followed by immediate 
replacement of the medium to eliminate debris generated by the scratch. The 
intersection between the two lines was used as a reference to position the microscope 
camera. Finally, pictures were taken at different time points (including time = 0) 
using a Nikon Eclipse Ti microscope. 
 
 
Figure 2. 15 Example of relative area calculations for wound-healing assays 
(A) Images were taken immediately after the scratch (t = 0h) and after 4-8h (in this 
particular example) with a Nikon Eclipse Ti (Nikon®) microscope. (B) The ImageJ 
software was used to calculate cell migration by measuring changes in cell-free 
occupation area over time. Scale represents 100µm. 
 
 
The ImageJ software (Schneider et al. 2012) including the wound healing tool was 
used to analyse images and compare changes in cellular properties between 
treatments (Fig. 2.15). As previously described in the WB section, images 
representing different time points of the scratch assay were loaded onto ImageJ and 
converted to 8-bit grey scale images. Subsequently, the ‘cell-free’ area of target 
images was calculated applying default ImageJ parameters (Straatman 2008). The 
difference between the final (e.g. after 4h) and the starting (t = 0) ‘cell-free’ value 
was denominated relative area (RA) and represented the field size that had been 
taken over by migrating cells (Fig. 2.15). The unpaired one-way ANOVA statistical 
Materials	and	Methods	
	 128	
analysis was performed on RA values of three biological replicates using Graphpad 
Prism. The Tukey’s Honest Significant Difference test was used to correct for 
multiple comparisons testing and a confidence level of 95% was selected, defining 
the statistical significance in p-value < 0.05 (*). 
 
The CytoSelect™24-Well Cell Invasion Assay (Basement Membrane, Colorimetric 
Format) (CBA-111, Cell Biolabs Inc.) was used to measure the invasiveness of 
cancer cells. Cells were cultured O/N (37°C) in Costar™ Corning™ 6-Well Clear 
TC-treated plates prior to the addition on the ‘Extracellular Matrix Invasion 
Chamber Plate’ (7x105 cells/mL), where they were incubated for 24-48h. The 
protocol was conducted following manufacturer’s instructions and the final 
absorbance signal was measured with a Safire2 micro-plate reader and the 
XFluor4SafireII software at 560 nm. 
 
 
2.24 Enzyme-Linked Immune-Sorbent Assays 
Several commercially available kits were used to perform enzyme-linked immune-
sorbent assay (ELISA) experiments: VeriKine™ Human IFN-α Multi-Subtype 
ELISA Kit (41110, PBL Assay Sciences), VeriKine™ Human IFN Beta ELISA Kit 
(41410, PBL Assay Sciences), Human IFN-γ ELISA Kit (KHC4021, Invitrogen™) 
and BrdU Cell Proliferation ELISA Kit (colorimetric) (ab126556, Abcam®). All 
protocols were performed following manufacturer’s instructions using EDP3-Plus™ 
Electronic Pipettes (17013796, Rainin) and common reagent reservoirs.  
 
The interferon alpha (IFNA/α), interferon beta (IFNB/β) and interferon gamma 
(IFNG/γ) ELISA protocols were used to measure the amount of these signalling 
proteins in TC medium. For this purpose, cells were cultured in Costar™ Corning™ 
12-Well Clear TC-treated plates (37°C; 80,000 cells/mL) and the TC medium was 
extracted after 24h; unless cells were transfected with siRNA, in which case the cell 
seeding was lower (50,000 cells/mL) and the TC medium was extracted 48h post-
transfection. The isolated TC medium was immediately centrifuged at 1,500 rpm (10 
minutes, 4°C), separated into aliquots and stored at -80°C until use. 
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The Bromodeoxyuridine (BrdU) ELISA Kit was used to study cell proliferation 
through the incorporation of BrdU to cultured cells. Approximately 20,000 cells 
were cultured O/N in Costar® 96-Well Clear TC-treated plates (37°C) and the BrdU 
labelling times were 4 and 24h. Again, cells transfected with siRNA were seeded in 
lower quantities (~12,000 cells/well) and the BrdU addition was conducted 48h post-
transfection. 
 
The absorbance of each sample, blank and standard was measured in duplicate using 
a Safire2 micro-plate reader and the XFluor4SafireII software at 450 nm. In the case 
of the VeriKine™ Human IFN-α Multi-Subtype ELISA kit, the protocol was 
performed as per manufacturer’s instructions using the High-Sensitivity range of the 
standard curve (12.5-500 pg/mL). Sample values lower than the standard were back 
extrapolated. The unpaired one-way ANOVA statistical analysis was performed on 
raw absorbance values of three biological replicates using Graphpad Prism. The 
Tukey’s Honest Significant Difference test was used to correct for multiple 
comparisons testing and a confidence level of 95% was selected, defining the 
statistical significance in p-value < 0.05 (*). 
 
 
2.25 ApoTox-Glo Triplex Assay 
The ApoTox-Glo™ Triplex Assay (G6320, Promega®) allows assessing of cell 
viability, apoptosis (caspase activity) and cell death (cytotoxicity) in the same 
experimental plate. Viability and cytotoxicity are measured by live-cell/dead-cell 
protease activity with the addition of glycyl-phenylalanyl-amino-fluorocoumerin 
(GF-AFC) and bis-Ala-Ala-Phe-rhodamine 110 (bis-AAF-R110) substrates 
respectively. Caspase activation is measured by luciferase activity dependent on 
caspase cleavage of the substrate present in the Caspase-Glo® 3/7 Reagent. 
 
Cells were cultured in Costar™ Corning™ 96-Well Clear TC-treated plates for 24h 
(37°C) (~12,000 cells/well) followed by the sequential addition of substrates and 
measuring of the resulting signal. After 30 minutes, cells were exposed to different 
excitation wavelengths (400/485), whose fluorescence emission was recorded as 
viability/cytotoxicity measurements respectively (505/520) using a Safire2 micro-
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plate reader and the XFluor4SafireII software. Luciferase activity was measured 
after 1h of substrate incubation and all samples were tested in triplicates. In case 
cells were transfected with siRNA prior to the assay, they were seeded in lower 
concentrations (6,000 cells/well) and the substrates were added 48h post-
transfection. In all circumstances and as additional controls, substrates were always 
added to un-treated wells and wells without cells. 
 
 
Table 2. 21 Example of relative cell calculations for ApoTox-Glo™ assays 
 
Sample 𝒙 Raw values – 𝒙 no substrate control Relative cell (%) activity 
Treatment 33,903 110.12 
Control 30,845 100 
Treatment 51,844 87.13 
Control 59,496 100 
 
 
The unpaired one-way ANOVA statistical analysis was performed on raw 
fluorescence/luminescence values of three biological replicates using Graphpad 
Prism. The Tukey’s Honest Significant Difference test was used to correct for 
multiple comparisons testing and a confidence level of 95% was selected, defining 
the statistical significance in p-value < 0.05 (*). The graphical depiction of relative 
cell viability, cytotoxicity and caspase activity represents the proportional difference 
(%) between a treatment and its control (Table 2.21). 
 
 
 
	
 
3. Expression and Regulation of 
HBO1 in Ovarian Cancer 
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3.1 Introduction and Aims 
Disturbances in epigenetic regulatory mechanisms are decisive in tumorigenesis and, 
particularly, in OC development (Balch et al. 2009; Brien et al. 2016). The wide-
reaching opportunities of epigenetic agents, which can reverse these alterations via 
multiple signalling pathways without relying on single gene mutations, open the 
door to new potential promising OC therapies (Azad et al. 2013). In this regard, one 
epigenetic regulator named ‘Histone acetyltransferase binding to ORC-1’ (HBO1, 
also known as KAT7 or MYST2) could be a potential target for OC treatment. 
 
The vast majority of studies on HBO1 in relation to tumour progression are based on 
breast cancer settings. In this context, HBO1 was found overexpressed in breast 
cancer tissues and cell lines (Iizuka et al. 2009; Duong et al. 2013), where it 
displayed pro-oncogenic properties (Iizuka et al. 2013). Importantly, Iizuka et al. 
(2009) detected strong HBO1 expression in a cohort of OC samples, pointing to a 
prominent role of the protein in OC development. 
 
The first objective of this project was to establish valid cell model systems for the 
study of HBO1 in OC. These models included the most prominent OC sub-types 
(serous, endometrioid, mucinous and clear-cell), which represent approximately 90% 
of all OC cases (Meinhold-Heerlein & Hauptmann 2014), alongside an appropriate 
non-cancerous control for comparison. Once established, the OC models were 
analysed for HBO1 expression both at transcript (qRT-PCR) and protein level (WB). 
HBO1’s precursor mRNA is spliced into 5 different isoforms, the expression of 
which was also analysed in the model systems. Furthermore, the study of HBO1 
expression allowed for the optimization of appropriate tools (e.g. antibodies) used in 
subsequent HBO1 functional studies. 
 
The next objective was to evaluate potential factors that may lead to HBO1 
overexpression in the OC models. For this purpose, the proximal promoter region of 
the HBO1 locus was analysed for well-known binding sites of possible nuclear 
receptor (NR) gene regulators. 
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The final aim of this chapter was to study the localization of HBO1 in the ‘OC 
genome’ via ChIP-Seq, in order to provide insights into HBO1 regulatory 
mechanisms, including potential gene targets and the association of HBO1 with 
repressive or activating genomic domains. In addition, features including subcellular 
protein localization and multi-protein complex associations were investigated. 
 
 
3.2 Ovarian Cancer Cell Line Model Systems 
There are two major approaches to study the mechanics of OC: immortalized cell 
lines and primary cells isolated directly from malignant ovarian tissues. Even though 
primary cells are more biologically relevant due to their genetic resemblance to the 
original patient, OC cell lines offer multiple other advantages including 
reproducibility, which allows the direct comparison of results between studies (Kaur 
& Dufour 2012; Geraghty et al. 2014). Based on this premise and to elucidate the 
role of HBO1 in OC, a representative panel of cell lines was selected (Table 3.1) 
(Beaufort et al. 2014). The chosen cell lines represented all the major OC histo-
types, but emphasized the predominance of serous histology. 
 
 
Table 3. 1 Ovarian cancer cell line model system 
 
Cell line Tissue of origin Histology Grade Stage 
HOSEpiC Ovary OSE1   
OVCAR-3 Ascites High-grade serous 3 und2 
SKOV-3 Ascites Serous 1/2 und 
UWB1.289 Ovary Serous und und 
UACC-1598 Ovary Serous 3 IV 
TOV-112D Ovary Endometrioid 3 IIIC 
TOV-21G Ovary Clear-cell 3 III 
COV644 Ovary Mucinous und und 
Cell line characteristics based on Beaufort et al. (2014) and the ATCC® website 
1OSE: Ovarian surface epithelium 
2und: Undetermined grade or stage 
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The HOSEpiC line is composed of human ovarian surface epithelial (OSE) cells 
extracted from healthy ovaries (Murdoch 1995). As such, they are not immortalized 
and hence expanded for a handful of population doublings. In this study, HOSEpiC 
cells were used as non-cancerous control and their properties were compared to 
those of OC cell lines. 
 
Amongst the OC cell lines, serous histology, the most prevalent subtype of OC 
(Soslow 2008), is represented by OVCAR-3, SKOV-3, UWB1.289 and UACC-1598 
(Table 3.1). Considering that this study was predominantly focused on this histo-
type, the selection of the most suitable serous-like cell lines was paramount. In this 
regard, it is noteworthy that SKOV-3 and OVCAR-3 together account for more than 
50% of PubMed citations for HGSC cell line models (Domcke et al. 2013). Domcke 
et al. (2013) and Beaufort et al. (2014) have extensively studied the main genomic 
characteristics and usefulness of SKOV-3, OVCAR-3 and UWB1.289 as HGSC 
tumour models. However, there is little publicly available information regarding the 
UACC-1598 cell line, probably due to its handling difficulties, with very slow 
doubling rates and preference for hypoxic growth. 
 
All serous-like cell lines carry mutated TP53, a characteristic feature of HGSCs 
(Beaufort et al. 2014). Another frequent alteration linked to HGSC, the mutation of 
genes related to HRR pathways (Lord & Ashworth 2016), is found in OVCAR-3 
(‘partner and localizer of BRCA2’ or PALB2) and SKOV-3 (PALB2 and the 
‘BRCA1 associated RING domain 1’ or BARD1) (Beaufort et al. 2014). 
Additionally, the UWB1.289 cell line carries a null BRCA1 gene mutation 
(DelloRusso et al. 2007). Other relatively common features of HGSC such as 
CCNE1 or ERBB2 amplification are also present in OVCAR-3 and SKOV-3 cell 
lines respectively (Domcke et al. 2013). Interestingly, the high-grade endometrioid-
like cell line TOV-112D presents a very clear mutational spectrum (carrying only 
mutations of TP53 and ‘catenin beta 1’ or CTNNB1) and probably falls into the type 
II OC classification, together with the rest of serous-like cell lines. It is important to 
note that even though the four serous-like cell lines have been catalogued as ‘serous’ 
and not ‘HGSC’, they all display HGSC characteristic features and none resemble 
the low-grade serous histo-type (Table 3.1). 
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The majority of OC cell lines used in this study, except SKOV-3 and OVCAR-3, 
were obtained from the primary localization of OC, the ovaries (Table 3.1). 
COV644, TOV-112D and TOV-21G were derived from un-treated patients with 
primary disease; OVCAR-3 and UWB.1289 were collected from relapsed platinum-
treated patients. The SKOV-3 cell line was derived from a patient treated with non-
platinum chemotherapy from which there is no clear information regarding the state 
of the disease (Beaufort et al. 2014). However, neither OVCAR-3 nor SKOV-3 nor 
UWB1.1289 developed strong resistance against broad chemotherapy, according to 
Beaufort et al. (2014). There is no information on the exact origin, treatment or 
resistance capabilities of UACC-1598. 
 
 
3.3 Basal Expression of HBO1 Transcripts 
One of the main hypotheses put forward advocates the involvement of HBO1 in the 
progression of OC. In order to evaluate the comparative levels of HBO1 in each OC 
cell line compared to the non-cancerous control, isolated RNA samples were 
analysed for HBO1 transcript expression. According to NCBI databases (NCBI 
Resource Coordinators 2017), the HBO1 locus codes for five alternative splicing 
variants that give rise to different protein isoforms. Consequently, and in order to 
quantify the total amount of transcript (mRNA) regardless of the splicing variant, 
primer pairs were design to amplify all isoforms of HBO1. 
 
The whole panel of OC cell lines displayed increased HBO1 mRNA relative 
expression levels compared to the non-cancerous HOSEpiC control (Fig. 3.1). The 
two cell lines that showed the lowest levels of HBO1 expression, yet still greater than 
HOSEpiC, were the clear-cell TOV-21G (FC = 1.76, *p = 0.0170) and the mucinous 
COV644 (FC = 2.21, *p = 0.0328) (Fig. 3.1). Interestingly, all serous-like cell lines 
including, OVCAR-3 (FC = 2.34, ***p = 0.0002), SKOV-3 (FC = 3.67, ****p = < 
0.0001), UWB1.289 (FC = 4.50, ****p = < 0.0001) and UACC-1598 (FC = 4.08, 
****p = < 0.0001), in addition to the endometrioid TOV-112D (FC = 3.64, ****p = < 
0.0001) displayed significant high levels of HBO1 transcripts compared to the 
HOSEpiC control (Fig. 3.1). 
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Figure 3. 1 Comparative analysis of HBO1 transcript expression 
RNA lysates from HOSEpiC and 7 OC cell lines were prepared and analysed by 
qRT-PCR. Relative levels of HBO1 expression were compared to those of the 
HOSEpiC non-cancerous control. GAPDH expression was used as control.  
Statistical analysis consisted of one-way ANOVA and the Tukey’s multiple 
comparison test. All values represent the mean ± standard deviation (SD) of three 
biological samples (*p < 0.05; ***p < 0.001; ****p < 0.0001). 
 
 
These results show a general augmentation of all HBO1 mRNA isoforms in OC lines 
compared to the non-cancerous control. Notably, there is growing evidence linking 
aberrant use of alternative mRNA isoforms with cancer phenotypes (Sveen et al. 
2016) and the aberrant use of one gene isoform over another has been directly linked 
to cancer cell growth (Rajan et al. 2009). In OC, one overexpressed splice variant of 
the ‘baculoviral inhibitor of apoptosis repeat-containing 5’ gene (BIRC-5 or 
‘survivin’) was associated with tumour growth in a taxane-resistant setting (Vivas-
Mejia et al. 2011). These links raised question as to whether HBO1 overexpression 
and its potential effects may be associated with the aberrant expression of specific 
HBO1 splice isoforms. 
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3.4 Basal Expression of HBO1 Isoforms 
3.4.1 Structure and characteristics of the HBO1 isoforms 
According to the NCBI, HBO1 codes a precursor mRNA transcript that is 
differentially spliced giving rise to five mature mRNA HBO1 isoforms, whose main 
characteristics are shown in Table 3.2. The specific isoform nomenclature was 
selected from the consensus coding DNA sequence or CCDS database of the NCBI 
(Pruitt et al. 2009), as opposed to other designations used by databases such as 
UniProt (UniProt Consortium 2008). A graphical depiction and comparison of the 
structure of each one of the HBO1 protein variants is illustrated in Figure 3.2. 
 
 
Table 3. 2 Structural composition of the five HBO1 isoforms 
 
Nomenclature DNA (bp) Protein (aa) MW1 (kDa) RefSeq2 
Isoform 1 1836 611 70 NP_008998.1 
Isoform 2 1746 581 67 NP_0.001186084.1 
Isoform 3 1419 472 55 NP_001186085.1 
Isoform 4 1506 501 58 NP_001186086.1 
Isoform 5 1329 442 51 NP_001186087.1 
1MW: Molecular weight in kilodaltons (unified atomic mass units) 
2RefSeq: Reference Sequence (O’Leary et al. 2016) 
 
 
All five HBO1 variants retain a full-length MYST domain but differ in the 
configuration of the N-terminus (Fig. 3.2). While HBO1 isoform 1 encodes the 
longest transcript and as a consequence the largest protein, isoform 2 lacks the small 
alternate in-frame exon 6 (Table 3.2 & Fig. 3.2). Both isoforms 1 and 2 share the 
same N and C terminus, as well as the main functional structures: Ser-rich and 
MYST domains, zinc fingers, nuclear localization signal (NLS) and the lysine 
acetyltransferase domain (LAT). HBO1 isoform 3 lacks the alternate in-frame exons 
3 and 4, which are part of the Ser-rich domain and are involved in the configuration 
of a zinc finger structure (C2H2C, amino acids 189-211) (Fig. 3.2). Similarly, 
isoform 5 lacks exons 3 and 4 and therefore the zinc finger, in addition to in-frame 
exon 6. HBO1 isoform 4 lacks in-frame exons 4 and 6, losing the zinc finger 
structure but conserving a bigger portion of the Ser-rich domain, as oppose to 
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isoforms 3 and 5 (Fig. 3.2). The N-terminus region of HBO1 (amino acids 1-230) is 
commonly regarded as an intrinsic repression domain (Sharma et al. 2000; 
Georgiakaki et al. 2006; Contzler et al. 2006). Consequently, splice variants that lack 
distinct fragments of this domain, such as isoforms 3, 4 and 5 (Fig. 3.2), might lose 
the corresponding repression function. 
 
 
	
Figure 3. 2 Schematic depiction of the human HBO1 protein variants 
The five HBO1 protein isoforms are separated into numbered exon sequences (1-8), 
except for their C-terminus MYST region (MYST). The serine-rich domain (Ser-
rich) located in the NTD (amino-terminus domain) of the HBO1 protein is 
represented in clear blue colour and comprises different exons depending on the 
specific isoform. ZNF1: C2H2C zinc finger; ZNF2: C2HC zinc finger; NLS: Nuclear 
localization signal; LAT: Lysine acetyltransferase domain; CTD: Carboxyl-terminus 
domain. 
 
 
3.4.2 Differential expression of HBO1 isoforms in OC cell lines 
Primer pairs spanning isoform-specific exon boundaries were designed to detect and 
quantify each HBO1 isoform transcript. The expression level of each of the five 
isoforms in the non-cancerous HOSEpiC control was compared to the expression 
level of those isoforms in each one of the 7 OC cell lines (Fig. 3.3 & Appendix 1). 
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Figure 3. 3 Comparative analysis of HBO1 isoform expression 
Graphical depiction of changes in HBO1 isoform transcript abundance comparing 
HOSEpiC non-cancerous control and the 7 OC cell lines. The red gradation diagram 
on the right of the panel represents qRT-PCR fold-change values. Individual graphs 
representing differential isoform expression can be found in Appendix 1 A-E. E: 
Endometrioid; C: Clear-cell; M: Mucinous. 
 
 
In general terms and following the trend observed in Figure 3.1, HBO1 isoforms 
were overexpressed in the panel of OC cell lines compared to the HOSEpiC control 
(Fig. 3.3). Interestingly, the majority of cell lines with high HBO1 expression levels 
(SKOV-3, UWB1.289, UACC-1598 and TOV-112D) displayed strong increase of 
several, if not all HBO1 variants, compared to the HOSEpiC control (Fig. 3.3). 
HOSEpiC control cells did not show higher levels of expression of any HBO1 
isoform in comparison with any of the OC cell lines. However, HOSEpiC cells did 
display a basal level of expression of all isoforms, implying that whatever the source 
of HBO1 overexpression in OC is, it does not rely on the expression of a distinctive, 
cancer-related unique HBO1 variant. 
 
OVCAR-3 cell line displayed moderate to high levels of isoform 1 (FC = 1.75, *p = 
0.0414), isoform 2 (FC = 1.49, p = 0.1628), isoform 3 (FC = 1.66, p = 0.0579) and 
isoform 4 (FC = 1.75, *p = 0.011), compared to the HOSEpiC control (Fig. 3.3). The 
rest of the serous-like cell lines, SKOV-3, UWB1.289 and UACC-1598, exhibited 
much greater up-regulation of most HBO1 isoforms. For instance, SKOV-3 
displayed high levels of isoform 1 (FC = 2.77, **p = 0.0029), isoform 2 (FC = 3.2, 
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***p = 0.0002), isoform 3 (FC = 5.77, ***p = 0.0007), isoform 4 (FC = 2.36, ***p = 
0.0001) and isoform 5 (FC = 7.37, **p = 0.00721). Likewise, UACC-1598 exhibited 
high levels of isoform 1 (FC = 4.3, ****p = < 0.0001), isoform 2 (FC = 3.92, ****p = 
< 0.0001), isoform 3 (FC = 3.14, *p = 0.0461), isoform 4 (FC = 3.65, ****p = < 
0.0001) and isoform 5 (FC = 2.47, *p = 0.042) (Fig. 3.3). 
 
All isoforms are overexpressed in the UWB1.289 cell line, which showed the highest 
expression levels of HBO1 (Fig. 3.1), compared to the HOSEpiC control: isoform 1 
(FC = 5.27, ****p = < 0.0001), isoform 2 (FC = 3.32, ***p = 0.0003), isoform 3 (FC 
= 3.28, **p = 0.0078), isoform 4 (FC = 3.51, **p = 0.00741) and isoform 5 (FC = 
4.11, *p = 0.036) (Fig. 3.3). The TOV-112D endometrioid-like cell line showed up-
regulation of isoform 1 (FC = 2.48, *p = 0.0107), isoform 2 (FC = 4.15, **p = 
0.0076) and isoform 4 (FC = 4.21, **p = 0.0011), compared to the HOSEpiC control 
(Fig. 3.3). 
 
The clear-cell TOV-21G cell line displayed non-significant moderate levels of whole 
HBO1 (Fig. 3.1), probably caused by the slight increase in isoform 2 (FC = 2.05, *p 
= 0.0489), isoform 3 (FC = 1.76, p = 0.5228) and isoform 5 (FC = 2.82, *p = 
0.0375), compared to the HOSEpiC control (Fig. 3.3). Similarly, isoform 2 (FC = 
1.96, *p = 0.0485), isoform 3 (FC = 1.99, *p = 0.0371) and isoform 4  (FC = 2.13, 
**p = 0.0028) are up regulated in the mucinous COV644 cell line, compared to the 
HOSEpiC control (Fig. 3.3). 
 
 
3.5 Basal Expression of HBO1 Protein in OC 
3.5.1 Selection of antibodies targeting HBO1 
Western blotting is the most common experiment used to interrogate protein 
abundance and there are a number of commercially available validated HBO1 
antibodies such as those from Abcam® (AB70) or Santa Cruz® (G-2, T-20, H-180, 
N-18); AB70 and G-2 antibodies were used in this study. 
 
Results	
	 141	
The monoclonal HBO1 antibody G-2 is specific for an epitope encoded by exon 2, 
mapping between amino acids 20-47, and therefore should recognize all 5 HBO1 
protein isoforms (Fig. 3.2). The AB70 polyclonal HBO1 antibody binds to an 
internal (and undetermined) region of the N-terminal domain, suggesting it may not 
recognize all protein variants, however, it was widely used for WB experiments in 
the literature (Miotto & Struhl 2008; Avvakumov et al. 2012; Zou et al. 2013; 
Lalonde et al. 2013). 
 
In order to test the performance of anti-HBO1 G-2 and AB70 antibodies, protein 
extracts from UWB1.289 and UACC-1598 cell lines were analysed by western blot 
(Fig. 3.4). Proteins were separated using SDS-PAGE gel electrophoresis on 4-12% 
gradient gels to ensure separation of HBO1 isoforms. An anti-GAPDH antibody was 
used as loading standard. 
 
	
Figure 3. 4 Western blot analyses of HBO1 antibodies performance 
Protein extracts of UWB1.289 and UACC-1598 were analysed by western blot and 
probed with: (A) G-2 and (B) AB70 anti-HBO1 antibodies. GAPDH was used as 
control. 1: UWB1.289; 2: UACC-1598; *Unknown bands. 
 
 
Both antibodies G-2 and AB70 revealed a ~70 KDa band identified as HBO1 
isoforms 1 and 2 (Fig. 3.4). The smeared appearance of this band is probably due to 
the presence of two similar proteins, isoform 1 (70 KDa) and isoform 2 (67 KDa), 
but also as a result of HBO1 post-translational modifications such as 
phosphorylation (Miotto & Struhl 2011). The absence of bands in the 50-60 KDa 
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range suggests that isoforms 3, 4 and 5 are expressed in low levels (Fig. 3.4). Other 
possibilities can be that the mature mRNA of these isoforms does not translate into 
protein or that the antibodies do not recognize these specific isoforms. 
 
The unknown bands present in the UACC-1598 lysate (Fig. 3.4 A) might be caused 
by high weight PTMs such as poly-ubiquitination (Sadowski et al. 2012) or 
SUMOylation (Flotho & Melchior 2013), nonspecific antibody binding, non-
catalogued HBO1 isoforms or cell line artefacts. HBO1 has been previously linked 
to ubiquitin-related activity, as it is marked by poly-ubiquitin chains for degradation 
in the cytoplasm (Zou et al. 2013), so in order to investigate this possibility, the G-2 
antibody was used to immune-precipitate (IP) HBO1 prior to ubiquitin detection 
(Fig. 3.5). 
 
	
Figure 3. 5 Analysis of HBO1 ubiquitination state via IP using the G-2 antibody 
UACC-1598 protein lysates were immune-precipitated using anti-HBO1 G-2 
antibody, separated using SDS-PAGE and probed with (A) anti-HBO1 and (B) anti-
ubiquitin antibodies. *Unknown bands. 
 
 
The G-2 antibody was able to specifically IP HBO1 protein (~70 KDa), while no 
product was isolated with the immunoglobulin G (IgG) control (Fig. 3.5 A). Again, 
and as seen in previous results (Fig. 3.4), G-2 detected a ~90-100 KDa undetermined 
band (Fig. 3.5 A). Surprisingly, the IP sample did not reveal any ubiquitin signal 
(Fig. 3.5 B), suggesting that the 90-100 KDa band does not represent ubiquitinated 
protein. The input control revealed multiple ubiquitinated proteins and an 8.8 KDa 
band representing monomeric ubiquitin protein (Fig. 3.5 B) (Parker et al. 2010). 
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Although both antibodies seemed to perform well, some drawbacks of the G-2 Santa 
Cruz® antibody include the un-recognized bands (Fig. 3.4 A & Fig. 3.5 A) and the 
fact that its use has not been previously referred in the literature. In contrast, AB70 
specifically recognized isoforms 1 and 2 (inferred by doublets in Figure 3.4 B), did 
not detect un-expected proteins and has been extensively used in the literature 
(Miotto & Struhl 2008; Avvakumov et al. 2012; Zou et al. 2013; Lalonde et al. 
2013). AB70 antibody was therefore selected to assess HBO1 protein levels. 
 
4.5.3 Differential expression of HBO1 protein in OC cell lines 
Protein extracts from 7 OC cell lines and the HOSEpiC control were separated using 
gel electrophoresis (4-12% gradient gel), transferred to PVDF membranes and 
probed with anti-HBO1 AB70 antibody. An anti-GAPDH antibody was used as 
loading standard. 
 
	
Figure 3. 6 Comparative analysis of HBO1 protein expression 
Protein extracts of HOSEpiC and 7 OC cell lines were analysed by western blot and 
probed with anti-HBO1 (AB70) and anti-GAPDH antibodies. E: Endometrioid; C: 
Clear-cell; M: Mucinous. 
 
 
All OC cell lines displayed higher HBO1 expression compared to the non-cancerous 
HOSEpiC control (Fig. 3.6). However, HBO1 protein intensity did not correlate 
exactly with previously determined mRNA levels in the OC cell lines. For instance, 
the SKOV-3 cell line, which expressed HBO1 transcript 3.67 fold-greater than the 
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HOSEpiC control (Fig. 3.1), displayed protein intensities analogous to COV644 
(2.21 fold-change over HOSEpiC) (Fig. 3.1 & Fig. 3.6). 
 
HBO1 protein expression in HOSEpiC cells was very low, preventing accurate 
comparative quantification, therefore, a per cent ratio of relative density (RD) values 
was expressed in natural logarithms (assuming HOSEpiC per cent ratio = 1). The 
serous-like cell lines displayed the highest RD compared to the HOSEpiC control: 
UACC-1598 (RD = 5.87, ****p < 0.0001), UWB1.289 (RD = 5.31, ****p < 0.0001); 
with TOV-112D (endometrioid, RD = 5.10, ****p < 0.0001), TOV-21G (clear-cell, 
RD = 4.86, ***p = 0.0009), COV644 (mucinous, RD = 4.75, **p = 0.0036), 
OVCAR-3 (serous, RD = 4.58, **p = 0.0019) and SKOV-3 (serous, RD = 4.47, **p 
= 0.0041) all having an RD > 4 (Fig. 3.6). 
 
 
3.6 Analysis of Potential Sources of HBO1 De-regulation in OC 
The proximal promoter region of HBO1 contains numerous experimentally proven 
binding sites (Transfac® Professional). Amongst those, the large numbers of nuclear 
receptor binding sites, such as AR, ER, PR and glucocorticoid receptor, was striking. 
Other relevant putative binding sites include sequences targeted by p53 and NF-κβ, 
transcription factors previously linked to HBO1 function and regulation (Contzler et 
al. 2006; Iizuka et al. 2008). The presence of nuclear receptor binding sites in the 
proximal promoter of HBO1 suggests that HBO1 expression may be modulated by 
those nuclear receptors, whose up-regulation could be the trigger for HBO1 
overexpression. To assess this possibility, the transcript expression of ERA, ERB and 
AR in the panel of OC cell lines was analysed (Fig. 3.7 & Appendix 2). 
 
The augmentation of HBO1 transcript levels compared to the HOSEpiC control did 
not show any clear correlation with the levels of nuclear receptor ERA mRNA 
expression (Fig. 3.7). While some OC cell lines with high HBO1 expression levels 
displayed no ERA transcript: UWB1.289 (FC = -17.26, **p = 0.0032) and TOV-
112D (FC = -22.69, **p = 0.0026); others, OVCAR-3 (FC = 5.13, *p = 0.0364), 
SKOV-3 (FC = 123, **p = 0.0015) and COV644 (FC = 13.73, **p = 0.0043) showed 
significant overexpression of the nuclear receptor (Fig. 3.7). 
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Figure 3. 7 Comparative analysis of nuclear receptor expression levels 
Graphical depiction of changes in nuclear receptors transcript abundance comparing 
HOSEpiC non-cancerous control and the 7 OC cell lines. The red gradation diagram 
on the right of the panel represents qRT-PCR fold-change values; absent value 
corresponds to cycle threshold 40. Individual graphs representing differential nuclear 
receptor expression can be found in Appendix 2 A-C. E: Endometrioid; C: Clear-
cell; M: Mucinous. 
 
 
High HBO1 expression did not display a clear correlation with nuclear receptor ERB 
transcript levels either, with most OC cell lines and the HOSEpiC control expressing 
similar amounts of the nuclear receptor:  OVCAR (FC = 1.17, p = 0.867), 
UWB1.289 (FC = -3.23, p = 0.4033), UACC-1598 (FC = -1.8, p = 0.9853), TOV-
21G (FC = 1.57, p = 0.7483) (Fig. 3.7). 
 
On the contrary, with the exception of the endometrioid cell line TOV-112D (FC = 
3.37, p = 0.40) and OVCAR-3 (FC = 2.81, p = 0.324), OC cell lines with high levels 
of HBO1 mRNA expression displayed very low levels of nuclear receptor AR: 
SKOV-3 (FC = -220.59, ****p = < 0.0001), UWB1.289 (FC = -60.78, ****p = < 
0.0001), UACC-1598 (FC = -113.82, ****p = < 0.0001), TOV21-G (FC = -44.72, 
**p = 0.0062) and COV644 (FC = -22.49, **p = 0.00356) (Fig. 3.7). 
 
The existence of genomic HBO1 modulation by ERA, ERB and AR appears 
unlikely, based on the expression analyses (Fig. 3.7). Nonetheless, additional forms 
of regulation cannot be discarded, e.g. protein-protein interactions. High levels of 
HBO1 seem to correlate with low levels of AR, suggesting that HBO1 negatively 
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regulates the expression of AR, a possibility that agrees with previous studies linking 
HBO1 with AR-mediated transcriptional repression (Sharma et al. 2000). 
 
Estradiol (E2) treatment induced HBO1 transcript expression in T47D and MCF7 
breast cancer cell lines through ERα and the ‘extracellular signal-regulated kinase’ 
or ERK1/2 signalling pathways (Wang et al. 2010). In order to investigate whether 
HBO1 overexpression is linked to E2-related induction of the ERα receptor in serous 
OC, ERα positive cell lines OVCAR-3 and UACC-1598 were treated with E2. The 
SKOV-3 cell line was not selected for treatment due to its known non-
responsiveness to E2 (Hua et al. 1995; Lau et al. 1999). A set of gene transcripts that 
have previously been shown to be modified by E2 treatment in serous OC cell lines 
were used as positive controls, including caspase 4 (CASP4), keratin 4 (KRT4), 
lipocalin 2 (LCN2) and the ‘TNF receptor associated protein 1’ (TRAP1) (O’Donnell 
et al. 2005). 
 
	
Figure 3. 8 E2 treatment of UACC-1598 cells 
UACC-1598 cells were treated with E2 (1-10-100nM) and the control vehicle 
(absolute ethanol). Cell lysates were extracted after 4, 8, 24, and 48h whereupon 
RNA samples were prepared and analysed by qRT-PCR. Relative levels of HBO1 
expression in E2-treated cells were compared to those of cells treated with the 
control vehicle. RPL5 expression was used as control. Results represent the mean ± 
SD of two biological replicates. 
 
 
The expression levels of HBO1 and the set of genes were tested 4, 8, 24 and 48h 
after the treatment with a range of E2 doses, including physiologic concentrations (1-
10nM) (O’Donnell et al. 2005; Celojevic et al. 2011), but no significant changes 
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were observed (Fig. 3.8). These results suggest HBO1 overexpression is not driven 
by E2 in these OC cell lines. The absence of target gene induction after E2 treatment 
could imply ERα/β signalling deficiencies or differing gene modulation patterns 
amongst OC cell lines. 
 
 
3.7 HBO1 Genome Wide Localization 
HBO1 is located in the cellular nucleus (Sharma et al. 2000; Burke et al. 2001) and 
associated with chromatin (Miotto & Struhl 2008). Therefore, if HBO1 is an 
important regulator involved in global OC development, the increased levels of 
HBO1 protein observed in OC cell lines compared to non-cancerous control (Fig. 
3.6) might cause an associated increase in HBO1 occupancy at promoter/enhancer 
regions of cancer-associated genes. 
 
The most common tool to study the interaction between proteins such as HBO1 and 
the DNA is ChIP, which coupled with qRT-PCR can be used to investigate protein 
enrichment in localized binding sites (Gade & Kalvakolanu 2012). Combined with 
massively parallel DNA sequencing (ChIP-Seq), this tool also allows for the genome 
wide mapping of DNA-binding proteins (Furey 2012). For instance, the genome 
wide localization of HBO1 has been characterized via ChIP-Seq using the RKO 
human colon cancer cell line (Avvakumov et al. 2012). Many other studies have also 
evaluated HBO1 localization at defined loci using ChIP-qRT-PCR (Miotto & Struhl 
2008; Saksouk et al. 2009; Miotto & Struhl 2010; Mishima et al. 2011; Avvakumov 
et al. 2012; Lalonde et al. 2013; Song et al. 2013). However, a consensus site 
associated with HBO1 binding has not been identified so far. 
 
3.7.1 ChIP optimization 
The quality of an HBO1 ChIP-Seq experiment is governed by the specificity of the 
antibody, as well as the degree of enrichment achieved in the affinity precipitation 
step (Park 2009). Several commercially available HBO1 antibodies have already 
been used for ChIP-qRT-PCR in the literature (Miotto & Struhl 2008; Lalonde et al. 
2013; Feng et al. 2015), but only one has been used for ChIP-Seq –Abcam® AB70 
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(Avvakumov et al. 2012). This antibody has also been used to perform ChIP-qRT-
PCR in numerous occasions (Miotto & Struhl 2008; Miotto & Struhl 2011; 
Avvakumov et al. 2012; Lalonde et al. 2013), and thus represented the best possible 
choice to start a ChIP-Seq optimization process. 
 
UWB1.289 was selected as a model to optimize ChIP-Seq based on the fact that 
this cell line represents the serous histology, exhibits high levels of HBO1 
expression at both the mRNA and protein levels (Fig. 3.1 & Fig. 3.6), and grows 
rapidly (an important aspect given that ChIP experiments require large cell 
numbers). 
 
3.7.2 Antibody validation 
According to the ENCODE consortia, an antibody that has been validated for ChIP 
in at least three different cell types (e.g. AB70 in HEK 293T, HeLa, CCL-156) 
(Miotto & Struhl 2008) does not need further testing (Landt et al. 2012). However, 
since ChIP-Seq is an expensive and complicated procedure, a series of experiments 
were performed in order to characterize the suitability of AB70 to accomplish ChIP-
Seq in an OC cell line. 
 
Following the guidelines recommended by the ENCODE consortia, antibodies 
directed against transcription factors have to pass several tests to reassure their 
recognition of the antigen of interest with minimal cross-reactivity toward other 
DNA-associated proteins. The effective use of an antibody for IP is usually the best 
indicator of ChIP success, since the antibody recognizes an epitope in its native 
conformation and within the context of any complexes that the epitope may be found 
in. In this regard, polyclonal antibodies, which recognize a number of different 
epitopes of the same protein, have higher probabilities to accomplish strong ChIP 
experiments. 
 
Consequently, the AB70 antibody was used to perform IP with UWB1.289 cell 
protein lysates, followed by SDS-PAGE separation and HBO1 antibody detection 
(Fig. 3.9 A). In addition, the AB70-IPed fraction was probed with an antibody 
targeting ING4, an important member of the HBO1 complex whose main functions 
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were described earlier (Doyon et al. 2006), in order to evaluate the capacity of AB70 
to pool specific targets (HBO1) alongside well-known associated proteins (e.g. 
ING4) (Fig. 3.9 B). 
 
	
Figure 3. 9 HBO1 IP and ING4 co-IP using AB70 antibody 
UWB.289 protein lysates were immune-precipitated using anti-HBO1 AB70 
antibody, separated using SDS-PAGE and probed with (A) anti-HBO1 and (B) anti-
ING4 antibodies. 
 
 
AB70 specifically immune-precipitated the HBO1 protein (~70 KDa) in UWB1.289 
cell lysates, while no product was isolated with the IgG control (Fig 3.9 A). 
Moreover, HBO1 co-precipitates with ING4 (~29 KDa) when immune-precipitated 
with AB70 (Fig 3.9 B), further demonstrating the specificity of the anti-HBO1 
antibody. HBO1 nuclear localization was then investigated. 
 
	
Figure 3. 10 HBO1 immune-fluorescence staining 
First column (Bright-field) displays optical microscopic images of UWB1.289 and 
HOSEpiC fixed-cells; second (DAPI: 4’, 6-diamidine-2’-phenylindole 
dihydrochloride) and third (Alexa Fluor® 488) columns show fluorescent-labelled 
DNA and HBO1 images respectively. Scale represents 10µm. 
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HBO1 was found to localize mainly to the nucleus of HOSEpiC and UWB1.289 
cells (Fig. 3.10), with the exception of the area corresponding to the nucleoli, a 
feature that has been previously described (Doyon et al. 2006; Yan et al. 2016). This 
phenomenon can be perceived more clearly in the HOSEpiC cell (Fig. 3.10), which 
has lower HBO1 expression compared to the UWB1.289 cell, in accordance with 
earlier mRNA and protein analyses (Fig. 3.1 & Fig. 3.6). HBO1 was not solely 
localized to the nucleus, but was also observed in the cytoplasm of the cells, where it 
accumulated at lower levels (Fig. 3.10). 
 
Subcellular protein fractionation was undertaken to demonstrate the association of 
HBO1 with nuclear chromatin. Total UWB1.289 protein was subcellularly 
fractionated and probed with different antibodies: anti-HBO1 (AB70), anti-EGFR, 
anti-XRCC1 and anti-histone H4. Antibodies against the ‘epidermal growth factor 
receptor 1’ (EGFR), the ‘x-ray repair cross complementing 1’ (XRCC1) and histone 
H4 were used as positive controls, since their targets are commonly restricted to 
specific cellular fractions: membrane (EGFR), nucleus (XRCC1) and chromatin 
(histone H4) (Lemmon et al. 2014; London 2015). 
 
	
Figure 3. 11 Subcellular protein localization of HBO1 in UWB1.289 cells 
(A) UWB1.289 protein lysates were segregated into subcellular fractions, 
subsequently separated using SDS-PAGE and probed with anti-HBO1 (AB70), anti-
EGFR, anti-XRCC1 and anti-Histone H4. CF: Chromatin Fraction; MF: Membrane 
Fraction; NF: Nuclear fraction; ChF: Chromatin-bound fraction. (B) Cellular 
distribution of HBO1 protein according to the subcellular protein fractionation. 
Localization percentages were calculated using ImageJ. 
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Approximately half of the HBO1 protein (44.38 ± 2.57%) was found associated with 
chromatin in UWB1.289 protein lysates, with 37.73 ± 2.73% of protein localized to 
the nucleus but un-bound to chromatin, while only 2.44 ± 0.67% and 15.39 ± 0.76% 
was located in the membrane and cytoplasmic fractions respectively (Fig. 3.11). 
 
EGFR, a trans-membrane protein (Lemmon et al. 2014) was localized in the 
membrane fraction, where the high lipid content in this fragment causes the 
formation of the large dot seen on the gel (Fig. 3.11 A). All of the DNA repair-
protein XRCC1 (London 2015) localized to the nucleus: 52.30 ± 4.17% in the so-
called nuclear fraction and 47.14 ± 2.17% in the chromatin-bound fraction, and 
100% of histone H4 signal was detected in the chromatin fraction (Fig. 3.11 A), 
validating the subcellular localization of HBO1. 
 
3.7.3 Chromatin shearing 
UWB1.289 cells contain high levels of chromatin-bound HBO1 protein (Fig. 3.6 & 
Fig. 3.11), which can be specifically targeted by the anti-HBO1 antibody AB70 (Fig. 
3.4 B & Fig. 3.6). A Chromatrap® kit was therefore used to perform ChIP-qRT-PCR 
validation experiments and test whether AB70 is able to selectively IP cross-linked 
HBO1-chromatin fragments. Chromatin shearing was optimized using the random 
sonication procedure to attain optimal size range of chromatin fragments for ChIP-
qRT-PCR and ChIP-Seq (100-500 bps, approximately the length of DNA wrapping 
2-3 nucleosomes). 10-15 million UWB1.289 cells, the highest number recommended 
by Chromatrap®, were cross-linked and samples sonicated for different time periods, 
power settings (medium-high) and number of cycles, reverse cross-linked and 
analysed by agarose gel electrophoresis to evaluate sonication efficiency (Fig. 3.12). 
 
The sonication setting 6 (high-power setting and 10 one-minute sonication cycles 
with 30 seconds resting time each cycle) resulted in the most appropriate distribution 
of DNA fragmentation, with most DNA fragments uniformly placed in the one 
hundred to five hundred base pair (Fig. 3.12). 
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Figure 3. 12 Sonication efficiency of UWB1.289 cross-linked chromatin samples 
Pellets of 10-15 million UWB1.289 cells were subjected to sonication using different 
conditions. Sonication settings: (1) MP, 15c, 1-1; (2) MP, 10c, 1-1; (3) MP, 15c, 1-
0.5; (4) MP, 10c, 1-0.5 (5) HP, 15c 1-0.5; (6) HP, 10c, 1-0.5; (7) HP, 10c, 1-1.5; (8) 
HP, 10c, 1-1; (9) HP, 15c, 1-1. HP = High power; MP = Medium power; c = cycles; 
1-0.5/1/1.5 = 1 minute sonication-0.5/1/1.5 minutes rest. 
 
 
3.7.4 ChIP-qRT-PCR enrichment 
Following the optimization of the shearing procedure, a final validation experiment 
prior to ChIP-Seq, which consisted of identifying HBO1-interacting genomic regions 
specifically enriched by the AB70 antibody via ChIP-qRT-PCR, was performed. In 
this experiment, non-specific IgG and anti-H3K4me3 antibodies were used as 
negative and positive enrichment controls respectively. H3K4me3 is a histone mark 
that maps to promoters of actively transcribed genes and, more importantly, co-
localizes with HBO1 (Hon et al. 2009; Avvakumov et al. 2012). 
 
There are several well-characterized eukaryotic origins of replication known to be 
targeted by HBO1 in different cellular backgrounds, which are named after the 
nearest gene and include: laminB2 (LMNB2), (Lee & Romero 2012), MCM4 
(Gundelach et al. 2007), ‘small nucleolar RNA host gene 12’ (SNHG12) and 
‘putative RNA-binding protein Luc7-like’ (LUC7L) (Feng et al. 2015). Feng et al. 
(2015) designed specific primer pairs that can be used to evaluate target occupancy 
on such genomic locations. As a consequence, the Chromatrap® Pro-A kit was used 
to perform ChIP followed by ChIP-qRT-PCR using (1) Feng et al. (2015) primer 
pairs and (2) three intergenic negative primers. These probes target intergenic 
regions (IGR) where neither HBO1 nor H3K4me3 are expected to be found and 
therefore allow evaluating whether detected enrichment is localized or non-specific. 
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Each primer pair was used to amplify DNA samples from two biological replicates 
of different UWB1.289 chromatin extractions with two technical replicates per 
antibody IP (Fig. 3.13). 
 
	
Figure 3. 13 Enrichment of potential HBO1 targets: origins of replication 
UWB1.289 cells were subjected to ChIP using IgG, anti-HBO1 (AB70) and anti-
H3K4me3 antibodies, followed by qRT-PCR amplification of LMNB2, MCM4, 
SNHG12 and LUC7L genomic regions. IGRs 1, 2 and 3 were used as controls for 
antibody-specificity. Final antibody enrichment, expressed as percentage of input, 
was calculated comparing sample qRT-PCR values with ‘Input’ control values. 
Results represent the mean ± SD of two biological replicates. IGR: Intergenic region. 
 
 
The percentage of input (PI) enrichment displayed by AB70 in the IGR 2 region (PI 
= 0.24 ± 0.12%) was higher than, or at least as high as, the enrichment found at the 
LMNB2 (PI = 0.18 ± 0.01%), MCM4 (PI = 0.25 ± 0.10%), SNHG12 (PI = 0.15 ± 
0.12%) and LUC7L (PI = 0.11 ± 0.03%) loci (Fig. 3.13); suggesting that AB70 
performed a nonspecific IP. In view of the data obtained, it was concluded that the 
anti-HBO1 AB70 antibody did not show significant enrichment compared to the 
negative controls (IgG antibody and IGR primer pairs) in any of the interrogated 
origin of replication regions. 
 
H3K4me3 antibody showed significant input enrichment in LMNB2 (PI = 3.04 ± 
0.52%), MCM4 (PI = 4.42 ± 0.62%), SNHG12 (PI = 6.04 ± 0.83%) and LUC7L 
(6.22 ± 0.51%) regions (Fig 3.13), suggesting an important presence of the histone 
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mark in those genomic regions. On the contrary, H3K4me3 did not show enrichment 
in any of the three interrogated IGRs: IGR 1 (PI = 0.26 ± 0.07%), IGR 2 (PI = 0.16 ± 
0.08%) and IGR 3 (PI = 0.14 ± 0.03%) (Fig. 3.13). The results obtained with 
H3K4me3 antibody demonstrate that the ChIP experiment itself worked, albeit 
AB70 IP either did not work or needed further optimization. In line with this, small 
variations of the ChIP protocol such as changes in AB70 or chromatin quantities per 
IP and IP duration were tested. However, these too failed to give any HBO1 specific 
enrichment at the tested loci. 
 
In order to evaluate the reasons for the lack of enrichment, origin-of-replication 
primer binding sites were assessed using the Integrative Genomics Viewer (IGV) 
(Fig. 3.14). For that, the only HBO1 ChIP-Seq available data and its correspondent 
‘Input’ were downloaded from the Gene Expression Omnibus database (GSE33221) 
(Avvakumov et al. 2012) and analysed following the procedure detailed in Figure 
2.3. Additionally, the raw data of an H3K4me3 ChIP-Seq performed in the same 
cellular background as the HBO1 ChIP-Seq, RKO colon carcinoma cells, was 
downloaded (GSE47190) and analysed (Lalonde et al. 2013). 
 
	
Figure 3. 14 IGV analysis of alleged HBO1-targeted origins of replication 
The first and second panels (starting from the top) represent peak enrichment 
obtained with anti-HBO1 and anti-H3K4me3 antibodies in ChIP-Seq experiments 
performed with the RKO cell line. The third panel (Input) represents unspecific 
peaks obtained from RKO chromatin samples that have not been subjected to 
antibody enrichment. Images were extracted from the Integrative Genomics Viewer 
(IGV). Selected origins of replication are named after the nearest gene, depicted at 
the bottom as longitudinal lines where black squares/rectangles symbolise exons. 
Specific primer amplification sites are illustrated on top of the first panel. TSS = 
Transcription Starting Site. X-axis scale represents 2Kb; y-axis scales represent peak 
enrichment value ranges. 
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As depicted in Figure 3.14, LMNB2 and LUC7L primer pairs amplify regions that, 
although close, do not show enrichment of either HBO1 or H3K4me3 in the RKO 
ChIP-Seq data, and could help explain the observed lack of enrichment (Fig. 3.13). 
However, MCM4 and SNHG12 primer pairs amplify regions that lie between the 
enriched areas of both HBO1 and H3K4me3 (Fig. 3.14). The design of new more 
accurate primers, closer to the region of HBO1/H3K4me3 enrichment at LMNB2 and 
LUC7L loci was problematic because of the area’s high guanine-cytosine content. 
 
3.7.5 Potential HBO1 targets for ChIP-qRT-PCR enrichment 
As the origins of replication did not reveal any specific recruitment of HBO1, 
promoter regions of genes transcriptionally regulated by HBO1 were investigated. In 
order to predict genes modulated by HBO1, an SQL database was built. 
 
First, publicly available literature was interrogated in order to obtain as much 
information as possible related with HBO1 transcriptional activity, links with cancer 
in general and/or OC in particular. Using this approach, a number of datasets were 
identified and downloaded from the NCBI website, the majority consisting of excel 
or plain text files that contained gene name lists with associated gene expression 
values (e.g. fold-change or peak enrichment values). These datasets make up the 
‘Tables’ of the SQL database, of which some examples are described in Table 3.3 
and depicted in Figure 3.15 A. The information contained in each one of these 
exemplary ‘Tables’ is detailed in Table 3.3. 
 
 
Table 3. 3 Relevant HBO1-related datasets integrated into the SQL database 
 
Dataset Background / Origin Dataset information 
HBO1 
ChIP-Seq 
RKO colon carcinoma 
(Avvakumov et al. 2012) 
HBO1-related peak localization 
HBO1 
Knockdown 
HeLa cervical cancer 
(Avvakumov et al. 2012) 
Fold change of genes affected by 
HBO1 knockdown 
HGSC  
Sub-types  
489 HGSC tumours 
(Network 2011) 
Fold change of genes differentially 
expressed in 4 HGSC signatures 
OC relevant 
genes 
Search results for ‘Ovarian 
cancer’ in NCBI databases  
List of genes implicated in OC 
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Figure 3. 15 SQL isolation of potential HBO1 targets 
HBO1-related datasets (A) containing gene names and associated values (B) were 
stored in an SQL database. Using SQL language (C), these datasets were linked 
together in order to obtain potential HBO1 targets (D). 
 
 
The ‘Tables’ incorporated into the SQL database were queried using SQL language 
(Fig. 3.15 C) in order to retrieve potential HBO1-modulated genes (Fig. 3.15 D). 
Using the SQL search engine, it is possible to compare thousands of data and filter 
them according to multiple variables. For instance, this database was used to narrow 
down the search of HBO1 targets from hundreds to as low as 6 gene transcripts (Fig. 
3.15 D & Table 3.4). 
 
 
Table 3. 4 List of potential HBO1 target genes derived from SQL correlations 
 
Gene  Function Relation with OC 
Cysteine rich angiogenic 
inducer 61 (CYR61) Cell adhesion  
Overexpression, prognosis 
(Shen et al. 2014) 
ERBB2 Receptor Overexpression (Teplinsky & Muggia 2014) 
ATP binding cassette subfamily 
C member 4 (ABCC4) 
Protein 
transport 
Resistance, prognosis 
(Ahmed et al. 2016) 
Activated leukocyte cell 
adhesion molecule (ALCAM) Cell migration 
Overexpression 
(Carbotti et al. 2013) 
Talin 1 (TLN1) Cell-cell contact 
Overexpression, metastasis 
(Xu et al. 2013) 
Ankyrin repeat domain 1 
(ANKRD1) 
Transcription 
factor 
Overexpression, prognosis 
(Lei et al. 2015) 
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The common characteristics of the selected genes included: (1) modified expression 
after HBO1 depletion in HeLa cells, (2) presence of enrichment peaks within the 
transcription starting site area of the pertinent gene in the RKO ChIP-Seq (TSS ± 
1Kb) and (3) the existence of at least 1 citation in NCBI databases linking their 
expression to OC (Table 3.3 & Table 3.4). 
 
Following the selection of predicted HBO1 targets, ChIP-qRT-PCR primer pairs 
were designed based on the genomic coordinates from RKO ChIP-Seq peaks. 
Two/three primer pairs were designed for each location, in an effort to cover as 
much genomic space as possible. Most probes target areas surrounding the TSS, an 
area where H3K4me3 marks were also observed in the RKO ChIP-Seq data and 
therefore could be used as positive controls. ChIP experiments were performed on 
two biological replicates and with 2 technical replicates using the newly designed 
probes together with the three negative control primer pairs (IGR) (Fig. 3.16). 
 
	
Figure 3. 16 Enrichment of potential HBO1 targets: SQL-derived genes 
UWB1.289 cells were subjected to ChIP using IgG, anti-HBO1 (AB70) and anti-
H3K4me3 antibodies, followed by qRT-PCR amplification of CYR61, ERBB2, 
ABCC4, ALCAM, TLN1 and ANKRD1 genomic regions. IGRs 1, 2 and 3 were used 
as controls for antibody-specificity. Final antibody enrichment, expressed as 
percentage of input, was calculated comparing sample qRT-PCR values with ‘Input’ 
control values. Results represent the mean ± SD of two biological replicates. IGR: 
Intergenic region. 
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AB70 antibody did not show significant enrichment compared to the negative 
controls (IgG and IGRs) in any of the interrogated loci (Fig. 3.16). The PI 
enrichment displayed in IGRs such as IGR 1 (PI = 0.17 ± 0.08%) or IGR 2 (PI = 
0.18 ± 0.13%) was higher than, or at least as high as the PI enrichment shown at 
CYR61 (PI = 0.11 ± 0.05%), ERBB2 (PI = 0.16 ± 0.07%), ABCC4 (PI = 0.19 ± 
0.05%), ALCAM (PI = 0.17 ± 0.03%), TLN1 (PI = 0.03 ± 0.02%) and ANKRD1 (PI = 
0.05 ± 0.03%) loci (Fig. 3.16). Leaving aside the IGR controls, ABCC4 and ALCAM 
loci showed higher enrichment with HBO1 than their IgG counterparts (ABCC4 IgG 
PI: 0.07 ± 0.06; ALCAM IgG PI: 0.08 ± 0.002). 
 
Importantly, the H3K4me3 antibody displayed significant input enrichment in 
CYR61 (PI = 8.76 ± 1.72%), ERBB2 (PI = 7.29 ± 1.79%), ABCC4 (PI = 3.50 ± 
0.56%), ALCAM (PI = 4.46 ± 1.07%), TLN1 (PI = 2.11 ± 0.40%) and ANKRD1 (PI = 
3.77 ± 1.01%) queried regions (Fig. 3.16). These results are in line with the 
localization of H3K4me3 peaks in the ChIP-Seq dataset. Furthermore, as H3K4me3 
generally maps to the promoter of actively transcribed genes, it is reasonable to 
expect this histone mark to be found along the promoters of OC highly expressed 
genes (Table 3.4). 
 
3.7.5 ChIP-Sequencing 
Although the previous ChIP-qRT-PCR trials did not yield HBO1 specific enrichment 
(Fig. 3.13 & Fig. 3.16), because the AB70 antibody had passed multiple tests (Fig. 
3.9, Fig. 3.10 & Fig. 3.11) and had been used previously for ChIP-qRT-PCR and 
ChIP-Seq, a ChIP-Seq experiment was carried out. Six chromatin samples (2 ‘Input’, 
2 ‘HBO1’ IPs and 2 ‘H3K4me3’ IPs) were sent for DNA sequencing. 
 
Each of the samples met library preparation and sequencing quality control 
parameters and generated approximately 30M reads. The resulting raw data was then 
analysed following the procedure described in Figure 2.3, but this analysis did not 
reveal any significant peaks in any of the IP samples (‘HBO1’ or H3K4me3’) when 
comparing them with the non-specific ‘Input’. The negative ‘HBO1’ result reflected 
the prior unsuccessful ChIP-qRT-PCR experiments (Fig. 3.13 & Fig. 3.16), 
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however, the absence of enrichment of the ‘H3K4me3’ sample was surprising given 
the successful results obtained for gene specific ChIP. 
 
In order to determine whether the lack of positive outcome to the HBO1 ChIP-Seq 
experiment was due to experimental procedures, a frozen pellet of fixed UWB1.289 
cells (~13-15M) was sent, along with a small aliquot of the AB70 antibody (10µg), 
to the Active Motif® (AM) laboratories to perform an ‘Antibody Validation Service’. 
This service consisted of a small-scale ChIP-Seq followed by data analysis and a 
simple yes/no answer to whether the antibody is valuable for ChIP-Seq purposes. 
AM confirmed that the HBO1 ChIP-Seq data looked more similar to the input 
control than to the positive/successful ChIP-Seq used for comparison, thus calling 
this assay unsuccessful (Fig. 3.17). The AM data analysis did, however, return a 
very limited number of HBO1 specific peaks that were interrogated further. 
 
 
 
Figure 3. 17 Graphical representation of Active Motif® ChIP-Seq results 
Active Motif® Epigenetics Services conducted a small scale ChIP-Seq using the 
AB70 anti-HBO1 antibody and generated a signal map showing peak enrichment 
densities along the genome. The top track represents HBO1 enrichment, followed by 
a track with yellow marks indicating the specific location of HBO1 peaks. The 
middle/third (Input) and forth (Positive Control) tracks represent negative and 
positive ChIP-Seq assays for comparison. The bottom track shows the corresponding 
RefSeq gene annotations. Y-axis scales represent peak enrichment value ranges. 
 
 
Two hundred and fifty seven peaks were identified using AM’s default cut-off p-
value (1x10-07). This number of peaks is often found at background level, since 100-
250 peaks are also typically obtained with input DNA. Indeed, 128 of these peaks 
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are enlisted in the ENCODE blacklist of known false ChIP-Seq peaks (Kundaje 
2013), leaving a list of only 129 filtered potential HBO1 targets. The peak list 
contained approximate genomic coordinates accompanied by a number of genes (0 
to 4) in closest proximity to such peak. The establishment of this relationship was 
evident in cases where the peak was mapped inside a gene locus or in the nearby 
promoter area. However, some genes were linked to peaks located up to 181Kb 
upstream or downstream the gene locus, suggesting that they are actually enhancer 
sites. All gene names regardless of their related peak were extracted to a new file, 
rendering a 173-gene list. 
 
The list of 173 candidate HBO1-regulated genes was added to the SQL database and 
compared with the existing datasets to select new targets for ChIP-qRT-PCR 
validation. Ultimately, SQL correlations rendered four genes that showed significant 
enrichment peaks within the gene body in both HBO1 ChIP-Seq experiments, RKO 
and UWB1.289, and also displayed significant H3K4me3 peaks in similar locations 
(RKO ChIP-Seq): Caspase 7 (CASP7), plakophilin 4 (PKP4), the ‘MRS2-like 
magnesium transporter’ (MRS2) and the ‘nuclear receptor subfamily 2 group F 
member 2’ (NR2F2) (Table 3.5). 
 
 
Table 3. 5 List of potential HBO1 target genes derived from ChIP-Seq 
 
Gene Function 
Average peak enrichment values 
RKO UWB1.289 1H3K4me3 
CASP7 Apoptosis  19.5 4.20 76.4 
PKP4 Cell adhesion 15.23 3.87 88.23 
MRS2 Protein transport 15.95 5.76 106.2 
NR2F2 Nuclear receptor 10.92 4.01 33.14 
1H3K4me3 data extracted from the RKO ChIP-Seq 
 
 
ChIP-qRT-PCR primer pairs were designed using the coordinates from the AM 
ChIP-Seq data for each of the peaks related to the set of 4 genes (Table 3.5). Similar 
to the process followed previously, two primer pairs were designed for each genomic 
location (Fig. 3.18). 
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Figure 3. 18 IGV analysis of potential HBO1 targets derived from ChIP-Seq 
The first and second panels (starting from the top) represent peak enrichment 
obtained with anti-HBO1 and anti-H3K4me3 antibodies in ChIP-Seq performed on 
UWB1.289 and RKO cell lines respectively. The third panel (Input) represents 
unspecific peaks obtained from UWB1.289 chromatin samples that have not been 
subjected to antibody enrichment. Images were extracted from the IGV browser. 
Selected genomic regions are depicted at the bottom as longitudinal lines where 
black squares/rectangles symbolise exons. Specific primer amplification sites are 
illustrated on top of the first panel. X-axis scale represents 2Kb; y-axis scales 
represent peak enrichment value ranges. 
 
 
In order to validate the peak enrichment observed in the AM ChIP-Seq (Fig. 3.18), 
ChIP experiments were performed on UWB1.289 cells followed by ChIP-qRT-PCR 
using the recently designed probes together with the three negative control primer 
pairs (IGR) (Fig. 3.19). Again, the anti-HBO1 antibody did not show significant 
enrichment compared to the negative controls in any of the loci interrogated (Fig. 
3.19). The PI enrichment displayed by AB70 in IGRs such as IGR 1 (PI = 0.13 ± 
0.1%) or IGR 2 (PI = 0.11 ± 0.065%) was higher than, or at least as high as the PI 
enrichment shown in PKP4 (PI = 0.11 ± 0.062%), MRS2 (PI = 0.03 ± 0.01%) and 
NR2F2 (PI = 0.10 ± 0.04%) loci (Fig. 3.19). Interestingly, AB70 displayed strong 
enrichment of the CASP7 locus (PI = 0.26 ± 0.03), although it was matched by IgG 
(PI = 0.28 ± 0.08), and therefore does not represent a specific HBO1 target. 
 
The H3K4me3 antibody displayed significant input enrichment in CASP7 (PI = 7.01 
± 2.01%), PKP4 (PI = 5.24 ± 1.56%), MRS2 (PI = 4.52 ± 1.31%) and NR2F2 (PI = 
3.01 ± 1.07) regions (Fig. 3.19). These results agree with the localization of 
H3K4me3 peaks in the ChIP-Seq dataset (Table 3.5 & Fig. 3.18). 
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Figure 3. 19 Enrichment of potential HBO1-targets: AM-derived genes 
UWB1.289 cells were subjected to ChIP using IgG, anti-HBO1 (AB70) and anti-
H3K4me3 antibodies, followed by qRT-PCR amplification of CASP7, PKP4, MRS2 
and NR2F2 genomic regions. IGRs 1, 2 and 3 were used as controls for antibody-
specificity. Final antibody enrichment, expressed as percentage of input, was 
calculated comparing sample qRT-PCR values with ‘Input’ control values. Results 
represent the mean ± SD of two biological replicates. IGR: Intergenic region. 
 
 
3.7.6 Further ChIP-qRT-PCR optimization 
The anti-HBO1 AB70 antibody, which has been previously used for ChIP and ChIP-
Seq experiments in a variety of cell line backgrounds (Miotto & Struhl 2008; 
Saksouk et al. 2009; Avvakumov et al. 2012), consistently failed to achieve HBO1 
positive enrichment over input in UWB1.289 cells (Fig. 3.13, Fig. 3.16 & Fig. 3.19). 
As a consequence, new ChIP experiments were performed using Santa Cruz® 
antibodies including, G-2, T-20, H-180 and N-18, some of which had been 
previously used by Saksouk et al. (2009), Miotto & Struhl (2010) or Mishima et al. 
(2011), as well as a pool of all these antibodies. 
 
Following ChIP (Chromatrap® Pro-A kit), a set of 6 primers targeting potential 
HBO1-binding sites and the intergenic negative controls were used for ChIP-qRT-
PCR. This set of primers included a random selection of two probes targeting 
HBO1-related origins of replication (Fig. 3.14), another two targeting potential 
HBO1-targets derived from the SQL database (Table 3.4) and two more targeting 
potential HBO1-targets derived from the AM ChIP-Seq data (Table 3.5). None of 
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the individual or pooled HBO1 antibodies succeeded in giving an HBO1 specific 
enrichment in the selected loci in UWB1.289 cells. Additionally, this approach was 
attempted in OVCAR-3 and HeLa cells, obtaining similar negative results. 
 
Apart from using different antibody combinations to successfully IP enriched 
HBO1-chromatin fractions, new approaches included the use of alternative ChIP 
protocols such as EZ-Magna ChIP™ A/G (Millipore) or the Chromatin® Native 
ChIP kit, which tackle the IP using different methodologies. New ChIP experiments 
were followed by ChIP-qRT-PCR using the set of 6 primers targeting HBO1-
potential binding sites and the pertinent negative controls. However, none of these 
methods succeeded in achieving HBO1 specific enrichment, even though the 
H3K4me3 positive antibody performed as outstandingly as how it did with the 
Chromatin® Pro-A kit (Fig. 3.13, Fig. 3.16 & Fig. 3.19). 
 
Lastly, a non-commercial protocol was used to perform ChIP on UWB1.289 cells. 
The procedure was based on the same principles followed by Avvakumov et al. 
(2012) to achieve the first and only publicly available HBO1 ChIP-Seq, which are 
explained in the materials and methods section of the publication. In general terms, 
the protocol hinges on the use of magnetic beads, analogous to the EZ-Magna 
ChIP™ A/G from Millipore™, but allows to scale-up and include millions of cells in 
each assay in contrast with Chromatrap® and Millipore kits, which can only evaluate 
target enrichment using 10-15 million cells per sample. Due to the huge number of 
cells required for each IP reaction, the IgG antibody was not used as negative control 
in this occasion. 
 
The non-commercial protocol was first tested using 30M of UWB1.289 cells and the 
H3K4me3 antibody, which displayed significant enrichment over the input sample, 
compared to the IGR negative controls (data not shown). Subsequently, the HBO1 
AB70 antibody was used with 30, 60 and 80M UWB1.289 cells, yet it was still 
unable to give specific enrichment in the tested loci. 
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HBO1 exerts its epigenetic regulatory role as part of a protein complex and as so, 
depends on the spatial and temporal conformation of this structure to bind DNA. 
Accordingly, changes in the configuration of the histone acetyltransferase complex 
may affect the way HBO1 binds to potential targets in UWB1.289 cells, and 
therefore the capability of ChIP procedures to capture and detect these interactions. 
In order to evaluate alterations in the abundance of components of the HBO1-
complex in UWB1.289 cells, JADE1-3, BRPF1-3 and ING4-5 gene transcripts were 
evaluated using qRT-PCR (Fig. 3.20).  
 
 
Figure 3. 20 Comparative analysis of HBO1-complex components 
RNA lysates from UWB1.289 and HOSEpiC cells were prepared and analysed by 
qRT-PCR. Relative levels of JADE1L-S/2/3, BRPF1/2/3 and ING4/5 expression 
were compared to those of the HOSEpiC non-cancerous control. GAPDH expression 
was used as control. Statistical analyses consisted of one-way ANOVA and the 
Tukey’s multiple comparison test. All values represent the mean ± SD of three 
biological samples (*p < 0.05; ***p < 0.001; ****< 0.0001). 
 
 
The expression level of isoforms JADE1L (FC = -5.64, ****p = < 0.0001) and 
JADE1S (FC = -4.34, ***p = 0.0002) was significantly lower in UWB1.289 cells 
compared to the HOSEpiC non-cancerous control (Fig. 3.20). In contrast, the 
transcript abundance of alternative scaffolding subunits such as JADE2 (FC = 7.90, 
****p = < 0.0001) and to a lesser extent BRPF1 (FC = 1.6, *p = 0.0485) was 
significantly higher in the cancerous subtype (Fig. 3.20). The expression level of 
other transcripts, JADE3 (FC = 1.18, p = 0.995), BRPF2 (FC = 1.06, p = > 0.9999), 
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BRPF3 (FC = -1.06, p = > 0.9999), ING4 (FC = -1.3, p = 0.7627) and ING5 (FC = -
1.15, p = = 0.7235) was not significantly different between the cell lines. Based on 
the observed patterns, it is possible that the very high levels of JADE2, for example, 
may cause the formation of an HBO1 complex where HBO1, whilst recruited to the 
promoter of target genes, is essentially masked by JADE2 and other components of 
the complex, rendering HBO1 inaccessible to the AB70 antibody thus interfering 
with the ChIP experiments. 
 
 
3.8 Discussion 
In order to efficiently investigate the role of HBO1 in OC, a number of model cell 
lines were evaluated, including a panel of OC cell lines representing the most 
common OC sub-types (Table 3.1) and a non-cancerous ovarian control. 
Importantly, four OC cell lines (OVCAR-3, SKOV-3, UWB1.289 and UACC-1598) 
were representatives of the serous histo-type, the most aggressive and prevalent form 
of OC. The principal concern regarding the use of cell lines to study OC is related to 
the genetic and phenotypical drifts, which raise doubts about their suitability since 
they do not exactly subscribe to the behaviours of original cancer cells. Even so, and 
assuming these limitations, the chosen cell lines compose a strong informative model 
that spans major HGSC-associated features, e.g. BRCA1/2 mutation (UWB1.289) or 
CCNE1 amplification (OVCAR-3). In fact, mutation, copy number analysis and 
others have confirmed the suitability of some of these cell lines to model OC 
(Network 2011). 
 
Following the trend previously observed in numerous cancer cell lines (e.g. MCF7 
and Saos-2), breast and ovarian cancer tissues, the whole panel of OC cell lines 
displayed HBO1 transcript overexpression, compared to the non-cancerous control 
cells (Fig. 3.1). This increased expression was also observed when individual splice 
isoforms of HBO1 were assessed (Fig. 3.3 & Appendix 1). Consistent high levels of 
HBO1 transcript expression amongst OC cell lines point to alterations in DNA 
replication and/or transcription, key cellular processes allegedly modulated by 
HBO1. 
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The overexpression of HBO1 transcripts in the panel of OC cell lines compared to 
the non-cancerous control was accompanied by similar HBO1 protein level increase 
(Fig. 3.6). Therefore, it can be assumed that increased HBO1 gene expression also 
occurs at the protein level. In order to investigate HBO1 protein abundance, 
antibodies G-2 and AB70 were optimized for use in western blot experiments (Fig. 
3.5), providing an essential tool for further HBO1 functional analyses. Both 
antibodies performed well, however, as UACC-1598 protein extracts probed with the 
G-2 antibody displayed un-identified bands (Fig. 3.4 & Fig. 3.5); AB70 was used for 
all further experiments. 
 
A significant number of nuclear receptor binding sites were found located in the 
HBO1-proximal promoter region (AR, ER, PR, GR), suggesting that HBO1 may 
undergo hormone-mediated regulation, which could provide a link between OC 
progression and specifically estrogen exposure. These results differ from previous 
studies, in which ERα binding sites were not found nearby the proximal promoter 
region of HBO1 using the TRSEARCH software (Wang et al. 2010). However, 
estradiol (E2) treatment, which induces ERα-mediated transcription, did not 
influence HBO1 transcript expression levels (Fig. 3.8). 
 
Finally, a ChIP-Seq experiment aimed at unravelling HBO1 widespread localization 
on the OC genome was attempted. In doing so, and throughout the relevant 
optimization process, HBO1 was found to localize mainly to the nucleus of OC cell 
lines, exemplified in UWB1.289 and the non-cancerous HOSEpiC control cells (Fig. 
3.10). Furthermore, approximately 45% of the whole HBO1 cellular protein was 
detected binding to the chromatin fraction (Fig. 3.11), confirming the presupposed 
relevance of HBO1 in nuclear phenomena such as DNA replication and 
transcription. However, HBO1 was not solely localized to the nucleus, but was 
observed in the cytoplasm of the cells (Fig. 3.10 & Fig. 3.11). Apart from synthesis, 
like any other protein, and degradation (Zou et al. 2013), the cytoplasmic 
localization of HBO1 molecules suggests other non-DNA-related functions. 
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Prior to ChIP-Seq, ChIP-qRT-PCR experiments using AB70 antibody did not detect 
any significant enrichment of HBO1 at the LMNB2, MCM4, SNHG12, LUC7L, 
CYR61, ERBB2, ABCC4, ALCAM, TLN1, ANKRD1 loci (Fig. 3.13 & Fig. 3.16). 
Nonetheless, certain genomic loci (ABBC4, ALCAM) did display differences 
amongst the enrichment attained by HBO1 and IgG (Fig. 3.16). Although the goal of 
finding a positive ChIP-qRT-PCR control was not achieved, successful steps in the 
optimization process offer a solid ground on which to base future experiments. For 
example, the specific enrichment of the H3K4me3 histone marker in UWB1.289 
cells (Fig. 3.13, Fig. 3.16 & Fig. 3.19). 
 
As expected from the absence of anti-HBO1 enrichment in various ChIP-qRT-PCR 
experiments, both ChIP-Seq performed by the Epigenomics Core and AM were 
deemed unsuccessful. Unexpectedly, the HBO1 ChIP-Seq carried out by the Weill 
Cornell Epigenomics Core was ineffective for H3K4me3 IP, which had previously 
given significant enrichment in numerous occasions and diverse loci (Fig. 3.13 & 
Fig. 3.16), suggesting sequencing related issues. Whilst the AM ChIP-Seq was 
deemed unsuccessful due to the very low number of peaks returned for HBO1 
(hundreds of peaks would normally be expected in a successful ChIP-Seq 
experiment), a limited number of HBO1 binding sites that represented 173 potential 
target genes were identified. Although these targets could not be validated via ChIP-
qRT-PCR (Fig. 3.19), they provide a starting point for future studies, e.g. these loci 
could be queried in order to assess HBO1-related changes in histone marks such as 
histone H3 or H4 acetylation. 
 
More experiments using new antibodies, different cell lines or methodology 
approaches could not give a positive enrichment of HBO1 in any of the queried loci, 
suggesting that the problem goes beyond technical issues. One possibility is that 
HBO1 is exerting its action at such fast pace that formaldehyde is not able to 
properly fix it to the chromatin. In this regard, it is worth considering the use of other 
fixing compounds such as glutaraldehyde for future studies. Also, the functions of 
HBO1 are highly tissue specific, meaning that its genomic localization may vary 
between differing backgrounds, a fact that could explain for the failure to detect 
ChIP-qRT-PCR enrichment. 
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Another possibility is that the isolation of fixed HBO1-chromatin complexes is 
somehow masked, as non-chromatin immune-precipitation of HBO1 worked well 
with two different antibodies (Fig. 3.5 A & Fig. 3.9 A). A simple qRT-PCR 
experiment was performed in order to analyse the transcript levels of different 
compounds of the HBO1 multi-subunit complex that might interfere with antibody 
isolation in the UWB1.289 cell line. Interestingly, the transcript levels of JADE2 
were very elevated in UWB1.289 compared to non-cancerous HOSEpic cells, while 
JADE isoforms JADE1L and JADE1S transcript levels were decreased (Fig. 3.20). 
 
The JADE2 paralog encodes a slightly smaller protein than JADE1, constituted by 
790 amino acids (~87.5 kDa) as opposed to the 834 amino acids (~94 kDa) of 
JADE1, of which little is known. The variable region of JADE2 compared to 
JADE1L is the C-terminal fragment, similar to JADE1S (Fig. 1.25), yet it still 
contains a full domain able to interact with ING4/5 and hEaf6 (Panchenko 2016). 
This initial observation suggests that a change in the conformation of the HBO1 
multi-protein complex could interfere the ChIP through preventing access of the 
AB70 to HBO1, ‘buried’ in a JADE2 dominated complex. 
 
Finally, it is worth mentioning that all previous HBO1 ChIP-qRT-PCR experiments, 
whereas not the ChIP-Seq, were performed on HBO1-transfected cell types, hinting 
previous struggles when conducting ChIP on physiological levels of HBO1. 
 
 
	
 
4. Optimization of Genetic 
Tools for the Study of HBO1 
Function 
 
  
Results		
	 170	
4.1 Introduction and Aims 
Some of the most direct ways to determine HBO1 functions in an OC background 
include the knockdown (KD) of the gene, as well as its up-regulation via expression 
vectors. Both processes are used to evaluate the effects of gene alteration through 
reverse genetics (Silva et al. 2004). 
 
There are several approaches to KD/silence the expression of a target gene that 
involve RNA interference (RNAi), including the use of small interfering RNAs 
(siRNAs) and short hairpin RNAs (shRNAs). These methodologies result in the 
post-transcriptional down-regulation of gene expression without changing the target 
cell genetic code (Mocellin & Provenzano 2004). Low amounts of target RNA and 
protein are always expressed however, the result being that gene-related functions 
are reduced, but may not be completely eliminated (Mittal 2004). Genome editing is 
an alternative approach, resulting in genetic code alterations that ultimately cause the 
complete elimination of gene function or knock-out (KO) (Shalem et al. 2014). 
Though there are several genome-editing tools available, a system that involves 
Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and the CRISPR-
associated protein 9 (Cas9) is the most widely used. Both KD and KO approaches 
are widely used to modify in vitro gene expression and each has certain advantages 
and disadvantages (Table 4.1). 
 
The CRISPR/Cas systems (I-III) are naturally occurring prokaryotic immune defence 
strategies among which the type II system has been adapted for RNA-directed DNA 
editing of mammalian genomes (Jinek et al. 2012). The basal CRISPR machinery 
has been engineered to deliver the nuclease Cas9 to any locus in the genome, 
whereupon it originates double strand DNA breaks that are repaired by either non-
homologous end joining (NHEJ) or homology directed repair (HDR) pathways (Mao 
et al. 2008). Most commonly, DNA double breaks are repaired via the NHEJ 
pathway, an error-prone process that can result in the introduction of stable 
insertions or deletions (INDELs) in the target region (Lieber 2010), leading to the 
disruption of the codon-reading frame and ultimately inducing erroneous transcripts 
and the ablation of gene expression (Unniyampurath et al. 2016). Newer 
technologies, e.g. CRISPR interference or CRISPRi, are able to repurpose the 
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CRISPR machinery for reversible and incomplete modification of gene expression 
(Qi et al. 2013), references to CRISPR hereafter refer only to the KO variation. 
 
 
Table 4. 1 Advantages and disadvantages of KD and KO available techniques 
 
Technique Advantages Disadvantages 
RNAi 
• Target any transcript regardless of 
ploidy (number of chromosomes). 
• Not inhibited by chromatin 
context. 
• Predictable, no genome mutations 
involved. 
• Rapid; does not require single 
clone isolation. 
• High off-target effect based 
on mismatch tolerance and 
interference with 
endogenous RNAi 
pathways. 
• Finds less true positive 
essential genes involved in 
fundamental pathways. 
CRISPR 
• Better at finding true positive 
essential genes. 
• Higher specificity. 
• Reduced mismatch tolerance and 
consequent off-targets effects. No 
interference with endogenous 
RNAi pathways. 
• More robust phenotypes. 
• Comparatively slower; 
requires single clone 
isolation. 
• Relies on presence of 
appropriate PAM sites. 
• Can be stymied by ploidy or 
by specific chromatin 
structures. 
(Shalem et al. 2014; Wang et al. 2015; Boettcher & McManus 2015; Housden & 
Perrimon 2016). 
 
 
RNA interference utilizes a naturally occurring double stranded RNA-mediated 
homology based mechanism that has evolved to post-transcriptionally regulate 
eukaryotic gene expression (Downward 2004). The core component of RNAi is the 
utilization of small interfering RNAs that are processed by the cellular RNA-induced 
silencing complex or RISC, which in turn uses the siRNAs as template to localize 
the correspondent complementary target mRNA for degradation, achieving a specific 
temporary/transient or stable gene KD effect (Wilson & Doudna 2013). Non-natural 
RNAi can also be induced by direct exogenous supply of short double stranded 
RNAs or small interfering RNAs (~21 nucleotides), achieving a transient gene 
inhibition effect. Alternatively, RNAi can also be induced in cells using plasmid 
delivery of shRNAs, which are processed in a similar way to siRNAs (Rao et al. 
2009). 
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The expression levels of shRNAs depend on the associated promoter driving their 
expression and can result in permanent (constitutive promoter) or induced (inducible 
on-off promoter) degradation of target mRNAs. RNAi-mediated KD of HBO1 is, 
thus far, the most widely used methodology to study gene functionality in numerous 
cell backgrounds (Table 1.7). The successful delivery of siRNAs or shRNAs to OC 
cell lines would provide a rapid and efficient system to study HBO1 functionality. 
Meanwhile, knockout studies on mice point to essential functions of HBO1 in 
embryo development (Kueh et al. 2011), yet most KD studies suggest that HBO1 is a 
non-essential gene and therefore susceptible to CRISPR-Cas9 editing (Table 1.7). 
The successful generation of a CRISPR-edited OC cell line would provide a robust 
and consistent HBO1 loss-of-function ‘phenotype’ (Shalem et al. 2014). To assess 
HBO1 functionality, both approaches were undertaken. 
 
A common tool to assess gene functionality, apart from the previously discussed 
silencing methodologies, is the use of vectors (e.g. plasmids) designed for gene 
expression. This approach is based on the delivery of expression vectors engineered 
to contain the target gene sequence as well as regulatory regions that lead to efficient 
transcription of the latter in transfected cells. In the case of study, the introduction of 
exogenous HBO1 could help to validate the effects of prior gene silencing methods, 
as well as regaining gene expression while potentially restoring normal cell 
phenotype in line with that identified prior to HBO1 KD. Consequently, the last goal 
of this chapter was to design a mammalian expression vector to drive HBO1 gene 
expression in OC cells. 
 
 
4.2 Generation of an HBO1 Knock-OUT Cell Line 
The UWB1.289 cell line, which represents a model of HGSC with high levels of 
HBO1, was selected to perform CRISPR-Cas9 KO. 
 
4.2.1 Cas9 transfection into UWB1.289 cells 
The transient or constitutive expression of ectopic Cas9 protein was the first step in 
achieving a successful HBO1 KO. Initially, the efficiency of different transfection 
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reagents to transfect sub-confluent populations of UWB1.289 cells was tested using 
a GFP-expression plasmid. Visual inspection of transfected cells resulted in the 
selection of the X-tremeGENE™ HP DNA transfection reagent (Roche), which 
showed high levels of GFP expression and very low cytotoxicity (Fig. 4.1), to pursue 
the Cas9 transfection in UWB1.289 cells. On the contrary, Lipofectamine® 3000 
presented higher cell cytotoxicity and X-tremeGENE™ 9 showed lower GFP-
expression levels compared to the selected reagent (Fig. 4.1). 
 
	
Figure 4. 1 UWB1.289 transfection efficiency test 
Sub-confluent populations of UWB1.289 cells were transfected with GFP-expressing 
plasmid [1.5 µg/mL] and different transfection reagents. Images were taken 24h 
post-transfection using a fluorescent microscope. Scale represents 100µm. 
 
 
Different concentrations of the Cas9 IDT® expression plasmid (0.5-1.5-3 µg/mL) 
were transfected into sub-confluent populations of UWB1.289 cells using X-
tremeGENE™ HP. HeLa cells were also transfected with the same concentrations of 
Cas9-expressing plasmid and used as positive control due to their high transfection 
efficiency. Whole-cell protein lysates were isolated, processed and analysed via dot-
blot to assess Cas9 transfection levels (Fig. 4.2). 
 
Whilst all transfected HeLa cells rendered considerable V5-Cas9 expression, none of 
the UWB1.289 transfections displayed any signal (Fig. 4.2). These results suggest 
plasmid-specific transfection issues in UWB1.289 cells, possibly due to the 
substantial size of the Cas9-expression plasmid in comparison with GFP (Cas9: 
~7.3Kb > GFP: ~3.4Kb). Adenoviruses expressing Cas9 protein were therefore used 
as an alternative method.  
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Figure 4. 2 Transfection of a Cas9-expressing plasmid in UWB1.289 and HeLa 
Protein extracts of UWB1.289 and HeLa cells transfected with different 
concentrations of Cas9-expressing plasmid [0.5-1.5-3 µg/mL] were analysed by dot-
blot and probed with V5-Cas9 and β-Actin antibodies. β-Actin was used as loading 
control. 
 
 
The Ad-GFP-Cas9 adenoviruses (Vector BioLabs) express GFP together with Cas9, 
providing a convenient system to corroborate the expression of a protein. First, 
varying concentrations of adenovirus particles were used to infect sub-confluent 
populations of UWB1.289 cells (10-500 MOI, multiplicity of infection). A 
preliminary infection test resulted in very low efficiencies (approximately 5% cells 
expressing GFP), so polybrene, a positively charged polycation that reduces the 
repulsion forces between cells and viruses enhancing transduction efficiency (Clark 
et al. 1999), was included to intensify the process (5-20 µg/mL). 
 
Optimal transduction conditions (low cytotoxicity and high GFP signal) were 
identified using 500 MOI and 10 µg/mL of polybrene. However, even though these 
conditions were innocuous to UWB1.289 cells after as long as 96h (over-
confluence), the subsequent transfection of CRISPR RNA (crRNA) complexes 
resulted in high levels of cell death, and the inability of UWB1.289 cells to 
proliferate after sub-culture. These results suggested cells were being subjected to 
excess stress (virus transduction plus immediate transfection), and thus prompted the 
need to try a different approach. 
 
One efficient approach that is commonly used to transfect plasmids into mammalian 
cells is electroporation (Potter & Heller 2003). First, confluent populations of 
UWB1.289 cells were transfected with a GFP-expressing plasmid [1.5 µg/mL] using 
different electroporation programmes (Nucleofector™, Lonza) in order to optimize 
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the conditions for Cas9 transfection. Twenty-four hours after the electroporation, 
treated samples were observed under the microscope to assess cell cytotoxicity and 
transfection efficiency (GFP-expression) (Figs. 4.3). 
 
	
Figure 4. 3 UWB1.289 electroporation efficiency test 
Sub-confluent populations of UWB1.289 cells were subjected to electroporation of 
1.5 µg/mL of GFP-expression plasmid under different electroporation programmes 
(D023, A020, L029, T030, X5) (Nucleofector™, Lonza). Images were taken 24h 
post-transfection using a fluorescent microscope. Scales represent 100µm. 
 
 
The majority of electroporation programs tested (D023, L029, T030, X5 and X1) 
rendered high levels of cell cytotoxicity (Fig. 4.3). However, programme A020 
resulted in efficient transfection of the GFP vector into viable UWB1.289 cells (Fig. 
4.3). This programme was therefore used to transfect different amounts of Cas9-
expression plasmid (1.5-3 µg/mL) into sub-confluent populations of UWB1.289 
cells. Subsequent analysis with dot-blot revealed that Cas9-electroporated 
UWB1.289 cells were able to express Cas9 (Fig. 4.4). However, higher 
concentrations of the Cas9 plasmid (e.g. 5 or 7.5 µg/mL) did not significantly 
increase Cas9 transfection efficiency, and also resulted in elevated cell death rates. 
Consequently, the electroporation methodology was adopted to transfect 3 µg/mL of 
Cas9-expressing plasmid into UWB1.289 cells. 
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Figure 4. 4 Electroporation of a Cas9-
expression plasmid in UWB1.289 cells 
Protein extracts of Cas9-electroporated 
UWB1.289 cells (Programme A020, 
Nucleofector™, Lonza) were analysed using 
dot-blot and probed with V5-Cas9 and β-
Actin antibodies. β-Actin was used as loading 
control. 
 
 
4.2.2 CRISPR RNA transfection and confirmation of mutational events 
The introduction of Cas9-expression plasmids in UWB1.289 cells (Fig. 4.4) 
represented the first step required to achieve successful HBO1 KO. Twenty-four 
hours after the electroporation with Cas9 plasmid, cells were transfected with crRNA 
1-3:tracrRNA complexes targeting HBO1 exon 2 using DharmaFECT 4 
(Dharmacon™) transfection reagent (Chang et al. 2014). Additionally, Cas9-
electroporated cells were transfected with crRNA:tracrRNA complexes targeting the 
positive control gene locus HPRT1 and the non-targeting negative control, 
computationally designed not to target any fragment of the human genome. All 
complexes were transfected to a final concentration of 30-60nM per well in a 6-well 
plate, as recommended by the manufacturer. Using this approach, cells retained their 
ability to proliferate and achieved full confluence 24 hours after the addition of the 
guide RNA. 
 
To confirm the generation of random INDELs in UWB1.289 cell genomes as a result 
of Cas9 cleavage, genomic DNA (gDNA) samples were extracted 24h after the 
transfection with crRNAs and subjected to T7EI digestion as part of a surveyor 
nuclease assay (Qiu et al. 2004). The region of interest containing potential 
mutational sites was amplified by end-point polymerase chain reaction. 
Subsequently, the PCR product was denatured and re-annealed to form DNA hetero-
duplexes containing a mismatch at the point of the mutation, which can be identified 
by surveyor nuclease treatment (T7 Endonuclease I or T7EI). Finally, T7-treated 
PCR samples were analysed by agarose electrophoresis gel (1%) (Fig. 4.5). 
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Figure 4. 5 T7EI surveyor assay of Cas9-electroporated UWB1.289 cells 
Cas9-electroporated UWB1.289 cells were transfected with different CRISPR RNA 
combinations. 1.3: crRNA 1 (3µM), 1.6: crRNA 1 (6µM), 3: crRNA 3 (3µM), Pos: 
crRNA HPRT (3µM), Neg: crRNA Negative (3µM). Genomic DNA samples of 
transfected UWB1.289 cells were subjected to end-point PCR amplification of the 
region encompassing potential mutational sites (HBO1: 892 bp, HPRT and Negative: 
692 bp). End-point PCR constructs were denatured and re-annealed to form DNA 
heteroduplexes. Next, an equal fraction of each sample was either treated with T7EI 
nuclease (+) or left untreated (-). Digested DNA fragments were analysed by gel 
electrophoresis. The transfection of crRNA molecules followed by specific end-point 
PCR amplification generated diverse digestion bands: crRNA 1 (~530 and ~360 
bps), crRNA 3 (~600 and ~290 bps) and HPRT (~430 and ~260 bps). Cleavage 
percentage was calculated using ImageJ. 
 
 
The transfection of crRNAs 1-3 led to the T7EI cleavage of the HBO1 exon 2 locus, 
suggesting the successful introduction of INDELs. Potential INDELs generated by 
crRNA 1 gave rise to two different DNA bands of ~530 bp and ~360 bp, as was 
expected given the size of the PCR product and the specific crRNA 1 binding site 
(Fig. 4.5). Different concentrations of crRNA 1 (3µM and 6µM) did not alter the 
efficiency of the cleavage significantly (3µM: 6.8 ± 1.5 %; 6µM: 8.06 ± 0.91 %) 
(Fig. 4.5). 
 
The transfection of crRNA 3 and subsequent T7EI analysis resulted in different 
digestion products (~600 bp and ~290 bp), as was expected given the crRNA 3 
binding site within the HBO1 exon 2 locus, and presented a low percentage of DNA 
cleavage (7.6 ± 1.14 %) (Fig. 4.5). 
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The positive control HPRT product was cleaved (2.1 ± 0.71 %) into the two expected 
size digestion products (~430 and ~260 bp), and the transfection of negative crRNA 
did not introduce any detectable alteration in the control PCR product (Fig. 4.5). 
Digestion products were not detected if sample PCRs were not treated with TE7I 
enzyme (Fig. 4.5: T7EI treatment ‘-’). Low percentages of DNA cleavage may be 
due to shortage of INDEL events, as well as other technical issues such as lack of T7 
enzyme or inadequate hetero-duplex formation, however, the presence of cleavage 
confirms the existence of INDELs. Consequently, UWB1.289 cells transfected with 
crRNA 1, which displayed the highest TE7I cleavage compared to other treatments, 
were selected to investigate the result of HBO1 KO. 
 
The TE7I assay identified UWB1.289 cells carrying INDELs in the HBO1 locus, 
possibly due to frame-shift mutations (Fig. 4.5). Two different approaches were used 
to efficiently isolate individual crRNA 1-treated HBO1 KO colonies: standard 
dilution and a single-cell pipetting device. The isolation and separate growth of 
individual HBO1 KO cells allowed for the propagation of single clones for analysis 
of HBO1 function. Isolated individual clones were therefore propagated for 
approximately 3-4 weeks, whereupon protein lysates were extracted to assess HBO1 
protein levels (Fig. 4.6). 
 
	
Figure 4. 6 Analysis of potential UWB1.289 knock-OUT individual colonies 
(A) Protein extracts of UWB1.289 individual colonies propagated for 3-4 weeks 
were analysed by dot-blot and probed with anti-HBO1 and β-Actin antibodies. β-
Actin was used as loading control. (B) Protein extracts of UWB1.289 individual 
colonies that did not show HBO1 expression in dot-blot were analysed by western 
blot and probed with anti-HBO1 and anti-GAPDH antibodies. GAPDH was used as 
loading control. 
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Protein lysates were isolated from 48 individual UWB1.289 colonies and analysed 
using protein dot-blotting to determine the presence or absence of HBO1 protein, a 
process exemplified in Figure 4.6 A. Four out of forty-eight colonies expressed β-
actin but not HBO1 (e.g. Fig. 4.6 A: Colony 4). These samples (I-IV) were analysed 
further by western blot and relative densities (RD) were calculated considering 
HBO1 signal of colony I as the control sample (RD = 100%) (Fig. 4.6 B). Even 
though HBO1 signal was null when dot-blotting individual colonies I-IV, western 
blot displayed different HBO1 protein levels, ranging from almost absent (III: RD = 
1.93%), to very low (IV: RD = 7.04%) and low (II: RD = 25.26%) (Fig. 4.6 B). 
 
	
Figure 4. 7 Sequencing analysis of the targeted HBO1 locus 
Genomic DNA samples of individual UWB1.289 colonies were amplified using end-
point PCR and the product of this reaction was sent for DNA sequencing. The 
sequencing chromatograms represent the nucleotide composition of the crRNA 1 
target region of: (A) the individual colony III and (B) a negative control colony. (C) 
The sequences of 4 individual colonies and the negative control were aligned using 
the Clustal Omega software. PAM = Protospacer Adjacent Motif. 
 
 
Conflicting results between dot-blot and western blot experiments may have 
occurred for various reasons, such as incomplete separation of individual colonies 
(mixture of two genetic backgrounds) or haplo-insufficiency (one mutated allele). 
Genomic DNA samples of individual UWB1.289 colonies I-IV were analysed using 
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end-point PCR to amplify the HBO1 locus target region, which was then sent to 
SeqWright (GE Healthcare) for DNA sequencing together with crRNA negative-
genomic DNA as non-mutated HBO1 locus sequence control. 
 
Very surprisingly, sequencing of crRNA 1-target regions within the HBO1 locus, the 
potential site of INDEL introduction, revealed no differences between the control 
and the so-called HBO1 KO colonies (I-IV) (Fig. 4.7). Further analysis of the 4Peaks 
trace viewer revealed that every peak in the sequence chromatogram was a single 
nucleotide, rejecting any possibility of heterozygotic mutations (Figs. 4.7 A, B). 
These results imply that no genomic mutation was introduced into the HBO1 locus, 
yet the presence of TE7I mismatches in crRNA-treated gDNA samples (Fig. 4.5) 
and the absence of HBO1 protein observed in both dot-blot and western blot 
experiments (Figs. 4.6) indicated otherwise. 
 
Multiple sequence alignment of the samples revealed no differences between the 
control and the putative HBO1 KO colonies (I-IV) in an area of approximately 600 
nucleotides surrounding the predicted crRNA 1 mutation site, which showed that any 
off-target mutations that resulted in the loss of HBO1 expression must be at a distal 
location. However, as the T7EI digestion of crRNA 1-targeted gDNA samples 
produced 3 DNA bands matching the expected sizes obtained as a result of the 
introduction of small INDELs in the target HBO1 locus (Fig. 4.5), it is unlikely that 
mutations have occurred off-target, since this would have resulted in different sized 
DNA bands after T7EI digestion. Even so, further testing may include the 
sequencing of the entire HBO1 gene to certify the absence of off-target mutations. 
 
As the presence of T7EI-cleaved bands (Fig. 4.5) and the absence of HBO1 protein 
expression in dot-blot (Fig. 4.6 A) and western blot experiments (Fig. 4.6 B), 
suggest the existence of UWB1.289 KO cells, it is possible that the DNA sequencing 
was erroneous, or that samples were contaminated with wild type cells. 
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4.3 Transduction of shRNAs to Constitutively Knockdown HBO1 
Given the conflicting results obtained with the CRISPR approach and in order to 
generate a stable HBO1 KD model, a lentiviral approach was undertaken using 
particles encompassing shRNAs targeting HBO1. Three different lentiviral shRNAs 
targeting HBO1 (shHBO1 1-3) and a non-targeting control (shCtrl) were used. 
 
 
	
Figure 4. 8 Lentiviral transduction of shRNAs into UWB1.289 cells 
UWB1.289 cells were transduced with lentiviral vectors expressing ‘shHBO1 1’ and 
non-targeting shRNA (‘shCtrl’). Images were taken 72h after the transduction using 
a fluorescent microscope. Scales represent 100µm. 
 
 
The transduction of either ‘shHBO1 1-3’ or ‘shCtrl’ in UWB1.289 cells was 
successful, as can be observed in Figure 4.8, where the majority of transduced cells 
express GFP protein. Furthermore, none of the populations displayed obvious 
changes in cell morphology, suggesting that the viruses have no overall effect. To 
assess the efficiency of lentivirus-delivered shRNA molecules (‘shHBO1 1-3’, 
‘shCtrl’), whole cell lysates were analysed by qRT-PCR (Fig. 4.9). 
 
UWB1.289 cells constitutively expressing shRNAs targeting HBO1 displayed 
significant reduction of HBO1 transcript compared to the ‘shCtrl’-transduced cells: 
shHBO1 1 (FC = -7.16, **p = 0.0014), shHBO1 2 (FC = -2.71, *p = 0.0261), 
shHBO1 3 (FC = -1.87, *p = 0.0483) (Fig. 4.9). 
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Figure 4. 9 HBO1 mRNA relative levels in transduced UWB1.289 cells 
UWB1.289 cells were transduced with ‘shHBO1 1-3’ targeting HBO1 and non-
targeting shRNA (‘shCtrl’). RNA samples were prepared and analysed by qRT-PCR. 
Relative levels of HBO1 expression in cells expressing ‘shHBO1 1-3’ were 
compared to those of cells expressing ‘shCtrl’. GAPDH expression was used as 
control. Statistical analysis consisted of one-way ANOVA and the Tukey’s multiple 
comparison test. All values represent the mean ± SD of three biological samples (*p 
< 0.05; **p < 0.01). 
 
 
As with HBO1 transcript expression, HBO1 protein levels were significantly 
lowered following ‘shHBO1’ lentiviral infection compared to the ‘shCtrl’ control: 
shHBO1 1 (RD = 6.33 ± 4.96 %, **p = 0.0025), shHBO1 2 (RD = 25.2 ± 10.97 %, 
*p = 0.0383), shHBO1 3 (RD = 58.93 ± 20.38 %, p = 0.0836) (Fig. 4.10). 
 
 
	
Figure 4. 10 HBO1 protein relative levels in transduced UWB1.289 cells 
UWB1.289 cells were transduced with ‘shHBO1 1-3’ targeting HBO1 and non-
targeting shRNA (‘shCtrl’). (A) Protein extracts were analysed by western blot and 
probed with anti-HBO1 and anti-GAPDH antibodies. (B) The relative level of HBO1 
protein expression was calculated using ImageJ. GAPDH was used as loading 
control. Statistical analysis consisted of one-way ANOVA and the Tukey’s multiple 
comparison test. All values represent the mean ± SD of three biological samples (*p 
< 0.05; **p < 0.01). 
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4.3 Delivery of siRNAs to Transiently Knockdown HBO1 
As well as achieving a stable KD phenotype via shRNA expression, an RNAi 
approach to transiently deplete HBO1 cellular levels was also implemented. To 
achieve this, siRNAs targeting HBO1 were exogenously introduced into five OC cell 
lines, including OVCAR-3, UWB1.289, SKOV-3, TOV-112D and UACC-1598. A 
pool of 4 commercial siRNAs targeting HBO1 (‘siHBO1’) was purchased and 
utilized to accomplish robust and specific HBO1 KD. Using a pool of siRNAs over 
individual duplexes gives several advantages such as whole-gene KD (as opposed to 
partial KD, which may lead to the expression of non-targeted isoforms), increased 
phenotypic penetrance and higher efficiency (Parsons et al. 2009). Importantly, the 
use of several siRNAs guaranteed that all HBO1 mRNA transcript isoforms were 
targeted for degradation (Fig. 2.8). 
 
Two different experimental controls were included alongside each HBO1 KD to 
ensure that any effects observed were due to HBO1 mRNA degradation, rather than 
off-target effects (‘siCtrl’) and/or the mere presence of exogenous RNA (‘Control’) 
in the cell. A pool of non-specific siRNAs was used as ‘siCtrl’ negative control, 
while the ‘Control’ cells were only treated with the transfection reagent. 
 
The serous-like OVCAR-3 was initially selected for transient KD of HBO1. This 
was due to it representing a HGSC cell line model (Domcke et al. 2013; Beaufort et 
al. 2014), its easy handling and the moderate-to-high HBO1 expression levels (Fig. 
3.1). In addition, OVCAR-3 KD transfection conditions had already been determined 
for the Dharmacon® siRNA transfection system used. 
 
4.3.1 Optimization of the siRNA delivery to OC cells 
To determine the post-transfection time point at which both mRNA and protein 
levels were lowest, whole-cell lysates from OVCAR-3 cells transfected with 
‘siHBO1’, ‘siCtrl’ and ‘Control’ were harvested 24h, 48h and 72h post-transfection 
for analysis. Whole-cell lysates were then analysed for HBO1 mRNA levels by 
qRT-PCR (Fig. 4.11). 
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Figure 4. 11 HBO1 mRNA relative levels following siRNA KD in OVCAR-3 
OVCAR-3 cells were transfected with a pool of siRNAs targeting HBO1 
(‘siHBO1’), as well as with non-targeting siRNAs (‘siCtrl’) and transfection reagent 
alone (‘Control’). Cell lysates were extracted after 24, 48 and 72h whereupon RNA 
samples were prepared and analysed by qRT-PCR. Relative levels of HBO1 
expression in cells treated with ‘siHBO1’ were compared to those of cells treated 
with: (A) ‘siCtrl’ and (B) ‘Control’. RPL5 expression was used as control. Statistical 
analyses consisted of one-way ANOVA and Tukey’s multiple comparison tests. All 
values represent the mean ± SD of three biological samples (*p < 0.05; **p < 0.01). 
 
 
The transcript abundance of HBO1 was lowest 24h after the transfection with 
‘siHBO1’, compared to the ‘siCtrl’ sample control (FC = -4.94, **p = 0.0078) (Fig. 
4.11 A). HBO1 mRNA levels remained reduced at 48h (FC = -3.21, **p = 0.0025) 
and 72h (FC = -3.23, **p = 0.0026) post-transfection (Fig. 4.11 A). A similar 
decrease in HBO1 transcript abundance was observed when ‘siHBO1’ was compared 
with the un-transfected ‘Control’ samples (Fig. 4.11 B). Here, HBO1 transcript 
levels remained low at 24h (FC = -4.67, ***p = 0.0002), 48h (FC = -3.45, **p = 
0.0012) and 72h (FC = -3.34, **p = 0.0016) post-transfection. 
 
Whole-cell lysates of ‘siHBO1’ and ‘siCtrl’ samples extracted 24, 48 and 72h post-
transfection were then analysed by western blot. Protein extracts were separated 
using gel electrophoresis gradient gels (4-12%), following transfer to PVDF 
membranes, and were probed with anti-HBO1 (AB70) and anti-GAPDH antibodies 
(Fig. 4.12). The levels of HBO1 protein decreased after 24h (RD = 40.64 ± 10.12 %, 
p = 0.0642), 48h (RD = 26.47 ± 6.87 %, *p = 0.0382) and 72h (RD = 37.84 ± 8.59 
%, *p = 0.0368) of siRNA transfection (Fig. 4.12), demonstrating the effectiveness 
of the siRNA approach. 
 
Results		
	 185	
	
Figure 4. 12 HBO1 protein relative levels following siRNA KD in OVCAR-3 
OVCAR-3 cells were transfected with a pool of siRNAs targeting HBO1 (‘siHBO1’) 
and non-targeting siRNAs (‘siCtrl’) and cell lysates were extracted 24, 48 and 72 
hours post-transfection. Protein extracts were analysed by western blot and probed 
with anti-HBO1 and anti-GAPDH antibodies. GAPDH was used as loading control. 
 
 
Interestingly, the maximal reduction of HBO1 protein was obtained 48h after the 
transfection of ‘siHBO1’ (Fig. 4.12), suggesting that protein turnover occurs more 
slowly than mRNA degradation. The reduction of HBO1 both at transcript and 
protein level was strong and followed a similar pattern when HBO1 fold-changes 
(FC) were calculated as percentages (Fig. 4.13). 
 
 
	
Figure 4. 13 Time-course analysis of HBO1 levels following siRNA KD 
OVCAR-3 cells were transfected with a pool of siRNAs targeting HBO1 
(‘siHBO1’), and non-targeting siRNAs (‘siCtrl’). Cell lysates were extracted after 
24, 48 and 72 hours whereupon RNA and protein samples were prepared and 
analysed by qRT-PCR and western blot respectively. Relative levels of HBO1 
mRNA and protein expression in cells treated with ‘siHBO1’ were compared to 
those of cells treated with ‘siCtrl’. Fold-changes were transformed into proportional 
percentages to fit the comparisons. 
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4.3.2 Delivery of siRNAs to OC cell lines 
Small interfering RNA molecules were also delivered to UWB1.289 and SKOV-3 
OC cell lines, expressing high and intermediate-high mRNA and protein HBO1 
levels respectively (Figs. 3.1 & 3.6). UWB1.289 and SKOV-3 cells were transfected 
with ‘siHBO1’ alongside with the two control samples, ‘siCtrl’ and ‘Control’. 
Whole-cell lysates were then harvested after 48h and analysed by qRT-PCR and 
western blot to confirm HBO1 knockdown both at transcript and protein levels (Fig. 
4.14). 
 
	
Figure 4. 14 HBO1 relative levels following siRNA KD in OC cell lines 
UWB1.289 and SKOV-3 cells were transfected with a pool of siRNAs targeting 
HBO1 (‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). Cell lysates were extracted 
after 48h whereupon RNA and protein samples were prepared and analysed by: (A) 
qRT-PCR and (B) western blot respectively. Relative levels of HBO1 expression in 
cells treated with ‘siHBO1’ were compared to those of cells treated with ‘siCtrl’. 
Statistical analysis consisted of one-way ANOVA and the Tukey’s multiple 
comparison test. All values represent the mean ± SD of three biological samples 
(***p < 0.001; ****p < 0.0001). PVDF membranes were probed with anti-HBO1 and 
anti-GAPDH antibodies. GAPDH expression was used as control in both 
experiments. 
 
 
HBO1 mRNA abundance decreased significantly in both UWB1.289 (FC = -15.65, 
****p < 0.0001) and SKOV-3 (FC = -8.02, ***p = 0.0004) cell lines after the 
treatment with ‘siHBO1’ compared to the ‘siCtrl’ negative control sample (Fig. 
4.14 A). Similarly, protein levels of UWB1.289 (RD = 23.10 ± 7.67 %, *p = 
0.0112) and SKOV-3 (RD = 34.64 ± 4.95 %, *p = 0.0225) were significantly 
reduced, demonstrating the ability of siRNA to knockdown HBO1 in two different 
OC cell backgrounds (Fig. 4.14 B). 
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In addition, siRNAs were also used to transfect the OC cell lines UACC-1598 (FC 
= -2.18 ± 0.59, **p = 0.0027) and TOV-112D (FC = -4.87 ± 1.63, ****p < 0.0001) 
(not shown). The successful delivery of siRNAs targeting HBO1 in OVCAR-3, 
UWB1.289, SKOV-3, UACC-1598 and TOV-112D provided a crucial tool for the 
study of HBO1 functions in OC. 
 
4.3.3 Validation of siRNA efficiency 
One of the possible origins of siRNA off-target effects is the use of a siRNA pool 
instead of individual, more specific siRNAs. This assumption is based on the fact 
that the greater the number of delivered siRNAs, the higher the mismatch tolerance 
of the pool, as well as the higher possibilities of interfering with endogenous RNAi 
pathways. In order to assess this, the four individual RNAs that constitute the siRNA 
pool were purchased independently and used to transfect UWB1.289 cells separately 
(Fig. 4.15). 
 
	
Figure 4. 15 Validation of HBO1 KD using individual siRNAs 
UWB1.289 cells were transfected with individual siRNAs targeting HBO1, a pool of 
siRNAs targeting HBO1 and a non-targeting pool (‘siCtrl’). Cell lysates were 
extracted after 48h whereupon RNA samples were prepared and analysed by qRT-
PCR. Relative levels of HBO1 and CDKN1A expression in cells treated with 
‘siHBO1’ were compared to those of cells treated with ‘siCtrl’. GAPDH expression 
was used as control. Statistical analyses consisted of one-way ANOVA and Tukey’s 
multiple comparison tests. All values represent the mean ± SD of three biological 
samples (*p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001). 
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The transfection of single siRNAs comprised in the siRNA pool led to the significant 
down-regulation of HBO1 in UWB1.289 cells, compared to the ‘siCtrl’ control: 
siRNA 1 (FC = -9.3, ****p = < 0.0001), siRNA 2 (FC = -9.01, ****p = < 0.0001), 
siRNA 3 (FC = -9.63, ****p = < 0.0001) and siRNA 4 (FC = -5.39, ***p = 0.0002) 
(Fig. 4.15 A). To validate specific siRNA efficiency, CDKN1A/p21, an HBO1-target 
previously identified in HBO1 KD experiments with HeLa cells (Avvakumov et al. 
2012), was analysed by qRT-PCR (Fig. 4.15 B). 
 
CDKN1A was significantly up-regulated when transfecting UWB1.289 cells with 
individual siRNAs 2 (FC = 1.90, *p = 0.025) and 3 (FC = 1.5, *p = 0.0375) (Fig. 
4.15 B). In the case of transfection with individual siRNAs 1 (FC = 1.21, p = 0.0981) 
and 4 (FC = 1.4, p = 0.0985), even though the results were not statistically 
significant under the established parameters for qRT-PCR (p < 0.05), the displayed 
p-values were situated above the 90% of confidence level (p < 0.1) and the 
expression change followed an up-regulatory trend, suggesting a strong and specific 
modulation of HBO1. Altogether, these results confirm the efficiency of individual 
siRNAs to KD HBO1 and elicit durable gene expression changes. 
 
 
4.5 Gene Expressing Vector: a Tool to Up-regulate HBO1 Levels 
Theoretically, an increase in HBO1 cellular levels could induce the opposite effect to 
HBO1 silencing and reverse prior KD-related events if utilized subsequent to HBO1 
KD. To evaluate this, a pCMV-Tag2B-hHBO1 expression plasmid was constructed. 
A mutated version of this plasmid, pCMV-Tag2B-hHBO1(G485A) was also 
constructed to investigate whether potential effect modulation is linked to HBO1’s 
intrinsic acetyltransferase activity. Lastly, a pCMV-Tag2B-Ø empty plasmid was 
constructed to use as a control. 
 
OVCAR-3 cells, whose plasmid transfection efficiency had been previously 
optimized when trying to obtain an HBO1 KO (not shown), were selected to test the 
transfection of the HBO1-expression plasmid. In this case, the X-tremeGENE™ 9 
(Roche) provided the best transfection conditions (low cytotoxicity and high GFP 
expression, data not shown). Consequently, different concentrations of pCMV-
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Tag2B-hHBO1 (0.1-1-10-50 ng/mL) were transfected into OVCAR-3 cells using X-
tremeGENE™ 9. Twenty-four hours post-transfection, mRNA and whole-cell 
protein lysates were isolated and analysed (Fig. 4.16). 
 
	
Figure 4. 16 Transfection of an HBO1-expressing vector into OVCAR-3 cells 
(A) OVCAR-3 cells were transfected with pCMV-Tag2B-hHBO1 and the empty 
pCMV-Tag2B-Ø plasmid in different concentrations [0.1-1-10-50 ng/mL]. After 
24h, RNA samples were prepared and analysed by qRT-PCR. Relative levels of 
HBO1 expression in Tag2B-hHBO1-transfected cells were compared to those of 
cells transfected with the empty plasmid. All values represent the mean ± SD of 2 
biological replicates. (B) Protein extracts of OVCAR-3 transfected with Tag2B-
hHBO1 and Tag2B-Ø [10 ng/mL] were analysed by western blot and probed with 
anti-HBO1 and anti-GAPDH antibodies. GAPDH expression was used as control in 
both experiments. 
 
 
Low plasmid concentrations, 0.1 ng/mL (FC = 0.96 ± 0.19) and 1 ng/mL (FC = 1.45 
± 0.53), did not increase HBO1 expression (Fig. 4.16 A). Transfection of 10 ng/mL 
of HBO1-expressing plasmid in OVCAR-3 cells led to a convenient 7.1 ± 2.1 fold-
change increase in HBO1 mRNA (Fig. 4.16 A). Very high plasmid concentrations 
[50 ng/mL] resulted in large increases in HBO1 mRNA levels (FC = 18.17 ± 3.01) 
(Fig. 4.16 A), which were considered too high to study the effect of HBO1 mRNA at 
physiological levels and were not used further. 
 
In order to investigate whether increased HBO1 transcript levels led to an increase in 
HBO1 protein levels, whole-cell lysates of 24h-transfected OVCAR-3 cells [10 
ng/mL] were analysed by western blot (Fig. 4.16 B). The incubation with anti-HBO1 
AB70 antibody showed that although the quantity of mRNA increased in the 
samples transfected with HBO1-expression plasmid compared to the empty control, 
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protein levels remained invariable (RD = 95.1 ± 6.52) (Fig. 4.16 B). A similar result 
was also obtained when OVCAR-3 cells were transfected for 48h (data not shown). 
These results suggest that the plasmid mRNA is not translated to protein, perhaps 
due to mistakes during the cloning process. Alternatively, HBO1 levels could be 
tightly regulated to prevent over-accumulation of the protein to either impede 
abnormal translation of HBO1 or promote rapid protein turnover. 
 
	
Figure 4. 17 Ectopic expression of HBO1 in shRNA-transduced UWB1.289 cells 
UWB1.289 cells expressing ‘shHBO1 1’ were transfected with 10 ng/mL of pCMV-
Tag2B-hHBO1, pCMV-Tag2B-hHBO1(G485A) and the empty pCMV-Tag2B-Ø 
plasmid. After 24h, RNA and protein extracts were analysed by: (A) qRT-PCR and 
(B) western blot respectively. Relative levels of HBO1 expression in Tag2B-hHBO1 
and Tag2B-hHBO1(G485A)-transfected cells were compared to those of cells 
transfected with the empty plasmid. All values represent the mean ± SD of 2 
biological replicates. Protein extracts were probed with anti-HBO1 and anti-GAPDH 
antibodies. GAPDH expression was used as control. 
 
 
To further assess the feasibility of the HBO1-expressing vector, the pCMV-Tag2B-
hHBO1 plasmid, alongside with its mutated variant and the empty control were 
transfected into UWB1.289 cells that constitutively express ‘shHBO1 1’ (Fig. 4.17). 
The introduction of 10 ng/mL of pCMV-Tag2B-hHBO1 and pCMV-Tag2B-
hHBO1(G485A) plasmids increased HBO1 transcript levels (hHBO1: FC = 7.32 ± 
1.03; hHBO1(G845A): FC = 8.07 ± 0.86). HBO1 protein levels were similarly 
increased following transfection with either plasmid (hHBO1: RD = 156 ± 28.4 %; 
hHBO1(G485A): RD = 211.34 ± 35.16 %) (Fig. 4.17 B). 
Results		
	 191	
4.6 Discussion 
In this chapter, three tools were developed in order to (a) constitutively KD HBO1 in 
the UWB1.289 cell line (b) transiently KD HBO1 in a variety of OC cell lines and 
(c) up-regulate the expression of HBO1 via the introduction of an HBO1-expressing 
vector. These strategies are then used, in later chapters, to analyse the functional 
roles of HBO1 in these cells. 
 
Genome editing of the HBO1 locus using the CRISPR-Cas9 system was attempted in 
order to generate an UWB1.289 cell line that did not express HBO1. After a number 
of optimization steps, including efforts to infect OC cells with adenoviruses 
expressing Cas9 and transfection of a Cas9-expression plasmid using either common 
transfection reagents (Fig. 4.2) or electroporation procedures (Fig. 4.3), 
electroporation using the Nucleofector™ system (Programme A020) proved 
successful (Fig. 4.4). This achievement was followed by the observation of 
successful T7EI band digestion (Fig. 4.5), confirming INDEL events, after the 
addition of crRNA:tracrRNA complexes targeting the HBO1 locus. Moreover, 
further colony isolation rendered several UWB1.289 colonies allegedly devoid of 
HBO1 protein expression (Fig. 4.6). Notwithstanding, DNA sequencing of target 
locus gDNA belonging to these UWB1.289 colonies did not display appreciable 
INDELs (Fig. 4.7). 
 
The inability to isolate individual clones carrying detectable INDELs, even though a 
number of experiments seem to indicate otherwise, could be due to a number of 
possibilities summarized in Table 4.2. Among all these options, and based on the 
knowledge and experience acquired in the development of this methodology, we 
favour the fact that the experiment did not achieve INDEL introduction in the HBO1 
locus. According to this hypothesis, the absence of HBO1 protein expression, both in 
DB and WB experiments (Fig. 4.6), could be explained as an artefact, consequence 
of the single cell cloning procedure. Since UWB1.289 cells were submitted to an 
abnormal type of growth, that is, without neighbouring cells, this may affect their 
development, thus enabling genomic and non-genomic alterations in order to achieve 
adaptation. As a consequence of these changes, it may happen that these cells reduce 
HBO1 expression, e.g. via promoter methylation, as suggested in Table 4.2. 
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Low levels of Cas9 protein expression in electroporated-UWB1.289 cells (Fig. 4.4) 
and the poor cleavage efficiency obtained in enzymatic surveyor assays (Fig. 4.5) 
further support this hypothesis. In addition, the ability of CRISPR-Cas9 to edit 
mammalian genes is known to vary widely, with some studies reporting varying 
efficiency in the range of 1% to 79% (Duda et al. 2014; Swiech et al. 2014; Liang et 
al. 2015), highlighting the complications currently associated with this approach, 
which appear to be cell line specific. 
 
 
Table 4. 2 List of possible outcomes of the CRISPR-Cas9 genome editing 
 
Hypotheses Controversies 
1. There was no INDEL introduction. Positive T7EI digestion and negative HBO1 signal (dot-blot, western blot). 
2. There was no INDEL introduction. 
However, the clonal isolation selected a 
highly HBO1-methylated-promoter 
clone. 
Positive T7EI digestion. 
3. INDELs were introduced in the 
expected HBO1 locus. However, 
isolated KO colonies died because 
HBO1 is an essential gene in OC cells. 
Negative HBO1 signal of isolated 
colonies (dot-blot, western blot). 
4. INDELs were introduced in the 
expected location within the HBO1 
locus. However, the isolation of 
individuals was inaccurate and more 
than one clone co-existed or cell-
specific ploidy confers the cell several 
copies of the HBO1 locus. 
Sequencing chromatograms are clear and 
do not suggest mixed populations or 
heterozygosis. 
5. INDELs were introduced in the 
expected location within the HBO1 
locus in only one allele.  
6. INDELs were introduced in off-target 
locations within the HBO1 locus. 
TE7I digestion displayed predicted sized 
bands and sequencing chromatograms 
covered as much as 600 base pairs of the 
HBO1 locus (~30% of HBO1’s ORF1). 
7. INDELs were introduced in off-target 
locations outside the HBO1 locus. 
Negative HBO1 signal of isolated 
colonies (dot-blot, western blot). 
8. INDELs were introduced in the 
expected location within the HBO1 
locus. However, the DNA sequencing 
procedure was erroneous. 
 
1ORF = Open Reading Frame. 
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A different approach, based on the expression of shRNAs, was developed to 
constitutively reduce cellular levels of HBO1. The successful integration of lentiviral 
particles carrying shRNA structures (‘shHBO1 1-3’ and ‘shCtrl’) in UWB1.289 cells 
was confirmed via fluorescent microscopy (Fig. 4.8). Furthermore, the expression of 
shRNAs and the subsequent reduction in HBO1 mRNA and protein levels when 
compared with cells infected with the ‘shCtrl’ control was confirmed for three 
different ‘shHBO1’-transduced cells (1-3) (Fig. 4.9 & Fig. 4.10). 
 
Another tool based on the use of RNAi, in this case the delivery of siRNAs to OC 
cells to reduce HBO1 expression, was also successful. This approach resulted in the 
transient KD of HBO1 in OVCAR-3, UWB1.289, SKOV-3, UACC-1598 and TOV-
112D OC cell lines (Fig. 4.11 & Fig. 4.14), providing valuable tools for the study of 
HBO1 function in OC. The decrease of HBO1 expression in OVCAR-3 cells, both at 
mRNA and protein level, was monitored for 24, 48 and 72 hours (Fig. 4.12) and was 
most effective at 48 hours post-delivery of siRNAs. Whilst previous shRNA-based 
experiments evaluated cellular changes promoted in the long-term absence of HBO1, 
this methodology allows the assessment of transient deficiencies. Together, these 
approaches will enable the functions of HBO1 in OC to be further characterised. 
 
In order to increase HBO1 levels, a pCMV-Tag2B-hHBO1 expression plasmid was 
utilised. Although the transfection of the vector resulted in a significant fold 
increment of HBO1 mRNA levels in OVCAR-3 cells, protein quantities were not 
altered (Fig. 4.16). This may be due to a number of reasons, including an inefficient 
translation of HBO1 mRNAs, a short mRNA lifetime, or a quick degradation of 
newly synthesised HBO1 protein, preventing its detection by immune blot. These 
effects could be related to defects in plasmid construction, but may also stem from 
specific cellular responses. Accordingly, it is possible that UWB1.289 cells may 
exert some form of regulation at the translational level or with PTMs, with the 
objective of maintaining the protein expression levels of this important HAT under 
control. In a similar study, however, where the pCMV-Tag2B-hHBO1 plasmid was 
transfected into stable HBO1 KD UWB1.289 cells, the levels of HBO1 protein were 
significantly increased (Fig. 4.17). These findings suggest that the plasmid is 
actually capable of synthesizing HBO1 transcripts that translate into protein under 
certain conditions. The question remains as to whether this protein is active, capable 
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of folding correctly, receive the appropriate PTMs and work in a coordinated way 
with the rest of complex components to perform its functions. 
 
 
	
 
5. Functional HBO1 Evaluation 
using a Stable RNAi-based 
Knockdown System 
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5.1 Introduction and Aims 
HBO1 is reported to have multiple and diverse tissue specific roles that are attributed 
to its involvement in major cellular processes such as DNA replication and 
transcription (Doyon et al. 2006; Kueh et al. 2011). For example based on previous 
KD studies (Table 1.7), one of the most obvious features of HBO1 is its ability to 
modulate cell proliferation in certain cellular backgrounds e.g. 293T embryonic 
kidney cells or MLE-12 murine lung cells (Doyon et al. 2006; Zou et al. 2013). In 
order to investigate the particular roles of HBO1 in OC, the effect of constitutive KD 
using lentivirus-infected UWB1.289 cells was investigated. 
 
Loss or gain of HAT activity is obviously reflected in the pattern of histone 
modifications, and several histone mark signatures have been associated with 
cancerous phenotypes e.g. reduction in histone H4K16 acetylation is thought to be a 
general hallmark of cancer cells (Fraga et al. 2005). Accurate screening of the 
changes of these marks could reveal tissue status and help predict the clinical 
outcome of a tumour (Di Cerbo & Schneider 2013). Accordingly, many studies have 
proposed general prognostic rules for a diverse panel of histone marks in different 
cancers types, including prostate (Seligson et al. 2005) and renal (Mosashvilli et al. 
2010) cancers. In ovarian tumours, the decrease of H3K9 acetylation has been linked 
with tumour progression (Zhen et al. 2010), a result that follows the established 
tendency to relate global loss of histone marks with a poorer prognosis (Kurdistani 
2011). HBO1 has been previously linked to histone H4 (K5, K8, K12 and K16) and 
histone H3K14 acetylation, whereas no significant association has been established 
with other H3 residues, histone H2A or H2B (Iizuka et al. 2009; Kueh et al. 2011). 
Based on these previous observations, the effect of reducing HBO1 levels in OC cell 
lines was analysed for changes in bulk histone H4 and H3K14 acetylation status. 
 
In order to evaluate changes in gene mRNA expression, RNA samples from 
UWB1.289 cells expressing either non-targeting shRNAs or shRNAs targeting 
HBO1 were sequenced (RNA-seq). Statistical analysis of the outcome resulted in a 
list of significantly up- and down-regulated transcripts, which, after compelled qRT-
PCR validation, were considered as candidate HBO1-target genes. The resultant 
gene list was further analysed to identify any cellular pathways governed or 
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influenced by HBO1 using Ingenuity Pathway Analysis® (IPA) (Krämer et al. 2014). 
Finally, the results of the in silico pathway analysis were tested in vitro to confirm 
any role of HBO1 in predicted pathways. The combination of pathway analysis and 
in vitro confirmation of predicted roles contributed to understanding the functions of 
HBO1 in OC. 
 
 
5.2 HBO1 Histone Acetylation Function 
The main nucleosome-substrates of HBO1 acetylation are histone H4 and histone 
H3K14 (Doyon et al. 2006; Iizuka et al. 2009; Kueh et al. 2011; Mishima et al. 
2011). Thus, as a consequence of stable HBO1 KD and therefore the reduction of 
acetyltransferase activity in OC cells, broad acetylation of histone H4 and specific 
acetylation of histone H3K14 would be anticipated to decline. In order to test these 
hypotheses, protein extracts from UWB1.289 cells expressing ‘shHBO1’ 1-3 and 
‘shCtrl’ were analysed using acetylation-specific antibodies (Fig. 5.1). 
 
	
Figure 5. 1 Histone acetylation patterns after stable HBO1 KD 
UWB1.289 cells were transduced with ‘shHBO1 1-3’ targeting HBO1 and non-
targeting shRNA (‘shCtrl’). Protein lysates were analysed by western blot and 
probed with anti-acetylated H3K14, anti-acetylated histone 4 (H4) and anti-H4 
antibodies. H4 was used as loading control. 
 
 
The constitutive delivery of shHBO1 1 (RD = 59.53 ± 7.59 %, *p = 0.0437) and 2 
(FC = 72.91 ± 8.82 %, *p = 0.0489) resulted in significant reductions in bulk histone 
H4 acetylation compared to the parental OC cell line, demonstrating that H4 is a 
major HBO1 target in these tumour derived cells (Fig. 5.1 & Fig. 5.2). ShHBO1 3 
(RD = 93.77 ± 6.87 %, p = 0.3980) did not cause any significant changes in 
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acetylation levels of H4, probably due to HBO1 expression levels being reduced by 
less than 40%, meaning functional HBO1 was still present in cells (Fig. 5.1 & Fig. 
5.2). In contrast, histone H3K14 acetylation levels did not display significant 
changes with any of the shHBO1 constructs that were tested: shHBO1 1 (RD = 
94.37 ± 7.15 %, p = 0.8752), shHBO1 2 (RD = 92.67 ± 8.36 %, p = 0.8608), 
shHBO1 3 (RD = 87.77 ± 6.16 %, p = 0.9255) (Fig. 5.1 & Fig. 5.2). These data 
suggest HBO1 specific regulation of H4 acetylation but not H3K14 acetylation in 
UWB1.289 cells. 
 
	
Figure 5. 2 Histone acetylation relative levels after stable HBO1 KD 
UWB1.289 cells were transduced with ‘shHBO1 1-3’ targeting HBO1 and non-
targeting shRNA (‘shCtrl’). The relative levels of acetylated H4 (H4ac) and 
acetylated H3K14 (H3K14ac) protein expression were calculated using ImageJ; H4 
was used as loading control. Statistical analyses consisted of one-way ANOVA and 
Tukey’s multiple comparison tests. All values represent the mean ± SD of three 
biological samples (*p < 0.05). 
 
 
In line with these findings, the ability of HBO1 to acetylate histone 4 substrates was 
used to evaluate the activity of HBO1 protein synthesized by the pCMV-Tag2B-
hHBO1 expression plasmid (Fig. 5.3). The increase in HBO1 protein levels that were 
measured following transfection of pCMV-Tag2B-hHBO1 and pCMV-Tag2B-
hHBO1 (G485A) plasmids into transduced-UWB1.289 cells was not accompanied 
with significant changes in H4 acetylation (hHBO1: FC = 71.47 ± 20.48; hHBO1 
(G485A): FC = 68.15 ± 20.61) (Fig. 5.3). These results suggest that HBO1 protein 
synthesized by the HBO1-expressing vector is not active at cellular level, and 
therefore cannot perform regular HBO1 functions. 
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Figure 5. 3 Histone acetylation patterns linked to HBO1 ectopic expression 
UWB1.289 cells expressing ‘shHBO1 1’ were transfected with 10 ng/mL of pCMV-
Tag2B-hHBO1, pCMV-Tag2B-hHBO1 (G485A) and the empty pCMV-Tag2B-Ø 
plasmid. (A) After 24h, protein extracts were analysed by western blot and probed 
with anti-HBO1, anti-acetylated H4 and anti-H4 antibodies. (B) The relative level of 
H4ac protein expression was calculated using ImageJ; H4 expression was used as 
control. 
 
 
5.3 Gene Expression Profiling of Transduced UWB1.289 Cells 
The transcriptional targets of HBO1 in UWB1.289 cells at a global gene expression 
level were determined using RNA-seq analysis by comparing transcript profiles from 
native and HBO1 KD cells. RNA-seq enables rapid transcriptome profiling and can 
detect novel transcripts and splicing isoforms, features that are not measurable in 
gene profiles performed by microarray. Sequencing yielded a total of 58,215 
different transcripts in each and every one of the samples examined (3 KD and 3 
control), whose expression was quantified and compared to determine significantly 
modified transcripts. Data analysis identified a list of 68 differentially expressed 
genes (FC ± 1.5; q-value < 0.05), including 30 up-regulated and 38 down-regulated 
gene transcripts (Table 5.1). The low numbers of HBO1-regulated targets point to a 
highly specific role of HBO1 in UWB1.289 cells. 
 
HBO1 isoforms 1 (FC = -3.38, q-value = 1.14x10-45) and 2 (FC = -2.73, q-value = 
1.59x10-06) were detected amongst the 38 down-regulated gene transcripts, 
confirming the success of the experimental approach. Even though isoforms 3, 4 and 
5 were detected amongst the 58,215 identified transcripts, their effective count, 
which could be interpreted as expression level, was very low compared to isoforms 1 
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and 2, confirming previous observations that suggested the predominance of 
isoforms 1 and 2 in the pool of HBO1 transcripts (Fig. 3.4). Furthermore, isoforms 3, 
4 and 5 did not display significant differences between samples. 
 
 
Table 5. 1 List of altered transcripts after constitutive KD of HBO1 
Up-regulated transcripts (30) are listed in descending order, with the ‘histone 
deacetylase 6’ (HDAC6) displaying the highest FC (2.48). Down-regulated 
transcripts (38) are listed in ascending order, with MYST2 (1) displaying the lowest 
FC (-3.38). Corresponding isoform numbers are represented in brackets. 
 
Up-regulated transcripts (30) Down-regulated transcripts (38) 
HDAC6 DCTN1 MYST2 (1) IAH1 
CEP131 SLIT2 MYST2 (2) FBXL12 
MAMLD1 TPRKB PRDM2 EPB4 
SNAP47 HDHD3 TFRC GAA 
SEC14L1 PPPIR12A AP351 UBALD1 
DAZAP2 STAT6 COL26A1 PPHLN1 
PPP6R3 FAM43A MED15 PCID2 (2) 
SMG5 PKIB GUCD1 ZNF562 
ZNF133 FOXQ1 GBGT1 NPERL1 
SNX10 REST PGAP2 FAM111A 
PDE2A VIM PMS2 ALG9 
PDP2  FAM114A1 SUGP2 
DDAH1  ADAL PCID2 (1) 
FGDS-AS1  NAT9 SF1 
ARHGAP44  ZNF426 PXRD3 
NCAPG  CRCP FBLN1 
CDK8  PHTF2 P3H2 
POLRIB  ZNF12 PCM1 
PGAP1  C19orf66 DSN1 
 
 
In order to validate these results, three of the top up and down-regulated targets were 
analysed using qRT-PCR, including the ‘histone deacetylase 6’ (HDAC6), the 
‘synaptosome associated protein 47’ (SNAP47), the ‘signal transducer and activator 
of transcription 6’ (STAT6), ‘periocentriolar material 1’ (PCM1), PMS2 and the 
‘transferrin receptor’ (TFRC) (Fig. 5.4).  
 
Up-regulated gene transcripts identified in the RNA-seq: HDAC6 (FC = 1.62, *p = 
0.0365), SNAP47 (FC = 1.59, p = 0.0642) and STAT6 (FC = 1.62, *p = 0.0455) were 
similarly up-regulated when analysed by qRT-PCR (Fig. 5.4 A). Conversely, down-
regulated gene transcripts identified in the RNA-seq: PCM1 (FC = -1.26, p = 
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0.0576), PMS2 (FC = -1.27, *p = 0.0388), TFRC (FC = -1.33, *p = 0.0644) were 
similarly down-regulated when analysed by qRT-PCR (Fig. 5.4 B). All genes 
selected to validate the expression profile of stable HBO1 KD in UWB1.289 cells 
displayed similar values in both the qRT-PCR experiments and the RNA-seq 
analysis, suggesting that the 68 altered genes are direct or indirect targets of the 
effects of constitutive HBO1 KD. 
 
	
Figure 5. 4 Validation of gene expression changes caused by stable HBO1 KD 
UWB1.289 cells were transduced with ‘shHBO1 1’ and non-targeting shRNA 
(‘shCtrl’). RNA samples were prepared and analysed by qRT-PCR to confirm the: 
(A) up-regulation of HDAC6, SNAP47, STAT6 and (B) the down-regulation of 
PCM1, PMS2 and TFRC. Relative levels of expression in cells expressing ‘shHBO1 
1’ were compared to those of cells expressing ‘shCtrl’. RPL5 expression was used as 
control. Statistical analyses consisted of one-way ANOVA and Tukey’s multiple 
comparison tests. All values represent the mean ± SD of three biological samples (*p 
< 0.05). 
 
 
 
5.3 Pathway Analysis of the Stable HBO1 Knockdown Profile 
In order to identify biological pathways affected by constitutive KD of HBO1 in 
UWB1.289 cells, the list of differentially expressed genes was analysed using the 
pathway-prediction programme IPA. HBO1 KD in UWB1.289 cells was found to 
cause no significant alterations of pathway activity using the ‘Canonical pathways’ 
feature of IPA, probably due to an insufficient number of differentially expressed 
genes (68). However, the IPA feature ‘Downstream effects’ identified several 
biological functions activated upon HBO1 depletion (Table 5.2). 
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Table 5. 2 List of predicted IPA alterations following stable HBO1 KD 
 
Categories Biological function Prediction Z-score 
Cellular organization Formation of protrusions Increased 1.81 
Cellular organization Organization of cytoplasm Increased 2.23 
Cellular organization Microtubule dynamics Increased 2.24 
Cancer Neoplasia of epithelial tissue Increased 2.41 
Cancer Tumorigenesis of tissue Increased 2.41 
 
 
The highest ranked IPA predictions were related to the activation of cancerous 
functions, including an increment in the ‘tumorigenesis of tissue’ (p = 8.92x10-03) 
and ‘neoplasia of epithelial tissue’ (p = 1.25x10-02) (Table 5.2). The predicted 
activation of oncogenic traits upon HBO1 depletion suggests a role for HBO1 in the 
inhibition of cancer-promoting pathways. 
 
Additionally, IPA predicted an association with cellular organization: microtubule 
dynamics (p = 8.97x10-04), organization of cytoplasm (p = 1.46x10-03) and the 
formation of cellular protrusions (p = 2.68x10-03) (Table 5.2). These results suggest 
the involvement of HBO1 in the regulation of cellular assembly and organization 
processes, a feature that has not previously been reported. Furthermore, the 
formation of protrusions on the membrane surface, as well as the activation of 
microtubule dynamics, are commonly linked with cell locomotion (Xue et al. 2010; 
Kaverina & Straube 2011), thus suggesting a role for HBO1 in cell movement and 
migration. 
 
 
5.4 In vitro Evaluation of HBO1-predicted Biological Functions  
The reported role of HBO1 in regulating cell proliferation (Doyon et al. 2006; Zou et 
al. 2013) motivated the first approach to better understand HBO1 functionality in 
OC, which was to evaluate the proliferative capacities exhibited by transduced 
UWB1.289 cells. Subsequently, different in vitro assays were undertaken in order to 
assess changes in cell motility and organization, both biological processes predicted 
to be activated following HBO1 KD in UWB1.289 cells according to IPA in silico 
analysis (Table 5.2). 
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5.4.1 Assessment of HBO1 suggested role in cell proliferation 
The essential role of HBO1 in DNA replication (Miotto & Struhl 2010) suggested 
the prospect of proliferative changes as a result of constitutive HBO1 KD. To 
investigate this possibility, shRNA-transduced cells were subjected to proliferation 
assays, which measured the incorporation of a labelled nucleoside (5’-Bromo-2’-
deoxyuridine or BrdU) into newly synthesized DNA of replicating cells. Since DNA 
replication must happen before cell division, measurement of DNA synthesis is 
considered synonymous with measurement of cell proliferation (Madhavan 2007). 
BrdU incorporation was followed by monoclonal antibody binding (anti-BrdU) and 
immune-peroxidase identification of BrdU-labelled replicative cells (Fig. 5.5). 
 
	
Figure 5. 5 Study of cell proliferation after constitutive HBO1 KD 
UWB1.289 cells were transduced with ‘shHBO1 1’ and non-targeting shRNA 
(‘shCtrl’). BrdU was added to the cells for 4h and 24h to assess cell proliferation. 
Statistical analysis consisted of one-way ANOVA and the Tukey’s multiple 
comparison test. All values represent the mean ± SD of three biological samples (n.s. 
not significant). 
 
 
UWB1.289 cells were treated with BrdU for 4h and 24h, in order to observe changes 
in DNA synthesis rates following reduction in HBO1 in OC cells. Analysis of final 
absorbance values revealed that HBO1 depletion did not appear to affect the 
replication process (Fig. 5.5), suggesting that HBO1 is not essential for DNA 
replication in OC cells and that its overexpression most likely do not function as a 
cancerous mechanism to enhance oncogenic cell proliferation. These results confirm 
IPA predictions, which did not identify cell proliferation changes as a consequence 
of HBO1 constitutive decline. 
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5.4.2 Assessment of HBO1 suggested involvement in cell motility 
In order to evaluate whether the predicted changes in cell organization (e.g. 
formation of protrusions) result in cell motility alterations, phenotypical changes 
were measured using a scratch/wound-healing assay, which measures cell migration 
in vitro (Fig. 5.6). This method is based on the observation that, upon creation of a 
new artificial gap, a so called ‘scratch’, on a confluent cell monolayer, the cells on 
the edge of the newly created gap will move toward the opening to close the 
‘scratch’ until new cell-cell contacts are established again. If HBO1 was involved in 
the regulation of cell movement, UWB1.289-transduced cells would migrate 
differently based on the different levels of HBO1 expression. 
 
	
Figure 5. 6 Example of scratch assay with stable HBO1 KD UWB1.289 cells 
UWB1.289 cells were transduced with ‘shHBO1 1’ and non-targeting shRNA 
(‘shCtrl’). After 48h, the confluent cell monolayer was partially removed by a 
pipette tip (scratch). Images were taken immediately after the scratch (t = 0h) and 
after 12-24h; ImageJ software was used to calculate cell-free area values. The 
relative area was calculated subtracting cell-free area values at 12-24h from cell-free 
area values at t = 0h. Scales represent 100µm. 
 
 
Analysis of wound-healing data did not reveal any differences in scratch closure as 
determined by the relative areas (RA) of ‘shHBO1 1’ and ‘shCtrl’ transduced cells 
12 or 24 hours after the scratch (Fig. 5.6). These results suggest that even though 
HBO1 depletion may enable cells to alter their internal sub-cellular organization as 
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predicted in silico, in vitro changes in cell motility were not observed. Therefore, 
scratch assay results agree with predicted IPA biological alterations of stable KD, 
which did not anticipate changes in cell movement per se. 
 
One common issue when performing wound-healing assays is to determine whether 
the observed changes are due to cell migration or cell proliferation. Typically, and in 
order to control interferences associated with cell propagation, target cells may 
undergo a period of serum-starvation prior to the assay, enabling cell cycle 
synchronisation. In this case however, proliferation rates do not change between 
samples (Fig. 5.5), so serum-starvation was considered unnecessary. 
 
5.4.3 Assessment of HBO1 suggested involvement in cell organization 
In order to evaluate the IPA predicted role for HBO1 in cellular organization, 
phenotypical changes were measured using Atomic Force Microscopy (AFM). AFM 
offers the possibility to perform force measurements at desired cellular locations, 
measuring mechanical properties of adherent cells and thus acting as a reliable 
indicator of the structure and function of the underlying cytoskeleton (Gavara 2017). 
Notably, AFM is emerging as a valuable tool for studying cellular mechanics 
because of its ability to maintain cell viability, so that living cells may be analysed in 
their culture medium without inducing irreversible damage. 
 
The cell cytoskeleton is a dynamic network of three main fibrous structures, namely 
actin filaments, microtubules and intermediate filaments, each type specifically 
distributed inside the cell but intricately linked (Cooper 2000). It has a central role in 
cell structure and intracellular organization, and thus affects cell mechanical 
properties that ultimately dictate cell functionality (Fletcher & Mullins 2010). 
Interestingly, oncogenic transformation not only leads to changes in cellular growth 
and differentiation, but also results in the modification of internal cytoskeleton 
structures (Jinka et al. 2012). Cell stiffness, the resistance of a single cell to an 
externally induced deformation, depends on the level of structure and organization of 
the cytoskeleton and can be measured using AFM, which delivers quantitative 
measurements of cellular elastic responses expressed as specific Young’s modulus E 
(Lekka 2016). Additionally, the application of external forces through AFM enables 
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the acquisition of quantitative information on the adhesion strength of living cells 
(Simon & Durrieu 2006). 
 
Sub-confluent populations of UWB1.289-transduced cells were analysed using AFM 
to measure mechanical cellular properties (on about 40 cells per cell type), including 
cell stiffness and cell adhesiveness (Fig. 5.7). 
 
	
Figure 5. 7 Study of cell organization after stable HBO1 KD in UWB1.289 cells 
UWB1.289 cells were transduced with ‘shHBO1 1’ and non-targeting shRNA 
(‘shCtrl’). After 24h, Atomic Force Microscopy (AFM) was used to measure: (A) 
cell stiffness and (B) cell adhesiveness of 40 transduced cells per type. All AFM 
values are expressed as median ± interquartile range (*p < 0.05; n.s. not significant). 
Pa: Pascal, pN: Piconewton. 
 
 
As shown in Figure 5.7 A, UWB1.289 cells were significantly more elastic (294 Pa) 
than cells subjected to HBO1 KD (397 Pa), which were stiffer, indicating that 
UWB1.289 cells require HBO1 to retain their oncogenic sub-cellular phenotype. 
When cell surface adhesiveness was analysed, no significant difference was 
observed between the samples suggesting that HBO1 does not play a part in cell-cell 
adhesion (Fig. 5.7 B). These findings point to a role for HBO1 in cytoskeletal and/or 
cytoplasmic re-organization, which were altered following its depletion (Table 5.2). 
Accordingly, these results suggest a role for HBO1 promoting the disorganization of 
microtubules, thus stimulating less organised/differentiated and more elastic 
phenotypes in OC cells, a common characteristic of invasive tumour cells (Lekka 
2016; Muroyama & Lechler 2017). 
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5.5 Discussion 
In order to extend our knowledge about the roles of HBO1 in OC, UWB1.289 cells 
were transduced with shRNAs constitutively targeting HBO1 to significantly reduce 
its expression, and subsequently monitored for gene and phenotypical alterations. 
 
First, previously described nucleosome targets of HBO1 H4 and H3K14, identified 
in other cell systems including 293T embryonic kidney cells and K562 leukemic 
cells (Doyon et al. 2006; Mishima et al. 2011), were evaluated using acetylation-
specific antibodies. Constitutive HBO1 KD resulted in the decrease of H4 acetylated 
residues (Fig. 5.1 & Fig. 5.2), supporting a major role for HBO1 in maintaining 
histone H4 acetylation throughout the genome of UWB1.289 cells. These results 
agree with a number of previous studies performed with siRNA (Doyon et al. 2006) 
and shRNA approaches (Sauer et al. 2015; M. S. Kim et al. 2015) (Table 1.7). 
Notably, one nucleosome target commonly associated with cancerous phenotypes, 
H4K16 (Fraga et al. 2005), appears to be specifically modulated by HBO1 HAT 
activity. Still, further studies are required in order to pinpoint HBO1 specificity 
within the group of H4 acetylated residues targeted by the antibody that was used. 
 
Constitutive HBO1 KD did not, however, affect H3K14 acetylation (Fig. 5.1 & Fig. 
5.2), in contraposition with several studies performed with siRNA (Zou et al. 2013), 
shRNA (Mishima et al. 2011; Kim et al. 2015) and KO mice (Kueh et al. 2011) 
(Table 1.7). These findings suggest that H3K14 is not a target of HBO1 acetylation 
in UWB1.289 cells. However, it is interesting to consider whether the preservation 
of H3K14 acetylation levels following HBO1 KD could be due to the action of other 
proteins that may compensate for an HBO1-related loss of H3K14 acetylation. This 
phenomenon could be derived from the activation/overexpression of different HATs, 
e.g. known regulators of H3K14 acetylation like Gcn5 (Kuo & Andrews 2013) or 
p300/CBP (Henry et al. 2013), HAT complex members or other regulatory proteins. 
The RNA-seq transcriptome analysis revealed no alterations in the expression level 
of HATs or known members of HAT complexes (FC ± 1.3, q-value < 0.25), and thus 
if this compensation were to occur, it would be most likely driven through non-
genomic pathways (e.g. increased HAT activity). 
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RNAseq analysis was used to determine gene expression changes elicited by HBO1 
depletion and identified 68 altered genes (Table 5.1). The number of targets is 
surprisingly low, considering previous HBO1 KD studies (Avvakumov et al. 2012), 
which could be a consequence of a partial effect on altering gene regulation due to 
only a 40% reduction in histone H4 acetylation (Fig. 5.1 & Fig. 5.2). In contrast, 
Avvakumov et al. (2012) reported the identification of 782 HBO1 targets (397 up-
regulated and 385 down-regulated) following transient KD in HeLa cells. The 
differences in the number of targets identified in the experiment performed by 
Avvakumov et al. (2012) and the RNA-seq (782 as opposed to 68 altered genes) can 
be due to many factors, including cell-type specificity, the silencing approach 
(transient siRNA silencing versus constitutive shRNA expression) or the presence of 
compensatory effects. In this regard, previous studies have suggested that the up-
regulation of HAT complex components after HBO1 KD could compensate the 
effects of protein depletion, e.g. up-regulation of BRPF1 in HeLa cells after HBO1 
KD could be due to loss of HBO1 activity being compensated for by the 
MOZ/MORF HAT complex (Avvakumov et al. 2012). 
 
The list of differentially expressed genes was examined using SQL queries, which 
identified 3 potential OC-related target genes: ‘slit guidance ligand 2’ (SLIT2) (FC = 
1.72, q-value = 7.84x10-04), the ‘globoside alpha-1,3-N-acetyl-galactosaminyl-
transferase 1’ (GBGT1) (FC = -1.94, q-value = 1.46x10-05) and PMS2 (FC = -1.88, q-
value = 3.94x10-05). SLIT2 proteins have highly conserved roles in axon guidance 
and cell migration (Brose & Tessier-Lavigne 2000) and the SLIT2 gene is regarded 
as a TSG whose promoter has been reported to be hyper-methylated in OC (Qiu et 
al. 2011). The up-regulation of SLIT2 as a consequence of HBO1 KD suggests that 
HBO1 may have a role in regulating its expression in UWB1.289 cells. On the 
contrary, GBGT1, another candidate TSG epigenetically silenced through promoter 
hyper-methylation in OC (Jacob et al. 2014), was down-regulated upon HBO1 
depletion, thus suggesting that HBO1 has a differential role in modulating different 
TSGs. GBGT1 is involved in the synthesis of a specific cell membrane antigen, 
whose function is not well understood yet. However, other members of this family 
have been associated with various biological processes, including multidrug 
resistance and cell proliferation (Behnam-Motlagh et al. 2010; Park et al. 2012). The 
DNA repair gene PMS2 (Jenkins 2009) is recurrently mutated in family cases with 
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Lynch syndrome (hereditary non-polyposis colorectal cancer) (Weissman et al. 
2011), which increases the risk of Lynch-associated cancers like OC (Daniels & Lu 
2015). Again, the down-regulation of putative TSG PMS2 suggests a role for HBO1 
in controlling the expression level of TSGs. 
 
Prior to the analysis of predicted activities and based on previous reports on HBO1 
function (Doyon et al. 2006; Mishima et al. 2011), UWB1.289 cells expressing 
‘shHBO1 1’ and ‘shCtrl’ were subjected to cell proliferation assays, which measured 
the incorporation of BrdU into newly synthesized DNA of replicating cells. 
However, cell proliferation assays revealed no changes in proliferative capabilities 
between KD and control samples (Fig. 5.5). These results differ from previous 
studies where HBO1 KD: (1) significantly affected DNA synthesis and cell 
proliferation of HEK 293T cells (Doyon et al. 2006) and (2) reduced cell 
proliferation rates of MLE-12 cells (Zou et al. 2013). Conversely, these findings 
agree with other studies that point to a non-essentiality of HBO1 for cell 
proliferation or DNA replication (Kueh et al. 2011; M. S. Kim et al. 2015). 
 
The increased formation of cellular protrusions, as well as increments in microtubule 
dynamics, are phenomena commonly linked to the generation of traction force that 
ultimately results in cell motility (Parsons et al. 2010; Sens & Plastino 2015). 
Consequently, transduced UWB1.289 cells were subjected to scratch/wound-healing 
assays in order to evaluate potential changes in cell migration prompted by HBO1 
KD. In silico predicted increase in cellular organization did not translate into 
variations in cell migration between KD and control samples (Fig. 5.6). 
 
Increased cytoplasm organization and microtubule dynamics are consistent with 
cytoskeletal rearrangements towards higher levels of cellular organization, a feature 
that was confirmed using AFM (Fig. 5.7). Interestingly, alterations in the 
cytoskeleton structure, which drive changes in the mechanical properties of 
individual cells, are associated with disease pathogenesis and progression (Lekka 
2016). As cells transform from non-malignant to cancerous states, their cytoskeletal 
structure changes from an organized to an irregular network, reducing the stiffness of 
single cells, a feature that has been reported for a variety of cancer cells including 
OC cells (Guck et al. 2005; Xu et al. 2012). For instance, singular cells belonging to 
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OC cell lines HEY and HEY A8 displayed very low Young’s modulus (884 Pa and 
494 Pa respectively) compared to non-malignant immortalised ovarian surface 
epithelial cells (2472 Pa) (Xu et al. 2012). Accordingly, the augmentation of single 
cell stiffness of HBO1 KD cells point to a role for overexpressed HBO1 in the 
maintenance of an elastic cancerous cell structure, perhaps promoting the acquisition 
of mesenchymal properties that would drive further tumorigenic growth. 
 
 
	
 
6. Functional HBO1 Evaluation 
using a Transient RNAi-
based Knockdown System 
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6.1 Introduction and Aims 
Despite consistent HBO1 level reductions, the implementation of a stable KD system 
in OC cells yielded somewhat inconclusive results using the functional assays 
reported in chapter 5. The effects of transient HBO1 KD were therefore evaluated in 
order to further investigate the roles of HBO1 in OC. The most significant advantage 
of this approach is that it allows overcoming problems associated with the 
application of a constant selective pressure onto the cells, which may lead to off-
target effects. Consequently, gene and phenotypical alterations were monitored 
following transient HBO1 KD using a similar study design as the one applied in the 
preceding chapter. 
 
After the examination of nucleosome targets of HBO1 acetylation (H4 and H3K14) 
in UWB1.289, OVCAR-3 and SKOV-3 OC cell lines, and in order to evaluate 
changes in gene mRNA expression, RNA samples from siRNA-transfected cells 
were hybridized to human whole-genome expression Illumina® microarrays. This 
type of microarray provided genome-wide transcriptional coverage of as many as 
47,323 well-characterized human genes, gene candidates and splice variants, 
generating specific gene expression profiles that help shape the understanding of 
HBO1 cellular functions in OC. Statistical analysis of the outcome resulted in lists of 
significantly up and down-regulated transcripts, which, after qRT-PCR validation, 
were compared in search for common regulated transcripts. 
 
Following the study of transient HBO1 KD effects at transcript level, derived gene 
lists were analysed to enable the identification of cellular pathways governed or 
influenced by HBO1 using IPA as well as Gene Set Enrichment Analysis (GSEA) 
predictor programmes (Subramanian et al. 2005). The results of the in silico pathway 
analysis were then tested in vitro to confirm any role of HBO1 in predicted 
pathways. The combination of pathway analyses and in vitro confirmation of 
predicted roles enabled a further understanding of HBO1 functions in OC. 
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6.2 HBO1 Histone Acetylation Function in OC Cells 
Histone 4 (K5, K8, K12, K16) and histone 3 (K14) nucleosome substrates are 
considered the main targets of HBO1 acetylation (Doyon et al. 2006; Iizuka et al. 
2009; Kueh et al. 2011; Mishima et al. 2011), and H4 acetylation levels were shown 
to be significantly reduced in UWB1.289 cells constitutively expressing shRNAs in 
the previous chapter. In order to further substantiate this function, protein extracts of 
siRNA-treated UWB1.289, OVCAR-3 and SKOV-3 cell lines were analysed using 
acetylation-specific antibodies (Fig. 6.1). 
 
	
Figure 6. 1 Histone acetylation patterns after transient HBO1 KD 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with a pool of siRNAs 
targeting HBO1 (‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). Cell lysates were 
extracted after 48h whereupon protein samples were analysed by western blot and 
probed with anti-acetylated H3K14, anti-acetylated histone 4 (H4) and anti-H4 
antibodies. H4 was used as loading control. 
 
 
HBO1 KD led to a significant depletion of acetylated histone H4 in all studied OC 
cell lines: UWB1.289 (RD = 28.47 ± 3.37 %, **p = 0.0088), OVCAR-3 (RD = 23.11 
± 4.11 %, *p = 0.0375), SKOV-3 (RD = 31.28 ± 2.85 %, *p = 0.0429) (Fig. 6.1 & 
Fig. 6.2). In contrast, there were no significant changes in H3K14 acetylation status 
as a result of the KD in UWB1.289 (RD = 85.48 ± 2.51 %, p = 0.550), OVCAR-3 
(RD = 88.91 ± 3.66 %, p = 0.7615) or SKOV-3 (RD = 94.67 ± 2.98 %, p = 0.9261) 
(Fig. 6.1 & Fig. 6.2). These data suggest specific regulation of H4 acetylation but 
not H3K14 acetylation in OC cell lines and agree with previous results on HBO1 
stable KD UWB1.289 cells (Fig. 5.1 & Fig. 5.2). 
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Figure 6. 2 Histone acetylation relative levels after transient HBO1 KD 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with a pool of siRNAs 
targeting HBO1 and non-targeting siRNAs (‘siCtrl’). Protein lysates were extracted 
after 48h whereupon they were analysed by western blot. The relative levels of 
acetylated H4 and acetylated H3K14 protein expression were calculated using 
ImageJ; H4 was used as loading control. Statistical analysis consisted of one-way 
ANOVA and the Tukey’s multiple comparison test. All values represent the mean ± 
SD of three biological samples (*p < 0.05; **p < 0.01). 
 
 
 
6.3 Microarray Analysis of Transient HBO1 Knockdown Profiles 
The effect of transient HBO1 KD on global gene expression was determined using 
whole-genome Illumina® microarrays. As the Illumina® microarrays contain only 
one probe for HBO1 that specifically recognizes the isoform 1 of the HAT, and lack 
probes for isoforms 2, 3, 4 and 5, the scope of HBO1 analysis is somewhat limiting. 
For each studied OC cell line, OVCAR-3, SKOV-3 and UWB1.289, three biological 
replicates transfected with ‘siHBO1’ and ‘siCtrl’ were used to generate specific gene 
expression profiles, which contained lists of differentially expressed genes, their 
associated fold-change values and statistical probabilities (q-value). 
 
6.2.1 Gene expression profiling of OVCAR-3 cells 
The depletion of HBO1 in OVCAR-3 cells caused the up-regulation and down-
regulation of 110 and 45 gene transcripts respectively, rendering a total of 155 genes 
altered by HBO1 KD (FC ± 1.5; q-value < 0.1) (Table 6.1). As a positive control, 
the HBO1 transcript (MYST2) was one of the 45 down-regulated targets (FC = -1.55, 
q-value = 1.65x10-02). 
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Table 6. 1 List of altered genes after transient HBO1 KD in OVCAR-3 
Up-regulated genes (110) are listed in descending order of expression, with the ‘2’-
5’-oligoadenylate synthetase 2’ (OAS2) displaying the greatest up-regulation (FC = 
4.16). Down-regulated genes (45) are listed in ascending order of expression, with 
the ‘lysine acetyltransferase 7 pseudogene’ (LOC648927) displaying the greatest 
down-regulation (FC = -2.1). 
 
Up-regulated genes (110) Down-regulated genes (45) 
OAS2 IRF7 ZC3HAV1 LOX LOC648927 AXL 
IFI6 OASL VCAN LOC389386 ADRB2 NNAT 
TRIM22 HERC5 LEF1 UBE2E2 LIFR MBNL3 
IFI44L DHX58 GBP4 ElF2AK2 SMPDL3B AQP6 
IFITM1 STAT1 HLA-B TSPAN7 C3orf64 KRT4 
IFIT1 CMPK2 LOC643384 NBPF20 MIR369 SMC4 
IFI27 IFIT5 TMEM140 C19orf66 KRT81 RNF141 
CXCL10 LAMP3 LOC6465562 HSPE1 NPFFR2 CDR2 
SLC15A3 PSMB9 GBP5 KCNE1 EDN2 TRIM47 
IFIT3 SP110 LAMA1 IRX3 CA12 WDR89 
1LOC100~ PARP14 TSPAN2 LOC646146 RABL2B MYADML 
BST2 LBA1 TDRD7 FLJ21986 CD46 LOH3CR2A 
RSAD2 PLSCR1 IFNB1 SLNF5 SCARNA27 CCL28 
ISG15 EPSTI1 CPA6 HRH1 GRIP2 PRPF40A 
DDX60 PRIC285 GBP1 PRSS35 CHORDC1 C11orf47 
IFIT2 IFI16 UBE2L6 PRM1K TRIM23 SPIRE2 
HERC6 CXCL11 PARP12 C21orf128 S100A2 RUNX1T1 
IFI44 IFI35 CMYAS SP100 TNFRSF10D  
SAMD9L C20orf103 LTBP1 TLE4 H2AFY 
USP18 PARP9 USP41 HLA-F RABL2A 
OAS1 MX1 LPIN2 MAP2 MYST2 
OAS3 2LOC100~ GABRA2 CD69 FOXS1 
DDX60L TAP1 ST8SIA1 SAMD11 YAP1 
RASGRP3 SPP1 IFITM3 NMNAT2 AGFG1 
IDO1 IRF9 TBX2 LOC401093 GREM1 
DDX58 ADAM32 AKR1C3 THAP7 TMEM55A 
IFIH1 LGALS9 MAP2K3  TNRC18 
SAMD9 INDO RASSF2 KRT16 
1LOC100129681, 2LOC100128274 
 
 
In order to identify potential meaningful OC-related genes that could be used to 
validate the microarray results, the list of differentially expressed transcripts was 
incorporated into the SQL relational database. Using SQL queries, the search for 
validation targets was narrowed down to 6 genes, each with functions involved in 
OC-related processes and which had been identified as HBO1 targets in a previously 
published RKO ChIP-Seq experiment (Avvakumov et al. 2012) (Table 6.2). The 
transcript abundance of these targets was confirmed using qRT-PCR (Fig. 6.3). 
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Table 6. 2 List of gene validation targets for the OVCAR-3 expression profile 
 
Gene target FC q-value Ovarian Cancer Link 
Bone marrow stromal cell 
antigen 2 (BST2) 2.79 1x10
-8 Up-regulated in metastasis (Walter-Yohrling et al. 2003) 
Interferon stimulated protein 
15 (ISG15) 2.66 1x10
-7 Linked to NF-κβ and survival (Darb-Esfahani et al. 2014) 
Signal transducer and activator 
of transcription 1 (STAT1) 1.97 1x10
-8 Linked to platinum resistance (Stronach et al. 2011) 
CD46 molecule/antigen 
(CD46) -1.62 2.6x10
-2 Up-regulated in OC tissues (Fishelson et al. 2003) 
Fibroblast growth factor 
receptor 4 (FGFR4) -1.56 1.6x10
-3 Linked to HGSC prognosis (Zaid et al. 2013) 
Yes-associated protein 1 
(YAP1) -1.51 3.5x10
-3 Up-regulated in OC tissues (Steinhardt et al. 2008) 
 
 
Up-regulated gene transcripts identified in the OVCAR-3 microarray: BST2 (FC = 
4.19, **p = 0.0025), ISG15 (FC = 4.22, **p = 0.0021) and STAT1 (FC = 2.37, *p = 
0.0268), were similarly up-regulated when analysed by qRT-PCR (Fig. 6.3 A). 
Conversely, CD46 (FC = -1.74, *p = 0.0278), FGFR4 (FC = -1.68, *p = 0.042) and 
YAP1 (FC = -1.8, *p = 0.0355), were significantly reduced (Fig. 6.3 B). 
 
	
Figure 6. 3 Validation of the HBO1 KD OVCAR-3 gene expression profile 
OVCAR-3 cells were transfected with a pool of siRNAs targeting HBO1 (‘siHBO1’) 
and non-targeting siRNAs (‘siCtrl’). Cell lysates were extracted after 48h whereupon 
RNA samples were prepared and analysed by qRT-PCR to confirm: (A) the up-
regulation of BST2, ISG15, STAT1 and (B) the down-regulation of CD46, FGFR4 
and YAP1. Relative levels of expression in cells treated with ‘siHBO1’ were 
compared to those of cells treated with ‘siCtrl’. RPL5 expression was used as 
control. Statistical analyses consisted of one-way ANOVA and Tukey’s multiple 
comparison tests. All values represent the mean ± SD of three biological samples (*p 
< 0.05; **p < 0.01). 
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The gene expression of a number of the target genes remained altered at additional 
time points (24 and 72h post-transfection). Up-regulation of BST2 (FC = 2.46 *p = 
0.0344), ISG15 (FC = 2.82, *p = 0.0305) and STAT1 (FC = 1.59, *p = 0.0489) were 
maintained after 72h, but to a lesser extent than at 48h (Fig. 6.4 A), demonstrating 
the transient nature of the siRNA treatment. 
 
The down-regulation of CD46 (FC = -1.83, **p = 0.0021) and YAP1 (FC = -1.41, *p 
= 0.0236) was significantly reduced after 24h, whereas reduction in FGFR4 
expression (FC = -1.75, p = 0.1336) was not statistically significant despite the 
downward trend (Fig. 6.4 B). The effect of siRNA treatment was sustained for the 
72h of the experiment: CD46 (FC = -1.69, *p = 0.0429), FGFR4 (FC = -1.45, *p = 
0.0124) and YAP1 (FC = -1.39, *p = 0.0477) (Fig. 6.4 B). These results suggest that 
the expression of this gene set (Table 6.2) is extensively regulated by HBO1 in 
OVCAR-3 cells. Interestingly, none of these genes were identified in the previous 
shRNA approach using UWB1.289 cells (Table 5.1). 
 
	
Figure 6. 4 Time-course analysis of the transient HBO1 KD effect in OVCAR-3 
OVCAR-3 cells were transfected with a pool of siRNAs targeting HBO1 (‘siHBO1’) 
and non-targeting siRNAs (‘siCtrl’). Cell lysates were extracted after 24, 48 and 72h 
whereupon RNA samples were prepared and analysed by qRT-PCR to confirm: (A) 
the up-regulation of BST2, ISG15, STAT1 and (B) the down-regulation of CD46, 
FGFR4 and YAP1. Relative levels of expression in cells treated with ‘siHBO1’ were 
compared to those of cells treated with ‘siCtrl’. RPL5 expression was used as 
control. Statistical analyses consisted of one-way ANOVA and Tukey’s multiple 
comparison tests. All values represent the mean ± SD of three biological samples (*p 
< 0.05; **p < 0.01). 
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6.2.2 Gene expression profiling of SKOV-3 cells 
Prior to the gene expression profiling study in SKOV-3 cells, gene targets identified 
in OVCAR-3 cells (Table 6.2) were assessed for expression in the SKOV-3 HBO1 
KD model. CD46 and YAP1 genes displayed significant down-regulation compared 
to the control, whereas BST2, ISG15, STAT1 and FGFR4 remained unchanged. 
These results indicate that successful HBO1 KD in SKOV-3 cells again perturbed 
HBO1 regulatory mechanisms, with some of the changes in target modulation 
conserved amongst cell lines and others displaying higher specificity. 
 
The depletion of HBO1 in SKOV-3 cells resulted in the up-regulation and down-
regulation of 20 and 60 gene transcripts respectively, a total of 80 genes products 
altered by HBO1 KD (FC ± 1.5; q-value < 0.1) (Table 6.3). 
 
 
Table 6. 3 List of altered genes after transient HBO1 KD in SKOV-3 
Up-regulated genes (20) are listed in descending order of expression, with the ‘p21 
protein activated-kinase 2’ (PAK2) displaying the greatest up-regulation (FC = 2.31). 
Down-regulated genes (60) are listed in ascending order of expression, with the 
‘cysteine and histidine rich domain containing 1’ (CHORDC1) displaying the 
greatest down-regulation (FC = -2.5). 
 
Up-regulated genes (20) Down-regulated genes (60) 
PAK2 CHORDC1 LOC442153 LOC100129379 
LOC729513 RNF141 YAP1 LOC100133803 
CAST RABL2A LOC100134504 LOC645630 
SLFN5 LOC648927 SUMO1 LOC728060 
PLAT LIFR MYST2 PRMT6 
FBXW27 SAR1A SPAST LOC100132499 
ABTB1 GCNT2 TOP1 LOC100133211 
GOLGA8A RABL2B NAPEPLD VPS36 
AAK1 CD46 LOC728602 SSR2 
CDCP1 C3orf64 ARL6IP1 ZNF268 
TSPAN2 LOC728843 PTMA LOC727821 
CNTNAP1 TOP1P2 LOC728026 LOC345041 
CHRNA9 C6orf192 DCTN4 PSG6 
PGM2L1 H2AFY LOC729362 PRPF38A 
LOC100133800 CDR2 LOC643668 LOC646966 
TOB1 NEK1 MIB1 LOC649839 
NUCKS1 LOC100131713 KPNA2 F3 
LOC643977 LOC728484 LOC100128060 LOC643308 
STK11IP AGFG1 LOC644889 ATMIN 
OLFML3 ASPH LOC100132547 UFM1 
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The HBO1 transcript (MYST2) was detected amongst the 60 down-regulated genes 
(FC = -1.63, q-value = 0.047), confirming the success of the experimental approach. 
To further validate the results, three of the top up- and down-regulated targets were 
re-analysed using qRT-PCR, including the ‘AP2 associated kinase 1’ (AAK1), the 
‘nuclear casein kinase and cyclin dependent kinase substrate 1’ (NUCKS), the 
‘serine/threonine kinase 11 interacting protein’ (STK11IP), the ‘ubiquitin ligase 
mindbomb’ (MIB1), spastin (SPAST) and the ‘small ubiquitin-like modifier 1’ 
(SUMO1) (Fig. 6.5). 
 
	
Figure 6. 5 Validation of the HBO1 KD SKOV-3 gene expression profile 
SKOV-3 cells were transfected with a pool of siRNAs targeting HBO1 (‘siHBO1’) 
and non-targeting siRNAs (‘siCtrl’). Cell lysates were extracted after 48h whereupon 
RNA samples were prepared and analysed by qRT-PCR to confirm: (A) the up-
regulation of AAK1, NUCKS1, STK11IP and (B) the down-regulation of MIB1, 
SPAST and SUMO1. Relative levels of expression in cells treated with ‘siHBO1’ 
were compared to those of cells treated with ‘siCtrl’. GAPDH expression was used 
as control. Statistical analyses consisted of one-way ANOVA and Tukey’s multiple 
comparison tests. All values represent the mean ± SD of three biological samples (*p 
< 0.05). 
 
 
Up-regulated gene transcripts identified in the SKOV-3 microarray: AAK1 (FC = 
1.6, *p = 0.0259), NUCKS1 (FC = 1.42, p = 0.0788) and STK11IP (FC = 1.51, *p = 
0.0452), were similarly up-regulated when analysed by qRT-PCR (Fig. 6.5 A), and 
MIB1 (FC = -1.56, p = 0.053), SPAST (FC = -1.34, *p = 0.0433) and SUMO1 (FC = 
-1.64, *p = 0.0297) were also significantly reduced (Fig. 6.5 B). 
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6.2.3 Gene expression profiling of UWB1.289 cells 
Prior to the gene expression profiling study, previously defined OVCAR-3 targets 
(Table 6.2) were assessed for expression in the UWB1.289 HBO1 KD model. As in 
OVCAR-3 and SKOV-3, CD46 and YAP1 displayed significant down-regulation 
compared to the control, whereas BST2, ISG15, STAT1 or FGFR4 expression was 
unchanged, suggesting a tight HBO1 regulation of selected genes across the OC cell 
model. The depletion of HBO1 in UWB1.289 cells resulted in the up-regulation and 
down-regulation of 507 and 382 gene transcripts respectively, a total of 889 altered 
gene products (FC ± 1.5; q-value < 0.1) (Table 6.4). 
 
 
Table 6. 4 Top altered genes after transient HBO1 KD in UWB1.289 
Top up-regulated genes are listed in descending order of expression, with 
‘chromosome 8 ORF 4’ (C8orf4) displaying the greatest up-regulation (FC = 4.34). 
Top down-regulated genes are listed in ascending order of expression, with the 
‘lysine acetyltransferase 7 pseudogene’ (LOC648927) displaying the greatest down-
regulation (FC = -4.01). 
 
Top up-regulated genes (78) Top down-regulated genes (78) 
C8orf4 TSHZ2 TSC22D3 LOC648927 FLI12684 SLC6A15 
MAFB COL22A1 SLC13A5 MYST2 GCNT2 KAT2B 
SLC2A12 CDKN1A LOC644612 SAR1A NEIL2 SNORD104 
PROC PROM1 RARRES2 CHORDC1 PLCB4 SLC7A2 
RASGRP1 SRGAP3 ATOH8 C16orf73 SERPINE1 RRP9 
DACT1 TNFRSF19 ITGB6 S1PR1 ADRB2 AADAC 
KCNK12 BEND5 ZBTB46 SNAPC1 HBEGF LHX6 
FAM107A TNFRSF10 SOX4 FOSL1 YAP1 LOC732371 
TSPAN8 HAPLN3 LOC606724 ESM1 C3orf64 MARS2 
KLHL24 TUBB3 CTDSP2 H2AFY IL1RL1 ZNF699 
PLA2G10 ASAP3 FLJ11235 AFAP1L1 CD46 JAG2 
CDH6 SGPP2 RASSF2 LOC729231 CREB5 CR2 
MUC16 FXYD6 LBH RABL2A SLC25A43 TLR4 
MAP2 D4S234E 1HIST2~ PDE1C BNC1 AOX1 
TP53INP1 VSNL1 YPEL2 C6orf192 GOLM1 SDCCAG3 
RASD1 RASD2 MFAP2 EDG1 MCOLN2 PRKAA1 
C5orf13 SYT11 NCCRP1 RABL2B PRNP CCND2 
ALPL ZMYND15 PCDHB5 NIPAL1 LOC647691 MLKL 
ID2 ANKRD34B PBX1 PLAGL2 S100A2 LOC732419 
SCNN1A SAMD14 PROX1 ADAMT56 NIN LOC201651 
JAM2 GRHL3 EDAR TNFRSF8 TOP1 STYK1 
RCAN2 CXXC5 MXD4 2LOC100~ RASL11B HPDL 
CCNG2 TRIM2 PGM2L1 LETM2 TAF1A SNAI2 
ARID5B GPR64 DLX5 TMEM184A SFXN1 FCF1 
CLIC3 EPN3 WNT10A PRPF38A VPS36 DCLK1 
BAPX1 CSDC2 CX3CL1 CDR2 ADPGK ACTR3B 
1HIST2H2AA3, 3LOC100132240 
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HBO1 transcript (MYST2) was detected amongst the 382 down-regulated genes (FC 
= -2.7, q-value = 1.1x10-09), validating the experimental approach. To further 
validate these results, three of the top up and down-regulated targets were analysed 
using qRT-PCR, including cyclin G2 (CCNG2), the ‘Dapper antagonist of catenin 1’ 
(DACT1), the ‘solute carrier family 2 member 12’ (SLC2A12), the ‘NIPA like 
domain containing 1’ (NIPAL1), the ‘pleiomorphic adenoma gene-like 2’ (PLAGL2) 
and the ‘secretion associated Ras related GTPase 1A’ (SAR1A) (Fig. 6.6). 
 
	
Figure 6. 6 Validation of the HBO1 KD UWB1.289 gene expression profile 
UWB1.289 cells were transfected with a pool of siRNAs targeting HBO1 
(‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). Cell lysates were extracted after 
48h whereupon RNA samples were prepared and analysed by qRT-PCR to confirm: 
(A) the up-regulation of CCNG2, DACT1, SLC2A12 and (B) the down-regulation of 
NIPAL1, PLAGL2 and SAR1A. Relative levels of expression in cells treated with 
‘siHBO1’ were compared to those of cells treated with ‘siCtrl’. GAPDH expression 
was used as control. Statistical analyses consisted of one-way ANOVA and Tukey’s 
multiple comparison tests. All values represent the mean ± SD of three biological 
samples (*p < 0.05; ***p < 0.001). 
 
 
Up-regulated gene transcripts identified in the UWB1.289 microarray: CCNG2 (FC 
= 3.22, *p = 0.0232), DACT1 (FC = 6.21, ***p = 0.0008) and SLC2A12 (FC = 4.31, 
*p = 0.0143), were similarly up-regulated when analysed by qRT-PCR (Fig. 6.6 A), 
and NIPAL1 (FC = -1.92, p = 0.0672), PLAGL2 (FC = -1.82, *p = 0.0423) and 
SAR1A (FC = -2.08, *p = 0.0478) were also significantly reduced (Fig. 6.6 B). 
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6.2.4 Study of HBO1 responsive genes in multiple OC cell lines 
The transient KD of HBO1 in OVCAR-3, SKOV-3 and UWB1.289 OC cell lines 
revealed some similarities, but also many differences in the numbers and identities of 
altered targets following HBO1 decline. Genome-wide comparisons of the effects of 
KD in the three cell lines are represented as scatter-plots in Appendix 3, illustrating 
the consistency of HBO1 KD amongst the studied cell lines. 
 
The number of genes that had significantly altered expression as a consequence of 
HBO1 KD could be linked to different levels of HBO1 expression in each cell line, 
as well as different stages of OC from which they were isolated. UWB1.289, which 
expressed the highest level of HBO1 protein compared to OVCAR-3 and SKOV-3 
(Fig. 3.6), had the highest number of altered target genes after transient HBO1 KD 
(Table 6.5). 
 
 
Table 6. 5 Summary of gene expression changes caused by transient HBO1 KD 
 
Cell line Total genes altered Up-regulated Down-regulated 
UWB1.289 889 507 382 
OVCAR-3 155 110 45 
SKOV-3 80 20 60 
 
 
The majority of genes identified were up-regulated following loss of HBO1, 
UWB1.289 (57%) and OVCAR-3 (71%), suggesting either a direct role for HBO1 in 
transcription repression or an indirect effect based on the activation of potential 
repressors (Table 6.5). To compare the overlap of HBO1 responsive gene transcripts 
in the three studied cell lines, UWB1.289, OVCAR-3 and SKOV-3, a Venn diagram 
was constructed from the lists of differentially expressed genes (Fig. 6.7 A). A set of 
13 genes including HBO1 and the ‘lysine acetyltransferase 7 pseudogene’ or 
LOC648927 (1.2% of the total number of HBO1-modulated genes) were common 
between the three OC cell lines (Fig. 6.7 B), a number of which were validated using 
qRT-PCR, including CD46, the ‘H2A histone family member Y’ (H2AFY), 
tetraspanin 2 (TSPAN2) and YAP1 (Fig. 6.8). 
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Figure 6. 7 Common response to HBO1 KD in OC cell lines 
(A) Microarray-derived lists of differentially expressed genes following HBO1 KD 
in UWB1.289, OVCAR-3 and SKOV-3 cell lines were collated using a Venn 
diagram. (B) The relative expression of genes that showed a common response to 
HBO1 KD in the three cell lines are represented in a heat map elaborated with 
MEV. Scale is shown at the bottom, where red represents gene up-regulation and 
green represents gene down-regulation compared to the control. AGFG1: arfGAP 
with FG repeats 1; C3orf64/EOGT: EGF domain specific O-linked N-
acetylglucosamine transferase; CDR2: cerebellar degeneration related protein 2; 
CHORDC1: cysteine and histidine rich domain containing 1; RABL2A/B: RAB, 
member of RAS oncogene family like 2A/B; RNF141: ring finger protein 141. 
 
 
The gene transcript for CD46, a membrane protein with roles in immunity and cell 
adhesion (Tang et al. 2016), was down-regulated in OVCAR-3 HBO1 KD cells (FC 
= -1.74, *p = 0.0278), UWB1.289 (FC = -2.09, *p = 0.0337) and SKOV-3 (FC = -
2.12, *p = 0.0462) (Fig. 6.8). Similarly, YAP1, a main downstream nuclear effector 
of the Hippo signalling pathway involved in tissue homeostasis and cell proliferation 
(Moroishi et al. 2015), was down-regulated in OVCAR-3 (FC = -1.8, *p = 0.0355), 
UWB1.289 (FC = -1.57, *p = 0.0371) and SKOV-3 (FC = -1.79, *p = 0.0477) (Fig. 
6.8). 
 
H2AFY, which encodes a replication-independent histone variant involved in 
transcription repression (Monteiro et al. 2014), displayed decreased expression in 
UWB1.289 (FC = -3.22, *p = 0.0467), OVCAR-3 (FC = -1.66, *p = 0.0398) and 
SKOV-3 (FC = -1.83, *p = 0.0352) cell lines (Fig. 6.8). TSPAN2, a trans-membrane 
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protein involved in signal transduction related to cell development, activation, 
growth and motility (Otsubo et al. 2014), was up-regulated in all cell lines: 
UWB1.289 (FC = 2.55, *p = 0.0264), OVCAR-3 (FC = 1.94, *p = 0.0448) and 
SKOV-3 (FC = 2.37, *p = 0.0396) (Fig. 6.8). 
 
	
Figure 6. 8 Validation of common gene expression changes caused by HBO1 KD 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with a pool of siRNAs 
targeting HBO1 (‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). Cell lysates were 
extracted after 48h whereupon RNA samples were prepared and analysed by qRT-
PCR to confirm the down-regulation of CD46, H2AFY, YAP1 and the up-regulation 
of TSPAN2. Relative levels of expression in cells treated with ‘siHBO1’ were 
compared to those of cells treated with ‘siCtrl’. GAPDH expression was used as 
control. Statistical analysis consisted of one-way ANOVA and the Tukey’s multiple 
comparison test. All values represent the mean ± SD of three biological samples (*p 
< 0.05). 
 
 
These genes were subsequently considered as an ‘HBO1 OC signature’ gene set 
(Fig. 6.7 B), the expression of which are normally up-regulated by the 
acetyltransferase, suggesting that these genes could be direct targets of HBO1. To 
determine the extent to which the ‘HBO1 OC signature’ was present in other OC 
derived cells, the serous-like cell line UACC-1598 and the endometrioid TOV-
112D were investigated. These two cell lines were transfected with siRNAs 
targeting HBO1, and qRT-PCR analyses were used to demonstrate the effective 
KD of HBO1 expression: UACC-1598 (FC = -2.18, *p = 0.0366), TOV-112D (FC 
= -4.87, ****p < 0.0001) (Fig. 6.9). 
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Figure 6. 9 Gene relative levels after HBO1 KD in UACC-1598 and TOV-112D 
UACC-1598 and TOV-112D cells were transfected with a pool of siRNAs targeting 
HBO1 (‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). Cell lysates were extracted 
after 48h whereupon RNA samples were prepared and analysed by qRT-PCR to 
confirm the down-regulation of HBO1, CD46, H2AFY, YAP1 and the up-regulation 
of TSPAN2. Relative levels of expression in cells treated with ‘siHBO1’ were 
compared to those of cells treated with ‘siCtrl’. GAPDH expression was used as 
control. Statistical analysis consisted of one-way ANOVA and the Tukey’s multiple 
comparison test. All values represent the mean ± SD of three biological samples (*p 
< 0.05; ****p < 0.0001). 
 
 
HBO1 KD in UACC-1598 resulted in the down-regulation of CD46 (FC = -1.74, *p 
= 0.0442), H2AFY (FC = -1.74, *p = 0.0418) and YAP1 (FC = -1.81, *p = 0.0437) 
(Fig. 6.9). TSPAN2 (FC = 0.94 ± 0.20, p = 0.6354) levels were not increased, 
suggesting that the extension of the ‘HBO1 OC signature’ is limited to certain gene 
products or certain OC cell lines. HBO1 KD in the endometrioid cell line TOV-
112D resulted in the down-regulation of CD46 (FC = -2.46, *p = 0.0284), H2AFY 
(FC = -2.01, p = 0.0577) and YAP1 (FC = -1.34, p = 0.0522), whereas TSPAN2 gene 
transcripts could not be detected by qRT-PCR (Fig. 6.9). 
 
These results suggest that tight regulation is exerted by HBO1 over a very specific 
subset of ‘HBO1 OC signature’ genes (CD46, H2AFY and YAP1) in all cell lines 
tested and could therefore represent key targets of HBO1 in OC development. 
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Table 6. 6 Comparison of gene expression changes between OC cell lines 
 
Comparison Common genes E1 
UWB1.289 and 
OVCAR-3 (16) 
OAS2, IFIT1, CXCL10, IFIT2, OAS1, MX1, IRF9, 
GBP5, GBP1, RASSF2, TLE4, MAP2 
12 
ADRB2, SMPDL3B, S100A2, TNFRSF10D 4 
UWB1.289 and  
SKOV-3 (19) 
ABTB1, CNTNAP1 2 
PAK2, LOC100133800, PGM2L1 3 
SAR1A, GCNT2, TOP1P2, C6orf192, TOP1, 
NAPEPLD, LOC643668, PRMT6, LOC100133211, 
VPS36, SSR2, LOC345041, PRPF38A, F3 
14 
OVCAR-3 and  
SKOV-3 (2) 
SLNF5 1 
LIFR 1 
1E: Expression. Red represents up-regulated genes in both microarrays. Blue 
represents down-regulated genes in both microarrays. Green represents common 
genes with opposing expression patterns between cell lines. 
 
 
Two-way comparisons of each cell line with UWB1.289 revealed additional 
common gene sets of genes that were similar in size to the signature set (Table 6.6). 
Because of the limited size of all of the overlapping gene sets identified through 
functional mRNA analysis, it remained challenging to establish functional or 
regulatory relationships. Pathway analyses, which take into consideration all HBO1-
modulated transcripts for comparison, could provide a better perspective on the 
differences and similarities of the roles of HBO1 in OC cell lines and were therefore 
undertaken. 
 
 
6.3 Functional Analysis of Transient HBO1 Knockdown Profiles 
The large numbers of differentially expressed genes identified as a consequence of 
HBO1 depletion (Table 6.5) point to a potentially important regulatory role for 
HBO1, directly or indirectly suppressing and enhancing gene transcription in OC 
cells. Inspection of HBO1 UWB1.289 microarray data identified key target 
molecules involved in important regulatory functions, including genes associated 
with general cancer features (e.g. CDKN1A/p21 or MYC), particular OC 
characteristics (e.g. MUC16), histone acetylation (e.g. KAT2B) or HBO1 
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functionality (e.g. AR, ING4). All six gene targets identified in the UWB1.289 
microarray were validated via qRT-PCR: KAT2B (FC = -2.39, ***p = 0.0002) and 
MYC (FC = -1.65, *p = 0.0107) were similarly down-regulated, whereas CDKN1A 
(FC = 2.32, ****p < 0.0001), MUC16 (FC = 2.68, ****p = < 0.0001), AR (FC = 2.32, 
***p = 0.0001) and ING4 (FC = 1.81, **p = 0.0014) were also significantly up-
regulated (Fig. 6.10). 
 
	
Figure 6. 10 Altered expression of key cancer genes caused by HBO1 KD 
UWB1.289 cells were transfected with a pool of siRNAs targeting HBO1 
(‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). Cell lysates were extracted after 
48h whereupon RNA samples were prepared and analysed by qRT-PCR to confirm 
the down-regulation of KAT2B, MYC and the up-regulation of AR, CDKN1A, ING4 
and MUC16. Relative levels of expression in cells treated with ‘siHBO1’ were 
compared to those of cells treated with ‘siCtrl’. GAPDH expression was used as 
control. Statistical analysis consisted of one-way ANOVA and the Tukey’s multiple 
comparison test. All values represent the mean ± SD of three biological samples (*p 
< 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). 
 
 
In order to determine whether the modulatory activity of HBO1 over these genes was 
UWB1.289-cell type specific or a more wide regulatory phenomenon, their 
expression patterns were analysed by qRT-PCR in the rest of OC models. With the 
exception of KAT2B, a histone acetyltransferase that plays an important role in 
transcriptional regulation (Poux & Marmorstein 2003), which was significantly 
down-regulated in all studied OC cell lines, none of the other gene targets were 
significantly altered in the serous-like cell lines OVCAR-3, SKOV-3, UACC-1598 
or the endometrioid TOV-112D. These limited results suggest restricted implications 
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of HBO1 in key cellular features. In order to elucidate which biological pathways are 
affected by HBO1 modulation, gene expression profiles were interrogated using two 
different pathway-prediction programmes: ‘Ingenuity Pathway Analysis’ (IPA) and 
‘Gene Set Enrichment Analysis’ (GSEA), which is specifically designed for 
microarray profile analysis. 
 
6.3.1 Ingenuity Pathway Analysis of HBO1 knockdown profiles 
Firstly, the IPA ‘Canonical pathways’ feature predicted the significant 
activation/suppression of a number of pathways in UWB1.289 and OVCAR-3 cells 
(p-value < 0.05) (Fig. 6.11). IPA did not detect any significantly altered canonical 
pathway or biological function in SKOV-3 cells, possibly due to the small number of 
differently expressed genes. 
 
	
Figure 6. 11 IPA canonical pathways prediction after HBO1 KD in UWB1.289 
The list of 889 differentially expressed genes (and their associated fold-change 
values) retrieved from the microarray analysis of HBO1 KD in UWB1.289 cells was 
uploaded into the IPA software. The IPA ‘Canonical pathways’ feature predicted 
pathway alterations following HBO1 KD. Scale is shown to the right, where orange 
represents pathway activation and blue represents pathway inactivation. 
 
 
The decrease of HBO1 levels in UWB1.289 cells was found to cause the significant 
activation of three canonical pathways: ‘Basal cell carcinoma signalling’ (Z-score = 
2, p = 4.9x10-02), ‘Leukocyte extravasation signalling’ (Z-score = 1.89, p = 2.2x10-
02) and ‘p53 signalling’ (Z-score = 1.38, p = 3.8x10-02) (Fig. 6.11). In addition, IPA 
predicted a decrease in activity of three signalling pathways, namely: Endothelin-1 
(Z-score = 1.26, p = 3.8x10-02), RhoGDI (Z-score = 1.63, p = 4.8x10-02) and ‘AMP-
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activated protein kinase’ or AMPK (Z-score = 2.64, p = 4.9x10-02) (Fig. 6.11). 
Conversely, depletion of HBO1 in OVCAR-3 was found to cause the significant 
activation of ‘Interferon Signalling’ pathways (Z-score = 3.46, p = 8.3x10-07). 
 
 
Table 6. 7 List of common altered IPA functions after transient HBO1 KD 
 
Categories Biological function 
Z-score 
UWB1.289 OVCAR-3 
Organismal survival Organismal death -3.26 -2.15 
Cellular movement Migration of cells 1.67 1.89 
Cellular movement Invasion of cells 2.01 2.14 
 
 
Next, the ‘Downstream effects’ feature of IPA was used to predict common 
biological functions affected by transient HBO1 KD in UWB1.289 and OVCAR-3 
cells, which are summarized in Table 6.7 (p-value < 0.05). These data suggest 
prominent roles for HBO1 in OC cell viability (organismal death) and the 
suppression of cell movement (Table 6.7), a feature that had been already predicted 
(but not confirmed experimentally) in previous HBO1 KD studies (Fig. 5.6). 
 
	
Figure 6. 12 IPA downstream effects prediction after HBO1 KD in UWB1.289 
The list of 889 differentially expressed genes (and their associated fold-change 
values) retrieved from the microarray analysis of HBO1 KD in UWB1.289 cells was 
uploaded into the IPA software. The IPA ‘Downstream effects’ feature predicted 
alterations in biological functions, grouped according to IPA categories (e.g. Cellular 
movement), following HBO1 KD. Scale is shown next to the right panel, where 
orange represents pathway activation and blue represents pathway inactivation. Grey 
coloration represents non-affected biological functions. 
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IPA ‘Downstream effects’ predictions in UWB1.289 cells alone infer the activation 
of biological processes including cellular movement and organization, cancer and 
inflammatory responses following transient HBO1 depletion (Fig. 6.12). 
Specifically, some of the activation predictions with the highest Z-score in 
UWB1.289 cells are associated with cellular motion, including the formation of 
filopodia (p = 3.15x10-04), cell invasion (p = 6.45x10-04) and metastasis (p = 5.48x10-
04), suggesting a role for HBO1 in regulating the movement and spread of OC cells 
out of the ovary (Table 6.8). Furthermore, IPA predicted an augmentation in 
cytoplasm (p = 4.85x10-04) and cytoskeleton (p = 5.06x10-05) organization, pointing 
to HBO1-dependant re-arrangements of the cellular internal machinery (Table 6.8). 
A number of these characteristics had been previously predicted in the analyses of 
stable HBO1 KD in UWB1.289 cells (Table 5.2), where cytoskeleton alterations 
caused by the depletion of HBO1 were confirmed by AFM experiments (Fig. 5.7). 
 
 
Table 6. 8 List of altered IPA functions after transient HBO1 KD 
 
 Categories Biological function Prediction Z-score 
U
W
B
1.
28
9 Cellular organization Org. of cytoskeleton Increased 2.31 
Cellular organization Org. of cytoplasm Increased 2.31 
Cancer Metastasis of cells Increased 2.32 
Cellular movement Formation of filopodia Increased 2.42 
O
V
C
A
R
-
3 
Infectious diseases Replication of viral RNA Decreased -3.94 
Infectious diseases Production of virus Decreased -2.57 
Inflammatory response Innate immune response  1.94 
Cellular movement Leukocyte migration Increased 2.19 
 
 
In OVCAR-3 cells, IPA ‘Downstream analysis’ predictions pointed to a role for 
HBO1 in the activation of response against infectious diseases, since processes like 
‘replication of viral RNA’ (p = 1.02x10-19) and the ‘production of viruses’ (p = 
1.97x10-06) were predicted to decrease upon HBO1 depletion (Table 6.8). 
Conversely, a decrease in HBO1 levels was predicted to result in the activation of 
inflammatory responses, an effect also identified by IPA ‘Canonical pathways’. An 
example of the inflammatory response is the activation of the innate immune 
response (p = 1.98x10-09) (Table 6.8). Another biological process identified was 
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‘Leukocyte migration’ (p = 3.77x10-03), which again links HBO1 with the regulation 
of cell motility (Table 6.8). 
 
6.3.2 Gene Set Enrichment Analysis of HBO1 knockdown profiles 
The GSEA software was used to predict which cellular functions were affected by 
the HBO1 KD loss-of-function phenotype in OC cells. To achieve this, each 
normalized microarray dataset was loaded into the GSEA programme, where it was 
converted to a ranked list of differentially expressed genes (‘siHBO1’ versus 
‘siCtrl’). Using the GSEA algorithm, this ranked gene list was compared 
sequentially with a collection of ‘Hallmark Gene-Sets’, representative of well-
defined biological states or processes. If a large proportion of genes that belong to a 
‘Hallmark Gene-Set’ are found at the top of the ranked list of differentially 
expressed genes, the GSEA prediction for this Gene-Set is activation. Conversely, if 
the genes were found at the bottom of the list, the Gene-Set prediction would be 
inactivation. Since the ‘Hallmark Gene-Sets’ represent biological states, processes or 
pathways, GSEA is therefore able to predict the activation/inactivation of biological 
processes or pathways. 
 
 
Table 6. 9 List of common altered Gene-Sets following transient HBO1 KD 
 
Common Hallmark Gene-Sets 
Q-value 
OVCAR-3 SKOV-3 UWB1.289 
IFNα response1 0.0001 0.002 0.0001 
IFNγ response1 0.0001 0.046 0.0001 
k-RAS signalling2 0.0054 0.014 0.001 
EMT3 0.0057 0.002 0.006 
1Genes up-regulated in response to IFNα/γ 
2Genes up-regulated by k-RAS activation 
3Genes defining Epithelial-mesenchymal transition 
 
 
GSEA analysis of OVCAR-3, SKOV-3 and UWB1.289 HBO1 KD profiles 
identified four common altered Gene-Sets, illustrated in Table 6.9. Amongst those, 
GSEA identified the up-regulation of genes associated to IFNα and IFNγ responses, 
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k-RAS signalling activation and epithelial-mesenchymal transition (EMT) (Table 
6.9). The OVCAR-3 GSEA enrichment plot for the IFNα Gene-Set is illustrated in 
Figure 6.13 A, as well as the graphical depiction of some of the genes that integrate 
the corresponding Leading-edge Subset (57) (Fig. 6.13 B). GSEA did not predict 
common alterations of cellular pathways/processes linked to the differential down-
regulation of transcripts (bottom part of the ranked list), likely due to the small 
number of altered genes in some of the datasets and the diversity of associated 
functions. 
 
	
Figure 6. 13 Example of Gene-Set enrichment after HBO1 KD in OVCAR-3 
Normalized microarray data obtained from the expression profiling of OVCAR-3 
cells transfected with ‘siHBO1’ and ‘siCtrl’ was loaded into the GSEA programme. 
(A) The comparative analysis of this data with a series of ‘Hallmarks Gene-Sets’ 
resulted in GSEA predictions anticipating the significant activation of 
pathways/processes upon HBO1 depletion, including an IFNα response. (B) 
Example of the corresponding leading-edge subset. Out of the 96 genes that make up 
the IFNα response Gene-Set, 57 were grouped at the top of the ranked gene list. Red 
colour represents gene up-regulation, whereas blue colour represents down-
regulation. 
 
 
Other GSEA predictions shared by at least two OC cell lines include the activation 
of ‘tumour necrosis factor alpha’ (TNFα) signalling, inflammatory responses and the 
TP53 network (Table 6.10), suggesting a general role of HBO1 in the inhibition of 
immune responses, inflammatory processes and ‘TP53 pathways’, mechanisms 
conventionally linked to OC progression. In addition, GSEA predicted the 
inactivation of the E2F pathway (Table 6.10), which would indicate a role of HBO1 
in the regulation of E2F-related transcription. Interestingly, IPA had predicted the 
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activation of some of these pathways, e.g. TP53 and inflammation (Table 6.10 & 
Fig. 6.11). The fact that GSEA and IPA, which use different statistical methodology, 
predicted the stimulation of analogous pathways suggests a strong link between 
HBO1 and these processes in OC cells. 
 
 
Table 6. 10 List of GSEA activated Gene-Sets after transient HBO1 KD  
 
Hallmark Gene-Sets 
Q-value 
OVCAR-3 SKOV-3 UWB1.289 
TNFα signalling via NF-κβ1 0.002 0.002 -* 
Inflammatory response2 0.006 - 0.01 
TP53 pathways3 - 0.004 0.026 
E2F pathways4 - 0.022 0.021 
*- Non identified Gene-Set 
1Genes regulated by NF-κβ in response to TNFα treatment 
2Genes defining inflammatory response 
3Genes involved in TP53 networks 
4Genes encoding cell cycle related targets of E2F transcription factors 
 
 
6.3.3 Validation of HBO1 KD inflammatory responses 
The activation of immune and/or inflammatory responses (Tables 6.8, 6.9 & 6.10) 
are often regarded as off-target effects of siRNA transfection (Marques & Williams 
2005; Robbins et al. 2009), and therefore the prediction analyses raised doubts about 
the specificity of potential HBO1 activities. 
 
In order to dismiss the possibility that siRNAs caused off-target effects, the 
expression levels of ‘DExD/H-box helicase 60’ (DDX60), ‘interferon induced 
protein 44’ (IFI44) and ‘radical S-adenosyl methionine domain containing 2’ 
(RSAD2), which have major roles in immune responses, were analysed in ‘siHBO1’, 
‘siCtrl’ and ‘Control’ samples (Fig. 6.14). These genes are inducible via IFN 
signalling and were part of the GSEA leading-edge subset of genes predicted to 
activate the IFNα response (Fig. 6.13). 
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Figure 6. 14 Validation of IFN-related gene changes in OVCAR-3 cells 
OVCAR-3 cells were transfected with a pool of siRNAs targeting HBO1 
(‘siHBO1’), as well as with non-targeting siRNAs (‘siCtrl’) and transfection reagent 
alone (‘Control’). Cell lysates were extracted after 48h whereupon RNA samples 
were prepared and analysed by qRT-PCR to confirm the up-regulation of DDX60, 
IFI44 and RSAD2. Relative levels of expression in cells treated with ‘siHBO1’ were 
compared to those of cells treated with ‘siCtrl’ and ‘Control’. RPL5 expression was 
used as control. Statistical analysis consisted of one-way ANOVA and the Tukey’s 
multiple comparison test. All values represent the mean ± SD of three biological 
samples (**p < 0.01; ****p < 0.0001). 
 
 
The expression level of gene transcripts DDX60 (FC = 1.59, p = 0.8036), IFI44 (FC 
= 1.43, p = 0.9274) and RSAD2 (FC  = 1.69, p = 0.6609) was very similar in the 
‘siCtrl’ and the transfection reagent alone samples (‘Control’) (Fig. 6.14). This 
largely suggests a role for HBO1 in this cellular response process, with DDX60 (FC 
= 4.44, **p = 0.0017), IFI44 (FC = 6.74, ****p < 0.0001) and RSAD2 (FC = 7.37, 
****p < 0.0001) significantly up-regulated in the ‘siHBO1’ sample compared to the 
‘Control’ (Fig. 6.14). 
 
 
6.4 In vitro Evaluation of HBO1-predicted Biological Functions 
Based on IPA and GSEA predictions on the activation and/or inactivation of similar 
biological processes and pathways, a number of in vitro assays were undertaken to 
assess the motility, invasiveness, viability and inflammatory responses of HBO1 KD 
cells. 
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6.4.1 Assessment of HBO1 suggested role in cell proliferation 
HBO1 has an essential role in DNA replication (Miotto & Struhl 2010) suggesting 
the possibility that rates of cell proliferation may become altered as a result of HBO1 
KD. To investigate this possibility, UWB1.289, OVCAR-3 and SKOV-3 cells were 
transfected with the correspondent siRNAs (‘siHBO1’ and ‘siCtrl’) for 48h, followed 
by the addition of BrdU for 4h and 24h and the measurement of the resultant 
absorbance. The proliferation assay is based on the use of the labelled nucleoside 
BrdU and its capability to incorporate into newly synthesized DNA of replicating 
cells. 
 
 
Figure 6. 15 Study of cell proliferation after HBO1 KD in OC cells 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with a pool of siRNAs 
targeting HBO1 (‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). After 48h, BrdU 
was added to the cells for 4h and 24h to assess cell proliferation at 450nm. 
Absorbance was measured in duplicates. 
 
 
The comparison of absorbance values between cells labelled with BrdU for 4 and 24 
hours demonstrated the incorporation into active replicative cells (Fig. 6.15). 
However, the transient loss of HBO1 did not significantly affect the rates of cell 
proliferation of any of the studied cell lines (Fig. 6.15), a similar result to that 
obtained previously when using a stable HBO1 KD approach in UWB1.289 cells 
(Fig. 5.5). These findings support IPA and GSEA predictions, which did not identify 
cell proliferation changes as a consequence of HBO1 KD. 
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The results of cell proliferation studies further confirm that HBO1 is not essential for 
DNA replication in OC cells and point to a non-proliferative role for overexpressed 
HBO1 in OC. 
 
6.4.2 Assessment of HBO1 predicted involvement in cell motility 
In order to evaluate the IPA predicted role for HBO1 in cellular movement (Table 
6.7), phenotypical changes were measured using a scratch/wound-healing assay, 
which measures cell migration in vitro. First, UWB1.289, OVCAR-3 and SKOV-3 
were transfected with the correspondent siRNAs (‘siHBO1’ and ‘siCtrl’) for 24h, 
whereupon cells were subjected to trypsin treatment for detachment and subsequent 
re-seeding aiming to obtain a confluent cell monolayer in the next 24h. After this 
(48h of siRNA transfection), a scratch was made and differences in cell migration 
were analysed (Fig. 6.16). In order to confirm the perpetuation of transient HBO1 
KD post-trypsin treatment, samples of re-seeded cells were extracted and analysed 
using qRT-PCR; the transcript levels of HBO1 remained very low (not shown). 
 
	
Figure 6. 16 Example of wound-healing assay after HBO1 KD in OVCAR-3 
OVCAR-3 cells were transfected with a pool of siRNAs targeting HBO1 (‘siHBO1’) 
and non-targeting siRNAs (‘siCtrl’). After 48h, the confluent cell monolayer was 
partially removed by a pipette tip (scratch). Images were taken immediately after the 
scratch (t = 0h) and after 12-24h; ImageJ software was used to calculate cell-free 
area values. The relative area was calculated subtracting cell-free area values at 12-
24h from cell-free area values at t = 0h. Scales represent 100µm. 
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Analyses of wound-healing data did not reveal any differences in scratch closure as 
determined by the relative areas (RA) of ‘siHBO1’ and ‘siCtrl’ transfected cells 12 
or 24 hours after the scratch in any of the studied cell lines (example of OVCAR-3 
assay in Figure 6.16). The analyses of pathway dysregulation elicited by HBO1 KD 
in the SKOV-3 cell line did not include alterations in cell migratory properties 
(Table 6.7), which could explain for the absence of wound-healing assay differences 
in cell populations of SKOV-3. However, both OVCAR-3 and UWB1.289 KD 
profile analyses predicted an activation of gross cell migration (Table 6.7), but 
corresponding phenotypic assay failed to show the expected changes. This lack of 
significant discernible differences was also observed in previous scratch assays 
undertaken with shRNA-transduced UWB1.289 cells (Fig. 5.6). 
 
Specifically, the differential expression of 25 (OVCAR-3) and 30 (UWB1.289) 
genes was associated with the activation of cell migration (Table 6.7). In OVCAR-3, 
some of these genes included: up-regulated BST2 (FC = 2.79), the ‘C-X-C motif 
chemokine 11’ (CXCL11, FC = 1.8), the ‘lymphoid enhancer binding factor 1’ 
(LEF1, FC = 1.67) and STAT1 (FC = 1.97), as well as down-regulated keratin 16 
(KRT16, FC = -1.5) and endothelin-2 (EDN2, FC = -1.72). This group of genes 
displayed significant up/down-regulatory trends –some of which were corroborated 
using qRT-PCR– and have been previously linked to the promotion of cell migration 
(X. Gao et al. 2014). However, alterations of this set of genes alone may not have the 
ability to drive gross cell motility changes that can be observed in vitro. This 
suggestion is supported by the low z-score values obtained from the pathway 
analysis (Cell migration: OVCAR-3 1.89, UWB1.289 1.67; Table 6.7), which 
highlight the weakness of the prediction. Accordingly, HBO1 does not appear to be 
controlling this pathway in OC cells. 
 
6.4.3 Assessment of HBO1 predicted involvement in cellular invasion 
In order to evaluate the IPA predicted role for HBO1 in cellular invasion (Table 
6.7), a CytoSelect™ cell invasion assay was undertaken. This assay utilises a 
basement membrane that serves as a barrier to discriminate invasive from non-
invasive cells, depending on their ability to degrade proteins in the layer and pass 
through the generated pores. 
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First, UWB1.289, OVCAR-3 and SKOV-3 were transfected with the correspondent 
siRNAs (‘siHBO1’ and ‘siCtrl’) for 24h, whereupon cells were subjected to trypsin 
treatment for detachment. Subsequently, cell suspensions (7x105 cells/mL) were 
added to the basement membrane layer for 24h or 48h of incubation. 
 
	
Figure 6. 17 Study of cell invasiveness after HBO1 KD in OC cells 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with a pool of siRNAs 
targeting HBO1 (‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). After 24h, cells 
were transferred to CytoSelect™ wells containing a basement membrane layer and 
allowed to invade toward 10% FBS for 24 and 48h. Invasive cells on the bottom of 
the invasion membrane were stained and quantified at 560nm. Absorbance of the 
final solution was measured in duplicates. 
 
 
Measuring the absorbance of the solutions containing invasive cells that have 
migrated through the membrane did not reveal any differences between KD and 
control samples in any of the studied cell lines (Fig. 6.17). Similar to the previous 
situation with cell migration predictions, pathway analyses of the SKOV-3 KD 
profile did not anticipate alterations in the invasive properties of cells, suggesting 
that HBO1 is not involved in this pathway in SKOV-3 cells. On the other hand, 
OVCAR-3 and UWB1.289 KD profile analyses predicted an activation of gross cell 
invasion (Table 6.7), but corresponding phenotypic assay failed to show the 
expected changes (Fig. 6.17). 
 
The differential expression of 22 (OVCAR-3) and 98 (UWB1.289) genes was 
associated with the activation of cell invasion (Table 6.7). In UWB1.289, some of 
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these genes included: up-regulated matrix metallopeptidases 2/9 (MMP2, FC = 1.52, 
MMP9 FC = 1.80), MUC16 (FC = 2.40) and E-cadherin (CDH1, FC = 1.67), as well 
as down-regulated YAP1 (FC = -1.84) and the ‘snail family transcriptional repressor 
2’ (SNAI2, FC = -1.65). In this case, both z-score values for predicted activation 
were significantly higher than those anticipating changes in cell migration (Cell 
invasion: OVCAR-3 2.14, UWB1.289 2.01; Table 6.7), and yet these findings 
suggest that HBO1 is not significantly linked to cell invasion in OC. However, since 
invasiveness requires several distinct cellular functions including adhesion, motility, 
detachment and extracellular matrix proteolysis, it is possible that HBO1 may be 
involved in the regulation of other processes, although it is not able to affect the 
process of cellular invasion in the studied in vitro conditions. 
 
6.4.4 Assessment of HBO1 predicted involvement in cell viability 
IPA ‘Downstream effects’ analysis predicted that transient KD of HBO1 in 
UWB1.289 and OVCAR-3 lines might affect cell viability (Table 6.7: Biological 
function - Organismal survival). In order to evaluate this prediction in vitro, 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with the correspondent 
siRNAs (‘siHBO1’ and ‘siCtrl’) for 48h, whereupon cells were subjected to the 
ApoTox-Glo™ triplex assay. This test combines three assay chemistries to easily 
assess cell viability, cytotoxicity and apoptosis events (caspase activity) in the same 
cell-based assay well. 
 
The decrease in HBO1 transcript and protein levels led to a significant augmentation 
of cell viability in UWB1.289 (*p = 0.0238), OVCAR-3 (*p = 0.0144) and SKOV-3 
(*p = 0.0482) (Fig. 6.18 A). This increase in viability was accompanied by a 
significant reduction in cell cytotoxicity in the UWB1.289 cell line (*p = 0.0369), 
whereas both OVCAR-3 (p = 0.7386) and SKOV-3 (p = 0.8842) displayed 
substantial variability (Fig. 6.18 B). All three OC cell lines showed a decline of 
caspase activity, indicating a general reduction of apoptotic processes: UWB1.289 
(*p = 0.0314), OVCAR-3 (*p = 0.0478), SKOV-3 (p = 0.0537) (Fig. 6.18 C). 
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Figure 6. 18 Study of cell viability, cytotoxicity and apoptosis after HBO1 KD 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with a pool of siRNAs 
targeting HBO1 (‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). After 48h, changes 
in (A) cell viability, (B) cytotoxicity and (C) caspase activity were measured using 
the ApoTox-Glo™ triplex assay. Relative cell values represent proportional 
differences between HBO1 KD and the correspondent ‘siCtrl’ raw measurements; 
only one control was plotted for simplification. (D) UWB1.289 protein extracts were 
analysed by western blot and probed with anti-CypA and anti-GAPDH antibodies. 
GAPDH was used as loading control. Statistical analyses consisted of one-way 
ANOVA and Tukey’s multiple comparison tests. All values represent the mean ± SD 
of three biological samples (*p < 0.05; **p < 0.01). 
 
 
To further investigate the reduction of cell death in HBO1 KD UWB1.289, protein 
lysates were analysed for Cyclophilin A (CyPA or PPIA). This protein is a 
biomarker of necrotic death or necroptosis, a caspase-independent form of 
programmed cell death linked to inflammatory processes (Christofferson & Yuan 
2010). HBO1 KD in UWB1.289 cells led to a significant reduction in the protein 
levels of CyPA/PPIA (RD = 39.35 ± 6.64%, *p = 0.04) (Fig. 6.18 D), supporting the 
ApoTox-Glo™ results that pointed to UWB1.289 cells being generally less apoptotic 
in the absence of HBO1. 
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These findings support a general role for HBO1 in the regulation of cell viability, 
agreeing with in silico predictions that linked HBO1 KD with organismal death 
(assuming that the death of an organism implies the death of the different cells that 
compose it) in the three studied cell lines (Table 6.7). 
 
6.4.5 Assessment of HBO1 predicted involvement in inflammatory responses 
HBO1 KD in UWB1.289, OVCAR-3 and SKOV-3 cell lines led to the up-regulation 
of genes involved in the response to IFNα and IFNγ (Table 6.9). Cellular membrane 
interactions of different cytokines are known to elicit the activation of IFN pathways, 
which trigger anti-viral, anti-tumour, anti-proliferative and immune-regulatory 
functions in cells, as well as the release of new IFN molecules (Haller et al. 2006; 
Kalliolias & Ivashkiv 2010). In order to evaluate whether the response to IFNα and 
IFNγ in OC cells triggers the secretion of newly synthesized IFNs, enzyme-linked 
immune-sorbent assays (ELISAs) were performed. 
 
Prior to the ELISAs, IFNA, IFNG and IFNB (non-activated control) expression 
levels of untreated cells were determined by qRT-PCR in UWB1.289, OVCAR-3 
and SKOV-3. IFNG was not present in any of the cell lines, suggesting very low 
expression levels that would make it difficult to detect via ELISA. These results are 
not uncommon, since the expression of type II IFNG is known to be limited to 
immune cells (e.g. T cells) (Schroder et al. 2003). In contrast, IFNB expression was 
detected in all OC cell lines, whereas IFNA expression was limited to OVCAR-3 and 
SKOV-3. 
 
Following HBO1 KD in UWB1.289, OVCAR-3 and SKOV-3 cells, the culture 
medium was analysed for IFNs, and IFN cellular mRNA levels determined (Fig. 
6.19). HBO1 KD led to a significant increase of IFNA transcripts in OVCAR-3 cells 
(FC = 1.59, *p = 0.0478) (Fig. 6.19 A). UWB1.289 cells did not express any 
detectable IFNA transcripts, while the expression levels in SKOV-3 cells appeared 
variable between experiments (FC = 2.09, p = 0.7731). None of the OC cells lines 
displayed significant changes in IFNB expression: UWB1.289 (FC = 0.962, p = 
0.7941), OVCAR-3 (FC = 1.12, p = 0.8566), SKOV-3 (FC = 1.35, p = 0.7689) (Fig. 
6.19 A). 
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Figure 6. 19 IFN production and secretion after HBO1 KD in OC cells 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with a pool of siRNAs 
targeting HBO1 (‘siHBO1’) and non-targeting siRNAs (‘siCtrl’). (A) Cell lysates 
were extracted after 48h whereupon RNA samples were prepared and analysed by 
qRT-PCR to assess the expression of IFNA/B. Relative levels of expression in cells 
treated with ‘siHBO1’ were compared to those of cells treated with ‘siCtrl’. GAPDH 
expression was used as control. (B) Cell media was extracted after 48h and analysed 
by ELISA. Sample measurements were compared to standard curves. Statistical 
analyses consisted of one-way ANOVA and Tukey’s multiple comparison tests. All 
values represent the mean ± SD of three biological samples (*p < 0.05). 
 
 
The increase in IFNA expression levels in OVCAR-3 cells (Fig. 6.19 A) 
corresponded with the detection of higher levels of IFNα in the sample medium (*p 
= 0.0437) (Fig. 6.19 B). For UWB1.289 and SKOV-3 cell lines, there were no 
significant differences in IFNα concentration in the media (Fig. 6.19 B). Similarly, 
IFNβ-ELISA experiments revealed no differences and IFNγ was undetectable by 
ELISA in all OC cell lines. These data support the predicted role of HBO1 
modulating IFNα in OVCAR-3 cells but not in UWB1.289 and SKOV-3, 
demonstrating that there are limitations suggesting inaccuracies in the prediction 
software. 
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6.6 Discussion 
In order to further extend our knowledge about the roles of HBO1 in OC, 
UWB1.289, OVCAR-3 and SKOV-3 cells were transfected with siRNAs targeting 
HBO1 and subsequently monitored for gene and phenotypical alterations. First, 
nucleosome targets histone H4 and H3K14 were evaluated using acetylation-specific 
antibodies. Transient HBO1 KD resulted in the decrease of H4 acetylated residues in 
all OC cell lines (Fig. 6.1 & Fig. 6.2), supporting a major role for HBO1 in the 
regulation of cellular H4 bulk acetylation. These results agree with previous findings 
observed in UWB1.289 cells expressing shRNAs targeting HBO1 (Fig. 5.1 & Fig. 
5.2), as well as with a number of previous RNAi-based studies (Table 1.7). 
Conversely, and again in accordance with previous observations (Fig. 5.1 & Fig. 
5.2), HBO1 transient KD did not affect histone H3K14 acetylation (Fig. 6.1 & Fig. 
6.2). 
 
Microarray analyses of gene expression changes caused by HBO1 transient depletion 
identified asymmetrical, yet compelling numbers of differentially expressed genes 
(Table 6.5). The largest number of HBO1 KD altered transcripts (889) was 
identified in the UWB1.289 cell line (Table 6.4), whereas a much smaller number of 
altered transcripts were identified in OVCAR-3 (155) and SKOV-3 (80). The 
number of genes identified was higher using this approach compared to using an 
shRNA approach (Table 5.1), which may be due to the differences in reduction of 
HBO1 expression levels, as well as the use of different cell lines. These differences 
could also reflect distinctive function for the HAT in diverse cancer stages/histo-
types, which remains to be elucidated in primary tumour samples. 
 
In order to analyse in depth the roles of HBO1 in OC, pathway analyses were 
implemented, followed by the in vitro confirmation of predicted phenotypes. IPA 
and GSEA analyses of the transient HBO1 KD expression profiles predicted 
differences and similarities on the functions of HBO1 in the three studied OC cell 
lines (Tables 6.7, 6.8, 6.9 & 6.10). Interestingly, some of these predictions (activated 
cell movement, reduction of cell death) were also anticipated by IPA analysis of 
HBO1 dependent genes in HeLa cells (Avvakumov et al. 2012), suggesting that 
certain HBO1-associated functions can be extrapolated to other cell lines with 
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different origins. Notably, GSEA predicted common HBO1 dependent effects on (1) 
IFN responses, (2) k-RAS signalling and (3) the activation of epithelial-
mesenchymal transition (Table 6.9). 
 
IFNs are a group of pleiotropic cytokines released in response to the presence of 
pathogens (e.g. viruses, bacteria and also tumour cells) with the consequence of 
causing nearby cells to enhance their anti-pathogenic defences (Haller et al. 2006). 
IFN signalling regulates the expression of many genes that could affect tumour cell 
growth, proliferation, differentiation, survival, migration or other specialized 
functions and interestingly, IFN signalling can either stimulate or suppress cellular 
immune response, depending on the targets of the IFN effects (e.g. cancerous, 
immune cells) and the nature of the IFN signalling pathway (Minn 2015). These data 
suggest that overexpressed HBO1 in OC could act as a negative regulator of: anti-
tumorigenic immune-stimulatory signals or pro-tumorigenic immune-suppression. 
The negative regulation of IFN production (e.g. IFNB) was previously observed with 
other HATs such as GCN5 and PCAF in several cell types (Jin et al. 2014). 
Interestingly, PCAF was down-regulated after HBO1 KD in all studied OC cell 
lines, suggesting a link between HBO1, PCAF and the inhibition of immune 
signalling. Nonetheless, the activation of IFN signalling was only confirmed in 
OVCAR-3 cells using IFNα-ELISA (Fig. 6.19). 
 
The activation of k-RAS signalling pathways involves the up-regulation of genes 
commonly associated with k-RAS activation, an oncogene involved in proliferation, 
differentiation, survival and other essential cellular mechanisms (Karnoub & 
Weinberg 2008), suggesting a role for HBO1 in the inhibition of oncogenic 
transformation. Interestingly, the over-expression of HBO1 was shown to have a 
modest inhibitory effect on the h-RAS induced transformation of NIH-3T3 fibroblast 
cells (Johmura et al. 2008), highlighting the possible links of another member of the 
RAS signalling family with HBO1 and cancer. 
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EMT is a biologic process that causes epithelial cells to lose their polarity and inter-
cellular adhesion capabilities, subsequently driving their migratory and invasive 
properties as mesenchymal stem cells (Yeung & Yang 2017). The up-regulation of 
genes that define epithelial-mesenchymal transition upon HBO1 KD suggests the 
involvement of HBO1 in the OC-associated acquisition of invasive properties. 
Interestingly, previous analysis of stable HBO1 KD phenotypes also pinpointed this 
characteristic role (Fig. 5.7), highlighting the importance of HBO1 in cancer 
differentiation. In fact, the association of HBO1 with cancer differentiation has been 
previously shown in 76NE6-LMW-E breast cancer cells (Table 1.7), where HBO1 
KD reduced cancer stem cell properties (e.g. mammosphere formation) and the 
expression of certain EMT gene markers, including CCNE1, E-cadherin (CDH1), N-
cadherin (CDH2), vimentin (VIM), the ‘twist family BHLH transcription factor 1’ 
(TWIST1) and the ‘snail family transcriptional repressor 2’ (SNAI2) (Duong et al. 
2013). 
 
Some of these effects had also been predicted using IPA in one or two OC cell lines. 
IPA predicted the significant activation of IFN signalling pathways in OVCAR-3 
and the enhancement of cell migration/invasion in both OVCAR-3 and UWB1.289 
(Table 6.7). However, and similar to the shRNA approach on UWB1.289 cells, the 
predicted increase in cellular migratory and invasive capacities was not confirmed by 
scratch/wound healing or invasion assays in UWB1.289, OVCAR-3 or SKOV-3 
cells (Fig. 6.16 & Fig. 6.17). Interestingly, the IPA ‘Downstream effects’ predicted 
HBO1-dependent changes in cell viability in OVCAR-3 and UWB1.289, a feature 
that was confirmed by viability, cytotoxicity and caspase activity assays in the three 
OC cell lines (Fig. 6.18). These results suggest a role for HBO1 in a live-dead 
balance and specifically point to repressive actions on the apoptotic-related death of 
cancerous cells. In this regard, it is worth highlighting the role of HBO1 as a 
regulator of CDKN1A/p21, a TP53 transcription target implicated in cell cycle arrest 
and apoptosis inhibition (Jänicke et al. 2007; Abbas & Dutta 2009). CDKN1A was 
up-regulated following transient HBO1 KD in UWB1.289 cells (Fig. 6.10), a 
phenomenon that agrees with the observed diminution of caspase activity (Fig 6.18). 
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The considerable number of differentially expressed genes identified after HBO1 
KD in UWB1.289 resulted in the highest number of predictions for the involvement 
of HBO1 in specific processes. For instance, IPA ‘Canonical pathways’ predicted the 
significant alteration of 6 biological pathways in UWB1.289 (Fig 6.11), of which the 
three potentially activated processes (basal cell carcinoma, leukocyte extravasation 
and p53 signalling) involve well-known cancer features and suggest a role for HBO1 
in oncogenic transformation. The development of basal cell carcinoma, and therefore 
the activation of ‘basal cell carcinoma signalling’ pathways, is related to the de-
regulation of the sonic hedgehog pathway, whose activation is implicated in several 
cancers and entails the increase of stem-like characteristics of cancer cells (Epstein 
2008). Interestingly, tumorigenic activation of the sonic hedgehog pathway has been 
reported in OC (Schmid et al. 2011), suggesting potential links between HBO1 and 
components of the pathway. Leukocyte extravasation is the movement of leukocytes 
out of the circulatory system and to the site of injury or infection, in order to trigger 
the subsequent immune response (Muller 2013). Accordingly, predicted HBO1-
associated suppression of this phenomenon in UWB1.289 cells agrees with previous 
observations that linked HBO1 with the inhibition of immune responses. The 
activation of ‘TP53 signalling’ pathways following HBO1 KD, also predicted by 
GSEA in SKOV-3 and UWB1.289 (Table 6.10), suggests a role for HBO1 in the 
regulation of the TP53-CDKN1A axis. 
 
Predictions regarding process inhibition upon HBO1 KD (Endothelin-1, RhoGDI 
and AMPK signalling) are also involved in cancer progression, suggesting 
conflicting roles for HBO1 in OC. The endothelin-1 (EDN1) axis is involved in 
cancerous cell proliferation, survival and neovascularization, amongst other roles, 
and its aberrant activation is recognized as a common mechanism underlying the 
progression of OC (Rosanò et al. 2013). AMP-activated protein kinase (AMPK) is an 
important mediator in maintaining cellular metabolic/energy homeostasis, situated in 
the centre of a signalling network involving established TSGs (e.g. TP53) that can 
exert pro- or anti-tumorigenic roles in cancer (Faubert et al. 2015). Interestingly, 
activation of AMPK suppresses the growth of OC malignant cells (Li et al. 2014; 
Yung et al. 2016), suggesting a pro-oncogenic role for HBO1 in the regulation of 
this network. RhoGDIs are signal transducers that control the location and activity of 
Rho guanosine triphosphate (GTP)-ases, and thus mediate several processes during 
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tumorigenesis and cancer progression (Harding & Theodorescu 2010). One member 
of the RhoGDI family (RhoGDI2) was found to antagonize OC growth, invasion and 
metastasis (Stevens et al. 2011), suggesting that the inhibition of ‘RhoGDI 
signalling’ may entail the promotion of cancerous properties and therefore an anti-
oncogenic role for overexpressed HBO1. 
 
Rho GTPases represent a family of small GTP-binding proteins involved in cell 
cytoskeleton organization, amongst other functions (Parri & Chiarugi 2010). 
Notably, predicted HBO1 KD-associated inhibition of ‘RhoGDI signalling’ in 
UWB1.289 cells was accompanied by IPA predictions of increased 
cytoskeleton/cytoplasm organization (Table 6.8). These results are consistent with 
the promotion of higher levels of cellular organization (e.g. enhanced microtubule 
dynamics), a feature that was also observed in UWB1.289 cells expressing shRNAs 
targeting HBO1 (Fig. 5.7), but this time phenotypical changes were not confirmed in 
vitro. One possibility for the negative AFM results using siRNAs could be the lack 
of treatment uniformity, given the absence of a marker indicating the cells in which 
HBO1 was in fact down-regulated (e.g. GFP) and that only a handful of cells were 
analysed at random due to the current limitations of AFM analysis. 
 
Other potential inhibited processes identified in SKOV-3 and UWB1.289 (GSEA) 
are the ‘E2F pathways’ (Table 6.10). The E2F family encompasses a group of genes 
that codify transcription factors critical in cell cycle control (Ahlander & Bosco 
2009) and its inhibition points to a role for HBO1 in cell cycle regulation. However, 
these predictions could not be confirmed since cell growth rates remained unchanged 
following HBO1 KD in the three OC cell lines (Fig. 6.15). 
 
Transcript levels of 13 genes, including HBO1, were similarly altered in three OC 
cell lines, revealing a small ‘HBO1 OC signature’ (Fig. 6.7). These common 
transcripts likely represent the core functionality of HBO1 in specific cellular 
processes involving these genes. Three ‘HBO1 OC signature’ genes have been 
linked to OC and other cancerous malignancies: CD46, H2AFY and YAP1. 
Interestingly, these transcripts were also down-regulated following HBO1 KD in 
UACC-1598 and TOV-112D cell lines (Fig. 6.9), suggesting a strong association of 
these genes with HBO1 across OC cell-types. 
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CD46 is a ubiquitously expressed membrane protein, whose main function is 
associated with the regulation of the complement system and plays other roles in 
immunity, autophagy and cell adhesion (Tang et al. 2016). This protein is commonly 
overexpressed in cancer tissues of the ovary, breast and lung, amongst others, with 
the aim to evade the immune system (Fishelson et al. 2003). In fact, CD46 
expression is indicative of shorter revival-free survival for OC patients (Surowiak et 
al. 2006). H2AFY encodes a H2A histone variant (often called macroH2A1) that 
usually marks repressed autosomal chromatin and participates in stable X 
chromosome inactivation (Ladurner 2003). However, H2AFY also positively 
regulates transcription when located in the transcribed regions of certain gene 
subsets (Gamble et al. 2010). This protein has two different isoforms (macroH2A1.1 
and macroH2A1.2) that are expressed with similar levels in normal adult cells, but 
differ in cancerous tissues (Monteiro et al. 2014). Notably, the percentage of 
macroH2A1.1 compared to total macroH2A1 was significantly reduced in OC 
samples compared to the percentage in the normal controls, a feature that has been 
commonly linked to tumours with poor prognosis (Novikov et al. 2011). YAP1 is a 
main downstream nuclear effector of the Hippo signalling pathway, which regulates 
tissue homeostasis, cell proliferation, organ size and regeneration (Moroishi et al. 
2015). Dysregulation of the Hippo pathway is associated with cancer development 
and overexpression of YAP1 has been reported in OC (Steinhardt et al. 2008), where 
it is thought to act as an oncogene (X. Zhang et al. 2011). 
 
Accordingly, the down-regulation of CD46, H2AFY and YAP1 as a consequence of 
HBO1 KD suggests a role for HBO1 contributing to their pro-oncogenic 
overexpression. In addition, common gene regulation analyses also point to a 
tumorigenic role of HBO1 in OC cell lines, since 11 of the 12 targets were down-
regulated following HBO1 depletion (Fig. 6.7 B). However, the basal expression 
levels of CD46 and YAP1 did not display significant increasing trends, and only 
H2AFY was highly expressed in all OC cell lines compared to the control (H2AFY 
qRT-PCR primers target both macroH2A1.1 and macroH2A1.2 isoforms). Notably, 
none of the ‘HBO1 OC signature’ genes were identified as differentially expressed 
genes in HeLa, suggesting an OC-specific regulation. Further implications of these 
findings are examined in the final discussion. 
 
	
 
7. Discussion 
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High-grade serous carcinoma is the most common and aggressive OC histo-type and 
its lethality is mainly due to the asymptomatic nature of early disease and the lack of 
effective treatment strategies for advanced conditions. With the exception of PARP 
inhibitors, and to some extent anti-angiogenic drugs like Bevacizumab, existing 
therapies ultimately yield disappointing results. Hence, the identification of 
druggable target molecules with key roles in HGSC phenotype and progression 
could facilitate the development of new therapies. In this scenario, the ‘histone 
acetyltransferase binding to ORC-1’ (HBO1, KAT7 or MYST2) was found 
overexpressed in a number of primary ovarian serous carcinomas (Iizuka et al. 
2009). HBO1 is a nuclear protein, member of the MYST family of HATs (N 
Avvakumov & Côté 2007), that functions within large multi-protein complexes and 
has roles in DNA replication and transcription (Doyon et al. 2006; Iizuka et al. 2006; 
Avvakumov et al. 2012). More importantly, HBO1 is an epigenetic regulator, 
specifically a ‘writer’, responsible for bulk H4K5, 8, 12, 16 and H3K14 acetylation 
(Iizuka et al. 2009; Kueh et al. 2011). Several lines of evidence suggest that HBO1 
may play important roles in the OC phenotype and therefore could represent an 
interesting novel target that circumvents reliance on infrequent mutated genes. 
 
The results of this study confirm the overexpression of HBO1, both at transcript and 
protein level, in representative OC cell lines compared to the HOSEpiC control (Fig. 
3.1 & Fig. 3.6). These findings are similar to overexpression of HBO1 in breast 
cancer cell lines (e.g. MCF-7, T47D) and bone osteosarcoma (Saos-2) cells (Iizuka 
et al. 2009; Duong et al. 2013), whereas conversely HBO1 expression was 
suppressed in acute myeloid leukaemia patients (Sauer et al. 2015), demonstrating 
the disease specific dysregulation of this protein. Additionally, other studies have 
documented overexpression of other HATs in a variety of carcinogenic 
malignancies, e.g. p300 in breast and prostate cancer (Debes et al. 2003; Xiao et al. 
2011), suggesting that overexpression of ‘writers’ may play a significant role in 
cancer, possibly through the up-regulation of oncogenes via acetylation of the 
regulatory regions of these genes (Di Cerbo & Schneider 2013). 
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HBO1 transcript levels were highest in the group of cell lines representative of a 
serous subtype, suggesting possible links between HBO1 expression and the histo-
type. Interestingly, two of the cell lines that displayed lower levels of HBO1 
expression, the mucinous COV644 and the clear-cell TOV-21G, were derived from 
un-treated patients, whereas OVCAR-3, UWB1.289 and SKOV-3 cell lines were 
derived from platinum-treated (OVCAR-3, UWB1.289) and non-platinum-treated 
(SKOV-3) patients diagnosed with HGSC. This suggests that HBO1 overexpression 
could, in some cases, be a side effect of the treatment with the potential outcome of 
increasing the resistance to chemotherapy (Koussounadis et al. 2014), although none 
of the cell lines display significant resistance according to previous studies (Beaufort 
et al. 2014). Furthermore, the endometrioid TOV-112D cell line, derived from an un-
treated patient, showed high levels of HBO1, suggesting that chemotherapeutic 
treatment may not be the only cause of elevated HBO1 in OC models. 
 
HBO1 is expressed as a number of splice isoforms, the overexpression of which does 
not appear to be linked to cancer type or patient treatment (Fig. 3.3). In general 
terms, most transcript isoforms were overexpressed in every cell line compared to 
HOSEpiC, pointing to a cancer-related promoter deregulation phenomenon (e.g. 
DNA de-methylation or histone [auto-] acetylation). Certain isoforms, however, 
were not up-regulated in specific cell lines, for instance, isoforms 3 and 5 were 
unchanged in TOV-112D compared to HOSEpiC (Fig. 3.3 & Appendix Fig. 1 C, 
E). These results suggest that the expression of specific isoforms of HBO1 
transcription is cell line dependant. 
 
All OC cell lines displayed overexpression of HBO1 splice isoform 1 or 2 (Fig. 3.3 
& Appendix Fig. 1 A, B), which corresponded with the only protein isoforms 
detected by western blot, and therefore considered the most abundant variants of 
HBO1 (Fig. 3.4). While the RNA-seq analysis obtained from shRNA-transduced 
UWB1.289 cells pinpointed all HBO1 variants amongst the 58,215 identified gene 
transcripts, isoforms 3, 4 and 5 displayed a very low effective count in both the 
control and KD samples, which translates to low basal transcript expression. 
Conversely, the effective count of HBO1 isoforms 1 and 2 was high in both control 
and KD samples (yet significantly higher in the control compared to the KD due to 
effective HBO1 silencing) (Table 5.1), further confirming the predominance of these 
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isoforms in the global HBO1 transcript composition. Microarray analyses did not 
identify HBO1 variants, as the human whole-genome expression Illumina® 
microarray incorporates bead probes corresponding only to HBO1 isoform 1. 
 
HBO1 protein analysis revealed a molecular weight that was different to the 
predicted 70 KDa for the unmodified protein (based on translation of the DNA 
sequence), as western blot exposed a smeared band that ranged from approximately 
67 KDa to 75 KDa (Fig. 3.4 B). Moreover, UACC-1598 cells exhibited additional 
bands in the 90-100 KDa range. These observations suggest that HBO1 is very likely 
to undergo post-translational modifications, which would lead to altered HBO1 
activity (Legube & Trouche 2003). PTMs are essential mechanisms used by 
eukaryotic cells to modulate protein function, influencing enzyme activity, protein 
turnover, localization, protein-protein interactions and most importantly coordinating 
signalling networks and pathways (Karve & Cheema 2011). Accordingly, cancer-
associated PTM defects can trigger the functional modifications of key regulatory or 
structural proteins, resulting in aberrant cell physiology, structural integrity and gene 
expression, thus favouring cancer progression (Krueger & Srivastava 2006). 
 
The HBO1 protein encompasses a number of motifs that are known to undergo 
PTMs, including phosphorylation, acetylation and ubiquitination (Fig. 7.1), a 
number of which have been documented in vitro (Wu & Liu 2008; Duong et al. 
2013; Matsunuma et al. 2015). The serine-rich domain of HBO1 is thought to be 
hyper-phosphorylated under normal conditions (Miotto & Struhl 2011), but few 
phosphorylation targets have been linked to changes in HBO1 activity. One of the 
sites that has been characterised is Ser57, the mutation of which eliminated its ability 
to be phosphorylated, resulting in decreased histone H4 acetylation activity of HBO1 
in HeLa cells, suggesting that phosphorylation of Ser57 is involved in modulating the 
HAT activity of HBO1 (Wu & Liu 2008). This observation was supported by others, 
as recombinant HBO1 protein expressed in E.coli had no detectable HAT activity 
(Iizuka & Stillman 1999), possible due to the lack of eukaryotic PTMs. 
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Figure 7. 1 Schematic depiction of potential HBO1 protein PTMs 
The HBO1 protein encompasses 65 phosphorylation sites (including serine, 
threonine and tyrosine residues), 21 acetylation sites and 8 ubiquitination sites, 
according to PTM predictors NetPhos (Blom et al. 1999), PAIL (Li et al. 2006; Deng 
et al. 2016) and UbPred (Radivojac et al. 2010). Each vertical line represents a 
potential PTM site. The density of phosphorylation sites within the Ser-rich (serine 
rich) domain is so high that sites are represented by a numeral. Phos: 
Phosphorylation; Ac: Acetylation; Ub: Ubiquitination; NTD: Amino-terminus 
domain; ZNF1, 2: Zinc finger 1 and 2; NLS: Nuclear localization signal; LAT: 
Lysine acetyltransferase domain; CTD: Carboxyl-terminus domain. 
 
 
Based on the literature and the specific composition of the HBO1 protein (Fig. 7.1), 
phosphorylation seems to be the most plausible source of protein size modifications. 
However, the addition of phosphate groups, which increase the weight of the target 
protein in approximately 0.08 KDa (Parker et al. 2010), would not explain the 
existence of additional bands observed in UACC-1598 cells in the 90-100 KDa 
range (Fig. 3.4 A), similarly neither would the addition of acetyl- groups, which 
cause a mass shift of only 0.042 KDa (Parker et al. 2010). In contrast, protein 
ubiquitination involves the attachment of 8.8 KDa ubiquitin molecules, and can 
result in mono-ubiquitination, multi-ubiquitination or poly-ubiquitination (addition 
of a chain of ubiquitin molecules to one protein residue) (Parker et al. 2010; 
Sadowski et al. 2012), and have been previously reported to mark HBO1 proteins 
(Zou et al. 2013). 
 
In order to assess the presence of ubiquitin molecules attached to HBO1, the protein 
was immune-precipitated and probed with an ubiquitin-specific antibody. The 
absence of ubiquitin-marked bands/smears in the gel suggests that the observed 
differences in the predicted molecular weight of HBO1 in UACC-1598 cells are not 
the result of protein ubiquitination (Fig. 3.5). Due to the presence of such an 
extensive array of putative phosphorylation sites within HBO1, the observed mass 
change may be due to phosphorylation of a number of these sites, and the size 
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deviation could be attributed to a shift in the charge as well as mass, which may 
affect protein mobility in SDS-PAGE. This, however, remains to be tested. 
 
It was confirmed that HBO1 is active in OC cells, since transient and constitutive 
HBO1 KD led to significant reductions in bulk histone H4 acetylation (Figs. 5.1, 5.2, 
6.1 & 6.2). These findings have been extensively discussed earlier and the main 
HBO1 acetylation targets in several KD studies are presented in Table 1.7 for 
comparison. Even though none of the KDs affected H3K14 acetylation levels, the 
evaluation of the capability of HBO1 to acetylate other lysine targets within the 
histone H3 tail might contribute to expand the current knowledge of its molecular 
range of action in cancer. Future objectives may include H3K9, an acetylation target 
that was found marginally regulated by HBO1 in a number of studies and has been 
linked to OC tumour progression (Zhen et al. 2010; Mishima et al. 2011; Yan et al. 
2016), but could also involve different histone targets such as H2A and H2B, which 
have never been linked to HBO1 activity before. 
 
The manipulation of cells with the FLAG-tagged expression vector pCMV-Tag2B-
hHBO1 increased HBO1 expression both at mRNA and protein level (Fig. 4.16 A & 
Fig. 4.17), yet did not promote enhanced acetylation of histone H4 in shRNA-
transduced UWB1.289 cells (Fig. 5.3). A similar phenomenon was reported by Foy 
et al. (2008), who observed that transfected HBO1 protein did not enhance H4 
acetylation in human embryonic kidney (HEK) 293T cells, unless either JADE1L or 
JADE1S was also ectopically co-expressed (Foy et al. 2008). This suggests that 
assembly and stabilization of the HBO1 complex may require specific 
concentrations of HBO1 and JADE proteins, e.g. JADE1 (L or S), in order to drive 
H4 acetylation (Foy et al. 2008). In support of this hypothesis, UWB1.289 cells 
showed relative low JADE1 and high JADE2 transcript levels compared to 
HOSEpiC (Fig. 3.20), suggesting that a presumable cell line specific shift in the 
HBO1 complex composition would retain enough JADE protein expression as to 
allow the successful acetylation of H4. In addition, the transfection of pCMV-
Tag2B-hHBO1 in stable HBO1 KD UWB1.289 cells did not affect the levels of 
HDAC6, SNAP47, PCM1 or PMS2 gene transcripts (data not shown), considered 
HBO1 targets as their expression was altered following HBO1 depletion (Fig. 5.4). 
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Several attempts were made to examine the localization of HBO1 in the OC genome, 
either via ChIP-qRT-PCR or ChIP-Seq, but none of these demonstrated any 
significant enrichment of HBO1 in the genome of OC cell models. CYR61 and 
ERBB2, potential HBO1 targets derived from SQL correlations and tested for ChIP 
enrichment (Fig. 3.16) were identified as HBO1 targets in UWB1.289 cells through 
the analysis of microarray KD data. However, ChIP did not reveal HBO1 at the 
promoter region of these genes, highlighting the difficulties in ‘ChIPing’ 
endogenous HBO1. ChIP-Seq, if successful, would have provided insights into the 
way the HBO1 regulatory network performs its functions. For instance, it would 
have provided evidence of targets directly regulated by HBO1 via promoter binding, 
as oppose to protein-protein interactions, as well as association with known histone 
marks. 
 
The potential reasons for this lack of success have been already extensively explored 
earlier, and point to the inability to immune-precipitate endogenous HBO1 protein in 
enough quantity to perform ChIP. A similar issue was reported by Hung et al. 
(2009), who were also unable to complete ChIP on HT1080 fibrosarcoma cells using 
an antibody targeting HBO1 (Santa Cruz®), whereas they did manage to detect ING4 
occupancy using an anti-Flag antibody targeting ectopically expressed Flag-ING4 
(Hung et al. 2009). One possible explanation for the recurrent ChIP failure, which 
we favour, is the distinctive composition of the HBO1 multi-protein complex in 
UWB1.289 cells, with JADE1L/S transcripts present at very low levels and JADE2 
present at very high levels (Fig. 3.20). The potential switch of complex scaffolding 
subunits may mask access to HBO1 by the antibody when recruited to the promoter 
of target genes, thus severely interfering with ChIP experiments.  
 
Transient HBO1 depletion in OC cell lines was accompanied by cell-specific 
changes in gene expression (Table 6.5), suggesting that HBO1 may play subtly 
different roles in different OC sub-types. Amongst the different responses to the 
transient HBO1 KD identified in OVCAR-3, UWB1.289 and SKOV-3, the latter 
stands out due to (1) its low number of altered transcripts and (2) the change in 
regulatory trend, with three times more down-regulated genes than up-regulated 
counterparts, compared to the other cell lines. These differences might have their 
origin in the contrasting levels of HBO1 expression, but could also be dependent on 
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the nature of the SKOV-3 cell line itself. SKOV-3 carries a null TP53 (due to a 
frameshift mutation) (Mullany et al. 2015), as opposed to the other serous-like OC 
cell lines that constitutively express TP53 due to missense point mutations (e.g. 
G743A in OVCAR-3), and has therefore recently been placed in the spotlight as to 
its suitability as a model for HGSC (Domcke et al. 2013; Coscia et al. 2016). 
 
The transfection of siRNAs targeting HBO1 in OC cell lines identified an ‘HBO1 
OC signature’ gene list (Fig. 6.7), and whilst the basal expression level of these 
genes was similar to that of the HOSEpiC control cells, the majority of these genes 
(12/13; including HBO1 itself) were down-regulated following HBO1 KD. 
Furthermore, the genome wide role of HBO1 may not have been fully revealed, as 
others have reported compensatory effects by certain HAT complexes after HBO1 
KD. Notably, Avvakumov et al. (2012) observed increased levels of BRPF1 
following HBO1 KD in HeLa cells, suggesting that the MOZ/MORF HAT complex 
may compensate for loss of HBO1 (Avvakumov et al. 2012). 
 
The transient KD experiments pinpointed a group of pro-oncogenic genes, CD46, 
H2AFY and YAP1, that were down-regulated following HBO1 depletion in five OC 
cell lines (OVCAR-3, SKOV-3, UWB1.289, UACC-1598 and TOV-112D), 
suggesting an oncogenic potential of HBO1 in OC. Previous studies have reported 
overexpression of these genes in OC tissues (Fishelson et al. 2003; Steinhardt et al. 
2008; Novikov et al. 2011) and this overexpression has been linked to shorter 
survival and poor prognosis (Surowiak et al. 2006; Novikov et al. 2011). CD46 is a 
complement inhibitor involved in the protection of tumour cells against the host 
immune system (Maciejczyk et al. 2011). HBO1 regulation of CD46 supports one 
pathway identified through in silico analysis of HBO1 function, namely the 
inhibition of IFN signalling pathways, confirmed in OVCAR-3 cells for IFNA/α 
(Fig. 6.19). These findings suggest that HBO1 overexpression could be a mechanism 
deployed by cancerous cells, accomplished by the up-regulation of targets such as 
CD46, in order to evade the immune system and their subsequent destruction. 
 
The Hippo pathway transcriptional co-activator YAP1 is an OC oncogene whose 
expression has been shown to stimulate migration, invasion and anchorage-
independent growth of OC cell lines (X. Zhang et al. 2011). HBO1 regulation of 
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YAP1 may serve as a mechanism to enhance the oncogenic potential of OC cells, 
especially in terms of enhancing cell migration capacity. However, this was not 
conclusively demonstrated using scratch test assays (Fig. 5.6 & Fig. 6.16). 
 
Tumour suppressor genes were also altered following HBO1 depletion, e.g. ING4 
was significantly up-regulated following HBO1 KD in UWB1.289 cells (Fig. 6.10). 
These findings suggest that HBO1 may not only act as an enhancer of pro-oncogenic 
gene expression in OC, but might also participate in the inhibition of certain TSGs. 
ING4, a member of the HBO1 multi-protein complex, has been shown to function in 
inhibitory activities including angiogenesis and cell migration (Garkavtsev et al. 
2004; Shen et al. 2007), and is commonly down-regulated in OC (Liu et al. 2012). 
Accordingly, it seems likely that HBO1-driven repression of ING4 could contribute 
to a pro-oncogenic function in OC cells. 
 
Another TSG up-regulated following HBO1 KD was the cyclin-dependant kinase 
inhibitor CDKN1A/p21 (Fig. 6.10). CDKN1A has previously been identified as an 
HBO1 target following transient HBO1 KD in HeLa cells, however, conversely to 
the result obtained in OC cells, its expression was down-regulated in HeLa 
(Avvakumov et al. 2012). Although initially thought to suppress tumour growth by 
promoting cell cycle arrest, halting cell proliferation either as a p53-mediator or 
independently, evidence suggests that under certain conditions, CDKN1A can inhibit 
the apoptotic process thus promoting cellular proliferation and oncogenicity (Fischer 
2017). The extent of CDKN1A expression in OC has been extensively studied, 
although the results obtained have not always been conclusive; while certain studies 
have found CDKN1A predominantly increased and associated with tumour 
progression (Ferrandina et al. 2000), others found significant links between low 
levels of CDKN1A and high-grade tumours accompanied by poor survival rates 
(Anttila et al. 1999). 
 
In UWB1.289 cells, the up-regulation of CDKN1A following HBO1 depletion 
coincided with a significant decrease in caspase activity (Fig. 6.18 C), suggesting a 
role in the inhibition of apoptosis and therefore a pro-oncogenic behaviour of 
CDKN1A. Thus, HBO1-mediated repression of CDKN1A points to an anti-oncogenic 
role for HBO1 in OC cells, which is supported by the significant augmentation of 
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cell viability rates following the KD (Fig. 6.18 A). Notably, and regardless of 
changes in cell caspase activity and cell viability, HBO1 KD did not elicit cell 
proliferation changes in OC cells (Fig 5.5 & Fig. 6.15). 
 
HBO1 KD using distinct silencing approaches in UWB1.289 cells revealed different 
gene expression signatures: whilst 889 genes where up/down-regulated in response 
to the transfection of siRNAs targeting HBO1, only 68 genes displayed significant 
up/down-regulation in cells expressing shRNAs targeting HBO1. Although this may 
seem conflicting, given that both approaches are aimed at reducing the expression 
level of the same target protein, the different cell contexts in which this reduction 
occurs may account for the discrepancies in number and identity of gene targets. 
 
The transfection of transient siRNAs involves that cells are in a situation in which, in 
less than one cycle of division (~24h), protein levels of an important regulator have 
drastically declined, and therefore the concomitant expression of numerous 
associated-gene products may get altered (e.g. 889 genes in UWB1.289). On the 
other hand, the constitutive expression of shRNAs gives rise to a situation in which 
the cells, after going through different cycles of division in the absence of target 
protein, have been able to adapt and coexist with this circumstance, perhaps via 
modification of their transcriptome. Consequently, the genes that remained 
destabilised at the time of analysis (e.g. 68 genes in UWB1.289) could represent 
either transcripts that depend entirely on HBO1 regulation, and might therefore 
delineate the core functionality of HBO1, or a genomic response to counteract the 
lack of HBO1, although up-regulation of other HATs or HAT complex proteins was 
not observed. 
 
Interestingly, the use of these two approaches to KD HBO1 (transient siRNAs and 
stable shRNAs) provides very valuable information about the possible effects that 
the silencing of this molecule would have at cellular level in different clinical 
contexts. The gene expression changes elicited by the transfection of siRNAs could 
be correlated to the genetic alterations that would take place at the beginning of a 
potential treatment against HBO1. As common therapeutic regimes are administered 
in cycles over time, it could also be assumed that after several cycles of KD 
treatment, cancer cells may adapt to a permanent shortage of HBO1, a situation that 
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correlates with the expression of shRNAs targeting HBO1. Therefore, the 
development of the two silencing approaches provides a clear advantage in the study 
of HBO1 as a potential therapeutic target. 
 
 
Table 7. 1 List of common altered IPA functions after HBO1 KD 
 
Biological function Prediction 
Z-score 
Transient Stable 
Microtubule dynamics Increased 1.67 2.24 
Organization of cytoplasm Increased 2.31 2.24 
Formation of cellular protrusions Increased 1.77 1.81 
 
 
As a whole, the genome wide analysis of HBO1 function revealed significant 
changes in the expression of more than 1000 genes, which when analysed for 
pathway/process activities in silico, resulted in a number of predictions, some of 
which were corroborated in vitro (e.g. activation of IFN signalling pathways in 
OVCAR-3). Most notably, in silico analyses of UWB1.289 gene signatures were 
successful in highlighting a role for HBO1 in microtubule dynamics and cytoplasm 
organization, pathways that were identified in both the individual analysis of 
transient and stable HBO1 KD datasets, thus suggesting a core function of HBO1 
regulation (Table 7.1). 
 
In line with these predictions, recent attention has been focused on extra factors that 
characterise cancer, including the study of mechanical changes undergone by tumour 
cells (Coceano et al. 2016). Such changes in the mechanical properties of single cells 
start early in tumorigenesis and involve several physiological processes that, by 
altering the membrane and cytoskeleton structure, convert a malignant cell into a 
metastatic one (Plodinec et al. 2012). It is known that cancer cells, regardless of 
cancer type, are softer/elastic and hence more deformable compared to normal, non-
malignant or even less differentiated cancer cells, which eventually leads to 
increased ability to infiltrate tissues and spread (Rother et al. 2014). For instance, the 
stiffness of metastatic cancer cells isolated from the pleural fluids of breast cancer 
patients was reported to be more than 70% lower than that of benign mesothelial 
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cells (Cross et al. 2007). However, the underlying cause for this reduced stiffness, as 
well as its cause-effect relationship with other conformational changes observed 
during cancer growth and metastasis, remains not fully elucidated (Calzado-Martín 
et al. 2016). 
 
AFM enables measuring cell stiffness, the resistance of a single cell to an externally 
induced deformation, helping to understand the correlation between cell structure, 
mechanics and functioning (Lekka 2016). Individual UWB1.289 cells expressing 
either ‘shHBO1 1’ (targeting HBO1) or ‘shCtrl’ (non-targeting control) were 
analysed using AFM in order to evaluate the state of internal cell mechanics upon 
shRNA expression. Analyses revealed that HBO1 KD cells presented higher 
stiffness in comparison with control cells (Fig. 5.7), a feature commonly linked to 
the development of significant internal cytoskeleton and cytoplasm rearrangements 
(Parsons et al. 2010). The reduced deformability of HBO1 KD cells probed by AFM 
suggests that they are likely to have reduced movement and migration, linked with 
decreased invasiveness (Lekka 2016), pointing to a pro-oncogenic role for HBO1 in 
OC cells. Specifically, the overexpression of HBO1 in OC cells is suggested to 
promote changes in chromatin architecture and cell mechanics towards more elastic, 
aggressive cancerous phenotypes. 
 
The results presented in this work propose a new function for HBO1 in OC: the 
regulation of cytoplasm and cytoskeleton organization. The acetylation/deacetylation 
of tubulin proteins within microtubules is known to regulate microtubule function 
(Howes et al. 2014), suggesting a mechanism through which HBO1 can drive this 
novel function. For instance, the ‘histone deacetylase 6’ (HDAC6), which mediates 
tubulin deacetylation, has been shown to affect cell motility of cancer cells (Hubbert 
et al. 2002; Haggarty et al. 2003). Accordingly, one would expect that the 
overexpression of a HAT that may target tubulin for acetylation (e.g. HBO1) could 
elicit cytoskeleton re-arrangements aimed at acquiring higher degrees of cell 
elasticity. However, as it was highlighted by the in silico analysis (Table 7.1), 
HBO1 may also drive this function through the transcriptional regulation of genes 
involved in such processes. These findings may imply the opening of a completely 
new field of study, in which the activity of a known epigenetic chromatin modulator 
is also involved in the regulation of the mechanical properties of single cells. 
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Even though HBO1 has never been directly linked with microtubule acetylation or 
with any other aspect related to cell organization, a number of studies have 
investigated its role in tumour cell differentiation towards cancerous phenotypes. For 
example, Kim et al. (2015) and Duong et al. (2013) reported that HBO1 is involved 
in the maintenance of murine embryonic stem cell self-renewal and pluripotency, as 
well as in the maintenance of breast cancer stem cell properties and expression of 
EMT markers. These studies point to a broad role for HBO1 in the establishment of 
aggressive cancer phenotypes, thus supporting the data obtained with AFM in OC 
cells. 
 
HBO1 is known to frequently exert antagonistic roles, thus acting as an oncogene or 
a TSG depending on the specific background. This antagonistic functional duality 
has been observed for several genes, some of which have been discussed earlier (e.g. 
CDKN1A) and it is a common characteristic of HATs (e.g. PCAF) (Cohen et al. 
2011; Stepanenko et al. 2013). The set of observations obtained in this study seem to 
support a dualistic role for HBO1 within the same cancer type, a kind of behaviour 
that has also been observed in HATs such as p300 in colorectal cancer cells (Gayther 
et al. 2000; Ishihama et al. 2007). HBO1 displayed certain pro-oncogenic features, 
which include (1) its overexpression in OC cells, (2) the positive regulation of OC-
associated oncogenes (CD46, YAP1), and (3) the promotion of elastic tumour 
phenotypes. However, HBO1 was also associated with anti-oncogenic properties, 
mainly linked to its role as a regulator of cell viability, as it can be inferred from the 
KD profile displayed in viability/cytotoxicity assays, typical of TSGs. 
 
While it may seem surprising that the overexpression of HBO1 in OC cells could be 
associated with anti-oncogenic activities, there are precedents for overexpression of 
proteins with anti-oncogenic activities in cancer cell types. The transcription factor 
nuclear receptor COUP-TFII (NR2F2) is overexpressed in breast cancer, yet NR2F2 
KD in MDAMB231 and MCF-7 breast cancer cells led to enhanced migration and 
invasion without changes in proliferation (Zhang et al. 2014). Human mammaglobin 
(hMAM) is also overexpressed in breast cancer plasma and multiple breast cancer 
cell lines, yet hMAM KD enhances migration and invasiveness in MDA-MB231 
cells (Koh et al. 2014). Finally, ‘F-actin capping protein α1 subunit’ (CAPZA1) is 
overexpressed in gastric carcinoma tissues and the MKN45 cell line, yet is 
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associated with decreased cancer cell migration and invasion in this context (Lee et 
al. 2013). 
 
Overall, the results of this study suggest conflicting activities for HBO1 in OC cell 
lines, which give an idea of the wide-ranging and dynamic roles of this important 
HAT. Based on the evidence contained herein, a potential therapeutic action 
reversing HBO1 overexpression in OC cells would have two major consequences: 
(1) it would decrease OC cell elasticity, interfering the progression towards more 
aggressive cancer phenotypes, and (2) it would increase the viability of OC cells, 
potentially benefiting the perpetuation of the disease. These responses may be 
considered as counterproductive since, while one seems to deter OC development, 
the other clearly favours its growth. Accordingly, more in depth studies and a better 
understanding of the roles of HBO1 in OC are needed in order to decide whether 
HBO1 would be a suitable target for OC treatment. In this regard, it would be 
particularly interesting to evaluate the behaviour of HBO1 KD OC cells in three 
dimensional (3D) culture models, closely related to the in vivo settings of OC 
growth. These in vitro 3D models may provide more relevant information about the 
actual effects of a potential therapeutic treatment targeting HBO1 in a population of 
OC cells. 
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Appendix 
Appendix 1 
	
Appendix Figure 1 Comparative analysis of HBO1 expression in OC cell lines 
RNA lysates from HOSEpiC and 7 OC cell lines were prepared and analysed by 
qRT-PCR to evaluate the expression of HBO1 isoforms 1, 2, 3, 4 and 5. Relative 
levels of HBO1 expression were compared to those of the HOSEpiC non-cancerous 
control. GAPDH expression was used as control. Statistical analyses consisted of 
one-way ANOVA and Tukey’s multiple comparison tests. All values represent the 
mean ± SD of three biological samples (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 
0.0001). 
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Appendix 2 
	
Appendix Figure 2 Comparative analysis of NR expression in OC cell lines 
RNA lysates from HOSEpiC and 7 OC cell lines were prepared and analysed by 
qRT-PCR to evaluate the expression of ERA (α), ERB (β) and AR. Relative levels of 
expression were compared to those of the HOSEpiC non-cancerous control. GAPDH 
expression was used as control. Statistical analyses consisted of one-way ANOVA 
and Tukey’s multiple comparison tests. All values represent the mean ± SD of three 
biological samples (*p < 0.05; **p < 0.01; ****p < 0.0001). 
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Appendix 3 
	
Appendix Figure 3 Comparative analysis of microarray KD profiles  
Microarray-derived lists containing the FC expression value of more than 47,000 
genes following HBO1 KD in UWB1.289, OVCAR-3 and SKOV-3 cell lines were 
plotted against each other for comparison. FC values were transformed into 
logarithms (log2) prior to the analysis. Blue dots represent individual genes/probes. 
Final scatter-plots illustrate the genome-wide consistency of HBO1 KD amongst OC 
cell lines. 
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